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Thesis overview
Background:
This thesis sits within the arena of weight status during and after childhood acute
lymphoblastic leukaemia (ALL), with a particular focus on the prevalence of unhealthy
weight status amongst (ALL), Saudi and UK populations. Each chapter in the thesis
explores different aspects of unhealthy weight status in ALL which had been
highlighted as gaps in the literature at  a conference in Puebla, Mexico, at the end of
2006. A summary of each study is given below.
Study 1:
Background: This study estimated prevalence of unhealthy weight status and
metabolic syndrome (MS) amongst Saudi survivors of standard risk ALL. Methods:
We recruited 56 survivors, mean age 13.4 years (SD 4.1), a mean of 9.1 years (SD
4.1) post-diagnosis. The BMI for age was used to define weight status relative to
national (Saudi) and international (Cole et al., International Obesity Task Force
(IOTF), World Health Organisation (WHO), and Centre for Disease Control and
Prevention (CDC)) reference data. We measured body composition by dual energy X-
ray absorptiometry (DXA), waist circumference, blood pressure, lipid profile (HDL-C,
Triglycerides), fasting glucose and insulin. Results: According to international
definitions based on BMI for age, around half of the sample had unhealthy weight
status. All of the approaches based on BMI for age underestimated over-fatness,
present in 27/51 (53%) of the sample according to DXA. Prevalence of MS was 7.1%
(3/42 of those over 9-years old) and 5.4% (3/56) by applying the International
Diabetes Federation (IDF) definition and National Cholesterol Education Program
Third Adult Treatment panel Guidelines (NCEP III), respectively. However, MS by the
NCEP III definition was present in 19% of the overweight and obese survivors and
7.1% of the sample had at least two of the components of MS. Conclusions:
Unhealthy body weight and over-fatness may be common amongst adolescent Saudi
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survivors of standard risk ALL, though overweight and obesity may be no more
common than in the general Saudi adolescent population. Defining weight status
using BMI underestimates over-fatness in this population, as in other populations.
Study 2:
Background: Underweight, overweight, and obesity at diagnosis may all worsen
prognosis in childhood ALL, but no studies have estimated prevalence of unhealthy
weight status at diagnosis in large representative samples using contemporary
definitions of weight status based on BMI for age. Methods: Retrospective study
which aimed to estimate prevalence of underweight, overweight, and obesity at
diagnosis for patients with childhood ALL on three successive UK treatment trials:
UKALL X (1985-1990, n 1033), UKALL XI (1990- 1997, n 2031), UKALL 97/97-99
(1997-2002, n 898) .The BMI for age was used to define weight status with both UK
1990 BMI for age reference data and the IOTF definitions. Results: Prevalence of
underweight was 6% in the most recent trial for which data were available.
Prevalence of overweight and obesity was 35% in the most recent trial when
expressed using IOTF definitions; 41% when expressed relative to UK 1990
reference data. Conclusions: Even with highly conservative estimates >40% of all
UK patients with ALL were underweight, overweight, or obese at diagnosis in the
most recent trial for which UK data are available (UKALL 97/99, 1997-2002).
Study 3:
Background: This study tested the hypothesis that overweight/obesity at diagnosis of
childhood ALL was related to risk of relapse. Methods and results: In a national
cohort of 1033 patients from the UK there was no evidence that weight status at
diagnosis was related significantly to risk of relapse: log ranks test (p value= 0.90)
with overweight and obesity as the exposure (n 917); individual (p value= 0.42) and
stepwise (p value= 0.96) proportional hazards models, with BMI z score as the
exposure (n 1033). Conclusion: The study does not support the hypothesis that
overweight/obesity at diagnosis impairs prognosis in childhood ALL in the UK.
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Study 4:
Background: In the sample of Saudi patients recruited to study 1 we compared DXA
whole body and lumbar spine bone mineral density (BMD) using manufacturers
software with a body size correction which derived bone mineral content (BMC) for
bone area and Apparent bone mineral density of lumbar spine (BMADLS). Methods
and results: The survivors of ALL were from Saudi Arabia (n 51, mean age 13.5
years). With no corrections, 29 patients (57%) had lumbar spine BMD z score < -1.0
and 21 (41%) had whole body BMD z score < -2. After correction, by using BMC for
bone area method only 6 (12%) had lumbar spine BMC z score <-1.0 and 4 (8%) had
whole body BMC z score <-2. By using BMADLSmethod, 18 (35%) had BMC <-1.0
and 6 (11%) had BMC Z score <-2. Conclusions: Correction for body size seems
essential to accurate interpretation of DXA bone health data in adolescent survivors
of ALL. The three correction methods provided different conclusions, but bone health
remains a concern after treatment for ALL.
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Chapter 1
General introduction
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1.1 Background
The issue of nutrition in children and adolescents is one of the main public health
challenges of the 21st century. Malnutrition as used in this thesis refers to both
overnutrition (being overweight/ obese) and undernutrition (being underweight/thin).
Moreover, malnutrition remains one of the most significant issues in childhood health
in both the developed and developing countries. It may have an effect on survival,
development and growth and consequently can lead to reduced strength and capacity
of those who are affected (Imdad et al., 2011).
1.2 Undernutrition
United Nations Children’s fund (UNICEF) (UNICEF, 2009) has reported that 129
million children in the world are currently underweight, of whom 25% are less than 5
years old. Undernutrition can be assessed by using the individual’s height-for-weight,
height-for-age and body mass index (BMI); or assessing for deficiencies in their
vitamins or minerals. Stunting which is defined as low height-for-age is considered a
predictor for chronically undernourished children, it has been observed to be related
to cognitive development in children; and low productivity and reduced stature in
adulthood. According to United Nations Children’s fund (UNICEF), there are 195
million stunted children in the world, 90% of whom are living in Asia and Africa
(UNICEF, 2009). Wasting (defined as low weight-for-height) is an indicator for
children who are acutely undernourished; which is also highly correlated with the
mortality rate (Imdad et al., 2011). Definitions of undernutrition in children will be
highlighted below.
From an underweight perspective, deficiencies have usually resulted as a
consequence of the macronutrients associated with fat, carbohydrates and protein-
energy malnutrition; or in the micronutrients, as in the case of vitamin or mineral
deficiencies. The World Health Organisation (WHO) has defined protein-energy
malnutrition as a pathological condition caused by diminishing protein-energy intake
24
24
which often appears in the first five years of life (Rodriguez et al., 2011). Black et al.,
(2008) have estimated that 0.6 million and 0.4 million deaths have resulted from
vitamin A and zinc deficiencies; respectively. In the non-supplemented vitamin A
population, relative risk (RR) of mortality related to vitamin A deficiency is 1.35 (95%
CI: 0.96 - 1.89) for measles mortality and 1.47 (95% confidence interval (CI): 1.25 -
1.75) of diarrhoea mortality. Furthermore, zinc deficiency has also been associated
with an increased risk of malaria, pneumonia and diarrhoea in the child population
(Black et al., 2008) .  The main causes of undernutrition are poverty (insufficient
food), war and confliction, lack of health services, natural disasters, lack of education,
natural disease and sometimes as a result of particular treatments e.g. cancer and its
therapy (Rodriguez et al., 2011). Undernutrition may also be caused by poor
gastrointestinal absorption, increased demands and high nutrient excretion. This has
been represented in figure 1.2.1.
The short-term consequences of undernutrition are disabilities, morbidity and
mortality (Imdad et al., 2011). It has been well-known for a long time that
undernutrition is highly associated with increased morbidity and mortality rate.
Undernutrition is the greatest cause of mortality in the first five-years of life for
children in developing countries (Black et al., 2008).
In the early 1990s, Pelletier et al., (1995) reported that mild to moderate undenutrition
was sufficient to increase mortality amongst children; and it potentiated the impact of
infectious disease for increased risk of death in developing countries. This is because
children are the most vulnerable group in accordance with their needs for growth and
development.  Thus malnourished children have greater susceptibility for infectious
diseases such as respiratory and gastrointestinal infection as a consequence of the
deterioration in the capacity of their immune systems in producing all of their cellular
components (Rodriguez et al., 2011).
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Figure 1.2.1: Causes of undernutrition and its consequences.
Source: Modified from Black et al., (2008)
A review article has estimated that around 2.2 million children deaths throughout the
world have been caused by severe wasting, stunting and intrauterine growth
restriction. Moreover, together these are responsible for 21% of disability-adjusted life
years “which is a measure of overall disease burden, expressed as the number of
years lost due to ill-health, disability or early death” (Black et al., 2008).
In the long-term the consequences of undernutrition can cause reduced body size,
poor intellectual ability, low life productivity and cardiovascular and metabolic
disorders. Dewey and Begum (2011) reviewed a number of longitudinal studies and
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reported strong evidence for the association between stunting in early life and short
stature in adulthood. Moreover, they also reported that there was a relation between
stunted men and lack of economic productivity.  There is also a link between stunted
women and low general health, survival of their babies and reproductive health.
Undernutrition in children, for any reason even with/without repeated infection, may
cause stunted and functional damage to the brain, which in turn, may lead to
cognitive impairment (Kar et al., 2008).
It is worth noting that  International Dietetics and Nutrition Terminology has defined
malnutrition as “ inadequate intake and/or energy over prolonged period of time
resulting in loss fat stores and/or muscle wasting including starvation-related
malnutrition, chronic disease-related malnutrition and disease or injury-related
malnutrition” (American Dietetics Association, 2010). Also, worth defining chronic
energy deficiency (CED) which is a condition of the body characterised by low body
weight and low energy stores and possibly limited physical capacity due to
deprivation of food over a long period of time, with body mass index (BMI) of less
than 5th percentile for children and adolescents or less than 18.5 kg/m2 for adults.
Moreover, based on WHO definition, CED is categorised according to BMI as having
either grade III chronic energy deficiency (BMI: < 16.0), grade II chronic energy
deficiency (BMI: 16.0–16.9) or grade I chronic energy deficiency (BMI: 17.0–18.49)
(Gibney, 2005).  Moreover, in the public health arena, starvation-related malnutrition
is related usually to famine secondary to conflict or natural disasters.  On the other
hand, disease-related malnutrition usually refers to patients with chronic disease and
an inflammatory component is commonly seen in various clinical settings. Figure
1.2.2 shows that anorexia is usually a result of some chronic or severe diseases such
as cancer AIDS and chronic obstructive pulmonary disease (COPD) which results in
disease-related malnutrition. Malnutrition combined with stress-associated catabolism
related to inflammation elevates the risk of organ dysfunction, frequent infections and
impaired healing (Norman et al., 2008). Also, acute illness such as infection and
trauma can be a trigger for an inflammatory response to cause starvation or/and
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stress-associated catabolism and which in turn exacerbates malnutrition (Norman et
al., 2008).
Figure 1.2.2: Vicious of the development and progression of disease-related
malnutrition
COPD: Chronic obstructive pulmonary disease
Source: Normal et al., (2008)
1.3 Childhood obesity
Childhood obesity is presently a major public health issue because it is widespread
and has multiple implications for present and future child health. Childhood obesity
has been made more complex as a consequence of many factors from multiple
settings during the growth and development of children (Davison and Birch, 2001).
WHO has defined obesity as the presence of a high body fat mass (FM) connected
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with high co-morbidities (World Health Organisation, 2000). Definitions of childhood
obesity will be discussed in the following section.
1.3.1 Global epidemic of childhood obesity
In recent years, obesity in children and adolescents has become a global epidemic.
The occurrence of being overweight and obese has risen considerably in industrial
countries since the early 1980s and in developing countries since the 1990s as
shown in figure 1.3.1 (Bawa, 2005, Lobstein T, 2007). The prevalence of those who
are overweight and obese has markedly increased 2.3 - 3.3 fold in the United State of
America (USA) over 25 years; 2.0 - 2.8 fold in England over 10 years;, 1.8 - 2.3 fold in
Scotland over 10 years and 3.9 fold in Egypt over 18 years (Ebbeling et al., 2002). In
the 1970s, the prevalence of overweight and obese children and adolescents was
defined as ≥85th percentile according to the Centres for Disease Control and
Prevention (CDC) for those aged 2-19 years and around 15 % in the USA;  whilst by
2003 - 2006 it had sharply risen to around 32 % (Ogden et al., 2008). In a recent
study in Saudi Arabia the overall prevalence of overweight and obese children and
adolescents had reached 35.4% (El Mouzan et al., 2010).
However, although the global epidemic of childhood obesity has been shown to be
continuing to increase; a recent US study suggests that the prevalence of obesity
defined as ≥95th percentile based on CDC has remained unchanged at around 17%
over the period 2009 - 2010 when compared to the period 2007- 2008 (Ogden et al.,
2012). A recent systematic review Rokholm et al., (2010) suggests that global
childhood obesity has been levelling off in recent years. However, they emphasised
that the current prevalence is much higher than before and could be in the future
followed by new elevations; and therefore there are sufficient reasons to focus on
cause, prevention and treatment (Rokholm et al., 2010).
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Figure 1.3.1: Increasing childhood obesity in selected countries
Source: Modified from Lobstein  (2007)
1.3.2 Health consequences of childhood obesity
The co-morbidity of obesity and the impact on children’s health is now well-
established. There is numerous evidence which now points to the consequences of
childhood obesity which can occur in both the short and long-term and has a potential
effect on the lifespan (Reilly et al., 2003, Olshansky et al., 2005). A high BMI in
children has a high linear correlation with risk of diabetes and impaired glucose
metabolism, hypertension, fatty liver, gallstones, dyslipidaemia, cardiovascular risk
factors and metabolic syndrome (MS) (Willett et al., 1999); and other medical
complaints such as psychological co-morbidity, orthopaedic problems and sleep
apnoea (Kiess et al., 2001) (summarised in figure 1.3.2 ). This thesis will briefly
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discuss some of these consequences as some of them are beyond the scope of this
research.
Figure 1.3.2: Consequences of childhood obesity
Source: Modified from Ebbeling et al., (2002)
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1.3.3 Psychological co-morbidity
Psychological co-morbidity is highly related to the presence of obesity in children
(Daniels et al., 2009, World Health Organisation, 2000). Griffiths et al., (2010)
reported that obesity in children and adolescents had an impact on the lowering of
their self-esteem and self-confidence and it could result in depression.
There are other psychological and social consequences which are related to
childhood obesity such as social functioning, eating disorders, body dissatisfaction,
discrimination, stigmatisation and prejudice (Griffiths et al., 2010, Daniels et al.,
2009).
1.3.4 Obesity tracking into adulthood
Childhood is a critical phase because it is precursor of adulthood. It is one of the most
concerning issues as a long-term childhood consequence.  Three systematic review
publications have examined the persistence of childhood obesity into adulthood.
Firstly, 18 publications, all of them of longitudinal designs, were reviewed by Singh et
al., (2008).  They stated that all studies pointed to the fact that being overweight or
obese in childhood increased the risk of being overweight or obese in adulthood. In
addition these studies showed that the tracking of being overweight in adulthood was
highly associated to the level of being overweight in childhood. High-quality studies
indicated that overweight children who were at risk of being overweight in adulthood
had at least a two-fold risk than normal weight children. Authors reported that the
percentage of those being overweight in adulthood as a result of being overweight in
adolescence ranged from 22 - 58% based on 3 high-quality publications. Moreover,
the percentage of being overweight or obese in adulthood as a consequence of being
obese in adolescence ranged from 24 - 90 %.  Therefore, risk of being overweight or
obese in adulthood is increasing consistent with the age of the groups of children.
They concluded that the evidence associated with the persistence of childhood
obesity into adulthood was ‘moderate’ (Singh et al., 2008). Similar findings were
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stated in systematic reviews by Reilly et al., (2003) and Power et al., (1997). The
review by Reilly et al., (2003) was the first systematic review regarding the impact of
childhood obesity in the long-term based on critical appraisal. They appraised 47
studies and concluded that obesity during childhood was likely to track into adulthood.
In addition a strong relationship was found between the percentage body fat in
childhood and adulthood (Power et al., 1997). However, most of the systematic
review evidence was based on either small numbers of subjects or old cohorts from
before the second war era; this evidence is questionable, particularly because of the
tracking of childhood obesity into adulthood in the modern ‘obesogenic’ environment.
There is strong evidence that childhood obesity leads to adulthood obesity according
to the literature based on large sample sizes and conducted in the modern
‘obesogenic’ environment. For instance, in a recent longitudinal study, Reilly et al.,
(2011) examined a large sample (n = 2175) of 7-year olds over a 6 -year period (at
age 13 years). They defined being overweight when BMI z scores ≥ 1.04 and obesity
when BMI z score ≥ 1.64 according to UK reference data. The findings showed that
there was an adjusted Odd Ratio (OR) of being obese at 13 years of age for being
overweight at age 7-year old which was 18.1 (95% CI: 12.8 - 25.6). They also found
that, at age 7, 34% children who had been considered to be overweight had been
classified as being obese at aged 13. In addition, Freedman et al., (2005a) examined
prospectively 2610 participants in the USA aged 2.5 - 17 years and followed them at
age 18 - 37 years. They reported that the percentage of overweight (defined as BMI
for age ≥ 95th percentile) children being obese in adulthood (defined as BMI ≥ 30
kg/m2) aged 2 - 5 years and 15 - 17 in males and females was 93% and 73%, 86%
and 90%; respectively.
Many factors have arisen which may play a role in increasing the tracking of
childhood obesity into adulthood in more recent years. These factors are low family
socioeconomic class at birth, maternal obesity, early menarche, adolescent obesity
and severity of obesity (Whitaker et al., 1997, Reilly et al., 2011, Laitinen et al., 2001).
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1.3.5 Cardiometabolic risk factors
1.3.5.1 Impaired glucose metabolism
Rise of prevalence of diabetes in obese young people is now emerged. So, impaired
glucose metabolism and diabetes in children is mainly the result of obesity as in the
adult population. However, the pathological nature associated with the development
of diabetes in adolescence remains unknown (Debelea et al., 1999). The prevalence
of impaired glucose metabolism in US obese children was found to be 20%; 27% in
Latino children living in the USA; whereas in France the prevalence was 15 - 20 %
(Weiss, 2007). One dire prediction from CDC estimated that third of newborns born in
2000 will have diabetes if the rate of obesity remains on the same current pace.
In a review paper Kempf et al., (2008) showed that the prevalence of impaired
glucose and diabetes was high in US children; whilst the rate was less noticeable in
European countries. Therefore, ethnic background is an important risk factor of
impaired glucose intolerance and diabetes.
There is good evidence of a relationship between adiposity in childhood and insulin
resistance, impaired glucose tolerance and type 2 diabetes. Sabin et al., (2006)
investigated the consequences of obesity in a clinical sample of 126 children with a
mean age of 11.2 years.  They reported that 10.3 % of the subjects had impaired
glucose tolerance, which was the main precursor for diabetes. In addition, a large
cohort Caucasian study in Germany conducted on 520 subjects (237 boys and 283
girls) aged between 8.9 - 20.4 years of age examined the prevalence of diabetes
amongst obese children and adolescents by using a 2-hour oral glucose tolerance
test.  They found that 1.5 % of the children had diabetes, and 6.7 % had impaired
glucose regulation. Weiss et al., (2003) have reported that obese children with
impaired glucose tolerance, which is a strong predictor for diabetes type 2, are more
likely to have insulin resistance, i.e. pre-diabetes, than those with normal insulin
tolerance.
34
34
Consequently, the American Diabetes Association (ADA) suggests screening children
and adolescents who have overweight (BMI≥ 85th) and having other risk factors of
diabetes such as high blood pressure, high lipids profile or ethnic minority (American
Diabetes Association., 2000). Furthermore, Daniels et al., (2009) have highly
recommended the screening of overweight or obese children for impaired glucose
metabolism in order for its prevention and management.
1.3.5.2 Cardiovascular diseases (CVD)
Many studies have shown a relationship between adiposity and CVD in adults
(Ingelsson et al., 2007, Manson et al., 1990).  Therefore, in the last few decades more
attention has been focused on investigating this risk within paediatrics as obesity
became globally epidemic.  There are data linking between high level of serum lipids
and lipoprotein during childhood and progression of the atherosclerosis in adulthood
(Berenson et al., 1998). Fatty streaks which progress into plaque formation in the
lining of the arteries, a condition known as atherosclerosis, can contribute to heart
disease (Berenson et al., 1998).
Post-mortem studies (Berenson et al., 1998, McGill et al., 2001) have revealed that
early atherosclerosis and advanced lesions are strongly associated with an increase
in total cholesterol, LDL-C and low level of HDL-C as well as in the presence of other
risk factors such as obesity, hypertension and smoking. Moreover, such studies have
demonstrated that there is a relationship between being overweight during childhood
and young adulthood and prevalence of atherosclerotic lesions in the aorta and
coronary arteries. Pos mortem studies have shown that coronary calcium in later life
could be predicted in those who are overweight during early life.  Coronary calcium is
known to be a marker of plaque formation in the arteries which can lead to myocardial
infarction. Also, in the Pathobiological Determinants of Atherosclerosis in Youth
(PDAY) over 5 decades of study, Zieske et al., (2002) have concluded that there is an
35
35
abundance of evidence which supports the argument that atherosclerosis begins
early in childhood.
Furthermore, findings from 3 pooled historical cohort studies, Lawlor et al., (2006)
demonstrated that a high BMI in childhood tended to be connected with increased risk
of adult CVD. Thus the adjusted hazard ratio per standard deviation of childhood BMI
was 1.09 (95% CI: 1.01 - 1.19) and 0.94 (95% CI: 0.82 - 1.08) for ischemic heart
disease and stroke; respectively. However, there was no observable correlation
between stroke and being overweight or obese. Hence, they assumed possible
explanations for these findings. Firstly, future CVD risk outcome has only been linked
with a morbid obesity level during childhood. Secondly, being overweight in childhood
has been unable to predict the CVD risk if other risk factors during the life cycle are
not present or are controlled in a proper manner. Finally, the BMI is not a good
indicator for child adiposity which has a link to both fat mass and fat free mass.
Moreover, Korsten-Reck et al., (2008) examined the relationship between
dyslipidaemia and obesity in children.  Thus 546 obese patients aged 7-12 years old
were observed.  Obesity was defined as at or above the 97th percentile using the
German reference. They found that 45.8% of overweight (at or above the 90th
percentile) children had an abnormal lipid profile; 10% of children had high LDL-C;
15% of children had high LDL-C and high triglycerides (TG) and 18.9% had high TG
and low high-density lipoprotein (HDL-C). Therefore, they demonstrated that obese
children were more likely to have an abnormal lipid profile.
However, to our best knowledge, no longitudinal population-based studies have been
conducted linking high lipid profile in childhood and actual CVD in adulthood.
Furthermore, no randomised controlled trials have been conducted which show that
improving adverse lipid profiles in childhood reduces actual CVD in adulthood. The
mentioned studies indicate that adverse lipid profiles accelerate atherosclerosis
processes from early life until late life, and consequently, point to the public health
importance of primary prevention and management of obesity in early life.
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Hypertension is one of main causes of cardiac problems such as stroke or heart
attack in adults (Ong et al., 2007). Obesity may play a key role in elevated blood
pressure in adults; and childhood obesity may also elevate the blood pressure.
However, the pathogenesis of this mechanism is still not completely understood
(Becton et al., 2012).  Epidemiologic studies have established a link between
hypertension and childhood or adult obesity. Rosner et al., (2000) showed that
overweight children and adolescents were 2.5 - 3.7 times more likely to suffer from
hypertension. In addition, researchers of the Muscatine study showed that the
progression of being overweight during childhood was considered a good predictor for
the level of hypertension during adulthood (Lauer and Clarke, 1989).
Moreover, hypertension is known to be persistence over time. Hypertensive
adolescents are more likely to have hypertension in adulthood than non-hypertensive
adolescents. The essential risk factors that remain high blood pressure tracking from
childhood to adulthood are obesity, low physical activity, dietary pattern such as high
sodium intake and smoking (Chen et al., 2008). Accordingly, these results are quite
crucial from a clinical perspective that health primary providers can early and
frequently investigate blood pressure in children and adolescents to identify pre-
hypertension and even hypertension, therefore, early intervention and management
can be offered.
Current recommendations have been made by the American Academy of Paediatrics
(AAP) and the American Heart Association (AHA) with regards to the management of
dyslipidaemia. The AAP has recommended the testing of children aged 2 years and
above who have an unknown family history or present with one of the cardio
metabolic risk factors such as diabetes, hypertension and obesity (Daniels and Greer,
2008). They have also found that increased screening of children has occurred with
the increased prevalence of obese children (Daniels and Greer, 2008). The AHA has
recommended the screening of children aged 2 - 18 years with consideration for high-
risk individuals with a family history of diabetes, HIV infection, nephritic syndrome and
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systemic lupus erythematosus. The AHA has also considered TG and HDL-C
abnormal when the level is ≥ 150 mg/dl and is ≤ 35 mg/dl; respectively (McCrindle et
al., 2007).
1.3.5.3 Metabolic Syndrome (MS)
MS is "a grouping of clinical characteristics including insulin and insulin resistance,
abdominal obesity, impaired glucose tolerance, elevated blood pressure (BP),
elevated TG and reduced HDL-C" (Saland, 2007). Moreover, the association between
these components has been disputed since 1920 (Wannamethee et al., 2005).
However, in 1988, Reaven illustrated the role of insulin resistance and its relationship
in adults with other diseases such as obesity, type 2 diabetes, dyslipidaemia,
hypertension and CVD (Bremer et al., 2012).
The prevalence of MS is found within around 25 % of the adult American population
(Ford et al., 2002); and more attention has been paid to this condition since the sharp
increase in obesity (Speiser et al., 2005). Obesity is known to be a strong indicator for
CVD  in adults (McGee, 2005). Consequently, the US national Heart, Lung and Blood
Institute has recommended that the diagnosis and treatment of MS should take place
in a clinical setting (Fernandez et al., 2009).
 MS in childhood and adolescence has only recently been recognised; and some
studies have found a relationship between CVD and obesity and insulin resistance in
children (Falkner et al., 2002). To be more precise, CVD is a rare disease in early life
and therefore it has received little attention from paediatricians. In fact, in children, it
is the process which leads to diseases which begin early e.g. vascular damage which
can occur in early life. Moreover, type 2 diabetes among obese children has recently
increased and may lead to serious complications in the entire life cycle (Fagot-
Campagna et al., 2000).
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1.3.5.3.1 Defining Metabolic Syndrome in Paediatrics
There are a number of diverse definitions of MS and many of these have been
developed for adults. For instance, definitions have been provided by the WHO
(Alberti and Zimmet, 1998); the National Cholesterol Education Program the Adult
Treatment Panel III (NCEP III) (Expert panel, 2001) the European Group for the study
of Insulin Resistance (EGIR); the American College of Endocrinology Task Force on
the Insulin Resistance Syndrome (Garber et al., 2004) and the International Diabetes
Federation (IDF) (Zimmet et al., 2005). However, still there is no consensus as to
which definition is recommended to use in defining MS in adults.
However, using MS adult definitions is unsuitable and would underestimate the
prevalence of MS in children and adolescents. Therefore, paediatric MS is defined by
a number of different approaches. Some of these definitions have been modified from
an adult definition such as those provided by Cook et al., (2003) and Weiss et al.,
(2004) modified from the NCEP III   definition; but produce different cut-offs.  However
in 2007, the IDF released a new international definition of MS in paediatrics. They
aimed to produce a useful and unified definition (Zimmet et al., 2007). Subsequently,
there has been no consensus in using the IDF definition by researchers and there has
been confusion regarding which definition of MS is most appropriate.
Table 1.3.1 summarises definitions of MS in the paediatric literature. So, the
prevalence of MS in the paediatric population has been broadly varied as a result of
lack of an existing universal definition and lack of nationally representative samples.
For example, a  recent study was carried out on a small number of obese adolescents
(n= 51) and those of normal-weight (n= 30) Danish adolescents aged 12 – 15 years
(Gobel et al., 2012). They reported that the prevalence of MS amongst obese
adolescents was 14% (7/51).
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Table 1.3.1: Some studies on metabolic syndrome in paediatrics
References Sample size
Place
Age (years)
Metabolic syndrome definition Prevalence of metabolic
syndrome
Globel et al., (2012)  51 (obese); M: 29, F: 22.    30
(normal weight);M: 13,  F: 17
 Denmark
 12 - 15 years
IDF (having central obesity plus 2 or more criteria):
 WC≥ 90 th
 FG ≥ 100 mg/dl
 TG≥ 150 mg/dl
 HDL-C ≤ 40 mg/dl
 DBP ≥ 130 or SBP ≥ 85 mmHg
 14% of obese had MS
 Non obese did not have MS
Al-Daghri et al.,
(2010)
 1231; M: 760. F: 471
 Saudi Arabia
 10 – 18 years
NCEP III modified by de Farranti et al. (3 or more of the
criteria):
 WC≥ 75 th
 TG≥ 100 mg/dl
 HDL-C < 50 (Girls) and < 45 mg/dl (boys)
 FG ≥ 110 mg/dl
 BP> 90th
 9.4% diagnosed with MS
 Prevalence of MS was 10.3%
and 8.1% in boys and girls;
respectively
Taha et al., (2009)  57 (obese); M: 33. F: 24
 Saudi Arabia
 Mean (SD): 9.8 (3.5) years
NCEP III and WHO (3 or more criteria):
 BMI > 95th
 TG > 95th
 HDL-C < 5th
 SBP and DBP > 95th
 FG > 110 mg/dl
 29.7% of the sample met MS
criteria
Eapen et al., (2010)  260 (obese); M: 153. F: 107
 United Arab Emirate
 Mean (SD): 14.5 (2.6) years
NCEP III modified by Cook et al. (3 or more of the criteria):
 WC> 90th
 TG≥ 100 mg/dl
 HDL-C ≤ 40 mg/dl
 FG ≥ 110 mg/dl
 BP >90th
 44% of obese had MS
Al-Isa et al., (2010)  431 (girls)
 Kuwait
10 -19 years
IDF and NCEP III modified by Cook et al.
 Discussed above
 By using IDF, 14.8% met MS
criteria
 9.1% had MS based on
NCEP criteria
M: Male; F: Female; IDF: International Diabetes Federation; WC: Waist circumference; FG: Fasting glucose; TG: Triglycerides; DBP: Diastolic blood pressure; SBP: Systolic blood pressure;
NCEP: National Cholesterol Education Program; WHO: World Health Organisation.
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In addition, there is no consensus in definition of MS in paediatrics even in the same
country or the same region. For instance two Saudi studies used different MS
definitions. Firstly, in a community-based cross-sectional study, Al-Daghri, (2010)
examined (n=1231) for prevalence of MS. The overall prevalence of MS was found to
be 9.4%.  However, A hospital-based Saudi study was carried out on 57 children who
were only obese with a mean age and standard deviation (SD) of 9.8 (3.5)(Taha et
al., 2009). The prevalence of MS was found to be 29.7%. A review article by Tailor et
al., (2010) found the prevalence of MS amongst children and adolescents around the
world was around 10%, however, it varied from around 2% in those of normal weight
up to around 32% in those defined as obese. Obese children and adolescents had an
approximately 15-fold increased risk of having MS when compared to those defined
as being normal weight (Tailor et al., 2010). Prevalence of obesity and MS was
shown to be elevated in a parallel manner in the review by Tailor et al., (2010).
In addition,  a United Arab Emirates study of 260 obese (defined as BMI > 95th
percentile) adolescents with a mean age (SD) of 14.5 years (2.6) (Eapen et al., 2010)
reported one of the highest prevalence amongst adolescents in the world at 44% with
MS. In a Kuwaiti study  amongst the female adolescent population aged 10 - 19 years
old (Al-Isa et al., 2010) prevalence of MS was 14.8% and 9.1% according to IDF and
NCEP III; respectively.
To sum up, the previous studies defined MS by using different approaches with
hugely different sample sizes and types of samples; consequently, there are
apparently enormous differences in MS prevalence even in same population. Reinehr
et al., (2007) aimed to compare the prevalence of MS according to the criteria of
Weiss, Viner, De Ferranti, Cook, WHO, European Group for the study of Insulin
Resistance (EGIR), NCEP III and the IDF. This study was carried out on 1205
German, Caucasian overweight children between 4 and 16 years of age defined in
line using IOTF criteria (Cole et al., 2000). They observed that the prevalence of MS
varied significantly (p value < 0.001) (6 – 39 %) in these definitions and only 9% of
participants conformed to all of the MS definitions. Also, some of MS definitions such
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as IDF and NCEP definitions use age-adjusted indicator criteria which are important
to classify MS according to a specific age because prevalence of MS is more likely to
occur in adolescents than younger children.
Even though the majority of studies that defined MS in paediatrics included the
following variables:  anthropometrics, blood pressure, plasma glucose and lipid
profile, there were substantial differences in defining abnormal values of individual
MS components. For example, the cut-off level for TG and HDL-C are fixed with more
than 150 mg/dl less than 40 mg/dl; respectively, by IDF definition. The NCEP III
modified by de Ferranti et al., 2004 on the other hand used for TG more than
100mg/dl and less than 50 mg/dl for girls and 45 mg/dl for boys.
The recent existence of a standard MS definition helps answering to what extent MS
affects children and adolescents, facilitates international comparisons of prevalence,
assists in conducts and interpretation of clinical trials, helps in investigate the
underlying pathological mechanisms and facilitates health professionals to identify
and manage MS.
1.3.5.3.2 Metabolic syndrome from childhood to adulthood
Abundant studies have pointed out the association between MS in childhood and its
persistence into adulthood. In a longitudinal study  which followed children aged 9
years old at the beginning of the study for 6 years the tracking of MS from childhood
to adulthood amongst 174 Swedish and 460 Estonian children (Martinez-Vizcaino et
al., 2011). MS and its risk factors showed persistence from childhood to adulthood.
Moreover, from the Bogalusa Heart Study, Freedman et al., (2001) examined 2617
subjects and followed them for up to 17 years; and 77% who had been overweight as
children with a BMI ≥ 95th percentile stayed obese in adulthood.  They also found that
being overweight in childhood was related to the elevation of adverse risk factors
such as high BMI, lipids, insulin, blood pressure (BP) and diabetes in adulthood; and
42
42
that this may be caused by the strong persistence of weight status between childhood
and adulthood. Correspondingly, Morrison et al., (2008) stated that children and
adolescents with MS and a family history of diabetes type 2 had  significantly elevated
risk of MS and diabetes type 2 in adulthood. Similarly, Srinivasan et al., (2002) stated
that childhood obesity was connected to the likelihood of clustering of all four MS
components (BMI, fasting glucose, BP, total cholesterol to HDL-C ratio to TG to HDL-
C ratio) in adulthood.  Children in the top quartile of BMI were 11.7 times more likely
than those in the bottom quartile to develop clustering of MS in adulthood. Moreover,
they concluded that obesity during childhood was considered to be a strong predictor
of MS risk components in adulthood, this conclusion was supported by Chen et al.,
(2007) as well. The Quebec Family Study, Katzmarzyk et al., (2001) examined the
stability of MS components from the paediatric phase to early adulthood. The sample
included 76 males and 71 females. They found significant tracking of MS components
from early childhood into adulthood.  To some extent, MS in adulthood may be
expected from an examination of children and adolescents; and therefore, when they
have low HDL-C, high central obesity, BP, cholesterol, TG and fasting glucose, they
are more likely to be at high risk in early adulthood.
However, an essential question is whether MS usefully predicts CVD and diabetes?
Sattar et al., (2003) investigated the association between MS and CVD and diabetes.
They recruited 6447 men to predict CVD and 5974 men (mean (SD) age 55.1 years
(5.5)) to predict incident diabetes and followed over 4.9 years. By using modified MS
definition, MS was associated with 70% higher risk of CVD in univariate model but, by
using multivariate model the higher risk dropped to 30%. Besides, they measured
fasting glucose at each 6 monthly visit. Men with MS were at 270% increased risk of
incident diabetes. Therefore, MS modestly predicts CVD and more strikingly predicts
incidence of diabetes. A meta-analysis (Gami et al., 2007) found that after adjusting
for traditional risk factors around a 50% higher risk of CVD events and death in
patients was found compared to those without MS. They included studies that had
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cohorts without baseline disease, the pooled RR was 1.49 (95% CI: 1.37 – 1.61).
Therefore, MS may be associated modestly with CVD in middle-aged people.
MS may be a weaker predictor of CVD than diabetes in part because high BMI or WC
are around 10 times more strongly related to diabetes than CVD.  Also,
hyperglycemia in non-diabetics is not very predictive of CVD (Sattar et al., 2003).
Likewise, high triglyceride concentration is more associated with diabetes than CVD
(Sattar et al., 2003). Accordingly, by using an MS definition such as NCEP III and
IDF, three out of five components are more closely associated with incidence of
diabetes than CVD. Moreover, there are other critical risk factors which are not
appreciated according to MS definitions and more closely aligned to risk of CVD such
as age, LDL-C and smoking status (Sattar et al., 2008).
1.4 Nutritional assessment in children
From a historical perspective, nutritional assessment was originally used in detecting
undernutrition and nutrient deficiencies especially with regards to energy and protein.
Later on, there was awareness of an increasing prevalence of overnutrition (being
overweight/obese) and recognition of undernutrition especially with regards to illness
(Gibson, 2005). Therefore, the aims of nutritional assessment are: to diagnose
whether the individual is over or under nourished, monitor the nutritional change over
time in individuals, groups and the population and finally determine the prevalence of
the under or overnutrition in groups and population (Gibson, 2005, Gibney, 2005).
Nutritional health is the cornerstone in maintaining children against illness.
Consuming a balanced nutrient intake (adequate nutrition) is essential for proper
development and growth. Any deficit in the energy intake is more likely to lead to
malnutrition. Weight status is also implicated in predicting the persistence of chronic
illness into adulthood (Yang et al., 2007, Herman et al., 2009).
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Nutritional status assessment is a broad topic and there is no single exact tool for its
use in clinical settings. Theoretically, it remains the ideal approach in assessing the
nutritional status that can screen individuals and identify those who are at risk from
morbidity and mortality (Mascarenhas et al., 1998). Consequently, there are several
different approaches and concepts behind them to evaluate nutritional status. The
main nutritional assessment approaches include: clinical, anthropometric, dietetic,
biochemical and functional methods. Some of these approaches have been used in
the present thesis; however the others are beyond the scope of the present thesis
and are discussed very briefly.
1.4.1 Clinical approaches to nutritional assessment
This approach is historical in nature and is based on physical examination of features
which would appear to be biologically meaningful. Furthermore, a medical history
should be recorded. For example, any weight changes over the previous period of the
patient and whether the changes were voluntary or not. In addition there are several
questions in the patients’ history which are necessary to provide a full picture such as
their number and sizes of meals, appetite and satiety, chewing and swallowing,
nausea and vomiting, bowel habits and use of herbal remedies or supplements
(Gibson, 2005, Gibney, 2005).  Thus, clinical nutrition assessment depends on the
signs which are observed by the qualified examiner and symptoms which are stated
by the patients (Gibson, 2005).
Subjective global assessment (SGA) is an example of a clinical approach for
assessing malnourished patients. It is based on a medical history such as weight
changes, changes to dietary intake and gastrointestinal symptoms; and physical
status such as muscle wasting, oedema and loss of subcutaneous fat (Gibney, 2005).
Nonetheless, this approach relies on signs and symptoms that are often not specific
and may emerge at the end stage of nutritional deficiency. Subjective global
assessment (SGA) has been validated in preoperative children according to Secker
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and Jeejeebhoy (2007). They evaluated prospectively 175  31 day to 17.9 year old
patients having major thoracic or abdominal surgery by using subjective global
nutrition assessment (SGNA) which was adapted from Subjective global assessment
(SGA). They tested the hypothesis that SGNA could predict nutrition-associated
complications i.e. infection, use of antibiotics and length of stay. They reported that
malnourished patients had significantly (p value= 0.04) higher rate of infectious
complications than well-nourished patients. Also, postoperative length of stay was
significantly (p value= 0.002) longer in malnourished patients (8.2 ± 10 day) than in
the well-nourished (5.3 ± 5.4 day).
Moreover, the qualifications of the physical examiner play an intrinsic role in
assessing the nutritional status of the patient; and inconsistency in observation is a
possible disadvantage (Smith et al., 2008, Gibson, 2005, Gibney, 2005). As an
example of the possible using clinical nutritional assessment of childhood obesity,
Smith et al., (2008) asked 80 healthy professionals to observationally rate 33 children
and adolescents aged between 10 - 17 using their full-length photographs. The health
professionals assigned the children into one of six categories (from very underweight
to obese) by using direct observation. There was significant under-recognition of
obesity (compared BMI percentile) between health professionals. They concluded
that health professionals should be aware of the limitations of the observational
approach in assessing obesity rather than using formal measurements. A further
discussion of clinical nutritional assessment is beyond the scope of this thesis.
1.4.2 Dietetic approach to nutritional assessment
Using this approach, inadequate nutritional intake as a result of low levels of the diet
(primary deficiency) would possibly be detected. In addition it would help in the
identification of secondary nutrient deficiency which had occurred according to
nutritional needs in certain conditions such as drug-nutrient interactions or in some
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diseases that influence nutrient absorption such as cystic fibrosis (Gibson, 2005).
Therefore, the main advantage of this approach is identified in the individual who is at
risk. So, Health professionals may be able to detect patients may be consuming less
energy than they need to maintain healthy weight status. For instance, many studies
reported that cancer treatments may cause low food intake, decrease gut absorption
and elevated metabolic demand (Lai et al., 2005). Moreover, cancer patients are
more likely treated with radiotherapy, chemotherapy and bone marrow
transplantation, which can cause taste perception (sourness, bitterness and metallic
taste), appetite and vomiting. These side effects might lower food intake and lead to
malnutrition (Chiodi et al., 2000, Epstein et al., 2002).
This approach has different ways of measuring dietary intake in children the choices
of which depend on the aim and characteristic of the sample of the study. The best
way is probably the 3-day weighted record of food intake which subsequently
analyses the data using a computerised analysis for nutrients and energy
(Mascarenhas et al., 1998).  In addition, 24-hour recall is used for estimating energy
intake (Mascarenhas et al., 1998). In a systematic review of children it was suggested
that 24 hours recall should be performed over at least a 3 day period, containing
weekdays and weekends, for the most accurate approach when compared to the
doubly-labelled water method as a reference (Burrows et al., 2010).
Nevertheless, this approach has been criticised because nutrient requirements are
often unknown in accordance with the reference value weaknesses and biological
variability in nutritional requirements. In addition, dietary assessment may be
imprecise, inaccurate and impractical especially amongst children (Baxter, 2009,
Black and Cole, 2001, Bingham, 1994). The dietetic approach to nutritional
assessment was not used in this thesis and so is not described in any detail here.
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1.4.3 Biochemical approach to nutritional assessment
The biochemical approach is used to assess the nutrients and its metabolites such as
vitamins, minerals and protein in biological tissue, fluid and urinary excretion (Gibson,
2005). Therefore, it is essential for testing the vitamin and mineral status of the
person, but it has a huge number of confounding variables. Moreover, some of
biological ways to assess nutritional status include nitrogen balance and the
creatinine high index.
Nitrogen balance is also used for measuring the changes of protein mass in the body.
The assumption behind this is that net body nitrogen is incorporated into protein when
protein has 16% nitrogen. A positive nitrogen balance means that nitrogen intake is
higher than nitrogen excretion (Gibney, 2005). In diseased patients, for example, in
cancer patients negative nitrogen balance may occur as a result of either inadequate
protein intake or/and high body protein catabolism. Therefore, if the nitrogen negative
balance is keeping on, this could lead to malnutrition which is a concern issue
especially in patients undergoing anticancer therapy (Geibig et al., 1991).  In
diseased patients, many researchers found that improving nitrogen balance using
high nitrogen parental nutrition than standard regimen and enteral nutrition (Geibig et
al., 1991, Mulder et al., 1989).   However, it has some disadvantages such as
impracticality especially with regards to the difficulty in collecting urine for 24 hours
and is often inaccurate in high protein consumers (Tarnopolsky et al., 1988).
The creatinine high-index is used as a proxy of muscle mass and it requires urine to
be collected over a 24 hour period. When increase muscles breakdown in the body,
creatinine excretion is increasing in the urine. It is a potentially helpful assessment to
determine malnutrition, and the need to supply a nutritional supplement for repletion
(Viteri and Alvarado 1970). Even though it is a simple predictor for nutritional status it
is not always practical. In addition, it is inaccurate in some diseases such as cardiac
and renal disease or for patients who receive diuretic treatment (Perrone et al., 1992,
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Gibney, 2005). However, the biochemical approach to nutritional assessment was not
used in this thesis and so is not described further.
1.4.4 Functional approach to nutritional assessment
This is comprised of biochemical and physiological functional approaches, but is
beyond the scope of this thesis. Briefly, by using the biochemical approach, metabolic
product abnormalities in plasma and urine which are related to malnourishment can
be measured. For example, excretion of xanthuranic acid is associated with vitamin
B-6 deficiency. Moreover, the growth and development process can be assessed for
instance by using growth velocity in children which would indicate undernutrition
(protein-energy deficiency). The functional approach is helpful in assessing changes
in blood components or enzyme activity. Alteration in glutathione peroxidase activity
in red blood cells is related to selenium status (Gibson, 2005, Gibney, 2005).
Vitamin C for example has a number of functions in the body. It works as a co-factor
in hydroxylation reactions for instance to help in hydroxylation of proline and lysine in
collagen. It acts also, as an electron donor in metabolism for example folic acid and
histamine. In addition, it is used to produce certain compounds such as steroids. The
immune system can be enhanced by vitamin C, but this is unclear. Therefore, an
insufficient vitamin C status in the body can lead to impairment in its mentioned
features (Gibson, 2005) and the functions of vitamin C can be measured to assess
vitamin C status.
The physiological functional approach is used to test responses which may point to
nutritional status. It includes the immune, muscle and respiratory function. Impaired
immune function could be an indicator of nutrient deficiency. Delayed cutaneous
hypersensitivity, which is used for the skin test, may show as decreased responses in
the undernourished as well Rowland 1991). However, this test was developed for
adults and need prior exposure to antigen; so, it is less used in paediatric clinical
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settings in nutrition, though it is used widely in allergy clinics. In malnourished
patients, the level of circulating of antibodies level can be affected and giving the
malnourished patients a false negative reading for Delayed cutaneous
hypersensitivity. Thus, an improvement in patient’s nutritional status should increase
reading of cutaneous hypersensitivity by stopping transitions from positive to negative
(Rowland 1991). However, the limitations of immune function are technically difficult
and the interpretation for detecting nutrient deficiency in the individual is also difficult
(Gibson, 2005, Gibney, 2005).
The functional approach to nutritional assessment was not used in this thesis and so
is not described further here.
1.4.5 Anthropometric approach to nutritional assessment
This is comprised of physical (growth) and body measurements. The physical
measurement can include weight, length (height) and head circumference.
1.4.5.1 Anthropometric assessment of growth
1.4.5.1.1 Head circumference
This measurement is related to brain size which is rapidly enlarged during the first of
3 years of life (Mascarenhas et al., 1998). It is a useful clinic tool for detecting
undernourished children. This approach could be used detect children who are
severely undernourished (Gibney, 2005, Hadlock et al., 1982). It is not useful for
certain illnesses which may cause macrocephaly or microcephaly (Mascarenhas et
al., 1998).
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1.4.5.1.2 Weight index
Weight for age alone as an index measurement is used to describe the body size and
is a simple, invasive, cheap, easy and reproducible measurement (Power et al.,
1997). It is used to describe malnutrition especially when measurement of height is
impossible (Gibney, 2005). Although, weight alone as an index measurement is highly
correlated to fat mass it is not recommended because it does not provide any
information about the body composition components such as fat or protein mass and
it will often over-estimate malnutrition (Uauy et al., 2001, Power et al., 1997). For
instance, an athletic person would be considered to be heavy in weight and therefore
their muscle mass would not be appreciated (Power et al., 1997, Kuczmarski and
Flegal, 2000). In children, this measurement is influenced by the length/height and
therefore tall children tend to be a heavier weight than those who are shorter within
the same age group (Power et al., 1997). However, weight and height should be
taken in hospitalised children and at outpatient visits (Power et al., 1997). In a small
number of patients and in some specialities body weight  is affected by  abnormalities
in body composition, fluid status, type of treatment and organ enlargement or tumour
mass (Warner et al., 1997).
1.4.5.1.3 Weight-for-height/length index
Firstly height should be measured in the supine length/height position in children who
are aged 2 years of age and under; and in the standing position in those over 2 years
of age (Mascarenhas et al., 1998). The weight-for-height index measures the weight
when adjusted to the current stature to provide the nutritional status without taking the
specific age into account. The weight measure with an adjustment in the height for
children is more meaningful than weight alone (Uauy et al., 2001).
This method is used to distinguish whether the child is actually wasting (defined as
very low weight-for-height) when weight-for-height z score is below -2.0 or less than
the 5th percentile by the National Centre for Health Statistics (NCHS)/WHO median
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reference data (Mascarenhas et al., 1998, de Onis and Blossner, 2000). Its
consideration of wasting is more useful than the underweight measurement alone. In
addition, the weight-for-height index is used for detecting those who are overnutrition
(defined as > 95th percentile through use of the NCHS/ WHO reference data) although
it does not measure fat mass (Mascarenhas et al., 1998). In some parts of the world,
dates of birth are not registered and therefore, this index is sensitive to the current
nutritional status (Gibney, 2005). However, the main disadvantage of using this index
is that it can lead to a biased outcome especially in infants and adolescents (Power et
al., 1997).  Weight or height index can classified children who have poor linear growth
as a normal (Gibney, 2005).
1.4.5.1.4 Height-for-age index
Height-for-age measures the stature of children and how much they deviate from the
normal reference population of children (Mascarenhas et al., 1998). Moreover, it is
often used to indicate the nutritional status amongst the population instead of the
individual (Gibney, 2005). This measurement represents the influence of nutritional
status over a long-term period as stature is affected by long-term malnourishment
(Mascarenhas et al., 1998).
The height-for-age index is a simple tool for the assessment of stunting. Stunting
means low height/length for age which is a more useful measure than being
underweight (Mascarenhas et al., 1998, Black et al., 2008).  Stature is expressed as
percentile which is defined in the following manner: 95th - 105th percentile is normal;
and the 90th - 94th,  85th - 89th and < 85th percentile are indicated for mild, moderate
and severe stunting; respectively based on NCHS/ WHO reference data
(Mascarenhas et al., 1998). Stunting can occur as a result of micronutrient deficiency
or as a complication of some diseases such as renal disease (Rosado et al., 1999)
and anticancer therapy and steroids (Olshan et al., 1992).
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1.4.5.1.5 The Body Mass Index (BMI)
The BMI is defined as weight (Kg) divided by height squared (m2).  This method has
been in use for a long time to detect obesity in adults, and has proven to be helpful
and low-cost ( World Health Orgnisation,1995).  The BMI in adults is usually classified
into categories as shown in table 1.4.1.
Table 1.4.1: Classification of the Body mass index in adults (Gibney, 2005)
* Note that this is for European/ Caucasian adults; and different cut-offs are used in Asia for example
The BMI is now a widely-accepted means of diagnosing those who are overweight
and obese in the child and adolescent population as well (Reilly, 2006a). However
interpreting the BMI in children and adolescents is more complex than in adults, as
differences in the BMI are found according to age, gender and maturation. Based on
the LMS method (L: measures skewness, M: the median and S: the coefficient of
variation) the BMI z score can be calculated (Cole and Green, 1992) by following the
equation:  [(BMI/M)L - 1]/(Lx S). Moreover, there is a straight connection which is
interchangeable between the BMI z score and percentiles.
BMI for age can be used to define underweight, overweight and obesity with
interpretation relative to national reference data and thresholds in the BMI distribution,
or by applying international reference data and thresholds. As shown in table 1.4.2,
several national and international definitions and cut-offs and how they were
developed will be discussed in more detail in the general methods chapter. The
advantage of using international definitions is to allow easy comparison with results
from other populations. Also, these definitions help in direct comparisons of trends in
Definition* Underweight Healthy
weight
Overweight Obesity
grade I
Obesity
grade II
Obesity
grade III
BMI
(kg/m 2) <18.5 18.5-
24.9
25.0-29.9 30.0-
34.9
35-39.9 >40
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childhood unhealthy weight status worldwide (Chinn and Rona et al., 2002). On the
other hand, the drawback of using international definitions is that they are based in
heterogeneous mix surveys collecting from different countries with widely differing
prevalence of unhealthy weight status (Cole et al., 2000). Additionally, Reilly et al.,
(2010b) found in a systematic review that BMI for age based on national reference
data is superior with higher sensitivity (lower false negative rate) than based on the
international reference data: international definitions have a higher false negative
rate, in the other words, some obese (excessively fat) children may classified as non
obese and therefore the international definitions underestimate the prevalence of
excessive adiposity (Reilly et al., 2010b).
Table 1.4.2: Some of national and international thresholds
National definitions International definitions
Saudi
(BMI)
UK
(BMI SD)
 CDC
(BMI)
WHO
(BMI SD)
IOTF/ Cole., 2000
(Pass through of
adult BMI)
Underweight  < 5th --- < 5th < -2.0 ≤ 18.5 kg/m 2
Overweight  85th – 94th 1.04 - 1.63 85th – 94th > +1.0 – 1.99 25 - 30 kg/m 2
Obesity ≥ 95th > 1.64 ≥ 95 th  > +2.0 ≥ 30 kg/m 2
CDC: US Centers for Disease Control and Prevention; WHO: World Health Organisation. IOTF: The
International Obesity Task Force
In theory, the BMI represents an index of the body mass independent of height, so
that a greater percentage of body mass may be attributed to increased body fat at
any age. A high BMI for age is now widely recommended e.g. in the WHO and
Scottish Intercollegiate Guidelines Network (SIGN) as the method through which
overweight and obese children and adults should be defined (Barlow, 2007, Scottish
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Intercollegiate Guidelines Network, 2010). There are also practical reasons for
recommending the use of the BMI because it is useful, cheap, non-invasive, simple
and more reliable than other indices of children in clinical settings (Gibson, 2005,
Dietz and Robinson, 1998). However, there is a debate whether it is useful to use the
BMI with national or international cut-offs in defining childhood obesity. Reilly et al.,
(2010b) have emphasised using national BMI for age and percentiles rather than
using the international BMI such as the IOTF.
The main drawback of the BMI is that it does not take into account the actual
composition of body mass (Eto et al., 2004), For example, the taller child would
sometimes be classified as being obese. Furthermore, adiposity is changed according
to some variables such as age, gender, ethnicity and sexual maturity, sitting height
and fat distribution (central adiposity) and these variables cannot be distinguished by
the BMI. However, Warner et al., (1997) examined the validity of BMI compared to
dual-energy X-ray absorptiometry (DXA) and skinfolds in diseased children with
growth hormone deficiency, previously treated for cancer, and healthy children as a
control group. They concluded that BMI in diseased children is imperfect in detecting
excess adiposity. However, systematic reviews show that a high BMI for age and sex
is highly predictive of excessive fatness and of co-morbid conditions. Reilly et al.,
(2010b) have concluded on the basis of systematic review and evidence appraisal
(number of included studies was 27); that a high BMI for age in children and
adolescents defines or diagnoses excessive fatness with high specificity (low false
positive rate) and moderately high sensitivity (reasonably low false negative rate). In
clinical settings, high specificity is considered as being of greater importance than
high sensitivity to keep away from assessing some non-obese children as obese and
then offering treatment which is not required and which risks stigmatisation of the
child (Reilly et al., 2010b).
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1.4.5.1.6 Waist circumference (WC)
In paediatrics, age and the gender-specific WC percentile is considered to be a
reasonably good indicator for risk of cardiovascular  diseases (Watts et al., 2008),
hyperlipidaemia and metabolic syndrome (Bitsori et al., 2009) that will likely continue
into adulthood (Goran et al., 1998). In children and adolescents, there is a relation
between a high WC and cardiovascular risk such as hyperlipidaemia and
hypertension (Taylor et al., 2000, Rudolf et al., 2007). It is used in paediatric research
partly because it has become popular in adult research and is a straightforward and
inexpensive tool.
The WC is also considered to be a good tool for assessing central adiposity. Fredriks
et al., (2005) in a cross-sectional study assessed WC, hip circumference and waist-
hip ratio on 14,500 Dutch participants aged between 0 - 21 years old and compared
the results to the IOTF. They concluded that the WC was a useful tool for detecting
increasing abdominal fatness.  Similarly, Taylor et al., (2000) found that the WC
identified a high trunk fat mass amongst 278 girls and 302 boys aged between 3-19
years old with DXA used as the reference standard, though DXA is not a reference or
a standard for body fatness (Wells and Fewtrell, 2006).
Conversely, the WC has not been recommended by the SIGN (Scottish
Intercollegiate Guidelines Network, 2010) because there is no evidence to support the
fact that WC is a better predictor for either excessive body fat or cardiovascular risk
factors in childhood than the BMI. A systematic review of studies which compared
WC and the BMI for age found no advantage in using WC for diagnosis of excess
fatness or cardio-metabolic comorbidities (Reilly et al., 2010a).
 The WC changes with age and differs between the genders and should be
interpreted in an age and sex- specific method. Therefore, there are many methods
which measure WC in children. Rudolf et al., (2007) examined the consistency across
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different waist measurement methods amongst 41 healthy children (75.6 % of whom
were girls). The mean (SD) age was 12.4 years (3.3). The waist measurement
methods involved the midpoint between the lowest rib and iliac crest, the creases
upon lateral flexion and the 4 cm above the umbilicus method and subsequently
compared them with the BMI z score from the UK 1990 reference data. As all
methods were highly correlated to each other and to the BMI z score, they
recommended using the 4 cm above the umbilicus method arguing that it would be
the simplest option in clinical settings.
1.4.5.2 Anthropometric assessment of body composition
1.4.5.2.1 Skinfold thickness
This method is beyond the scope of the present thesis and so is described briefly
here. It is used for estimating the subcutaneous adipose tissue and it allows an
estimation of the total body fat (TBF) (Brozek and Keys, 1951). It is useful, cheap and
invasive and it is appropriate for large sample surveys (Kuczmarski et al., 1994). Five
different sites  in which to use the skinfold thickness for estimating TBF are as
follows: subscapular, triceps, biceps, mid-axillary and supra-iliac (Gibney, 2005). The
principle behind this method is that there is association between skinfold thickness
and body density.
In addition the independent predictor of body density amongst males and females is
age (Gibney, 2005). The skinfold thickness relies on the age and sex equation in a
certain population as it is affected by age, sex, race and level of physical activity
(Heyward and Stolarczyk, 1996). The skinfold thickness method is not always
practical because it is dependent on the skill of the examiner, subject characteristics,
precision of skinfold thickness clippers and the used equation and its reference data.
In addition, it is advisable to repeat the measurement to estimate the TBF (Gibney,
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2005). Also, in diseased children, the reading of skinfold thickness method can be
influenced by dehydration, fluid retention and steroid therapy (Manning et al., 1995).
1.4.5.2.2 Dual energy x-ray absorptiometry (DXA)
DXA was initially used for detecting bone mineral density (BMD) in the spine and hip
by using single and dual photon absoptometry. DXA has become more attractive with
regards to body composition as because it is relatively simple, fast and requires
minimal participant effort.  It is widely accepted for children beyond about 4 years old
and it can also be used in infants (Wells and Fewtrell, 2006).
Moreover, a wide range of photo-energy is produced as a result of the beam that is
created by the x-ray tube. In rectilinear scanning the supine body is divided into a
series of pixels, therefore, this wide beam produces to only two distinct photoelectric
peaks to distinguish between bones and soft tissue which is produced. As a response
to low intensity neutron beam to the body, the DXA machine is based on an analysis
of gamma rays emitted from the body (Ellis et al., 1994). The DXA assumes that the
body has three main components: fat, bone and soft “lean” tissue. These components
can be distinguished by their x-ray attenuation proprieties. Also, soft tissue (water
plus organic compounds) decreases photon flux more than bone mineral which easily
distinguished from those regions with no bone present. The composition of soft tissue
is extrapolated to the soft tissue overlying bone to give percentage of whole body fat
and soft tissue. This extrapolation is performed according to specific algorithms which
vary between manufactories (Lindsay and Plank 2005). The whole body or a specific
region such as the lumbar spine or hip can also be measured by this instrument (as
illustrated in figure 1.4.1) (Fewtrell, 2003).
There are different types of DXA machines which are currently being manufactured.
Firstly the Lunar DXA is based on narrow or pencil beam machines. It employs a
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narrow x-ray that moves across the body or part of the body that needs to be scanned
in a rectilinear scan path with detector(s) (Fewtrell , 2003, Bonnick, 2010).
Secondly, the Hologic DXA uses wide or fan-shape beams and array of detectors to
employ alternating pulses power at 70 and 140 kV; respectively to the x-ray tube
sources (Bonnick, 2010). Additionally, the latter is faster in its scanning times, but it
produces higher radiation which is a most important issue amongst children.
Conversely, even though the Lunar narrow fan beam is slower in time scanning, it has
a lower radiation dose (Fewtrell, 2003).
However, some differences in outcome values were found between these different
company machines.  Lunar DXA showed lower absolute bone density values than the
Hologic DXA even though high correlations between each other were reported  for
example (Laskey et al., 1992, Lai et al., 1992).
Figure 1.4.1: Real images from the present studies: (left) the total body bone
image; (right) the total body composition image by Lunar DXA
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Moreover, DXA uses a very low radiation dose (the range: 0.5- 15 microseverts) but
is not suitable during pregnancy. This measurement tool can detect two major
components of the body composition: fat mass (FM) and BMD (represented in figure
1.4.2) (Wells and Fewtrell, 2006). It relies on different assumptions according to the
manufacturer and is a two-component model; whilst the gold standard measurements
are characterised as four-component models (Goodpaster, 2002). However, it has a
relatively high precision when compared to other body composition methods (Jebb et
al., 1993). The accuracy of DXA for measurement of body fat has had insufficient
attention paid to it as it is broadly used in clinical paediatric settings. DXA
measurement could be affected by age, fatness and underlying disease state in some
cases.  Therefore, more attention is required in interpreting the body composition data
from children (Wells and Fewtrell, 2006).
DXA is used for research and clinical purposes. In research, the DXA machine is
useful for measuring the impact of for example dietary and exercise intervention in
different groups (Fewtrell, 2003).
DXA is becoming accepted for assessing body composition and bone health in
clinical paediatric settings. Sala et al., (2007) examined 179 healthy Canadian 3 – 18
year olds by using Hologic DXA. They found that total body bone mineral content, fat
mass and fat-free mass were highly correlated with directly measured body weight (r>
0.997) and BMI. They generated z scores for each facet of body composition and
they recommended comparing ill children with healthy ones. However, the small
representative normative data becomes a concern limitation even they compared
their results with Argentina and Netherlands data.
Furthermore, DXA   is a commonly used technique in paediatric settings because it is
precise, relatively low cost, safe and with widespread availability. Recently, DXA is
recommended as the most appropriate technique in assessing bone health in children
by the International Society for Clinical Densitometry (ISCD) (Gordon et al., 2007).
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Also, patients in general are examined to identify risk of low BMD and for observing
the impact of treatment. Moreover, there are some conditions which may increase of
risk of low BMD in children such as systemic long-term corticosteroids, chronic
inflammatory disease, apparent osteopenia on x-ray and hypogonadism (Fewtrell,
2003).
However, it is sometimes difficult interpreting DXA data, for instance, due to changing
BMD in children and adolescents. Briefly, the difficulty of interpretation refers to
significant gaps in this area, there are few large sets of representative normative data
from healthy children and adolescents (for example small sample sizes in specific
ethnic groups are common) and a lack of consensus in which the best method to
adjust the results of DXA in children as it is discussed in details in general method
chapter (Gordan et al., 2007).
In addition, some artifacts can falsely affect the results of DXA scans such as frames
or plaster-casts, jean studs, surgical prostheses and navel rings. Therefore,
unaffected areas have only to be included in the calculation and data interpretation
(Gnanasegaran et al., 2007).
Figure 1.4.2: An example of total body composition data by DXA (extract from
the thesis studies)
T. mass: Total mass; BMC: Bone mass content
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1.4.5.2.3 Bioelectrical impedance (BIA)
The present thesis is dealing with BIA because it is useful clinically and so can be
used in the thesis studies. BIA is a non-complex, convenient and relatively cheap
instrument to assess body composition, which has become more popular in recent
years in clinical settings and research (Sung et al., 2009). It does not require a high
level of skill by the examiner and needs little subject cooperation (Schaefer et al.,
1994).
BIA is based on two main principles. First of all, the technique measures the
resistance (impedance) to a low level (at usually 50 kHz) electrical current travelling
through biology tissues or opposition to the current electricity. There are high levels of
water and electrolytes in a fat-free mass (FFM), and FFM is therefore an electrical
current conductor. In the other words, at low frequencies (around 1 kHz), the current
passes through only the extracellular fluids but at high frequency (at usually 50 kHz),
it passes through interacellular  and extracellular fluids when it passes cell membrane
(Lukaski et al., 1987).  Secondly, the impedance is a function of resistance and
reactance, where 22 cXRZ   . Whereas (R) is a measure of opposition
to the current flow through the body and (Xc) is the opposition to current flow
produced when it penetrates the cell membrane (Kushner et al., 1992).
In children, BIA seems to be correlated with body composition. Vizcaino et al., (2007)
assessed in a cross-sectional study 1280 healthy children aged 8 - 11 years in Spain
of whom 51.5% were female.  Their percentage of body fat was measured using BIA
(Tanita Corp.) with the use of DXA measurements as a reference standard method.
They reported a strong correlation between BIA and the BMI and the triceps skinfold
thickness, though as noted earlier in the thesis a high correlation need not mean
agreement. However, other studies emphasised care in choice of regression
equations which are essential in estimating total body water and fat-free mass
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because they noted the significantly different outcomes in regression equations by
using two different BIA devices (Warner et al., 2004).
Until now, BIA is less frequently used in previous cancer survivor studies than DXA
and other anthropometric measurements (Link et al., 2004, Warner et al., 2004, Follin
et al., 2006). Data on prognostic significance of BIA analyser estimates in assessing
body composition are not presented. However, BIA analyser seems to be more
reliable in children in case of presence other body composition techniques (Lewy et
al., 1999).
Some devices have been developed based on homogenous subgroups to adjust the
differences in prediction of fatness due to age, sex, race, physical activity level and
adiposity. Generally speaking extrapolating equations developed from one population
into a different population would produce a bias. There are limited body fat reference
curves adjusted to specific age and sex for BIA estimates of body fat. Jebb et al.,
(2004) for example provided categories for body fat based on the age and sex of
children. In addition, McCarthy et al., (2006) established BIA age and gender specific
percentiles based on the estimation of FM in both boys and girls aged 5 - 18 years.
However, McCarthy et al., (2006) and Jebb et al., (2004) emphasised that the
estimate of body fat is specific to the model of the BIA device being used.
1.4.5.2.4 Magnetic Resonance Imaging (MRI)
MRI, is beyond the scope of this current thesis, but can be used to identify adiposities
throughout the whole body, skeletal muscles, brains and visceral organs. It measures
the hydrogen nuclei which is located in fat or water with a magnetic moment; and
estimates the volume of the adipose tissue instead of the mass.  It can also assess
the regional differences in the body composition or changes in fat or muscle.
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Nevertheless, it has several disadvantages in practice because MRI requires
hundreds of images and that cost time, funds, and limited availability and require
sophisticated software (Goodpaster, 2002, Wells and Fewtrell, 2006). In addition, it
can estimate the FM that is only allocated in adipose tissue versus other body
compositions such as hydrometry, densitometry and the multi-component model.
However, it is a useful device for the assessment of regional body composition and is
accurate in detecting intra-abdominal adipose tissue in children when compared with
other approaches (Wells and Fewtrell, 2006).
1.5 Acute lymphoblastic leukaemia (ALL)
ALL is one of the forms of Leukaemia. It is characterised by producing high amounts
of lymphoblast found in the bone marrow and is formed as immature cells normally
differentiated to create mature lymphocytes, which is one type of white blood cells
(WBC). Therefore, ALL is the cancer of WBC (Pui, 2006).
ALL accounts for about 25% of total childhood cancers (Link et al., 2004). In addition,
ALL is one of the most common malignancies within Saudi paediatrics. The incidence
of paediatric ALL in 2006 when compared to other malignancies was 72% and 75.1%
in boys and girls; respectively (Saudi Ministry of Health, 2006) as shown in figure
1.5.1.  In the UK, ALL is also the most common type of cancer. The numbers of newly
diagnosed ALL cases in children each year in the UK are around 380 (Medical
Research Council, 2006).
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Figure 1.5.1: The most common paediatric malignancies in Saudi Arabia
ALL: Acute lymphoblastic leukaemia; AML: Acute myeloid leukaemia; A Mon L: Acute monocytic
leukaemia; BCL: Burkitt cell leukaemia; A Meg L: Acute megakaryoblastic leukaemia
Source: Extracted from cancer incidence report in Saudi Arabia (Saudi Ministry of
Health, 2006)
1.5.1 Survivors of ALL
The survival rate of ALL has increasingly improved in children. In the UK, the Medical
Research Council (MRC), in 1955 established randomised controlled trials (RCTs) in
many medical centres to improve treatment. Besides which, they also compared the
potential new treatment based on the survival outcomes to reduce the possible side
effects and improve treatment efficiency (Medical Research Council, 2006). Thus,
tailoring of treatment to known prognostic factors has been established by the recent
trials such as the MRC as summarised in the general method table 2.2.1 and US
Cancer Study Group (CCG) as summarised in the general method table 2.1.1.
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In the UK, for example, four out of five children with leukaemia now recover from the
disease; whilst one out of five was cured 25 years ago (Medical Research Council,
2006). The survival rate of children with leukaemia has dramatically increased to 80%
(Medical Research Council, 2006).
The percentage of event-free survivors of ALL has gone up to around 80% (Ries et
al., 2006). In Saudi Arabia, for instance, overall 5-year survival has been significantly
improved by using more advanced treatment protocols (Fryer, 2006). The 5-year
survival rate for all patients in Jeddah (the second biggest city in Saudi Arabia) aged
less than 15 years who have been treated by different protocols has shifted
significantly over 15 years (Fryer, 2006).  It was originally 55% by using the UKALL X
protocol; 72% by using the United Kingdom Acute Lymphoblastic Leukaemia  (UKALL
XI) and the Berlin-Frankfurt-Munich (BFM) protocols and reached 87% when using
the MRC 97 and CCG 199 (Fryer, 2006).
In general, survivors of childhood cancer are highly exposed to increased morbidity
and premature mortality. Oeffinger et al., (2006) reported in a retrospective study that
the occurrence of chronic health conditions affected up to 73.4% of surviving patients
and life-threatening diseases or death resulted in 42.4% of cancer survivors. Obesity
is one of the most common adverse health outcomes in survivors of childhood cancer
(Robinson et al., 2008, Courneya et al., 2008); and obesity is particularly common in
patients during and after a diagnosis of ALL (Razzouk et al., 2007, Baillargeon et al.,
2006, Garmey et al., 2008, Reilly et al., 2000a, Nysom et al., 1999, Butturini et al.,
2007, Chow et al., 2007, Oeffinger et al., 2003, Reilly et al., 1999b). Therefore, the
following section will discuss the prevalence of those who are overweight, obese and
underweight in this group and its effect on the prognosis for malignancies.
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1.5.2 Medical therapy intervention for acute lymphoblastic leukaemia
Presently the treatment regimens for ALL categorises therapy as remission induction,
consolidation and central nervous system (CNS) prophylaxis, and maintenance or
continuous treatment phase.  Induction chemotherapy typically consists of a 1-month
treatment programmed of vincristine, prednisone, and L-asparaginase alone or with
other agents; and has as its objective a reduction in blast cell percentage in the bone
marrow to ≤5% (Oeffinger et al., 2000).
Subsequently, in the consolidation stage, the treatment is intensified, using
antimetabolites and other agents together with intrathecal chemotherapy for CNS
prophylaxis.   Following this there is maintenance therapy, which lasts for around two
years in most moderate treatment protocols and depends to a great extent on the use
of methotrexate and 6-mercaptopurine.  Over the past twenty years, in the light of the
discovery of variations in the phenotype of the leukaemic cells, the protocol has been
modified to minimise the side effects of toxic drugs in the short and long-term and
improve outcome. This has led to more effective treatments of the T-cell phenotype
associated with childhood ALL using intensified regimens that incorporate
cyclophosphamide, cytarabine, and anthracylines (Oeffinger et al., 2000). However,
there is stratification of treatment the adjusting of treatment dependent on the risk
profile at diagnosis.
Furthermore, there are several types of protocol for treating ALL; for example, CCG
protocols, which have been used in many Saudi cancer centres such as the King
Faisal Specialist Hospital and Research Centre (KFSH&RC) (Al-Nasser et al., 2008).
In addition, Medical Research Council Protocols and MRC-UKALL protocols are used
in the UK for treating children with ALL (Eden et al., 2000). The mentioned protocols
will be discussed in the methodology chapter (summarised in the tables 2.1.1 and
2.2.1).
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1.5.3 Weight status during and after treatment for childhood cancer
There is some controversy regarding the prevalence of obesity during and after
treatment for childhood cancer (Meacham et al., 2005, Robinson et al., 2008, Miyoshi
et al., 2008, Pietila et al., 2009, Courneya et al., 2008, Coups and Ostroff, 2005,
Gurney et al., 2003). This is due to the complexity of evidence since most studies
have been affected by a wide range of different factors; different cancers; different
patient groups; different therapies; changes in therapy over time; population changes
in obesity prevalence; different complications of therapy; different definitions of
obesity used in different studies; the enormous range of diseases which can be
termed ‘cancer’; variety of therapies and outcomes; limited number of patients
involved; use of non-recommended obesity definitions and the lack of comparison
between patients with cancer with population reference data meaning that confidence
about the prevalence of obesity in most childhood cancers is difficult (Reilly, 2009).
Moreover, the majority of the studies in this field have focused on the treatment of
cancer which is mainly separated into two main categories. Older protocols which
used cranial radiotherapy (CRT) widely and are mostly used in ALL and brain
tumours; and treatment on modern protocols based on corticosteroid therapy which
do not use CRT or restrict use of CRT and are mainly used in ALL patients (Brouwer
et al., 2007).
1.5.4 Prevalence of unhealthy weight status in general malignancies
As mentioned above, other malignancies are not of one type and do not have unified
treatments, therefore, it is hard to give an overall estimation of prevalence of
unhealthy weight status in entire group of childhood cancer. Briefly, they are quite
heterogeneous in terms of weight status. For instance, a Canadian study Collins et
al., (2010) studied different cancer types in both child and adolescent patients (n=99)
at diagnosis, median (range) age 7.1 years (2.1 -15.3), in order to explore nutritional
status. It was found that the prevalence of underweight (BMI z <5 th percentile) and
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overweight/obesity (BMI z > 85th percentile) according to CDC reference data were
9.1% and 25.3%; respectively. However, the study had several of limitations such as
small sample size, a heterogeneous sample which included patients with several
types of cancer, and lack of comparison with a control group.
Moreover, weight status in other malignancies may depend on severity of the natural
of the disease.  A cross-sectional study of 20 Malawian patients (eight females, 12
males) aged between one and 8.5 years who had been diagnosed with a Wilms
tumour reported that about half had underweight at diagnosis (BMI ≤ 5 th percentile
based on CDC definition), whereas in a community control group (n= 43) the figure
was 11.0% (Israels et al., 2009). The high prevalence of underweight possibly
according to limited number of patients and the study included metastatic disease
patients (n=8) who are more likely to be undernourished because of the disease
progression.
Schulte et al., (2010) examined weight status by using the BMI according to the CDC
definition in 54 survivors aged 8 - 18 who had been treated for childhood brain
tumours in Canada. The prevalence of those who were underweight at (15%) was
high when compared to the normal population (4%). However, they included many
types of brain tumours such as astrocytoma, medulloblastoma and others that treated
by using different type of treatments. Also, they recruited a relatively small sample
and without a comparison /control group. The lack of a representative sample, lack of
a comparison group, inclusion of different cancer types with different treatments such
as surgery, CRT and chemotherapy and progression of the disease are all likely to
have had an on the prevalence of unhealthy weight status.
From previous studies, discussing in general malignancies in order to increase
confidence of the prevalence of unhealthy weight status is complex and forked and it
is beyond the present scope of this particular thesis.
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1.5.4.1 Prevalence of obesity at diagnosis and during ALL treatment
Several studies dealt with the prevalence of obesity at diagnosis, during, and after
ALL therapy as summarised in table 1.5.1. The literature (as summarised in table
1.5.1) reported a varying prevalence of obesity at diagnosis from 2% to around 17%
and from 6% to around 30% during the therapy. This variation may be explained by
many factors and these are discussed briefly below.
First of all, almost of all reviewed studies were conducted retrospectively, except the
Withycombl et al., (2009) study which was prospectively performed with a relatively
large sample size (n= 1638) and with ALL patients only treated with chemotherapy
and all on the same protocol; however, prevalence and trends of unhealthy weight
status over time was not studied. Moreover, the majority of these studies have had a
relatively small sample size and were not nationally representative, usually conducted
in one or two centres (Reilly et al., 2000, Asner et al., 2008). However, from the
reviewed literature, only three studies  recruited relatively large number of patients
with ALL (Withycombl et al., 2009 , Reilly et al., 1999b , Butturini et al., 2007).
Although, Reilly et al., (1999b) were evaluated the patients treated with the same
protocol (UKALL X- discussed later), they used at that time of the study what would
now be non consensus cut-offs for defining obesity in the UK. Butturini et al., (2007)
included ALL patients who were treated with different treatment protocols (CCG 1881,
CCG 1891, CCG 1882, CCG 1922) which may affect prevalence of obesity.
Moreover, it is noted that most of literature dealt with the types of treatment of ALL
such as chemotherapy and CRT as having similar outcomes in term of prevalence of
unhealthy weight status when they are not (discussed later). However, Baillargeon et
al., (2005) and Asner., (2008) studied patients who had been treated with only
chemotherpy but  both studies had a small sample size.
Nowadays, It is well known that the obesity has becomes epidemic but it is unknown
if cancer patients have been affected by the obesity epidemic to the same extent as
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the rest of the population. Therefore, it is hard to report that the prevalence of obesity
at diagnosis is higher or lower than general population and whether the prevalence
reflects what is happing in the general population rather than ALL specific problems.
Unfortunately, the majority of the studies to date have not compared the prevalence
of obesity in their sample of patients with ALL with prevalence in the general
population. Also, all of the reviewed studies relied on data not collected recently. For
instance, the Withycombl et al., (2009) and Chow et al., (2007) studies included data
up to 2003 whereas the others studied were based on even older data, for instance,
the highly cited Van Dongen-Melman et al., (1995)  study depended on data of ALL
patients diagnosed between 1978 – 1990.
As shown in table 1.5.1, several different BMI reference data and BMI thresholds
were used to define obesity in previous studies which would cause variation in the
prevalence of obesity. Most studies used their national obesity definition but Asner et
al., (2008) applied the international approach (IOTF) in Swiss patients.
Moreover, the evidence table 1.5.1 also shows an apparently clear picture of
increasing obesity from the first year of treatment and at the end of treatment
whereby a high prevalence of obesity reached up to half of the sample as reported by
Odame et al., (1994). For example, Reilly et al., (2000b) pointed out that the
prevalence of obesity (defined as BMI z score > 2.0) at diagnosis of ALL in the UK
was < 2%. However, the prevalence dramatically increased during treatment to 4%
during the 1st year; 9% during the 2nd year until it reached 16% by the 3rd year post-
diagnosis in patients with ALL in first remission in the UK treated on protocol MRC
UKALL XI.
Many factors could contribute to excess weight gain during treatment of ALL patients
first of all the therapy itself (discussed below). Also, from another perspective the
gaining of excess weight during the ALL therapy may be affected by the weight status
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at diagnosis. Baillargeon et al., (2005) studied weight changes (based on the CDC
definition) over the time of the treatment amongst 141 Hispanics aged 2 - 18 years.
The weight status increased from the baseline until the age of 24 months and then
was slightly reduced at 30 months in those patients of normal weight at diagnosis.
Amongst those who were overweight (BMI ≥ 85th) at diagnosis there was no
consistent increase or decrease in weight status over the process of therapy. Love et
al., (2011) observed that 35.6% of ALL survivors (n=102) were classified as being at
normal weight at diagnosis and they became by the end of the treatment classified as
overweight (using the CDC definition); and half of them remained overweight at most
of the subsequent follow ups.
In summary, the variation in the prevalence of obesity in different studies of patients
with ALL is due to a combination of different therapy protocols; different definitions of
obesity, different study design and sample sizes, and different times (as the obesity
epidemic moved fairly quickly in the general population (Reilly and Dorosty (1999)).
Also, the prevalence of obesity may have increased in ALL over time; but the
available literature is complex and does not allow us to define time (secular) trends
with any confidence.
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Table 1.5.1: Prevalence of obesity at diagnosis, during and after ALL therapy
Reference No. of
subjects
Assessment period Definition of obesity At diagnosis
(%)
During therapy
(%)
After therapy
(%)
Reilly et al., (1999b) 1019 Dx BMI= 97th-98th 2 --- ---
Withycombe et al., (2009) 1638 Dx + 3 yr BMI ≥ 95 th 14 23 ---
Baillargeon et al., (2005) 141 Dx + 2.5 yr BMI ≥ 95 th 17 6 ---
Asner et al., (2008) 54 Remission + 12 yr BMI ≥ 97.5 13 14 18
Reilly et al., (2000b) 98 Dx + 3 yr BMI > 2.0 2 9 16
Odame et al., (1994) 40 Dx + 4 yr BMI > 97.7th 5 F: 43; M: 26 F: 57; M: 21
Van Dongen-Melman et al., (1995) 113 Dx + 4 yr BMI> 90th 8 30 24
Chow et al., (2007) 165 Dx + 10.5 yr BMI ≥ 95 th 10.9 21 20
Butturini et al., (2007) 4260 Dx + 3 yr BMI ≥ 95 th 8 --- 14
Razzouk et al., (2007) 248 Dx + 11.9 yr BMI ≥ 95 th 7 --- 21
Breene et al., (2011) 77 Dx + 3 yr BMI z score > 2.3 2 --- 29
Didi et al., (1995) 114 Final height BMI> 85th --- --- 46
Sklar et al., (2000) 126 Final height BMI ≥ 85th --- --- 30
Nysom et al., (1999) 95 Dx + 11yr BMI> 90th --- --- 25
Talvensaari et al., (1996) 50 Dx + 13 yr BW> 120% ideal --- --- 32; Control: 10
van Beek et al., (2006) 90 12.7 yr BMI ≥ 30 kg/m2 --- --- 8
Jarfelt et al., (2005) 35 20 yr BMI 25- 29.9 Kg/m2 --- --- 34
Love et al., (2011) 102 1 yr BMI ≥ 95 th --- --- 21
Meacham et al., (2005) 1665 Adulthood BMI ≥ 30 kg/m2 --- --- M: 16; F: 18
M: male; F: female; yr: year; Dx: diagnosis; BW: Body weight
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1.5.4.2 Prevalence of obesity in ALL survivors
As summarised in evidence table 1.5.1, overweight and obesity since diagnosis is
more likely to progress during and after the treatment course. Therefore, the evidence
is fairly clear that survivors of ALL might be expected to show an elevated likelihood
of obesity in childhood, adolescence and adulthood. For example, a longitudinal study
from the USA, Chow et al., (2007) illustrated that the prevalence of being overweight
(defined as a BMI = 25 - 29 or the 85th - 94th percentile) and obese (defined as BMI
≥30 or 95th percentile) based on the CDC 2000 growth chart at the diagnosis of ALL
were 12.7% and 10.9%, respectively. However, after completion of treatment, the
rates were 17.0% and 21.2% (p value = 0.01); respectively.
However, it is not straightforward interpreting the prevalence of obesity amongst ALL
survivors from the data of all reviewed papers (see table 1.5.1) because of several
reasons. First of all, the majority of studies were cross-sectional and often
retrospective. The studies performed prospectively generally recruited less
homogeneous groups with smaller sample size, i.e. typically included patients who
had been treated with both CRT and chemotherapy (van Beek et al., 2006 , Nysom et
al., 1999 , Love et al., 2011), or they were conducted in long-term survivors (adult
patients ; van Beek et al., 2006).
Moreover, almost all studies again used different treatment protocols and included
patients who had different risk categories such as having high or standard risk. In
addition, almost all studies analysed weight status in patients treated with CRT and
combination chemotherapy. So, this could lead to increased heterogeneity in the
survivors recruited and make it difficult to separate of influence of these major
therapies. Also, the majority of reviewed studies were performed amongst relatively
small and probably non-representative survivors. However, Butturini et al., (2007)
recruited a relatively large sample size (n= 4260) but, patients were treated with
several treatment protocols. Also, Meacham et al., (2005)  assessed adult survivors
(n=1665) rather than child or adolescent survivors.
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In addition, excess weight gain was defined according to different cut-offs and using
reference data in most studies. For instance, Talvensaari et al., (1996)   defined
obesity in  survivors if their body weight  was > 120% ideal. Few if any studies used
even slightly more sophisticated measurements of body composition for defining
excess body fat such as DXA or BIA. Finally, lacking any comparison with control or
normative population data was noted from all the studies of survivors, except the
Talvensaari et al., (1996) study. Also, the prevalence of obesity in the literature is
probably time-dependent since the obesity epidemic progressed rapidly in most
countries as described above. So, the majority of studies to date quite old data, for
example, Didi et al., (1995)   analysed patients who were treated between 1971 –
1987.
To sum up, the evidence has shown widely varied prevalence of obesity in survivors
of ALL. Prevalence is likely to be affected by the therapy protocol, obesity definition
the time of the study and the sample size.  It is obvious from this literature review that
there no study that focused on adolescent survivors from a quite homogenous ALL
group patients (treated with the same treatment protocol), and using a modern and
accepted obesity definition. Finally, almost all previous studies of weight status in
survivors of ALL have been in western countries, and studies from non-western
populations are lacking.
1.5.4.3 Prevalence of underweight at diagnosis and after ALL treatment
The Childhood Cancer Survivors Study (CCSS) Meacham et al., (2005) stated that
male ALL survivors were at increased risk of being underweight (OR= 2.4; 95% CI:
1.6 – 3.6). Furthermore, Razzouk et al., (2007) reported a highest  prevalence of
underweight (23%;  based on the CDC definition using BMI) whereas the prevalence
was 29% amongst children between 0 - 6 years old.
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Nonetheless, there is limited literature available as summarised in table 1.5.2, on the
prevalence of underweight at ALL diagnosis. There are several limitations in the
studies that could influence the prevalence of underweight at diagnosis in ALL
patients. Limited sample size is common in the studies to date. For instance, a
French study with 15 patients  found that 20% (weight-for-height < 85%) of patients
were underweight (Delbecque-Boussard et al., 1997). Only two studies to the best of
my knowledge assessed patients at diagnosis with relatively large sample sizes.
Firstly, Reilly et al., (1999b) analysed 1019 patients in the UK, a fairly homogeneous
ALL group (standard risk ALL only), but they used an old definition of underweight.
Secondly, Hijiya et al., (2006) recruited 621 ALL patients but, they were mixed
between patient who had low, standard and high risk, consequently this was a
heterogeneous group. Therefore, there is a great need for a relatively large and
representative national sample in a fairly homogenous group of ALL patients, and
which defines underweight based on a modern definition.
Table: 1.5.2: Prevalence of underweight at ALL diagnosis
Reference No. of
subjects
Definition of underweight Prevalence at
Diagnosis (%)
Hijiya et al., (2006) 621 BMI ≤ 10th 16.4
Razzouk et al., (2007) 248 BMI < 10th 23
Viana et al., (1994) 128 Height for age z score <-2.0 17.4
Delbecque-Boussard
et al., (1997)
15 Weight for height < 85% 20
Reilly et al., (1999b) 1019 BMI z score <-2.0 7.4
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1.5.5 Effect of nutritional status at diagnosis on prognosis of childhood cancer
The use of unhealthy weight status (defined here as being overweight, obese or
underweight) as a prognostic factor and its effect on treatment outcomes has
dramatically increased; but its usefulness is still limited and the studies which have
focused on this field are limited in number and are also conflicting. This conflict in the
findings may be related to the fact that the majority of the literature has used
retrospective study design, different cancer treatment protocols, a small sample size
or that cancer is not only of one type (heterogeneity of the disease). For instance, a
large cohort retrospective study by Fernandez et al., (2009) looked at the effect of
body weight on survival of children with a Wilms tumour: 1532 patients were enrolled
with a median follow-up of 4.9 years. Authors found that 15% of children were
underweight (< 10th BMI-for-age percentile) (p value < 0.00001) and 13% were
overweight (> 90th BMI-for-age percentile) (p value < 0.001). This study demonstrated
no relationship (p value= 0.28) between body weight and BMI-for-age at diagnosis
and event-free survival (EFS) (defined as the time between diagnosis and death
(Hargrave et al., 2001)).
Conversely, a retrospective study which reviewed 768 patients with AML at diagnosis
aimed to determine the percentage of patients who were overweight (BMI ≥ 95th
percentile) or underweight (BMI ≤ 10th percentile) at diagnosis according to the CDC
definition. Lange et al., (2005) showed that the percentage of overweight patients at
diagnosis was 14.8% (n = 114) and underweight at 10.9% (n = 84). They illustrated
that overweight or underweight AML patients had a reduced chance of survival
(hazard ratio= 1.88; p value = 0.002) and had high chance of treatment-related
mortality (hazard ratio= 3.49; p value < 0.001) compared to healthy weight (BMI= 11-
94 %) patients. Similarly, patients who were classified as being underweight had a
reduced chance of survival (hazard ratio= 1.85, p value = 0.006) and had a greater
chance of experiencing treatment-related mortality (hazard ratio= 2.66, p value =
0.003). In a South African study, Wessels et al., (1999) carried out on 59 patients with
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a Wilms tumour, 35% of the patients were poorly nourished at diagnosis.  However,
there was no relationship between being poorly nourished at diagnosis and the
prognosis and survival rate in children with Wilms tumours in this study. However the
sample size may have been too small to be adequately powered in this case.
1.5.5.1 Role of nutritional status at diagnosis on prognosis in ALL patients
Clarifying the role of weight status (being overweight, obese and underweight) for ALL
survival is one of the biggest questions in this field (as summarised in tables 1.5.3
and 1.5.4). To the best of our knowledge, only four studies have investigated the role
of obesity at diagnosis on the outcome for ALL and they are in both developed and
developing countries.
1.5.5.1.1 Effects of overnutrition
In developed countries- obesity and relapse risk in ALL patients
A study by Butturini et al., (2007) recruited 343 obese and 3971 non-obese ALL
patients. The hazard ratio for events and relapse was 1.36 and 1.29 (p value = 0.40);
respectively for obesity. They also found that obesity had a high impact on patients
who were aged ≥ 10 years old at diagnosis; hazard ratio for events and relapse was
1.5 (p value= 0.01) and 1.5 (p value = 0.01); respectively. Although the obesity
prevalence (based on the CDC definition defined as BMI ≥ 95th) was only 8.7%, they
concluded that obesity played an intrinsic role in terms of predicting relapses and for
paediatric ALL patients.
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Table 1.5.3: Role of obesity at diagnosis on prognosis in ALL
Reference Type of study
No. of subjects
Place
Age
Ethnicity
Definition of obesity Results Findings
Gelelete et
al., (2011)
 Retrospective
 181
 Brazil
 ≤ 10yr (n= 111),
>10 yr (n= 5)
 White (n= 62),
non-white (n= 54)
 Obesity : BMI z score ≥ 2.0 ,
overweight: BMI z score ≥
1.0 (based on WHO criteria)
 35.9% were overweight or obese at Dx
 In intermediate and high risk, 5 Event
free survival was sig. decreased (p=
0.02).
 Overweight and obesity
are prognostic factors
Butturini et
al., (2007)
 Retrospective
 4260 (1733 were
verified after 10
yr)
 USA
 1-10 yr
 White, African
American,
Hispanic and other
 Obesity:  BMI ≥ 95th
percentile. At risk of obesity:
85th – 95th percentile (based
on CDC definition)
 8.7% of pt were obese at Dx Sig risk
rate of relapse obese Pt than non-obese
were 72% ± 2.4%, 77% ± 0.6%;
respectively
 Sig obese HRs for events were 1.36
(95% CI: 1.04 – 1.7; p= 0.021) and
relapses were 1.29 (95% CI: 1.02- 1.56;
p = 0.04).
 9.5 % of Pt ≥ 10 yr were obese

 Obesity at Dx is
predictive of a worse
prognosis
 Obesity among ALL
children pt at Dx
independently performs
as prognostic and cure
factors in > 10 yr
Hijiya et al.,
(2006)
 Retrospective
 621
 USA
 1 – 16.9 yr
 White, black and
other
 Overweight defined as BMI ≥
85th and < 95th percentile
(based on CDC definition)
 Underweight defined as BMI
≤ 10th percentile
 Overall survival was not Sig in weight
status groups (p= 0.53)
 Complete remission and incidence of
relapse were not Sig (p value= 0.63)
and (p value= 0.86); respectively
 BMI at Dx does not
affect on the outcome
Baillargeon
et al.,
(2006)
 Retrospective
 322
 USA
 2-9 yr (n= 241),
10-18 Yr (n= 81)
 Hispanic white,
Non-Hispanic
white
 Obesity: BMI ≥ 95th
percentile. Overweight: BMI
> 85th – 95th centile. (based
on CDC definition)
 Obese prevalence was 15.2 % while
overweight prevalence was 10.9 %
 In all 2 age groups, obesity at Dx was
not Sig correlated to reduce overall or
event-free survival, HRs were 1.40 (95%
CI: 0.69- 2.87) and 1.08 (95% CI: 0.65-
1.82), respectively
 Obesity at diagnosis
does not play as
prognostic factor at age
2-9 Yr
 Obesity prognostic factor
was absence at age 10 –
18 yr
Yr: year; CDC: US Centres for Disease Control and Prevention Program for Children; Pt: Patient; Sig: Significant; HRs: Hazard Ratio; CI: Confidence Interval;
Dx: Diagnosis; Wt: Weight; ♂: Male; ♀: Female; Ht: Height; p: p value
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Nevertheless, Baillargeon et al., (2006) found that obesity (defined as a BMI ≥ 95 th
based on CDC definition) had no role in ALL prognosis.  They examined 322
predominantly Hispanic subjects (aged 2 - 18 years) who had been treated from 1990
- 2002. In their study, the percentage of those who were either overweight or obese
(defined as BMI >85th and BMI > 95th percentiles; respectively) was 26.1%. Hazard
ratio for overall survival of obesity was 1.4 but it was not significant (95% CI: 0.69 -
2.87). However, the sample size in this study was relatively small.  This findings also
supported by Hijiya et al., (2006). They examined 621 children who treated for ALL in
USA to discover the influence of BMI on the outcome. The estimate of overall survival
was not significant (p value= 0.53). They did not find any effect of high or low BMI on
the outcome.
The cause of these inconsistent findings may be in part due to differences in sample
size.  The sample size was relatively small in Hijiya et al., (2006) and Baillargeon et
al., (2006) . However, Butturini et al., (2007) had a relatively large sample size (n=
4260). Furthermore, there are other important confounders such as type of treatment
protocol and severity of the disease (low risk, high risk or standard risk). The previous
studies were not consistent in terms of ALL classifications (low risk, high risk or
standard risk), and treatment protocols (Butturini et al., 2007). For example, Butturini
et al., (2007) included ALL patients who had been treated by different protocols (CCG
1881, CCG 1891, CCG 1922) and so, CRT and chemotherapy were used, whereas
Baillargeon et al., (2006)  included only patients treated with chemotherapy.
In developing countries- obesity and relapse risk in ALL patients
Gelelete et al., (2011) recently studied the effect on survival of being overweight and
obese (combined) in children with a diagnosis of ALL. They examined in a
retrospective study 181 children which were treated according to BFM protocols in
Brazilian hospitals. The median (range) follow up period was 4.8 years (3.2 - 6.3).
They found that 35.8% of the sample were classified either as being overweight (BMI
z score > 1.0) or obese (BMI z score > 2.0) using the WHO BMI reference data. In
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addition, 5 years event-free survival was significantly (p value= 0.02) reduced in both
intermediate and high risk group patients deemed overweight and/or obese compared
to the non-overweight or obese (58.8%, 76.7%; respectively). However, in the
standard risk group, the 5- year event-free survival was not shown significantly to be
different between overweight or/and obese and non-overweight or obese (92.8%,
90.0%; respectively).
Nonetheless, in the study by Gelelete et al., (2011), the missing relationship between
obesity at diagnosis and outcome may have been due to a lack of power as it was a
relatively small sample. Generally speaking, in the studies pertaining to the
developing countries regarding being underweight at diagnosis, it is likely that being
underweight reflects other nutritional deficiencies and difficult socio-economic
circumstances and a lack of access to chemotherapy which is less likely to be  the
case in developed countries.
1.5.5.1.2 Effects of undernutrition on survival in ALL
From the literature search, it would appear that a very limited number of studies have
looked for a role regarding those who are underweight on prognosis of the disease as
well in both developing and developed countries.
In Developing countries- undernutrition and relapse risk In ALL
A Mexican case-control study which involved 17 cases and 76  controls who had at
least survived the induction and consolidation phases of ALL (Meji´a-Aranguré et al.,
1999). They defined malnutrition when the subject had ≤ 80% of their weight
expected for height. They found that amongst those who were undernourished at
diagnosis, the risk of dying during the initial phase of therapy was 2.6 times greater
than for those who had a normal nutritional status at diagnosis. They emphasised that
being malnourished was a good predictor of mortality during the induction phase in
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ALL patients. Similar findings were found by Viana et al., (1994) in Brazil who
identified that the relapse risk was 8.2 times higher in 128 ALL patients than amongst
the underweight (Undernourished detected as Ht-for-age z score < -2.0). They stated
that undernutrition at diagnosis of ALL was a strong prognostic factor. Contrary to
this, Pedrosa et al., (2000) studied 283 ALL patients with a median age at diagnosis
of 4.9 years in Brazil and San Salvador.  They defined malnutrition as weight-for-
height, weight-for-age and height-for-age expressed as a z score < - 2.0. They
reported that there was no association between nutritional status and the survival rate
even when they added 160 solid tumour patients.
It is obvious that there is a conflict in the literature about the role of underweight at
diagnosis on the prognosis of ALL. It may be because of the sample size in studies
was relatively small. The definition of malnutrition that was used for example in
Pedrosa et al., (2000) study was inconsistent with what had been used by other
studies. Also, studies were based on different type of ALL patients and different
therapy protocols which are considered as independent factors in the prognosis of the
disease. Also, in the developing world, undernutrition and outcome may be
confounded by factors related to socio-economic status such as ability to access
treatment- those who are undernourished may be much poorer than those who are
adequately nourished and so might not be able to afford treatment.
Developed countries- undernutrition and relapse risk In ALL
Few studies focused on the effect of underweight at diagnosis on prognosis of ALL.
Hijiya et al., (2006) recruited 621 participants in the USA with ALL. They defined
being underweight if the BMI ≤ 10 th percentile and being overweight when the BMI ≥
85th and < 95th percentile according to the CDC definition. They found that weight
status did not have an impact on overall survival (p value = 0.533). They stated that
the BMI at diagnosis did not affect the risk of relapse or complete remission.
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However, they included patients with different types of ALL and who had been treated
with different   therapy protocols.
In addition, an earlier Glasgow study carried out in one centre and in patients treated
according to the same treatment protocol (UKALL X), Reilly et al., (1994) tested
relatively small sample  (n=78) of ALL  patients at diagnosis and the impact of weight
for height was expressed as a z score status. Being underweight was classified as
having a weight for height z score < -0.5.   They reported a significant influence of low
weight for height in the outcome. However, by using a much larger sample size from
a multicentre UK trial, Weir et al., (1998) examined an entire treatment cohort
retrospectively in the UK (n= 1025). They defined being underweight as a BMI z score
<- 2.0 according to UK reference data. They reported that there was no significant
relationship between weight status and relapse (p value= 0.553).
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Table 1.5.4: Role of underweight at diagnosis on prognosis in ALL patients
Reference Type of study
No. of subjects
Age
Ethnicity
Place
Definition of obesity Results Findings
Weir et al.,
(1998)
 Retrospective
 1025
 0.2 – 14.9 yr
 European, Non-
European
 UK
 BMI z score >0.5 for
overweight and < -0.5 for
underweight
 No Sig relationship between BMI z
score and relapse (p = 0.55).
 After adjusted to WBC, age, sex and
intensification, no Sig correlation
between BMI z score and relapse
risk (P = 0.72)
 In developed countries,
nutritional status at Dx more
likely do not affect expectation
relapse risk
Meji´a-
Aranguré et
al., (1999)
 Case-control 17
cases (9 ♂, 8 ♀)
76 control (44 ♂,
32 ♀)
 Median age of
cases and controls
were 7.3 Yr and
5.1 yr;
respectively.
 Mexican
 Sever malnutrition, 1st degree
malnutrition, normal and
obese classified < 80%, 81% -
90 and  > 91% of  Wt for Ht;
respectively
 Undernourished Pt had dying chance
high, but not Sig (OR = 2.6, 95% CI:
0.55 – 11.89).
 Sig association between sever
under-nourished and risk of death
( p= 0.04)
 Undernutrition plays a role in
term of occurring of relapses
or death
 Malnutrition may be
considered as early predictor
for mortality during induction-
to-remission phase of
treatment
Viana et al.,
(1994)
 Prospective
 128 (68 ♂, 60 ♀)
 0.9- 14 yr
 Brazilian
 Undernourished detected as
Ht-for-age z score < -2
 All undernourished Pt did not
complete continuous remission
(P>0.0001)
 7 of 10 Pt who classified
undernourished, had relapsed
 Relapses risk for z score < -2 was
8.2 times (95% CI: 30.1 - 21.9)
 After adjusting risk factor,
percentage of prevalence of
malnutrition in developing
countries was high
 Malnutrition affects on the
outcome and the prognosis of
ALL during treatment and
remission in children
Pedrosa et al.,
(2000)
 Retrospective
 283
 Median age: 4.9 yr
 El Salvador and
North Brazil
 Undernutrition: W-for-HT, Wt-
for- age and Ht-for-age z
score < - 2.0
 No sig found between malnutrition
and the survival outcome (p= 0.89)
 Underweight is not affected on
prognosis of the outcome in
developing countries
Reilly et al.,
(1994)
 Retrospective
 78 (47♂, 31 ♀)
 1 – 13 yr
 UK
 Underweight and overweight
were classified as Weight-for-
height z score < -0.5 and
>0.5; respectively
 Weight status was sig affected the
risk of early relapse (p= 0.01)
 Underweight as is prognostic
factor
ALL: Acute lymphoblastic leukaemia; yr: year; CDC: US Centres for Disease Control and Prevention Program for Children; Pt: Patient; Sig: Significant; CI: Confidence Interval;
OR: Odd ratio; Dx: Diagnosis; Wt: Weight; ♂: Male; ♀: Female; Ht: Height; IBW: Ideal body weight; TSFT: Triceps skin fold thickness; MUAC: Mid upper arm circumference
84
1.5.5.1.3 Conclusion
These studies which studied the role of nutritional status at diagnosis on prognosis in
ALL patients have many limitations such as having inherent retrospective study
disadvantages. The sample size has often been small, and in particular, obese and
underweight percentages have been relatively low in the sample. Some of the studies
have also relied on the BMI, which is not an ideal indicator for obesity or being
underweight (Warner et al., 1997); and the follow-up BMI usually has not been taken
just BMI around the time of diagnosis. Moreover, there are other confounding factors
rather than simply the nutritional status which could lead to worse side effects.
Examples are chemotherapy dose complications, type of medicine, WBC, severity of
the disease, infections and nervous system status and socio-economic status.
Consequently, there is limited evidence on links between nutritional status and
survival in ALL and much of it seems contradictory. This suggests the need for more
survival analyses and more evidence in general to establish if there is any affect or
association. For obesity and survival this may be especially important if the
prevalence of obesity had increased in ALL patients over time, and if it continues to
increase during and after therapy (Reilly, 2009).
1.5.6 Possible underlying mechanisms of development of obesity during and
post treatment of ALL
The aetiology of obesity in ALL patients is complicated and could be produced by
multiple-factors.  The present thesis will briefly discuss the possible causes because
a complete discussion is beyond the scope of this thesis.
1.5.6.1 Hypothalamic damage
CRT and to a lesser extent other forms of CNS prophylaxis such as chemotherapy
has the potential side effect of hypothalamic damage. Therefore, obesity might be
promoted according to many possible mechanisms: reduced resting energy
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expenditure or energy spent in physical activity; insufficient growth hormone
production, which in turn, changes fat deposition and substrate oxidation;
hypothalamic damage may lead to impairment of food intake. Also, the low dose of
irradiation could damage the more radiosensitive pathway of CNS, in which
hypothalamus is included, involving the regulation of satiety or thermogenesis
regulation (Wallace and Green, 2004).
Consistent evidence has shown a strong relationship between CRT and growth
hormone deficiency(Gurney et al., 2006, Link et al., 2006, Brennan et al., 1999b). Old
protocols that use CRT for treating patients with ALL are strongly related to obesity
risk (Groot-Loonen et al., 1996, Odame et al., 1994). Other effects of hypothalamic
damage also result for example in alteration to appetite regulation. Bulow et al.,
(2004) demonstrated that ALL patients with growth hormone deficiency had a high
body fat mass, but when they were treated with growth hormone replacement for 12
months, body composition was normal. Moreover, Link et al., (2004) illustrated that
91% of ALL patients had growth hormone deficiency that was induced by CRT and
that obesity prevalence was high in the sample when compared to the control. Even
though growth hormone deficiency may occur in both chemotherapy and CRT (Haddy
et al., 2006).
However, Brennan et al., (1999b) suggested that growth hormone deficiency was not
the main cause of weight gain in ALL patients. Consequently, high body weight was
observed whether chemotherapy was used alone or mixed with CRT (Birkebaek and
Clausen, 1998, Reilly, 2009). Additionally, Davies et al., (2004) have pointed out that
the role of leptin and Insulin-Like Growth Factor-I (IGF-I) which may be affected by
CRT. Leptin is formed in adipose tissue and plays an intrinsic role in the regulation of
appetite and energy expenditure.  Some researchers believe there is a relationship
between leptin and obesity risk (Blum et al., 1997). Davies et al., (2004) and
Janiszewski et al., (2007) reported that leptin was significantly higher in irradiated ALL
patients p value < 0.05 and p value = 0.03 and p value <0.05; respectively, compared
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to the control. However, Insulin-Like Growth Factor-I (IGF-I), which is a proxy marker
for growth hormone insufficiency, was low in ALL patients treated with CRT.
Furthermore, they suggested that there was a relationship between reduced Insulin-
Like Growth Factor-I (IGF-I) and adiposity
In summary, all treatment protocols using CRT as part of treatment probably lead to
an increased risk of obesity; however this is not the only cause since obesity during
and after treatment remains high even among patients with ALL who have not
received CRT (Reilly et al., 2000b, Mayer et al., 2000, Birkebaek and Clausen, 1998,
Reilly et al., 1996). Steroid agents could cause weight gain in ALL patients. The
possible underlying mechanisms are increased energy intake (by increasing
appetite), reduced energy expenditure (by lower physical activity) and substrate
oxidation and fat deposition (Reilly et al., 2001a, Wallace and Green, 2004).
1.5.6.2 Physical activity
The loss of physical activity may firstly occur during hospitalisation of the patient. It
may be due to a several factors such as diminished exercise capacity, impaired motor
function, diminished interest in recreational physical activity and over-protectiveness
of patient’s parents (Jenney et al., 1995). Moreover, pathophysiological changes in
the cardio- respiratory system and growth hormone deficiency may influence to
minimise the physical activity in cancer patients (Reilly et al., 1998).
Physical activity in ALL patients has been measured during and after the end of
treatment. A limited number of studies have focused on the evaluation of physical
activity whilst the patients were being treated. A pilot study by Aznar et al., (2006)
assessed physical activity during the treatment of 7 children with ALL aged 4 - 7
years. These children were compared with a control group of 7 children. Aznar et al.,
(2006) used an MTI actigraph accelerometer to measure the level of physical activity
for a one week period and showed a significantly lower moderate-to-vigorous physical
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activity amongst those with ALL during weekdays (p value = 0.048) when compared
to the control group.
Tillmann et al., (2002) investigated physical activity in 28 surviving UK ALL patients
(treated by UKALL XI protocol) by using an uniaxial accelerometer and questionnaire
for 3 days at an average 5 years post-treatment survival, the physical activity
measured was significantly less in the survivors than in the healthy controls.
Similarly, Jansen et al., (2009) carried out a study in the Netherlands on 16 patients
with ALL and 17 healthy siblings. Patients were evaluated during and between
dexamethasone courses. Physical activity (measured by pedometer) and energy
intake were measured by parental reporting records and a pedometer for counting
steps. They found that patients gained weight between the time of diagnosis and the
end of the study (mean change of the BMI z score was 1.4±1.1). Therefore, they
stated that this weight excess gain may have occurred due to the consumption of high
energy intake and inactivity during the dexamethasone treatment. Physical activity
assessed by pedometer was lower in patients compared with the controls.
Reilly et al., (1998) attributed excess weight gain amongst 20 ALL patients to reduced
total daily energy expenditure, (total daily energy expenditure = Basal Metabolic Rate
+ energy expended on physical activity + diet-induced thermogenesis), with mean
paired differences of  282 kcal/day relatively to  controls (n = 20) which was caused
by lower physical activity thermogenesis.   Moreover, they found that energy
expended on physical activity was lower and this was highly related to weight gain.
Furthermore, Warner et al., (1998)  assessed in the UK the total daily energy
expenditure in 34 survivors with childhood ALL compared to 21 survivors of other
malignancies and 32 healthy siblings by using heart rate technique. The median age
(range) was 10.4 years (7.2 – 18.4).  They found that the total daily energy
expenditure amongst ALL survivors was significantly (p value< 0.01) reduced in ALL
survivors than other malignancies survivors and the controls.
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Therefore, the physical activity during and after ALL treatment changes happen not
clear, it may be that children are overprotected by parents/guards for instance they
encourage their patients to stay inside or even sometimes not become involved in
play or games.
1.5.6.3 Energy intake
Few studies of energy intake of children with ALL have been published (Bond et al.,
1992, Delbecque-Boussard et al., 1997, Reilly et al., 1998, Reilly et al., 2001a). As
overeating probably leads to an energy imbalance, it might be important for weight
gain. Also, it should take in account that these patients are usually exposed to
treatments such as chemotherapy, radiation and some drugs that are likely to reduce
appetite; the energy intake may be affected by being reduced or increased.
However, it has been well-established that an increase of energy intake is related to
ALL treatment. Reilly et al., (2001a) tested 68 ALL patients and excessive energy
intake to marked positive energy balance was observed in patients who had been
treated by prednisolone or dexamethasone. In addition, Jansen et al., (2009)
demonstrated that increases in the energy intake of 16 patients with ALL and 17
healthy siblings were found with dexamethasone (p value < 0.05).  Therefore, the
evidence from patients indicates that the most of ALL patients regardless CRT
undergo a considerable positive energy balance during the ALL treatment and the
most of them continue the gain weight during and even post therapy (Gregory et al.,
2004).
1.5.6.4 Adiposity rebound
Adiposity rebound is one of the possible causes of adult obesity in ALL. Adiposity
rebound occurs when the BMI reaches to nadir at around 4 - 5 years old and starts to
increase at around 5 - 7 years old. However, the mechanisms of Adiposity rebound
that lead to obesity in adulthood are still unknown (Reilly et al., 2001b).
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To the best of our knowledge, only one study has investigated the timing of Adiposity
rebound in ALL. The study by Reilly et al., (2001b) included 68 Scottish paediatric
patients (35 boys, 33 girls) with ALL; and Adiposity rebound was measured by visual
inspection of BMI charts for the children. They found that Adiposity rebound occurred
earlier in ALL children (p value < 0.001) than in a comparison group of children taking
part in the Avon Longitudinal Pregnancy and Childhood birth cohort study. By the age
of 3- 4 years old, adiposity rebound had occurred in 43% of the comparison group
and in 81% of the patients. In addition, they argued that the positive energy balance
typical of ALL treatment, as mentioned, can produce early Adiposity rebound.
Patients of ALL with early adiposity rebound or patients treated before assumed
adiposity rebound showed increase in BMI post therapy compared to with those with
late adiposity rebound (above age 5 – 6 years old) or with patients who diagnosed
over 6 years old. Therefore, an early adiposity rebound (before age 4 years) may be
one of aetiology of high prevalence of excess weight status in ALL patients (Oeffinger
et al., 2003). However, the underlying cause of an early adiposity rebound is still
unknown.
1.5.7 Late effects of childhood cancer
1.5.7.1 Metabolic syndrome
Taskinen et al., (2000) showed that impaired glucose tolerance, dyslipidemia and MS
components appeared following childhood cancer treatments. Therefore, MS could
present in short and long-term survivors of childhood cancer.
In a cross-sectional study, 52 survivors were assessed to define the prevalence of
MS and its components amongst adolescent brain tumour survivors. The mean age
(range) was 14.2 years (3.8 - 28.7). The median age at diagnosis (range) was 6.0
years (0.1 - 15.5). The mean time since being off therapy (range) was 6.2 years (1.2 -
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14.8). MS was defined by applying the IDF definition (explained in method chapter).
They reported that MS was present in 8% of this population.
1.5.7.2 Metabolic syndrome in ALL survivors
MS exists in survivors of childhood ALL and its prevalence might be higher than
expected. For instance, a Swedish study  was carried out on 44 ALL survivors with a
median age of 17 years (Link et al., 2004). They were treated with CRT; according to
Swedish child leukaemia group protocol, and were found to have a significantly high
insulin concentration (p value = 0.01), serum glucose (p value = 0.01) and LDL-L, TG,
fibrogen, apolipoprotein, and leptin (all p value ≤ 0.05) and low HDL-C (p value=
0.03). In addition, 91% of the subjects had growth hormone deficiency. Therefore,
they argued that, ALL patients treated with CRT and chemotherapy had a significant
risk for cardiovascular problems including MS. However, (Link et al., 2004)  recruited
a relatively small sample of heterogeneous ALL survivors  (i.e. mixed low, standard
and high risk groups) and the survivors were treated by different treatments
(chemotherapy or/and CRT).
Furthermore, Oeffinger et al., (2001) studied young adult survivors of ALL (median
age was 20.9) to examine MS risk factors. The survivors who were treated by CRT
were 38% and other 62% were only treated by chemotherapy. MS risk factors were
defined by Oeffinger et al (2001) as following: BMI ≥ 30; diastolic blood pressure
(DPB) and systolic blood pressure (SBP) ≥ 85 and 130 mm Hg; respectively, total
cholesterol ≥ 200 mg/dl; HDL-C < 35 mg/dl; LDL-C ≥ 130 mg/dl; TG ≥ 200 mg/dl;
cholesterol to HDL ratio ≥ 5 mg/dl; insulin ≥ 14 μU/ml; and glucose ≥ 110 mg/dl. They
reported that 61% of survivors had one MS risk factor whereas 30% had two or more
risk factors. However, Oeffinger et al., (2001) were examined MS in long term
survivors (in adulthood) and survivors had different ALL classifications at diagnosis
and so, they were treated with very different therapy protocols.
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To the best of our knowledge, in non-western countries, Reisi et al., (2009) has been
the only study which has examined the prevalence of MS amongst survivors with ALL
in childhood in the medium term. They assessed 55 survivors aged 6 - 19 years. MS
was defined as NCEP III criteria modified by de Ferranti et al., (2004). They reported
that 20% of the subjects met the criteria of MS; whereas 50.9% had one risk factor.
However, this study was carried out on survivors who were treated by the ALL-BFM
protocol (including CRT).
Conversely, Gurney et al., (2006) did not find a difference between the prevalence of
MS in 75 ALL adult survivors (the mean age was 30.2 years at interview) (16.6%, p
value = 0.87) and the 132 control (mean age was 30.9 years) (prevalence of MS was
17.5%) by using the NCEP III definition. Gurney et al., (2006) studied long term
survivors but with a relatively small sample size and using an adult MS definition.
Thus evidence from surviving standard risk ALL patients in the short or medium term
is therefore very limited at present and further studies are needed. Studies in non-
western countries are also required to investigate the prevalence of MS in other
populations of patients with ALL.
1.5.7.3 Bone mass concerns in children and adolescents with cancer
The anatomy of normal bone is comprised from two main elements: trabecularor
cancellous and cortical or compact bone. Normal BMD usually happens when
balance occurs in between bone formation and resorption. Therefore, if there was a
lowering  in the bone formation level or elevation in bone resorption this would lead to
occurrence of low BMD (Wallace and Green, 2004).
The T-score results from the DXA instrument refers to the observed BMD in adults
when compared to healthy young adults. Therefore, in adults, definitions of
osteoporosis or osteopenia (low bone mass) are well-established by the WHO in
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order to predict the fracture risk. The thresholds of osteoporosis and osteopenia for
adults are as follows: T-score ≤ -2.5 and T-score ≤ -1 (Fewtrell, 2003).
Generally, it is widely accepted that reaching a low peak bone mass in early life is
more likely to be osteoporotic in later life (Hansen et al., 1991). Moreover, some
osteoporosis research has reported that the peak of mass is generally reached in the
early 20s; and possibly in girls earlier than boys (Matkovic et al., 1994, Gordon et al.,
1991). However, the big challenge is for children when there is no guideline for testing
BMD as adults(Gordon et al., 2008, Wallace and Green, 2004).
1.5.7.4 Bone mineral density in children with malignancies
Some studies (Al-Tonbary et al., 2011, Muszynska-Roslan et al., 2009) have shown
low BMD and low bone turnover at diagnosis, during the treatment and off-therapy
amongst children with cancer. Al-Tonbary et al., (2011) scanned the total body by
DXA for 27 children (of whom 59% were boys) at the diagnosis of neuroblastoma.
The mean (SD) age was 6.1 years (4.8). They reported that 11.1% of the sample had
low bone mass in the lumbar spine and a total body BMD (z score < -2.0). In addition
Muszynska-Roslan et al., (2009) ascertained whether the therapy of solid tumours
related to low bone mass than leukaemia and Hodgkin’s disease. They recruited 114
patients (34, 35 and 36 had been treated for ALL, Hodgkin’s disease and solid
tumours; respectively). The median (range) age was 8.4 years (7.3 - 27.2). They
scanned the total body twice using DXA during and after therapy. The age and sex-
adjusted bone z score was calculated (low BMD defined as z score < -2.0). They
reported that in the first examination, 30.5% of patients with solid tumours had low
BMD; whereas ALL and Hodgkin’s disease patients had 10.5% and 6.9%;
respectively. In the second examination, the patients who had low BMD were 16.6%,
8.7% and 6.9%; respectively. They concluded that there was a relationship between
the radiation used in treatment and low BMD.
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1.5.7.5 Bone mineral density in children with ALL
ALL patients are at risk of diminished BMD (Wallace and Green, 2004). Numerous
studies have examined the low BMD and ALL patients from therapy and beyond (for
more details see the bone chapter 6). At the diagnosis of ALL, many pathological
alterations are manifested in bone mineral metabolism (Halton et al., 1996). In a
Polish study, Swiatkiewicz et al., (2003)  evaluated a small sample (n= 27) of ALL
patients (of whom 48% were girls) with intermediate risk according to the Non-B- cell
precursor ALL Berlin- Frankfurt- Munster (BFM)-90 protocol. From 1990 – 1995, 2300
patients were enrolled to participate in BFM-90 trial from 96 centres in Austria, and
Switzerland.  Non-B BMF-90 protocol Included both chemotherapy involved
prednisone, vincristine, daunorubicin, asparaginase, cyclophosphamide, cytosine
arabinoside, mercaptopurine, thioguanine, high dose methotrexate, doxorubicin, and
dexamethasone and included CRT (12 Gy) as CNS prophylaxis.The patients in the
study by Swiatkiewicz et al., (2003) were scanned by DXA (age and sex adjusted to
the local reference data) twice at   diagnosis and during the treatment (between CRT
and maintenance phase). The median (range) age was 10.5 years (5 - 18). They
reported that 30% and 22.2 % of the sample had low (z score < 1.645) BMD and
bone mineral content (BMC). CRT and growth hormone deficiency is an issue which
the thesis deals with below. However, this study had a small and heterogeneous
sample exposed to both CRT or/and chemotherapy and the authors did not adjust
DXA output to bone area.
Moreover, there is some evidence that ALL patients are at risk of bone morbidity such
as osteoporosis, osteopenia, osteonecrosis and fractures (Rayar et al., 2012, van der
Sluis et al., 2002b). For instance, in a recent study, Rayar et al., (2012) studied 124
patients (aged 18 years old and less) with ALL who had been treated only by
chemotherapy and they used DXA for diagnosis BMD status. They defined
osteopenia as a lumbar spine BMD z score of – 1.01 – 1.99 and defined osteoporosis
as a lumbar spine BMD z score ≤ -2.0. They reported that at diagnosis 30% patients
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had osteopenia and 11% had osteoporosis. During the therapy, 39.5% had
osteopenia and 8% had osteoporosis.  Also, 18.5% of patients developed the risk of
fractures during the continuation of the therapy. However, the DXA outputs were not
adjusted to bone area which is recommended by ISCD 2007 (Baim et al., 2008) but,
the authors reported only the DXA output.
In a longitudinal study, van der Sluis et al., (2002b) examined 61 patients with ALL
(median age was 7.1 years) at diagnosis, during treatment and one year after off-
therapy. They used Apparent bone mineral density of lumbar spine (BMADLS) (it will
be described in chapter 2) for adjustment BMD. They found that risk of fractures
increases markedly during the therapy and shortly after off-therapy as well. However,
even though the survivors were not treated with CRT but they treated to different type
of treatment according to classification of high or standard risk condition at diagnosis.
1.5.7.6 The possible underlying causes of low bone mineralisation in childhood
cancer
The nature of cancer is not a single disease although the disease itself may play a
role in alteration of the bone metabolism and bone mass. Halton et al., (1995)
measured endocrine, vitamin D status and other biochemical indicators of minerals
amongst 40 children (67% of whom were boys) with ALL. The median (range) age
was 3.9 years (0.3 - 17). They scanned the patients using dual-photo absorptiometry.
They suggested that the process of the disease was the causative factor for changing
vitamin D and defects in the mineralisation. Conversely, Arikoski et al., (1999)
showed that apparent volumetric BMD (measured by DXA) in ALL and other cancer
patients at diagnosis was not affected when compared to controls. However, the
conclusion from both studies was influenced by the method of measuring BMD. The
latter study adjusted the BMD according to age and sex while the first had not.
Adjusted BMD in children will be discussed in greater detail in the general
methodology chapter (chapter 2).
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1.5.7.6.1 Chemotherapy agents
Chemotherapy and steroids in particular may influence bone metabolism during and
after therapy. Arikoski et al., (1999) found that chemotherapy significantly increased
bone turnover and reduced the development of BMD.  Furthermore, steroids during
the therapy may play a role in the short and long-term amongst cancer patients
(Halton et al., 1996). It could impair bone formation and relate to the lowering of
osteocalcin levels (osteoblastic function marker) (Wallace and Green, 2004).
Elmantaser et al., (2010) studied 186 ALL patients retrospectively who were
measured using DXA with age and sex adjustment. They found patients who were
treated by dexamethasone had a significantly (p value = 0.03) higher incidence of
skeletal morbidity than those treated by prednisone. In contrast, van Beek et al.,
(2006) found that after using BMADLS to adjust bone size, there was no difference in
using dexamethasone or prednisone protocols amongst ALL survivors aged 8.6 - 38.5
years. However, they found that the total body BMD was reduced in patients who had
been treated by CRT.
Chemotherapy has in almost all protocols for ALL involved methotrexate in the
treatment of cancer. This is known to increase urinary calcium excretion (Wallace and
Green, 2004). Meister et al., (1994) used different doses of methotrexate amongst
infants with tumours without the use of steroids. They demonstrated that the patients
who had osteopathy were those who had received high doses of methotrexate (20 –
135 g/m2).
1.5.7.6.2 Growth hormone deficiency
The endocrine system is one of most sensitive systems in the body and may be
disrupted by cancer treatments. Most of the ALL studies published until recently have
used old protocols which have used CRT. In more modern treated protocols CRT has
been replaced with chemotherapy for most patients .There are many long-term
survivors who have been treated by “old protocols”; some with a lower height
96
96
compared to age and sex groups. Moreover, CRT is still being used widely in some
types of cancers such as brain tumours and in patients with ALL considered to be at
high risk.
Some studies have shown that bone mass is due to growth hormone deficiency in
survivors of childhood ALL (Follin et al., 2011). For instance in a recent study, Follin
et al., (2011) examined 44 (21 female) survivors treated for childhood ALL by using
CRT and chemotherapy. The median age (range) was 25 years (22 - 32) and each
patient was matched with a healthy control. BMADLS was used by DXA for correction
of the bone size. The survivors were followed over the period of 5 - 8 years. Some of
them (n= 16) were given growth hormone therapy (0.5mg/day). They reported a
significantly low z score at the fermoral neck which was noticed amongst patients with
growth hormone deficiency.  However, the study did not clarify the benefits of growth
hormone therapy in BMD.
It is worth stating that growth hormone deficiency may not be such an issue for some
of the studying in this thesis as CRT not used widely in patients in chapters 3 and 6
but may be more relevant to study in chapters 4 and 5.
1.6 Scope of this thesis
To summaries this literature, previous studies had several limitations and differences
which led to large variations in prevalence of unhealthy weight at diagnosis. In the
absence of studies that included a representative sample of ALL children who had
been treated with same protocol, and using the most recent definitions of unhealthy
weight status, prevalence of unhealthy weight status at diagnosis of ALL is unclear.
Additionally, there is no study up to now which focused on the secular trends of
unhealthy weight status over time at diagnosis amongst ALL children. Clinically in the
UK there is no formal anthropometric or other nutritional screening for assessing
unhealthy weight status in ALL. Therefore, It would be helpful to conduct a study
based on a large nationally representative sample that included most of UK ALL
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patients (80 – 95 %) (Mitchell et al., 2010) and which used evidence-based definitions
of unhealthy weight status (Cole et al., 2007), and which assessed the secular trends
of unhealthy weight status over time.
Furthermore, there are limited and conflicting studies that examined the role of
unhealthy weight status at diagnosis on prognosis in children with ALL. The
conflicting literature has been caused by a combination of small sample sizes,
included heterogeneous ALL groups (mixed low, standard and high risk), different
treatments (using CRT, chemotherapy or/and both) and applying different definitions
for assessing unhealthy weight status. Therefore, the present thesis conducted a
study that included a fairly homogenous sample of ALL children treated with same
protocol (UKALL X), with a relatively large sample size and using evidence-based
definitions and the most recent definitions (Cole et al., 2007) for defining unhealthy
weight status to test the influence of weight status on risk of relapse of ALL patients.
In addition, the prevalence of obesity has becomes epidemic worldwide. In Saudi
Arabia for example the prevalence of obesity in children and adolescents is now very
high (34% overweight or obese) (El Mouzan et al., 2010). Studies that estimated
prevalence of unhealthy weight status and MS amongst survivors ALL in first
remission children in non-western countries are   scarce and no study applied modern
definitions for defining weight status. Also, no study examined over-fatness in non-
western countries in ALL survivors to observe whether over-fatness by using BIA and
DXA is consistent with BMI for age for defining overweight or obesity. Therefore, the
present thesis examined prospectively the weight status, over-fatness and MS
amongst Saudi standard risk ALL survivors in medium term (to early intervention) of
fairly homogenous group in first remission treated with modern and same protocol (no
CRT used).
Finally, low bone mineralisation in childhood cancer survivors is a widespread
concern (Elmantaser et al., 2011, Elmantaser et al., 2010, van der Sluis and van den
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Heuvel-Eibrink, 2008, Warner et al., 1998b, White et al., 2005). However, many
studies report conflicting conclusions, due largely to relatively small and not
representative samples, different study designs, inclusion of heterogeneous groups,
i.e. mixed survivors who had been treated with different type of treatment and
protocols, and failure to use an adjustment to DXA output for body size (described in
detail in general methods chapter). Therefore, the present thesis aimed to test for the
effect of adjusting DXA output amongst a fairly homogeneous sample of Saudi ALL
survivors in first remission.
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Chapter 2
General methods
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2.1 Chapters 3 and 6 methodology
2.1.1 Participants
Cross-sectional studies of Saudi survivors with childhood standard risk ALL (as
defined below) in first remission (i.e. no relapse) were carried out from October 2009
until April 2010. The reason to include only standard risk ALL patients was to have a
relatively homogenous group: to reduce variability due to disease (e.g. high risk vs.
standard risk, more versus less aggressive disease and disease treatment),and
patient age/development (high risk  status is denoted by being very young at
diagnosis and older at diagnosis); to control for treatment e.g. patients on older
protocols with CRT, patients on mixed protocols where some received CRT, more
homogeneity on modern protocols where CRT was not used for standard risk patients
or not used at all.
All survivors who included in the Saudi studies in the present theses had been treated
according to the modified CCG 1891 protocol (summarised in table 2.1.1 and for
more details see appendix C) at KFSH&RC between 1994 and 2009. In Saudi Arabia,
there are few centres that deal with childhood cancer. KFSH&RC is placed in the
capital the Kingdom of Saudi Arabia (Riyadh) and it served all regions in the country.
Also, it is the most famous and one of the most modern hospitals in the Middle East
region (see figure 2.1.1).
2.1.1.1 Saudi Arabia in context
The country was established by King Abdul-Aziz Bin Saud in 1932.  The capital is
Riyadh. It has the second largest oil reserves and in the second largest exporter in
the world. Saudi Arabia is growing rapidly and per capita income was £15,200 in 2010
compared to £9,400 in 2006. The total population according to the last census (2010)
was 27,448,000 (United Nations, 2012).
101
101
Also, stability in politics and economic is helping in improving reducing level of
morbidity and mortality rates. The government provides free education and health for
citizens. The mortality rate (per 1,000) under-five was sharply decreased over 40
years ago from 179 in 1970 and reached to 17.5 in 2010 (Child mortality estimates,
2011) as show in figure 2.1.2.
Figure 2.1.1: King Faisal Specialist Hospital & Research Centre (KFSH&RC)
view
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Also, female and male adult mortality rate (per 1,000 adults) reached in 1960 up to
325 and 418; respectively. However, the curve sharply decreased to 97 and 129 in
female and male adults; respectively (United Nations, 2012).
However, as a result of fast economic transition in very short period, the Saudi life
style has had a profound shift in both dietary habits and physical activity patterns a
‘westernisation’ of life style. Al-Hazzaa et al., (2011) reported that about half of male
Saudi adolescent and about 75% of female Saudi adolescent were insufficiently
active based on the physical activity daily guidelines.  Also, they found high
prevalence of unhealthy dietary habits such as the majority of adolescents did not
consume the daily requirements of milk and fruit; however, there is no specific Saudi
milk recommendation.
Figure 2.1.2: Mortality rate, under-5 (per 1,000)
Source: extracted the data from the United Nations Inter-agency Group for Child
Mortality Estimation (Child mortality estimates, 2011)
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Table 2.1.1: The modified CCG 1891 protocol therapy at KFSH&RC
Phase IV. Delayed
Intensification I
Phase VI. Delayed
 Intensification II
Phase I.
Induction
(4 weeks)
Dose
Phase II.
Consolidation
(4 weeks)
Dose
Phase III.
Interim
Maintenance I
(8 weeks) Re-induction:
(0 – 27 days)
Re-
consolidation
(28 - 49)
Phase V.
Interim
Maintenance II
(Begun at Day
49) Re-induction(0 – 27 days)
Re-
consolidation
(28 – 49 days)
Phase VII.
Maintenance
(12 weeks)
Dexamethasone
6 mg/m2/day
Dexamethasone
3 mg/m2/day
Methotrexate
20 mg/m2/ Week
Dexamethasone
10 mg/m2
Dexamethasone
Complete taper
6-
Mercaptopurine
75 mg/m2
Dexamethasone
10 mg/m2
Dexamethasone
Complete taper
Methotrexate
8, 10 and 12 mg
based on age
Vincristine
1.5 mg/m2 IV
6-
Mercaptopurine
75 mg/m2
Vincristine
1.5 mg/m2 IV
Vincristine
 1.5 mg/m2 IV
Cyclophamide
1000 mg/m2
Methotrexate
20 mg/m2
Vincristine
1.5 mg/m2 IV
Cyclophamide
1000 mg/m2
Vincristine
1.5 mg/m2 IV
L’Asparaginase
6000 U/ m2
Methotrexate
8, 10 and 12 mg
based on age
Dexamethasone
6 mg/m2
Adriamycin
25 mg/m2 IV
6-thioguanine
60 mg/m2
Vincristine
1.5 mg/m2 IV
Adriamycin
 25 mg/m2 IV
6-thioguanine
 60 mg/m2
Dexamethasone
6 mg/m2
Methotrexate
8, 10 and 12 mg
based on age
Vincristine
1.5 mg/m2 IV
6-
Mercaptopurine
75 mg/m2
L’Asparaginase
6000 U/ m2
Cytosine
Arabinoside
75 mg/m2 /day IV
Dexamethasone
6 mg/m2
L’Asparaginase
6000 U/ m2
Cytosine
Arabinoside
75 mg/m2 /day IV
6-
Mercaptopurine
75 mg/m2
Methotrexate
8, 10 and 12 mg
based on age
Methotrexate
8, 10 and 12 mg
based on age.
Methotrexate
8, 10 and 12 mg
based on age
Methotrexate
20 mg/m2
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2.1.1.2 Inclusion criteria for studies in chapters 3 and 6
Saudi citizens aged between 5 and 20 years in first remission for ALL at the end of
ALL therapy with standard risk were selected in order to ensure a fairly homogenous
sample as explained above.
The standard risk criteria were applied using KFSH&RC’s Department of Paediatric
Haematology oncology criteria in which patients with precursor B-cells are considered
standard risk only if all of the following criteria apply:
 Age > 1 year and < 10 years at diagnosis.
 Initial WBC < 50 x 109 /L.
 DNA index (The ratio of ALL test divided by standard DNA fluorescence) ≥
1.16 or ≤ 1.6.  DNA Index in ALL patients has been used as prognostic tool.
Also, some protocols have relied on DNA index to classify the risk categories
(Rachieru-Sourisseau et al., 2010).
 Lack of adverse cytogenetic/molecular genetic studies (t(9;22)/ BCR-ABL; t
(1;19)/ E2A-PBX1; t (4; 11)/AF4–MLL).
 Negative for central nervous system or testicular involvement.
 Note: all other criteria are considered as high risk.
It should be emphasised that “10 years old” refers to the age at the time of diagnosis.
However, the age range in this study (5 -20 years) refers to the age at the time of
conducting the present study. The age range (5 – 20 years) was based on the ages
allowed in the ALL survivors’ clinic at the KFSH&RC.
2.1.1.3 Exclusion criteria for studies in chapters 3 and 6
Patients were excluded if they:
 Had relapsed at any stage. Patient who relapsed will undergo in another
therapy protocol and may receive intensive more treatment than the group.
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 Currently or previously had a secondary malignancy that would increase the
variability in the sample for instance patient with secondary malignancy will be
exposed to different type of treatments than the group in the first remission.
 Were younger than five or older than 20 at the time of the present study. This
criterion is based on practical reasons because the KHFSH&RC survivors’ clinic
included patients 5 – 20 years old.
 Had high risk ALL (High risk ALL patients have different and more intensive
treatment than standard risk patients).
 Were being or had been treated for MS or related diseases such as diabetes
before the diagnosis of ALL.  The present study was aimed to investigate the
‘late effects’ of ALL amongst survivors and not to examine the late effects in
patients who already had these diseases.
 Had longbone fractures because it was impractical to take measurements for
most nutritional assessments.
The potential participants who were treated in the same protocol and had their annual
follow in the survivors’ clinic during the period of the carried out of the present study
were 77 survivors aged between five and 20 years.
Survivors were ineligible if:
 They had relapsed (n= 3).
 Were pregnant (n=2).
 Had pre-existing type I diabetes before diagnosis of ALL (n=1).
Or
 Had a longbone fracture in plaster (n=2).
Note: This left 69 potential eligible survivors for the present study who were invited to
take part.
106
106
Comments on Recruitment:
 They or their parent (s) were contacted by telephone before attending their annual
follow-up appointments at the Department of Paediatric Haematology/Oncology in
KFSH&RC.
 Seven survivors living in Riyadh who did not have appointments at the hospital
were telephoned after obtaining permission from their physicians. Of the
potentially eligible survivors, 56 (81%) agreed to participate (see figure 2.1.3).
 No control group such as a healthy control group or a “positive control” group with
chronic disease was collected because of limited resources (budget).  Also, the
study was restricted by limited time by the author’s sponsor (i.e. no more than 3
months at a time outside the UK) and restrictions placed by the University of
Glasgow (no more than 12 months outside of Glasgow in total in the three year
period).
2.1.1.4 Confidentiality
All participants’ data were collected confidentially. All information relating to personal
identities, such as names, file numbers or contact numbers, was coded. Each
participant was assigned a coded number to link them to their data.
2.1.2 Ethical approval
The study proposal was submitted to the Research Advisory Council (RAC) at the
KFSH&RC. The RAC was reviewed and the proposal was approved on 26 October
2009 (see appendix B). The consent form was written according to the RAC
procedure. It was singed by the participant’s parent. All consent forms were kept in
the participant’s medical files according to KFSH&RC instructions.
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Figure 2.1.3: Chapter 3 and 6 studies recruitment follow diagram
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2.1.3 Anthropometric measurements
2.1.3.1 Height, weight and BMI
Height and weight were measured to 0.1cm and 0.1kg; respectively. All Saudi
survivors’ heights and weights in the present studies were measured using a Scale-
Tronix 5002 stand-on scale (shown in figure 2.1.4). They were wearing light clothes
and removed shoes and outdoor clothes. Height was measured as participants stood
in front of a wall looking straight ahead (Gibney, 2005). One reading was recorded.
BMI was calculated using the following equation: Weight (kg)/Height (cm) 2. However,
BMI was expressed with age and sex-specific z scores or percentile if the BMI z score
was not available such as in Saudi reference data (El-Mouzan et al., 2007). Various
BMI sex and age-specific reference data was used for the classification of weight
status in present studies as summarised in table 1.4.2; Saudi (El-Mouzan et al.,
2007), CDC (Kuczmarski et al., 2000), WHO (de Onis et al., 2007), IOTF (Cole et al.,
2000) and Cole et al., (2007) reference data. All the present studies survivors were
Saudis and so, the national (Saudi) reference data were also used. Also, the present
studies used the international reference data such as  CDC (Kuczmarski et al., 2000),
WHO (de Onis et al., 2007), IOTF (Cole et al., 2000) and Cole et al., (2007)
population reference data as they widely used in the literature and recommended in
clinical for obesity management and epidemiological surveillance (Scottish
Intercollegiate Guidelines Network, 2010, Reilly et al., 2010b).
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Figure 2.1.4: Scale-Tronix 5002 stand-on scale
2.1.3.1.1 Saudi reference data for BMI
In 2007, El-Mouzan et al., (2007) produced the Saudi growth (BMI for age) charts for
both genders . Data from a stratified multistage probability sample were based on
representative samples of healthy children and adolescents collected from 13 regions
in Saudi Arabia between 2004 and 2005. This national survey examined 11,874
apparently healthy children and adolescents who were subjected to anthropometrics
measurements (Al Herbish et al., 2009). They also, used for chart percentiles Epi info
2002 software program produced by CDC and LMS method proposed by Cole et al.,
(1992) for curve construction.
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Data were available in the form of centile charts for boys and girls and BMI z scores
were unavailable (El-Mouzan et al., 2007). Study participants were defined, therefore,
manually (by plotting of data on BMI charts) by the author as: obese (BMI ≥95 th
percentile), overweight (BMI 85th to <95th percentile) and underweight (BMI <5th
percentile) (Al Herbish et al., 2009, El-Mouzan et al., 2007). However, as far as the
author is aware, no research on the validity to detect fatness or thinness, ability to
predict co-morbidity or premature mortality of using BMI for age with the Saudi BMI
for age reference data exists.
2.1.3.1.2 US CDC reference data for BMI
BMI z scores were calculated for study participants based on the US CDC 2000
reference data (Kuczmarski et al., 2000) by using software available at:
http://stokes.chop.edu/web/zscore/result.php. The CDC  reference data (Kuczmarski et
al., 2000) of children and adolescents are based on four nationally representative
surveys in the USA conducted between 1963-1965 and 1976-1980. A survey of
children aged two to five was carried out from 1988-1994.  Participants aged between
two and 20 years were included. The national survey designs are based on stratified,
multistage probability samples of the civilian, noninstitutionalised population. The
anthropometric measurements (weight and length), age and gender were recoded.
They used the modified LMS method proposed by Cole et al., (1992) to produce
smoothed percentile curves.
Use of CDC reference data is customary to classify   weight status according to BMI
for age and sex as follows: obese: (BMI ≥95 th percentile), overweight (BMI 85th to
<95th percentile) and underweight (BMI <5th percentile) (Kuczmarski et al., 2000), so
these definitions were used in the present study.
Freedman et al., (2005b) studied the validity of BMI (based on US CDC reference
data) to define high body fatness amongst 1,196 healthy children and adolescents
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aged between five and 18 using the DXA instrument. Accuracy of BMI was found to
vary depending on the degree of fatness. The FM index (FM in kg divided by height2
in cm) highly correlated with BMI≥ 85 th centile (r= 0.85- 0.95). However, a weaker
correlation between BMI for age < 50th and FM (r= 0.22- 0.65) than for the FFM index
(r= 0.56 – 0.83) was observed. Therefore, they concluded that a high BMI for age
based on US CDC reference data is a good predictor in term of detecting high
adiposity and it is moderately sensitive and specific for high fatness. Moreover, Reilly
and Kelly (2011) reviewed studies where the US CDC reference was used to define
excessive fatness and showed that those with overweight and obesity as defined by a
high BMI are risk of morbidity and premature of mortality in adulthood. Mei et al.,
(2002) investigated (sample was 11,096 aged 2 – 19 years) the validity of BMI for age
and weight for stature in term detecting underweight (defined as below the 15th
percentile) and overweight (defined as above the 85th percentile) compare with DXA
and skinfold thickness.  They concluded that BMI for age is to some extent a better
proxy for underweight and overweight than weight for stature in children and
adolescents.
2.1.3.1.3 WHO reference data for BMI
The WHO updated the BMI for age and sex reference data for children and
adolescents in 2007 but it is based largely on data from National Centre for Health
and Statistics (NCHS)/ WHO which were conducted from 1977 growth reference for
who age 1– 24 years old. They used three data sets for developing WHO reference
data. The first data set was from the National Health Examination Survey (NHES)
Cycle II (6–11 years), the second data set was from Cycle III (12–17 years) and the
third data set was from Nutrition Examination Survey Cycle I (1 to 24 years) (de Onis
et al., 2007). The sample size was 22 917 (11 410 boys, 11 507 girls). The Box-Cox
power exponential (BCPE) method was used to generate BMI percentile curves.
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BMI z scores were calculated using the WHO Anthro version 3.2.2, January 2011
software available at: http://www.who.int/childgrowth/software/en/. The WHO
reference data for children and adolescents aged between two and 19 years was
used (de Onis et al., 2007). The BMI z score was converted to weight status
categories as follows: overweight as >+ 1SD (conceptually equivalent to BMI 25
kg/m2 at age 19 years), obesity as >+ 2 SD (conceptually equivalent to BMI 30 kg/m2
at age 19 years) and underweight/thinness as < -2 SD (de Onis et al., 2007).
2.1.3.1.4 International Obesity Task Force (IOTF)
In 1997, the IOTF working group recommended the use of BMI as an indicator of
excessive fatness in children and adolescents (Bellizzi and Dietz, 1999).
Consequently, Cole et al., (2000) established standard cut-offs to define overweight
and obesity for children and adolescents aged between two and 18 years and they
were published in 2000. Data were collected from Brazil (1989), UK (1978 - 1993),
Hong Kong (1993), the Netherlands (1980), Singapore (1993), and the United States
(1963 - 1980).  They had a data set for children and adolescents from birth to 25
years old and it consisted of 97,876 and 94,851 males and females; respectively.
Subsequently, they extrapolated the classification for BMI in adult (overweight ≥ 25
and obesity ≥ 30) in the six countries datasets at age 18 years afterward created a
curve which passed through these cut- offs the ages from adulthood at 18 years old
until childhood at 2 years old. In other words, the cut-off points are conceptually
equivalent to adult BMI-based definitions of overweight and obesity of 25 and
30kg/m2 respectively and were applied in the present study using software (available
at www.healthforallchildren.com). They established and recommended the use of this
definition for international epidemiological studies.
However, there is no consensus on the adoption of this definition nationally or
internationally (Reilly et al., 2010b). The argument was mainly focused on the
sensitivity of the definition and usefulness in clinical settings. Reilly et al., (2000a)
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showed that IOTF (Cole et al., 2000) has high specificity but it is associated with low
sensitivity i.e. a high false negative rate for excess fatness. Also, a review article for
example, found that 40 – 50% of children with excessively high body fatness were not
classified as obese by using the IOTF definition (Reilly, 2006a).  Furthermore, a
systematic review paper showed that using national BMI is superior to using IOTF
(Cole et al., 2000) and the national BMI reference generally has higher sensitivity and
similar specificity to use of IOTF definition (Reilly et al., 2010b).
2.1.3.1.5 Cole et al. (2007) definition of underweight
More recently, Cole et al., (2007) proposed an international definition of children and
adolescent underweight “thinness” based on BMI for age and gender using same
data used in Cole et al., (2000) from the same six countries. Underweight was
classified for children and adolescents aged between two and 18 years as three
grades corresponding were extrapolated to an adult BMI of 16, 17 and 18.5 kg/m2
which is proposed by WHO. They merged data and produced a curve which passed
through these cut- offs the ages from adulthood at 18 years old until childhood at 2
years old. These are conceptually equivalent to (at age 18 years old) a BMI ≤18.5,
namely “chronic energy deficiency as defined by the WHO” (James et al., 1988,
World Health Organization, 1995).  However, this thesis will define all different
underweight grades as one grade instead of Cole et al. (2007) classification as: grade
1, 2 and 3 underweight. (For values to define thinness at each age and in both sexes)
Underweight was assessed by Tuan and Nicklas (2009) using CDC and Cole et al.
(2007) definitions in 53,826 Vietnamese, 11,756 Indonesian and 1600 Chinese
children aged 2 – 18 years.  They found that according to the Cole et al. (2007)
definition, the prevalence of underweight in Chinese, Indonesian and Vietnamese was
6%, 10% and 13%; respectively and 10%, 13% and 19%; respectively based on the
CDC reference data. They reported that there are age, sex and ethnic differences in
prevalence of underweight by different definitions. So, they advised the evaluation of
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any international definition before using in any specific-population. As a result the
Cole et al., (2007) of thinness is used continuously in this thesis.
2.1.3.2 Waist circumference (WC) measurement
Interest in WC measurements has increased in recent years as it may be used as an
indicator for cardiometabolic risk factors in both children and adults (McCarthy et al.,
2003, Speiser et al., 2005). The waist size of all Saudi participants in the present
studies (chapters 3 and 6) was thus measured using measuring tape. The
measurement was taken by two trained observers (a female dietician (Mrs. Hanan
Almutairi) measured some of girls (n= 19) and the author measured boys and some of
girls). The measurement was taken to the nearest 0.1 cm while the participant stood
without any compressions on the skin and the waist was measured at a site 4 cm
above the umbilicus (Rudolf et al., 2007).
The WC changes with age and differs between the sexes. So, it must be interpreted
in an age- specific and sex- specific methods measured WC in children. Rudolf et al.,
(2007) examined the consistency across different waist measurement methods
amongst 41 healthy children (75.6 % was girls). The mean (SD) age was 12.4 years
(3.3).The waist measurement methods were the midpoint between lowest rib and iliac
crest, crease on lateral flexion and 4 cm above umbilicus and compared them with
BMI z score from UK 1990 definition (Cole et al., 1995). As all methods were highly
correlated to each other and to BMI z score, they recommended using 4 cm above
umbilicus method arguing that it would be the simplest option in clinical settings as
described in section 1.4.5.1.6.
2.1.4 Blood pressure (BP) measurement
BP was measured in all Saudi participants using an automated electronic vital signs
monitor that included BP monitoring (CASMED® 740 monitor) (see figure 2.1.5). The
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measurement was performed by staff nurses at KFSH&RC. Before the measurement,
subjects were seated for at least five minutes in a waiting room. Participants were
seated comfortably on a chair for the BP measures. The cuff was covered at least
one-third of the right upper arm between the olecranon and acromion. The BP
reading was repeated twice and the average of both readings recorded (Bird and
Michie, 2008). The definition of hypertension depends on MS definitions as discussed
below.
Figure 2.1.5: CASMED® 740 monitor for blood pressure (BP)
2.1.5 Body composition measurement
BMI for age and sex is a simple and cheap indicator of high and/or low body
adiposity, as noted above (Reilly et al., 2010b). Nevertheless, body composition may
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be considered as more informative than the BMI method in healthy children and
adolescents (Wells and Fewtrell, 2008) as well as amongst survivors of childhood
cancer (Warner et al., 1997). It has also been highlighted by the IDF consensus group
as a useful parameter to collect when considering metabolic syndrome and its
potential use in future research studies was emphasised by IDF, even though the IDF
panel did not recommend body fatness to be included as one of the MS criteria
(Alberti et al., 2006). Warner et al., (2004) also recommended that in clinical settings
such as ALL more than one body composition method should be used. Body
composition was hence measured using two instruments in the present studies: DXA
and BIA. These two methods are convenient and practical for clinical use and were
available in the KFSH&RC (as explained in general introduction chapter).
Levels of total body fat % which are excessive (because of associations with adverse
cardiometabolic risk profiles) have been established by previous studies (Lohman,
1992). Over-fatness was defined in this thesis as percentage total body fat (%TBF)
was more than 25% in males and 32% in females amongst survivors aged 18 years
and more. However, For those aged 5- <18 years, over-fatness was defined as % BF
more than 25% for boys and more than 30% for girls (Lohman, 1992).
2.1.5.1 Bioelectrical impedance (BIA)
After receiving training on the use of the BIA instrument from the charge staff under
KFSH&RC supervision, 53 Saudi survivors of childhood ALL were measured by BIA.
The instrument could not analyse the remaining participants (n=3) because they were
so young and it was difficult to stand on the device.
All BIA procedures were performed by the author. Total body bioimpedance was
measured by using a Biospace Inbody 3.0 Composition Analyser (Biospace © 2001)
(see the figure 2.1.6). General prediction equations for estimation of body water (and
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body water can be used in turn to estimate body composition) were proposed by Cha
et al., (1995) as following:
1. “ The resistance (R) of the body is a function of the resistivity (p), the length
(L), and the cross-sectional area of the conductor (A):
      R = p x (L/A)
2. Multiplying the numerator and denominator by L yields:
      R = p x (L x L)/(A x L)
3. A x L is the volume of the conductor (V):
           V = p x (L2/R)
4. When R at low frequency (R low) is included in the above equation,V
approximates extracellular water (ECW); when R at high frequency (R high) is
included, V approximates total body water (TBW). Because the specific
resistivity is different between ECW and TBW (p1 and p2, respectively),as
expressed:
           ECW = p1 x (L2/ R low )
           TBW = p2 X (L2/ R high)
5. The ratio ECW/TBW can be expressed as the ratio of two equations above:
           ECW/TBW = p1 X (L2/ R low)/p2 X (L2/ R high )
                              = p1 X (L2/ R high)/p2 X (L2/ R low)
6. Assuming that p1 and p2 are constant:
           ECW/TBW α R high/R low ”
BIA Inbody 3.0 uses a direct segmental multi-frequency bioelectrical analysis to
measure the trunk, arms and legs. This instrument was maintained by the biomedical
engineering department. Personal information (ID, age, gender, weight, and height)
was entered and this information will be used in an algorithm for prediction of body
composition which is commercially sensitive. The instrument has eight point tactile
electrodes (two front sole electrodes, two rear sole electrodes, two thumb electrodes
and two palm electrodes). Total body impedance was measured at a 50 kHz
frequency.
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All participants measured did not eat or drink and were asked to go to the bathroom
before the test as instructed by the instrument’s manufacturers. The test was
performed at room temperature.  Participants were instructed to touch the palm
electrode using four fingers, to place their thumb on the thumb electrode and to press
gently. They stood on the foot electrodes but were instructed to place the heel on the
rear sole electrode before their forefoot touched the front sole electrode. They were
advised to stand comfortably; the angle between the arm and side was about 15
degrees. The BIA total body fat percentage (%TBF) results were then used. One
reading was recorded.
Figure 2.1.6: Biospace Inbody 3.0 Composition Analyser (Biospace © 2001)
Validity of the Biospace BIA monitor
The Segmental multi-frequency BIA (InBody 3.0 Biospace Co. Ltd. Soul, South-
Korea) used in the present study has been evaluated for validity and reliability
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purposes, but in studies which used DXA a gold standard measurement for body
compositions (which it is not). For instance, Kriemler et al., (2009) aimed to examine
the cross-validation of tetrapolar BIA (4-BIA model 101A, RJL system, MI, USA) and
octopolar (8-BIA; Inbody 3.0, Biospace, Seoul, Korea) analysers for assessment of
body composition with DXA as a reference method. They recruited 333 Swiss
children and adolescents aged 6 -13 years old. Total body fat-free mass and
appendicular lean tissue mass were assessed by Lunar DXA. They reported that 8-
BIA analyser (used in the present thesis) was more accurate in total body fat-free
mass assessing than 4-BIA (root mean square error= 0.90 kg and 1.12 kg;
respectively, equivalent to 3.2 % and 3.7 %). Also, that 8-BIA analyser was more
accurate for estimation of appendicular lean tissue mass (root mean square error ≤
0.10 kg for arms and ≤ 0.24 for legs) assessing than 4-BIA. Therefore, they
concluded that the 8-BIA analyser is a superior and more accurate predictor of
segmental body composition than the 4-BIA analyser.
Furthermore, Lim et al., (2009) studied the validity of multifrequency BIA with eight
tactile electrodes or BIA-8 (Inbody 720, biospace, Seoul, Korea) in assessing FM,
FFM and %BF compared to Lunar DXA. The sample size was 166 (86 boys and 80
girls) healthy children and adolescents (mean (SD) age was 11.4 years (3.1)). The
correlations between BIA and DXA were r= 0.995 (p value< 0.01) for FFM, r= 0.981 (p
value< 0.01) for FM and r= 0.926 (p value < 0.01) for %BF. By using linear regression
analysis between DXA and BIA, r2= 0.99 (standard error was 1.16 kg) for FFM, r2=
0.93 (standard error was 1.34 kg) for FM and r2= 0.86 (standard error was 3.03%) for
%BF. A Bland-Altman plot was used to analyse the limits of agreement and the
differences for FMM, FM and %BF-the limits of agreement were 0.7 ± 2.3 kg for FFM,
0.9 ± 2.9 kg for FM and 2.2 ± 6.1% for %BF. They concluded that even though the
BIA analyser was not interchangeable with DXA in assessing body composition, it
remains useful in healthy and diseased children because of its high precision and
reasonable accuracy.
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Jensky-Squires et al., (2008) carried out a study in 254 adults aged 21 – 80 years old
and 117 children and adolescents aged 10 – 17 years old. They evaluated %BF by
using BIA (InBody 3.0 Biospace Co. Ltd. Soul, South-Korea) analyser, Omron body
analyser (Omron healthcare, Inc., Veron Hills, IL, USA), Bod-eComm near- infrared
interacatance (uses wavelengths of harmless low intensity near- infrared light
absorbed by body fat  and reflected by lean body mass). In adult subjects, they
compared their %BF with DXA and compared the outcome of BIA (Inbody 3.0) with
underwater weighing in children. However, the underwater weighing method is not a
gold standard, and it can be influenced by hydration, the subject’s comfort and ability
to expire air (Thomson et al., 1991). They found that all used body composition
methods were correlated with DXA (r= 0.54, p value ≤ 0.01), except Bod-eComm in
elderly women (r= 0.54, p value= 0.12). BIA (Inbody 3.0) was significantly correlated
with underwater weighing in both boys (r= 0.69, p value ≤ 0.01) and girls (r= 0.79, p
value ≤ 0.01). By using Bland- Altman analysis, all body composition methods
underestimated %BF except BIA (Inbody 3.0) which overestimated %BF in boys and
girls. There were large individual errors for all methods.
2.1.5.2 Dual energy X-ray absorptiometry (DXA)
DXA was performed by two trained technicians working in the nuclear medicine
division at the (KFSH&RC). The % TBF was measured by DXA using a whole body
scanner (DXA Lunar Prodigy, software version 9.15) (see the figure 2.1.7). Coefficient
variation for total body BMD was 0.73% and lumbar spine was 1.0% as they have
been reported by Crabtree et al., (2005). According to the KFSH& RC laboratory’s
intra-assay variation coefficient for fat mass was 0.76± 0.41%.
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Figure 2.1.7: DXA Lunar Prodigy, software version 9.15
A total of 56 Saudi ALL survivors were recruited and booked in for a scan
appointment. However, five of them did not attend the appointments in the main
hospital (which is situated about 45 minutes by car from the oncology centre) as their
flight time was at the same time of DXA procedure. Therefore, the number of
survivors scanned for the present studies was 51.
Before the scan, survivors were instructed to remove shoes and metal objects such
as keys, watches and rings. They were scanned whilst lying comfortably in a supine
position. The whole body was scanned from the head to feet. The scanning
procedure took approximately seven to 15 minutes depending on the height of the
survivors and their cooperation during the procedure. The dose of radiation
participants were exposed to using DXA is very small and at a safe level (<0.05 mSv)
(Laskey, 1996).
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The outcome from DXA instrument measurements consisted of body FM (g), % TBF,
lean fat mass (g), body mass content (BMC) (g), bone area (BA) (cm2) and areal
(aBMD)/ BMD (g/ cm2), illustrated in figure 2.1.8 . It should be evident that DXA is
composed of two separate sets of equations, each used to describe a 2-C model.
However, there is big debate as which is the best method to adjust BMD so, the
author explains the different approaches below.
2.1.6 Measuring bone mass in children
First of all, children are not little adults. Childhood is affected by different factors that
might lead to misinterpretation of the results of bone mass assessment. For example,
it is a consistent bone growth phase and bone age is not closely related to the
chronological age (Bonnick, 2010). The DXA instrument calculates BMD as an areal
(aBMD) or a 2-dimensional measurement by measuring BMC and projected bone
area (BA). The equation is the following: (BMC (g) ÷ BA (cm2)). Therefore, aBMD
(combined cortical and trabecular bone) is affected by BMC and bone size rather than
the true density (Fewtrell, 2003).
Volumetric density, such as Quantitative Computed Tomography, uses  3-
dimensional measurements to produce height, width and depth to obtain volumetric
density (Kroger et al., 1995). Even though the computed tomography machine is
based on a 3-dimensions measurement (volumetric measurement), which is an
advantage, it requires a high dose of radiation to be exposed which is unacceptable
for children and adolescents (Warner et al., 1998b) and so it was not used in the
present studies.
Therefore, aBMD as produced by DXA is a not true volumetric density because the
anterior and posterior diameter of the bone are not measured (Kroger et al., 1995).
Consequently, aBMD seems to be overestimated in large children and
underestimated in small ones (Fewtrell, 2003).  The aBMD should therefore ideally be
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adjusted to the bone size to avoid mislabelling of children as osteoporotic, possibly
receiving unneeded treatment. Also, it is important when labelling children with “low
bone mass” to prevent future risk fractures (Ahmed et al., 2004). Consequently,
there is controversy as to how to diagnose a low BMD in children with DXA and what
approach is the best to correct the bone size on areal measurements (2-dimension
measurements) to something closes to true density.
Figure 2.1.8:  An example of ancillary lumbar spine data by Lunar DXA. (This
real image is extracted from the present study).
L: lumber spine; BMD: Bone mineral density; BMC: Bone mineral content
In  figure 2.1.9,  The small box dimensions are 2 x 2 x 2 = 8cm3 , which is the volume
of the small box, and the large box dimensions are 3 x 3 x 3 giving a volume = 27
cm3.  True density of a material is defined by weight divided by volume in centimetres
cubed (cm3).  Therefore, if you imagine the small box to be made up of 8 x small 1cm
cubes each weighing 2g, (16g divided by 8 = 2g/cm3) and the large box is made up of
27 x small 1cm cubes each weighing 2g (54g divided by 27 = 2g/cm3).  This is the
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true volumetric density and will remain so, no matter how many cubes 2g/cm3 you
piled on top of either box in the diagram.  With areal density (or aBMD), which is what
the DXA scan gives as a result, the projected area is given (computed by a pixel by
pixel account of bone edge detection) in cm squared (not cm cubed).
In the second small box in the diagram under the small box that is 2 x 2 cm2 to
represent the areal density of this cube = 4cm2, and a box that is 3 x 3 cm2 or 9cm2.
When the mineral weight of each box is divided by the areal density or projected area
as with DXA, the diagram below shows 16/4 = 4g/cm2 for the small box and 54/9 =
6g/cm2 Hence, a larger value for a larger box.  This means that the technique of DXA
scanning to measure bone density is size-dependent and will systematically
overestimate bone density in larger patients and underestimate it in smaller patients
unless some adjustment made.
In reality- a patient example
If we imagine that two healthy boys are identical in age and in true volumetric density,
but one of them is large in size for his age and the other is very small for his age.  A
different aBMD result and an age specific z score will be generated by the software
will be obtained for each boy (for example: z= + 2.5 for the large and z= -2.5 for the
smaller boy), neither of the results will reflect the true volumetric density, but the size
of the child.  Consequently, aBMD should be adjusted to the bone size or it could lead
to misinterpretation (see figure 2.1.10).  This will involve comparing the paediatric
patient to other healthy children of the same size rather than the same age.
125
125
Figure 2.1.9:  Concept of volumetric density
Source: Adapted from  Bonnick (2010)
Mineral weight = 16 g
Volume= 8 cm3
Projected area= 4 cm3
Volumetric density = 2 g/ cm3
Areal density= 4 g/ cm3
Mineral weight = 54 g
Volume= 27 cm3
Projected area= 9 cm3
Volumetric density = 2 g/ cm3
Areal density= 6 g/ cm3
126
126
Figure 2.1.10: Three healthy children (aged 3.5, 4.5 and 6.7 years old
respectively) with different height for age
Note: Niece (left), daughter (middle) and niece (right) of the author
2.1.6.1 Approaches to identify osteoporosis in children and adolescents:
The International Society For Clinical Densitometry (ISCD) in the office position
statement (2007) recommended that diagnosis of osteoporosis in children and
adolescents aged 5 – 19 years old should not made only on the basis of
manufacture’s DXA results alone (Baim et al., 2008). It was emphasised that children
with chronic disease may have shorter bones than healthy children (Ahmed et al.,
2004) and so particular care has to be taken when interpreting DXA bone data in
children and adolescents with chronic disease, or survivors of chronic disease.
In addition, according to the ISCD (Baim et al., 2008) the diagnosis of osteoporosis
required the presence of the following:
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First, child has to have clinical significant fracture history for the diagnosis. It includes
one or more the following:
 Of the lower extremities, one or more long fracture.
 Of the upper extremities, two or more long bone fractures.
 Vertebral compression fracture.
Second, the child has to be diagnosed with low BMC or low aBMD. Low BMC or
aBMD are defined as z score ≤ -2.0 which is adjusted for specific- age, sex and body
size as appropriate. This adjustment is for avoiding the large body size variation,
though the position statement does not suggest what adjustment should be made
(Baim et al., 2008).
There are two adjustment methods for body size. Firstly, DXA software does apparent
adjustment for age and sex to produce z score. Secondly, there is a need for an
additional adjustment for body size as described above and the in next section.
2.1.6.1.1 Tackling of bone size issues using DXA
There are different approaches that use in adjustment of DXA body size, however,
still no consensus exists (Fewtrell, 2003, Bonnick, 2010).
2.1.6.1.1.1 Apparent bone mineral density of lumber spine (BMADLS)
It can be assumed that the lumbar body has a cylindrical-shape rather than the bone
area. Therefore, BMADLS can be calculated  according to Kroger et al., (1995)
equation as following: BMADLS= aBMDLSX [4/ (Ω X width)] where the width is the
mean of the second, third and fourth of lumbar spine (L2-L4) (illustrated in figure
2.1.11) as it is accepted as the average BMD and Ω is constant value (Ω= 3.14).
Then, we can adjust BMADLS according to mean (SD) age and gender reference data
as suggested by van der Sluis et al., (2002) in a study based on 444 healthy Dutch
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children, adolescents and young adults aged 4 – 20 years. For how to calculate
BMADLS see appendix E.
Figure 2.1.11: Lumbar spine bone density image (this real image is extracted
from the present study).
Kroger et al., (1995) examined the validation of this model compared with in vivo to
magnetic resonance imagining (MRI) provides volumetric density measurements as
described above. They recruited 24 men and 8 women aged 25-69 years. They
reported that BMADLS from DXA was correlated moderated with MRI (r= 0.665 –
0.822). However, they emphasised that the calculated volume here is only estimated
lumbar spine volume not the true volume.
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2.1.6.1.2 Warner et al., (1998b) approach
Similarly, Warner et al., (1998b) described an approach to minimising the relation
between aBMD and BA. They suggested that adjusting BMC for BA (a size-adjusted
measure of DXA-derived BMD) based on assuming that BMC is related to BA. The
Warner et al., (1998b) approach also, adjusted other independent variables that could
influence the measurement of BMD using DXA. These variables are age, gender,
pubertal status and body size (height and weight) as means of correcting for short
stature.
By using the van der Sluis et al., (2002) (based on healthy Dutch children) reference
data and by applying linear interpolation to calculate percentage predicted BA for age
according to the reference data, a chid with low percentage predicted BA for age
would have a either short bones (short stature) or narrow bones, or a combination of
both when compared to his/her age matched peers.  In addition, by comparison of
the child actual BMC to the size matched rather than age matched reference data,
percentage predicted BMC for BA can be calculated and expressed as BMC for BA z
score.  Hence, a child with low BMC for BA Z-score would have a low degree of
mineralisation for his/her size regardless of whether his/her bones were short/tall or
wide/narrow (Ahmed et al., 2004, Ahmed et al., 2005).
2.1.7 Blood collection and biochemical analysis
All survivors or one of their parents were telephoned before the study to instruct them
to fast for at least 12 hours prior to blood collection the following morning. Blood was
withdrawn by lab technicians using the venipuncture technique; therefore, the
antecubital vein was used. All participants were advised to sit in a comfortable
position. The forearm was supported by a cushion to ensure it was in a downward
position. The antecubital vein was allocated using a tourniquet above the elbow.
Blood was withdrawn using a needle and syringe.
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Blood samples were analysed at the KFSH&RC laboratories. Collected samples were
therefore split into two different tubes:
o 4ml of blood was drawn in a plasma separating tube with lithium Heparin.  This
was centrifuged immediately for seven minutes at 3000 revolutions per minute.
The plasma was used for total cholesterol, TG, HDL-C, and glucose fasting
tests.
o 4ml of blood was taken in a red top tube with serum clot activator. It was then
left for 30 minutes at room temperature to clot and centrifuged for seven
minutes at 3000 revolutions per minute. The serum was transferred into an
aliquot tube for the fasting insulin test.
Total cholesterol, TG, HDL-C and LDL-C was quantified by using the enzymatic
colorimetric test in-vitro assay (Roche/Hitachi 912 analyser). In enzymatic in-vitro
assay, glucose was measured using an ultraviolet test (Roche/Hitachi 912 analyser).
The in-vitro quantitative determination of plasma insulin was measured via
immunoassay. The period of the test was about 18 minutes (Cobas e immunoassay
analyser). The coefficient of variation for intra-assay and interassay  for total
cholesterol were 2.1% and 2.7%; respectively, for TG were 2.3% and 2.5%;
respectively, or HDL-C were 3.3% and 3.8%; respectively, for glucose were 0.8% and
1.3%; respectively, for insulin were 3.4% and 3.9%; respectively, for LDL-C were
0.9% and  1.9%; respectively.  All these mentioned assays were performed in
accordance with the manufacturer’s instructions.
2.1.8 Metabolic syndrome (MS) definitions
Two widely accepted MS definitions were selected for this study: the IDF approach
(Zimmet et al., 2007) and NCEP III approach modified by Cook et al., (2008). Both of
the definitions are summarised in appendix D.
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2.1.8.1 IDF approach in defining MS in children and adolescents
The IDF approach defines MS as having central obesity plus two criteria based on
age. According to the definition, children aged between five and < 10 years old cannot
be diagnosed with MS. However, the MS definition for those aged between 10 and 15
years was:
 Central obesity assessed by WC ≥ 90th  centile based on Fernandez et al., (2004).
 plus two or more:
1. TG ≥ 1.7 mmol/L.
2. HDL-C < 1.03 mmol/L.
3. SBP ≥ 130 or DBP ≥ 85 mm Hg.
4. Fasting glucose ≥ 5.6 mmol/L.
 Additionally, the MS definition amongst those aged ≥ 16 years was:
 Central obesity assessed by WC ≥94 cm for men and WC ≥ 80 cm for women.
  Plus two ≥ 2 MS criteria:
1. TG ≥ 1.7 mmol/L.
2. HDL-C < 1.03 mmol/L in males and < 1.29 for females.
3. SBP ≥ 130 or DBP ≥ 85 mm Hg.
4. Fasting glucose ≥ 5.6 mmol/L.
2.1.8.2 NCEP III approach to defining MS in children and adolescents
The NCEP III approach defines MS as:
 Having ≥ 3 MS criteria according to two age groups. For patients aged 5- 19
years, the MS criteria recommended by NCEPIII were:
1. Central obesity, WC ≥ 90 th centile based on cut-offs established by Li et al.,
(2006) as recommended by Cook et al., (2008) who modified the NECP III for
children and adolescents.
2. TG ≥ 1.24 mmol/L.
3. HDL-C ≤ 1.03 mmol/L.
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4. SBP and DBP ≥ 90th  centile based on the National Heart Lung and Blood
Institute table (available at:
http://www.nhlbi.nih.gov/guidelines/hypertension/child_tbl.pdf) as
recommended by Cook et al., (2008).
5. Fasting glucose ≥ 6.1 mmol/L.
 For those ≥ 19 years, the NCEPIII MS criteria were:
1. Central obesity assessed by WC ≥102 cm for men and WC ≥ 88cm for women.
2. TG ≥ 1.69 mmol/L.
3. HDL-C ≤ 1.03 mmol/L for men and HDL-C ≤ 1.29 mmol/L for women.
4. BP ≥ 130/85 mm Hg.
5. Fasting glucose ≥ 6.1 mmol/L.
2.1.9 Homeostatic model-assessment of insulin resistance (HOMA-IR)
HOMA- IR from plasma glucose and insulin concentration was first published in 1985
(Matthews et al., 1985) and has since become widely accepted and of interest to
researchers. HOMA-IR is used as a proxy for insulin resistance because HOMA-IR is
most viable method for assesses insulin resistance (Alvarez et al., 2006). The IDF
consensus group has consequently suggested also using HOMA-IR in research
studies as it appears to be related to MS (Alberti et al., 2006), though it is not one of
the MS criteria as defined by the IDF, as noted above.
HOMA-IR was calculated in the present study using a HOMA calculator (software
version 2.2.2) ©University of Oxford 2004. This software was developed by Levy et
al., (1998) and is also based on Matthews et al., (1985). The following equation is
used: serum fasting glucose (mmol/L) × insulin (µIU/ml)/22.5. Any participant with
HOMA- IR ≥ 2.5 is then classified as having insulin resistance (Sharma et al., 2011).
However, there is a debate around the best cut-offs for HOMA-IR in children and
adolescents as one of MS criteria instead of fasting glucose. Some studies supported
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that but they used different cut-offs: HOMA-IR ≥ 1.77 (Arshi et al., 2010)  , ≥ 2.5
(Sharma et al., 2011) and HOMA-IR > 3.16 (Bitsori et al., 2009) as one of MS criteria
instead of fasting glucose in children and adolescents. Therefore, there is currently no
consensus as to the optimal cut-offs for HOMA-IR amongst children and adolescents,
and it is likely that different cut-offs will produce different prevalence estimates for
abnormal values. This thesis will use the following cut-off HOMA-IR ≥ 1.77 (Arshi et
al., 2010) as it seems to have been used most widely in the relevant literature.
Further original research as to the optimal cut-off was beyond the scope of the
present study, and the present study was not able to make more direct measures of
insulin resistance.
2.2 Chapter 4 and 5 methodology
2.2.1 Participants
UK children and adolescents with ALL at diagnosis were studied retrospectively,
using national data was collected at the time of diagnosis by clinical staff who were
responsible for entering the patients onto the trial in the UK (Reilly et al., 1999b).
Around 80 – 95% of UK patients with ALL were entered into the one of national trials
covering the period of the studies (summarised in table 2.2.1) described in this thesis
(Mitchell et al., 2010).
2.2.2 Ethical approval:
The Clinical Trial Services Unit (CTSU) in Oxford argued that as all UKALL trials data
are anynomised and no specific informal consent was needed for studies in this
thesis. The original trial consent forms included a statement that data could be used
by other researchers in future.
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2.2.3 Exclusions
 The present study excluded patients whose height, weight, age or sex was not
recorded in national trial records, as these variables are required for the
calculation and interpretation of BMI.
 In addition, it was not possible to define the weight status of all patients due to
their age not being covered in the Cole et al., (2007) and IOTF (Cole et al.,
2000) definitions of weight status. Patients below the age of two at diagnosis
had to be excluded from these definitions of weight status as the Cole et al.,
(2007) and the IOTF (Cole et al., 2000) definitions do not include this age range.
 Girls aged 2 – 9 years who were deemed low risk of relapse (presenting WBC <
20 x 109/L) from the UKALL X dataset (as it is explained below).
2.2.4 UKALL trials studied in the present thesis
2.2.4.1 UKALL X protocol
The UKALL X trial involved 1,635 patients aged between one and 14 years. However,
23 patients were subsequently excluded from UKALLX trial as they were
misdiagnosed (Chessells et al., 1995). A total of 1,612 eligible patients therefore
entered into the trial between January 1985 and September 1990 (Chessells et al.,
1995, Mitchell et al., 2010).
This thesis will exclude patients of UKALL X data deemed to be high risk (Down’s
syndrome, diagnosed with CNS or presenting WBC > 100 x 109/L) and girls deemed
to be low risk (aged 2- 9 years old and presenting WBC > 20 x 109/L). Standard risk
was defined at the time of the trial as patients who had no CNS disease, initial WBC <
100 x 109/L (Weir et al., 1998). In the present study, 12 patients were excluded as
they were diagnosed with CNS disease at presentation because it is considered as a
confounder as it affects risk of obesity and affects risk of relapse. The exclusion
included 213 diagnosed as high risk to relapse that included patients with Down’s
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Syndrome because it is considered as a confounder since Down’s Syndrome both
increases the risk of obesity and increases risk of relapse in ALL; 347 girls were
diagnosed as low risk (Weir et al., 1998).  Therefore, the present study comprised
data on 1,040 ALL patients, all of whom were defined as standard risk as described
above.
The aim of this trial was to examine of the advantage of post-remission intensification
(Mitchell et al., 2010). Under the basic protocol treatment design, patients received a
four-drug induction therapy containing daunorubicin and L-asparaginase. In addition,
all patients received CNS directed therapy based on the child’s age, comprising
intrathecal methotrexate (three doses during induction, three doses during CRT and
one dose with each intensification block) and CRT (18 or 24 Gy) (Chessells et al.,
1997a, Wheeler et al., 1996). The five-year-survival rate for those with complete
remission was 98%, EFS (defined as the time between diagnosis and death) was
62%  and the overall survival (defined as the time since diagnosis until relapse or
death for any reason) was 77% in the total trial patients (Hargrave et al., 2001).
2.2.4.2 UKALL XI
The UKALL XI treatment protocol was for patients aged between one and 14 years
and covered all UK patients with ALL who consented to enter the trial from 1991 to
1997. A total of 14 patients were excluded from the trial due to misdiagnosis. The
number of patients entered into the trial was 2,090 (Mitchell et al., 2010). However,
patients who died before 28 days may not have been not included as a result of no
early randomisation and no binding requirement to register them in the trial (Hargrave
et al., 2001). UKALL XI was then modified during the trial up to the UKALL 92
protocol version; 1,688 of 2,090 patients were treated by UKALL 92 protocol (Hann et
al., 2001).
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Standard risk ALL patients were defined as presenting with WBC < 50 x 109/L and
aged 1 – 9 years old. However, the high risk patients were defined as initial WBC >
50 x 109/L and age less than one or more than 10 years old (Chessells et al., 2002).
So, patients with initial WBC < 50 x109/L were randomised to receive intrathecal
methotrexate with or without high dose intravenous methotrexate. However, patients
presenting with WBC > 50 x109/L were randomised to receive high dose systemic
methotrexate and CRT up to dose of 24 Gy (Mitchell et al., 2010).
There were some differences in the treatment protocols between UKALL XI and
UKALL 92 but these are broadly and generally considered to be the same trial (Hann
et al., 2001). For instance, induction anthracycline was used in UKALL XI, but was
cancelled in UKALL 92. Moreover, in UKALL XI, all patients were randomised
(regimen D) during early intensification (Week 5) whilst all UKALL 92 patients
underwent this stage. On the other hand, the UKALL XI protocol had a third
intensification stage which the UKALL 92 protocol lacked (Hargrave et al., 2001,
Richards et al., 1998). In both protocols, patients with positive CNS were treated with
24 Gy of CRT. The complete remission percentage was 99%.  EFS and overall
survival at five years were 63% and 85%; respectively, for patients who had been
treated using the UKALL XI protocol (Hargrave et al., 2001)
2.2.4.3 UKALL 97/97-99
The UKALL 97/97-99 (1997-2002) data comprised 1,935 patients who were entered
into the trial, whilst 13 patients were excluded due to misdiagnosis (seven AML, two
mature B-cell ALL, three non-Hodgkin’s lymphoma, one isolated CNS disease)
(Mitchell et al., 2005). Standard risk ALL patients were those aged less than 10 years
old and initial WBC < 50 x 109/L whereas the high risk patients were those aged more
than 10 years old and with initial WBC > 50 x 109/L (Mitchell et al., 2005).
The UKALL 97 trial enrolled patients aged between one and 18 years and began in
April 1997. UKALL 97 was broadly similar to previous protocols, namely UKALL XI
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(1992-1997). Induction anthracycline was not used in UKALL 97. Short intensification
blocks were given at weeks 5 and 20 and patients were selected at random to receive
a third intensification (Hann et al., 2001).
In 1999, MRC-UKALL amended UKALL 97 to resemble the US Children’s CCG trial
1992 protocol and labelled it UKALL 99.
In the case of the UKALL 97 protocols, CNS-directed therapy in all patients used 16
doses of intrathecal methotrexate based on the age of the child. Nonetheless, UKALL
99 used protocols based on Regimen A (23 doses of intrathecal methotrexate for
boys and 19 for girls) and Regimens B and C (26 doses of intrathecal methotrexate
for boys and 22 for girls). Patients with CNS disease at diagnosis were treated during
induction with additional intrathecal therapy and received CRT (24 Gy) during the
consolidation stage (Mitchell et al., 2005). EFS and overall survival at five years were
77% and 86%; respectively (Mitchell et al., 2010).
2.2.5 Confidentiality
Data were totally anonymised by CTSU in order to not identify any patients in any
way and each had a unique study ID. No personal ID, file numbers or anything related
to patients was shown in the data which the CTSU provided to the authors.
2.2.6 Anthropometric measurements
2.2.6.1 Height, weight and BMI
Height and weight were measured to 0.1cm and 0.1kg respectively in clinic at or
around the time of entry into the trials. Weight and height were therefore measured
for clinical rather than for research-based purposes, which could potentially lower the
quality of some of the measurements used. However, Power et al., (1997) note that
obtaining a high degree of precision in typical weight measurements is unlikely to
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require trained observers and continuous quality control. There is also an issue of
whether any individual errors are likely to be biased as the individual error is very
likely but the study was dealing with group assessments of nutritional status here and
these will only be affected if measures are biased rather than just erroneous.
Furthermore, it is worth noting that drug dosage depended on the methods (weight
and height) which might raise measurement standards.
Calculation of BMI was described earlier in this chapter, Software applying the LMS
method (available at :
http://www.healthforallchildren.com/index.php/shop/product/Software/Gr5yCsMCONp
F39hF/0.) was used to calculate BMI z score in this study according to the UK
reference population from 1990 (Cole et al., 1995).
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Table 2.2.1: Comparison of UKALL trials
UKALL X
(1985 - 1990)
UKALL XI
(1991 - 1997)
UKALL 97-99
(1997 - 2002)
n= 2090 n=1935Entered n= 1635
Pre-1992 Post-1992 Pre-1999 Post-1999
Induction
Anthracycline
Yes Yes No No No
Early
intensification
(week 5)
Randomised
(Arm B + D)
Randomised
(Arm D)
Yes Yes Yes
Second
intensification
( week 20)
Randomised
(Arm C + D)
Randomised
(Arm C + D)
Yes Yes Yes
Third
intensification
( week 35)
No No Randomised Randomised Yes
High dose MTX No Randomised
 WBC < 50: IT MTX
WBC > 50: CRT
Randomised
 WBC < 50: IT MTX
WBC > 50: CRT
 Pre-1999: the dosage
based on age.
 Post-1999: the dosage
based on gender.
CRT Yes
(18 or 24 Gy)
CNS-diseased
(24 Gy)
CNS-diseased
(24 Gy)
Period of
therapy
2 years 2 years 2 years
The protocol
results
(5 yr)
CR: 95%
EFS: 62%
OS: 77%
CR: 99%
EFS: 63%
OS: 85%
CR: 99%
EFS: 77%
OS: 86%
IT: Interathecal, MTX: Methotrexate, CRT: Cranial radiation therapy, WBC: White blood account (x
109/l), CR: complete remission, EFS: Event-free survival, OS: overall survival, Gy: Gray
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2.2.6.1.1 UK 1990 reference data for BMI
 Prevalence estimates in this study for overweight and obesity used UK BMI
population reference data from 1990 (Cole et al., 1995). The use of BMI for UK
children for age and sex expressed relative to national references has a significantly
higher sensitivity with no loss of specificity (few non-obese children will be classed as
obese) compared to the IOTF definition based on BMI (Reilly et al., 2010b, Reilly et
al., 2000b).
BMI z scores were calculated based on the UK 1990 reference (a survey of 15,636
males and 14,899 females was carried out between 1978 – 1990, which relied on a
combination of 11 distinct surveys). The UK 1990 reference data  was proposed to
represent weight, height and BMI in UK children (Cole et al., 1995). Centile curves for
UK children from 33 weeks gestation to 23 years were presented by (Cole, 1994) on
Cole’s LMS method to allow all individuals to be measured according to the z score
score. BMI distribution was adjusted for skewness (Cole et al., 1995) and z scores
and centiles can be calculated using software downloaded from
www.healthforallchildren.com. Weight status was classified as follows: healthy weight
(BMI SDS <1.04 (less than the 85th centile)), overweight (BMI z score 1.04≤ 1.64
(above the 85th centile, but < 95th centile )) and obese (BMI z score >1.64 (above the
95th centile)) (King et al., 2010, Cole et al., 1995, Barlow and Dietz, 1998, Reilly et al.,
2010b).
Validity of UK 1990 reference data as a means of describing weight status and
growth of British children in 1990
A number of studies have stated that the UK 1990 reference data (Cole et al., 1995)
are applicable in terms of growth and weight status assessments. For instance,
Savage et al., (1999) examined the validity of the UK 1990 reference data  for
assessing growth and nutritional status in 127 infants whose BMI was calculated at
the ages of six, nine, 12, 18 and 24 months. It was concluded that the UK 1990
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reference data contained only small biases and was clinically useful. Moreover, a
longitudinal study  examined the validity of the UK 1990 reference data amongst 694
primary school children in Leeds (Rudolf et al., 2001). They were first measured
between the ages of seven and nine and three years later when aged between nine
and 11. The use of the UK 1990 reference data in monitoring growth was
recommended. Reilly et al., (1999a) studied a community sample of 240 Scottish
prepubescent children (124 boys, 116 girls) whose mean age was 8.5 years (0.4) and
recommended applying the UK 1990 reference data to the assessment of obesity. A
growth reference group also reviewed the UK 1990 reference data  and found it
suitable for monitoring weight relative to height (Wright et al., 2002). However, as the
prevalence of overweight and obesity has increased substantially over time (Reilly et
al., 1999a, Kinra et al., 2000, Rudolf et al., 2001, Lobstein et al., 2003), it is
recommended that growth references should not be updated when comparing rates
of childhood obesity, as this will be affected by changes in obesity rates over time.
Updating them would thus define obesity as normal after the obesity epidemic (Wright
et al., 2002).
2.2.6.1.2 International Obesity Task Force and Cole et al. (2007) definitions
IOTF (Cole et al., 2000) and Cole et al. (2007) definitions were discussed in detail in
sections 2.1.3.1.4 and 2.1.3.1.5 in this chapter.
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Chapter 3
Weight status and metabolic syndrome in adolescent
survivors of standard risk childhood acute lymphoblastic
leukaemia in Saudi Arabia
This chapter describes a study which is now published, publication details as follows:
Pediatr Blood Cancer. 2012 Jul 15;59(1):133-7. doi: 10.1002/pbc.24012. Epub 2011 Dec 11.
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3.1 Introduction
As noted in chapter 1, briefly, Overweight and /or obesity in childhood and
adolescence leads to increase of risk of many well-recognised complications, notably
cardiovascular risk factors for instance hyperlipidaemia, hyperglycaemia and
hypertension (Freedman et al., 1987, Freedman et al., 1999, Han et al., 2010).
Moreover, underweight is also, related to short and long- term complications such as
disabilities, morbidity, mortality, adult size, intellectual ability, and metabolic and
cardiovascular disease (summarised in figure 1.2.1 and 1.2.2).
Using the recently developed Saudi growth chart for BMI for age (El-Mouzan et al.,
2007), a recent Saudi study (El Mouzan et al., 2010) ( the national sample size was
19,317) concluded that amongst 19317 children and adolescents aged 5- 18 y, the
prevalence of overweight ( ≥85th percentile ) was  23.1%, while prevalence of obesity
was 9.3%   ( ≥95 th percentile) and 2% of the sample was defined as severely obese
(≥97th percentile). Since the Saudi BMI for age chart is a very conservative way of
defining obesity, as it has very high BMI values at standard percentiles such as the
95th centile, this suggests that obesity prevalence among adolescents in Saudi Arabia
is now extremely high.
According to some studies, obesity risk in ALL patients increases at or after treatment
(Chow et al., 2007 , Meacham et al., 2005). A longitudinal study from the USA
illustrated that the prevalence of being overweight (defined as BMI= 25- 29 or 85th -
94th percentile) and obese (defined as BMI ≥30 or 95 th percentile) based on CDC
2000 growth chart at the diagnosis of ALL were 12.7% and 10.9%, respectively.
However, after completion of treatment, the rates were 17.0% and 21.2% (p value=
0.01); respectively (Chow et al., 2007). Furthermore, it has been reported in the
Childhood Cancer Survivors Study (CCSS) in the US that the OR for being
underweight in ALL survivors was 2.4 (Meacham et al., 2005). However, the
estimated prevalence of unhealthy weight status according to all reviewed literature
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(as listed in table 1.5.1) was influenced by many factors. First of all, the survivors
were studied retrospectively with sometimes small sample sizes. Also, most of the
previous studies included heterogeneous groups of survivors diagnosed with different
ALL types and  treated with different protocols which included CRT and
chemotherapy in most studies (van Beek et al., 2006 , Nysom et al., 1999 , Love et
al., 2011), and all of these differences are likely to have an influence on weight status.
Furthermore, good estimates of prevalence of unhealthy weight status in the long-
term for more modern protocols are needed so that proper intervention by health
practitioners can be considered.
MS may be more common than might be expected in children or adolescents who are
survivors of ALL. Gurney et al., (2006) examined the prevalence of MS as defined by
NCEP III criteria and growth hormone deficiency in adult survivors (the mean age was
30 years) of childhood ALL.  The sample size was 75 (25 did not receive CRT, 25
received < 24 Gy CRT, 25 received ≥ 24 Gy CRT) survivors randomly selected. They
reported that 11 (14.7%) of the survivors met MS criteria. Moreover, 9/11 who had
met MS criteria had received CRT. Nevertheless, several major problems exist in the
literature on MS in childhood ALL: to our knowledge most of the studies to have taken
place in survivors were very limited. No studies were carried out children and
adolescents from outside  western countries world except the Iranian study that was
mentioned above (Reisi et al., 2009).   However, no evidence to date has shown the
prevalence of MS outside the western world amongst children and adolescent
survivors with Standard Risk ALL (Reisi et al., 2009).
3.2 Aims
The present study was not hypothesis testing, but aimed to provide estimates of the
prevalence of unhealthy weight status and MS in medium term survivors of standard
risk ALL in Saudi Arabia, providing evidence that should be useful in the future
planning of clinical nutritional services for ALL survivors. A secondary aim was
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methodological, i.e. to test the extent to which the different definitions of unhealthy
weight status and different definitions of MS produced differences in prevalence.
3.3 Methods
The present thesis methods are described in detail in section 2.1; however, it is worth
mentioning some of methods briefly here.
3.3.1 Participants and study design
The present study is a cross sectional study in which, the survivors recruited
numbered 77. The number of survivors excluded was 8. The potentially eligible
participants numbered 69, and 56 of these survivors agreed to take part in the study,
13 did not. This sample numbering 56 had characteristics that were similar to the
sample of 69 though the small number of those who did not consent precluded
statistical analysis of differences between those who consented and those who did
not (see table 3.3.1) - the characteristics available from the KFSH&RC system were
gender, age, age at diagnosis and period of the therapy, therefore. The limited
sample size and limited number of potential variables meant that for some aspects of
the present study only an exploratory statistical analysis could be made.
3.3.2 Anthropometric data
Height and weight were measured to the nearest 0.1 cm. WC was measured using
the 4 cm above umbilicus method as recommended by Rudolf et al., (2007) and as
described above in section 1.4.5.1.6.
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3.3.3 Classification of weight status
The international BMI reference data related to age is available and provided by the
WHO(de Onis et al., 2007), the CDC (Kuczmarski et al., 2000), IOTF (Cole et al.,
2000) and Cole et al., (2007). These definitions were also applied within the study.
Table 3.3.1: Characteristics of the potentially eligible survivors who did not
agree (n=13) and who agreed (n= 56) to participate
Patients not consented Patients consented
Total group, mean (± SD)
Gender 69.2% (n= 9) boys,30.8%
(n= 4) girls
60.7% (n= 34) boys, 39.7%
(n= 22) girls
Age (yr) 13.2 (5.5) 13.4 (4.1)
Age at Diagnosis (yr) 4.2 (1.5) 4.3 (1.9)
Period of chemotherapy (yr) 2.9 (0.5) 3.0 (0.5)
3.3.4 Body composition
Body composition was measured by using, firstly, DXA Lunar Prodigy hardware, and
software version 9.15. The number of survivors who were examined was 51 as
described above in section 2.1.5.2 and adult and paediatric manufacturer’s reference
data were used. Secondly, a BIA instrument (Body Composition Analyser; Inbody 3.0;
Biospace © 2001) was used to estimate body composition 53 out of 56 survivors as
described above in section 2.1.5.1.  The algorithm used by the BIA analyser was
unknown and is a commercial secret.
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3.3.5 Blood collection
The Blood sample was withdrawn by the lab technicians. The sample was analysed
to test HDL-C, TG, fasting glucose and fasting insulin at KFSH&RC laboratories (see
section 2.1.7).
3.3.6 Metabolic syndrome: definition and measurement
The present study was able to determine the presence or absence of MS by using:
the IDF approach (Zimmet et al., 2007) and  NCEP III as modified by Cook et al.,
(2008) as described above in section 2.1.8. Blood pressure measurement was
performed by staff nurses at KFSH&RC using CASMED® 740 monitor for measuring
BP as described above in section 2.1.4. Also, HOMA calculator (version 2.2.2) was
used for HOMA-IR as described earlier in section 2.1.9.
3.3.7 Statistical analysis, power and sample size
A fixed number of standard risk ALL Saudi survivors of ALL were available, treated at
KFSH&RC on protocol 1891. No formal power calculation was therefore carried out
for the present study, since the number of survivors available was fixed. However, the
number of survivors who were recruited was similar or larger from many previous
studies of weight status and MS in ALL (Reisi et al., 2009a, Pakakasama et al., 2010,
Warner et al., 2004b). For some aspects of the studies formal post-hoc power
calculations were available and could show that the sample available was sufficient
for those particular studies (Warner et al., 2004).
Means (SD) are presented in the results unless otherwise stated. Normality of data
was tested by using Normality tests in Minitab 15.1.30.0 software package and the
data were considered to be normally distributed when p > 0.05. Minitab 15.1.30.0
software was used for all statistical analyses except for the weighted kappa (k)
analysis described below. A p value of < 0.05 was considered as significant.
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A two-sample t-test for normal distribution was used to test the significance of the
difference in the mean between the numerical variables in different groups. Also, two
proportions tests were applied to compare between two proportions. Multivariate
linear-regression analyses were performed to test for associations between BMI z
score and a number of different explanatory variables in exploratory analyses.
Exploratory analyses were statistical analyses which were used to examine possible
associations in the data which had been proposed by other studies. These were
exploratory because they might not have been adequately powered. Also, the age
variable was split into the age at the time of study and age at diagnosis to test the
influence both of them on weight status, body fatness and MS.
The k test was used to identify the degree of agreement between the different
approaches to defining underweight, healthy weight, overweight, obesity, and over-
fatness with calculation of 95% CI. We also used the k analysis as a preliminary test
of agreement between the two definitions of paediatric MS. The k statistics were
interpreted as recommended by (Landis and Koch, 1977): ‘‘slight agreement’’ 0.0–
0.20; ‘‘fair agreement’’ 0.21–0.40; ‘‘moderate agreement’’ 0.41–0.60; ‘‘substantial
agreement’’ 0.61–0.80; ‘‘almost perfect agreement’’ 0.81–1.00). The k statistic
analyses were performed using Medcalc software version 11.5.0.0.
3.4 Results
Characteristics of study participants
The number of consented survivors was 56 (34 male, 22 female). The mean (SD)
weight of the sample was 46.7 kg (17.5). The mean (SD) age at the time of the study
was 13.4 years (4.1). The mean (SD) age at diagnosis was 4.3 years (1.9). Mean
time (SD) from diagnosis was 9.1 years (4.1), and time from end of therapy was 6.2
years (3.9) Characteristics of study participants are shown in table 3.4.1.
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Table 3.4.1: Overall sample characteristics, mean (SD)
Males
n= 34
(60.7%)
Females
n= 22
 (39.7%)
Total group
Mean ( SD)
Age (yr) 13.0 (4.6) 14.0 (3.1) 13.4 (4.1)
Height (cm) 1.49 (0.20) 1.51 (0.11) 1.50 (0.17)
Weight (kg) 42.0 (16.9) 49.3 (18.4) 46.7 (17.5)
Age at diagnosis 3.9 (1.9) 4.9 (1.9) 4.3 (1.9)
Time from diagnosis (yr) 9.1 (4.5) 9.1 (3.2) 9.1 (4.1)
 Time since completion of therapy (yr) 5.9 (4.5) 6.7 (3.1) 6.2 (3.9)
CDC BMI-z score * -0.17 (1.6) 0.16 (1.3) -0.03 (1.48)
WHO  BMI-z score^ 0.14 (2.0) 0.31 (1.5) 0.21 (1.77)
% Body Fat by BIA (for 31 M, 22 F) § 20.7 (8.6) 29.1 (9.4) 24.2 (9.8)
% Body Fat by DXA (for 33 M, 18 F) § 24.7 (10.6) 37.6 (8.8) 29.2 (11.7)
CDC: US Centres for Disease Control and Prevention; WHO: World Health Organisation; BIA:
Bioelectrical impedance; DXA: Dual-energy X-ray absorptiometry; yr: years §% total body fat >25% and >32% in males and females amongst > 18 years. For who aged 5- 18 yrs
defined as % total body fat > 25% for males >30% for females
* No significant difference between genders (p vale= 0.4; 2 sample t-test)
^ No significant difference between genders (p vale= 0.7; 2 sample t-test)
3.4.1 Prevalence of overweight and obesity
The prevalence of combined overweight and obesity was lower when using the local
Saudi BMI reference data (El-Mouzan et al., 2007) (prevalence 21.4%; 12/56
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survivors) than when applying the alternative approaches (prevalence of combined
overweight and obesity varied between 28.6% (n= 16/56) and 32.1% (n= 18/56) for
CDC (Kuczmarski et al., 2000), IOTF (Cole et al., 2000) and WHO (de Onis et al.,
2007) approaches. Prevalence data are shown in figure 3.4.1 and table 3.4.2 for more
details.
3.4.2 Prevalence of underweight
Underweight prevalence slightly differed between the four approaches, as illustrated
in table 3.4.2 and figure 3.4.1. The highest prevalence of underweight survivors was
21.4% (n= 12), using the Cole et al., (2007) definition, however, the lowest prevalence
was 8.1% (n= 5) estimated using the national definition (El-Mouzan et al., 2007). Use
of the WHO (de Onis et al., 2007), and CDC (Kuczmarski et al., 2000) definitions the
prevalence of underweight ranged from 12.5% (n= 7) -17.9% (n= 10).
Table 3.4.2: Prevalence of obesity, overweight and underweight by four
different approaches
Reference approaches Obesity
(n), %
Overweight
(n) %
Underweight
(n),%
Saudi* (4) 7.1 (8) 14.3 (5) 8.9
 IOTF and Cole et al. (2007) § (5) 8.9  (13) 23.2 (12) 21.4
CDC* (6) 10.7 (10) 17.9 (10) 17.9
WHO† (6) 10.7  (12) 21.4 (7)12.5
* Obesity defined as ≥95 th percentile; overweight defined as 85th to <95th percentile and underweight
defined as <5th percentile; † BMI z score defined Overweight as >+ 1 z score; obesity as >+ 2 z score
and underweight/ thinness as < -2 z score; §Definitions for underweight, overweight and obesity
tabulated values of BMI for age and sex for who aged between 2- 18 years
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Figure 3.4.1: Prevalence of Overweight and Underweight by different
approaches
CDC: US Centres for Disease Control and Prevention; WHO: World Health Organisation. Cole et al:
the international obesity task force (IOTF) and Cole et al. (2007)
3.4.3 Body composition of the sample by BIA and DXA
The mean (SD) of % total body fat (%TBF) by using DXA was 24.7% (10.6) for males
and 37.6 % (8.8) for females. The difference in %TBF between males and females
was significant (2 sample t-test; 95% CI for difference: (7.1, 18.8); p value < 0.001).
The mean (SD) %TBF by using BIA was 20.7 (8.6) for males and 29.1% (9.4) for
females-this was a significant difference between males and females (2 sample t-test;
95% CI for difference: (- 13.3, -13.4); p value < 0.001).
According to the DXA estimates of body fatness, more than half (52.9%, 27 out of 51)
survivors had over-fatness. By using BIA, more than third of the sample had over-
fatness (35.9%, 19 out of 53).
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3.4.4 Exploratory analysis of factors associated with weight status and body
fatness of the sample
BMI z scores were not significantly different between male and female survivors when
using both CDC (Kuczmarski et al., 2000) (2 sample t-test; 95% CI for difference:
(-1.136, 0.807); p value=0.4) and WHO reference data (de Onis et al., 2007) to
calculate the z scores (2 sample t-test; 95% CI for difference: (-0.450, 1.122); p
value=0.7)).
In this section, the survivors were separated into those diagnosed ≥6 or < 6 years old,
and this is a ‘natural’ breakdown of age for ALL patients, into those diagnosed at a
typical time and those diagnosed later (mean age of diagnosis usually around age 4
years) which has been used in a number of other studies. So, BMI z score was not
significantly different between males and females diagnosed ≥ or < 6 years old (2
sample t-test; p value=0.07). However, none of the patients diagnosed at age ≥ 6
years old were underweight using Saudi (El-Mouzan et al., 2007), CDC (Kuczmarski
et al., 2000), IOTF and WHO (de Onis et al., 2007) definitions.
The over-fatness by using DXA was 11.8% (6 out of 13), 21.6% (11 out of 21) and
19.6% (10/17) for survivors aged 5 - 10 years, 10 -15 years and >16 years;
respectively. By Using BIA, over-fatness for survivors aged 6 -10 years was 5.7% (3
out of 11), for who aged 10 -15 years was 16.9% (9 out of 24) and for who >16 years
was 13.2% (7 out of 18).
Moreover, prevalence of over-fatness by using DXA was higher in those diagnosed at
< 6 years (43.9% (18 out of 41)) than those diagnosed ≥ 6 years (90.0% (9 out of10))
(p value <0.0001, 95% CI: -0.70 , -0.22; two proportions method).  Similarly, over-
fatness by using BIA was higher in those diagnosed < 6 years (6 out of 10) than those
aged ≥ 6 years (13 out of 43) but it was not significant (p value= 0.08, 95% CI: -0.03,
0.63; two proportions method).
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Since the above mentioned exploratory analyses were univariable, multivariate
regression was also carried out in the exploratory analyses., In the multivariate,
analysis BMI z score was not significantly influenced by gender (p value = 0.63), age
(p value= 0.06), and period off therapy (p value= 0.61).
3.4.5 Agreement between different approaches in defining weight status
Agreement between the different approaches based on BMI for age, using weighted
Kappa statistics (k) (Landis and Koch, 1977), was ‘‘moderate-substantial’’ (Landis and
Koch, 1977) between use of the Saudi (El-Mouzan et al., 2007) approaches versus
those from the CDC (Kuczmarski et al., 2000) (k = 0.70; 95% CI: 0.55- 0.85) and
WHO (de Onis et al., 2007) (k = 0.67; 95% CI: 0.51- 0.83). There was poorer
agreement between the Saudi approach (El-Mouzan et al., 2007) and the Cole et al.,
(2007) and IOTF (Cole et al., 2000) approaches to defining weight status (k = 0.47;
95% CI: 0.27 – 0.67).
“Almost perfect’’ (Landis and Koch, 1977) agreement was shown between CDC
(Kuczmarski et al., 2000) and WHO (de Onis et al., 2007) approaches (k = 0.86; 95%
CI: 0.75- 0.96). CDC (Kuczmarski et al., 2000) and IOTF (Cole et al., 2000) had
substantial agreement (k = 0.63; 95% CI: 0.45- 0.81), whereas “moderate” agreement
was found with IOTF (Cole et al., 2000) and WHO (de Onis et al., 2007) approaches
k= 0.52; 95% CI: 0.33- 0.71) as shown in table 3.4.3.
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Table 3.4.3: Extent of agreement (weighted kappa statistic) between different
Approaches
Weight status
approaches
Weighted
kappa
95%
Confidence
interval
Level of
agreement
(Landis and
Koch, 1977)
Saudi vs. CDC 0.70 0.55 - 0.85 Substantial
Saudi vs. IOTF 0.47 0.27 - 0.67 Moderate
Saudi vs. WHO 0.67 0.51 - 0.83 Substantial
CDC vs. IOTF 0.63 0.45 - 0.81 Substantial
IOTF vs. WHO 0.52 0.33 - 0.71 Moderate
CDC vs. WHO 0.86 0.75 - 0.96 Almost perfect
CDC: US Centres for Disease Control and Prevention; WHO: World Health Organisation. IOTF: The
International Obesity Task Force
3.4.6 Agreement between different approaches in assessing over-fatness:
The agreement between the various approaches that defined overweight and obesity
using the BMI for age with measures of over-fatness using DXA when assessed by
weight kappa analysis was “fair” when based on Saudi reference data (El-Mouzan et
al., 2007) (k= 0.24; 95% CI: 0.08 – 0.39), the CDC (Kuczmarski et al., 2000) (k= 0.34;
95% CI: 0.16 – 0.51), the WHO (de Onis et al., 2007) (k= 0.39; 95% CI: 0.21 – 0.57)
and IOTF (Cole et al., 2000) approaches (k= 0.22; 95% CI: 0.03 – 0.41). Also, “Fair
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agreement” was also found between DXA and BIA (k= 0.34; 95% CI: 0.13- 0.55) (as
shown in table 3.4.4).
Table 3.4.4: Extent of agreement (weighted kappa statistic) between different
approaches for defining over-fatness
Over-fatness
references
Weighted
kappa
95% Confidence
interval
Level of agreement
(Landis and Koch, 1977)
DXA vs. BIA 0.34 0.13 - 0.55 Fair
DXA vs. Saudi 0.24 0.08 - 0.39 Fair
DXA vs. CDC 0.34 0.16 - 0.51 Fair
DXA vs. IOTF 0.22 0.03 - 0.41 Fair
DXA vs. WHO 0.39 0.21 - 0.57 Fair
BIA vs. Saudi 0.24 0.02 - 0.46 Fair
BIA vs. CDC 0.47 0.25 - 0.69 Moderate
BIA vs. WHO 0.48 0.26 - 0.70 Moderate
BIA vs. IOTF 0.27 0.04 - 0.51 Fair
CDC: US Centres for Disease Control and Prevention; WHO: World Health Organisation; IOTF: The
International Obesity Task Force; BIA: Bioelectrical impedance; DXA: Dual-energy x-ray
absorptiometry
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Defining overweight and obesity based on BMI for age by using different approaches
versus measurement of over-fatness by BIA was “fair-moderate agreement” by using
Kappa statistics. The Saudi (El-Mouzan et al., 2007) and IOTF (Cole et al., 2000)
approaches had the lowest agreement with BIA (k= 0.24; 95% CI: 0.02- 0.46) and (k=
0.27; 95% CI: 0.04- 0.51); respectively. However, “moderate agreement” was
observed between BIA and CDC (Kuczmarski et al., 2000) approaches (k= 0.47; 95%
CI: 0.25- 0.69) and the WHO approach (k= 0.48; 95% CI: 0.26- 0.70); as shown in
table 3.4.4.
3.4.7 Descriptions and prevalence of MS and ‘metabolic syndrome components’
(MSC)
Characteristic of the MS and metabolic syndrome component(s) (MSC) for the
sample is shown in the table 3.4.5.
In the overall sample, 5.4% of survivors (3/56) were defined with MS using the NECP
III definition, as well as 7.1% (3/42) with MS by the IDF definition. Prevalence of
survivors who had 1 MSC were 37.5% (21/56), 35.7% (15/42) by applying NECP III
and IDF criteria; respectively. Also, by using both criteria, 7.1% (4/56) and 11.9% of
survivors had 2 MSC; respectively.
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Table 3.4.5: Characteristic of metabolic syndrome components (MSC)
IDF NCEP IIICardiometabolic risk factors Mean (SD)
% (n) of patients
above criteria
Waist circumference  (cm) 67.2 (12.0) 10.7 (6) 7.1 (4)
Systolic blood Pressure (mmHg) 112.8 (11.6)
Diastolic blood Pressure (mmHg) 68.1 (9.3)
16.7 (7) 25 (14)
Fasting glucose (mmol/l) 5.20 (0.53) 16.7(7) 14.3 (8)
Triglycerides  (mmol/l) 0.83 (0.40) 4.8 (2) 3.6 (2)
HDL-C (mmol/l) 1.36 (0.31) 0 (0) 0 (0)
IDF: the International Diabetes Federation; NCEP III: The National Cholesterol Education Program
Third Adult Treatment Panel guidelines modified by Cook et al. (2008), HDL-C: High density lipoprotein
cholesterol
Metabolic syndrome components above IDF and NCEP III criteria
Prevalence of each single individual MSC (table 3.4.5) amongst the survivors was as
follows: WC was above the normal range in 10.7% (6 out of 42) aged 10 and above
according to IDF criteria. However, 7.1% (4 out of 56) were diagnosed with central
obesity by using NCEP III criteria.  One quarter of the patients (14 out of 56) had
abnormal BP by applying NCEP while IDF defined 16.7 % (7 out of 42) of the patients
with abnormal BP.  Hyperglycaemia was present amongst 16.7% (7 out of 42) and
14.3% (8 out of 56) of the patients by using IDF and NCEP III as modified by Cook et
al., (2008) criteria; respectively.
In both definitions, 2 patients were diagnosed with high triglycerides and all of them
were either overweight or obese male (defined by CDC BMI (Kuczmarski et al.,
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2000)). By applying NECP III and IDF criteria, the percentage of male patients
diagnosed with high BP was 14.3% and 9.5%, respectively, and for female patients
was 10.7% and 7.1%, respectively. Insulin resistance was identified in 29.1% of the
survivors by using HOMA-IR defined as ≥ 1.77 (Arshi et al., 2010).
3.4.8 Metabolic syndrome components (MSC) in different age groups
All patients were divided into 3 age group periods, those age groups suggested by
the IDF, to spotlight the number and percentage of risk factors by using both IDF and
NCEP III definitions as shown in table 3.4.6 and figure 3.4.2. The IDF does not
provide a definition of MS for any child 5 – 10 years old.
One quarter of the patients had one MSC by applying IDF criteria and about one third
of them had one risk factor when NCEP III was applied. In both definitions, half of
patients  aged ≥16 years old had one MSC, whereas 11.1% (2 out of 18) and 5.6%
(one out of 18) of them were identified with two MSC by IDF and NCEP III definitions;
respectively.
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Table 3.4.6:  Prevalence MSC according to different age group
IDF NCEP
Age Period
1 MSC
n, (%)
2 MSC
n, (%)
1 MSC
n, (%)
2 MSC
n, (%)
5-10 yr (25%) - - -* - - -* 5/14 (35.7) 1/14 (7.1)
10-16 yr (42.9%) 6/24 (25) 3/24 (12.5) 7/24 (29.2) 2/24 (8.3)
≥16 yr (32.1%) 9/18 (50) 2/18 (11.1) 9/18 (50) 1/18 (5.6)
IDF: the International Diabetes Federation; NCEP III: The National Cholesterol Education Program
Third Adult Treatment Panel guidelines modified by Cook et al. (2008). MSC: Metabolic syndrome
component. * IDF definition does not define metabolic syndrome for any child aged 6 – 10 years
3.4.9 Metabolic syndrome components and weight status classification
Amongst the overweight and/or obese (defined by CDC (Kuczmarski et al., 2000))
survivors, who had 12.5% (2/16), had one MSC while a quarter of them (4/16) had 2
MSC. However, non- overweight survivors who had 1 MSC were 37.5% (15/40)
although only 5% (2/40) had 2 MSC. Approximately a fifth of overweight and obese
survivors were defined with MS (defined by NECP III), but non-overweight survivors
were not defined with MS defined by NCEP III, as shown in figure 3.4.3.
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Figure 3.4.2: Prevalence metabolic syndrome components/risk factors
according to different age groups
A: Based on NCEP III definition
B: Based on IDF definition
IDF: The International Diabetes Federation; NCEP III: The National Cholesterol Education Program
Third Adult Treatment Panel guidelines modified by Cook et al. (2008); MSC: Metabolic syndrome
component(s)
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Figure 3.4.3: Weight classification defined by CDC definition and MSC defined
by NECP III definition
NCEP III: The National Cholesterol Education Program Third Adult Treatment Panel guidelines
modified by Cook et al. (2008); CDC: US Centres for Disease Control and Prevention; MS: Metabolic
syndrome; MSC: Metabolic syndrome component(s)
3.4.10 Metabolic syndrome and metabolic syndrome components and age at
diagnosis
All survivors defined with MS using NCEPIII criteria (n= 3) were diagnosed with ALL
when they were less than 6 years old. The number of survivors diagnosed after 6
years old with one MSC was 5 (8.9%), while 28.6 % (n= 16) had one MSC for those
diagnosed before 6 years old.
Survivors diagnosed before 6 years old with 2 MSC were 7.1% (n= 4), while only one
survivor (1.8%) had 2 MSC for those who diagnosed after 6 years old. None of
survivors who diagnosed after 6 years old had MS, as shown in figure 3.4.4.
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Figure 3.4.4: Metabolic syndrome components (defined by NCEP III) amongst
patients diagnosed with ALL before and after 6 years old
3.4.11 An exploratory analysis of factors associated with MSC
The WC absolute value measurement was not significant different between male and
females (Mann-Whitney; p value= 0.72). WC was correlated with TG, LDL-C, HDL-C
and HOMA-IR (r=0.38, 0.35, -0.29 and 0.27 and p value= 0.004, 0.01, 0.03 and
0.046; respectively). Moreover, there was a significant correlation between high WC
measurement and high BP reading which are based on IDF cut-offs (r=0.43; p value=
0.001). According to NECP III criteria, 75% (3 out of 4) of central obese (defined as
high WC) survivors were hyperglycaemic, while 40% (2 out of 5) who met IDF criteria
for non-central obese (defined as high WC) survivors were hyperglycaemic.
A higher CDC BMI z score was significantly correlated with high TG or LDL-C
similarly (r=0.35; p value=0.01). Also, There was an association between the periods
of chemotherapy and serum TG (Pearson correlation=0.37; p value=0.005).There
was no correlation between fasting glucose and CDC BMI z score and LDL-C.
There was a significant correlation between high insulin resistance and high %TBF by
DXA (r=0.31; p value= 0.03) and trunk %TBF by DXA (r= 0.33; p value= 0.02).
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Furthermore, a significant correlation was found between fasting insulin and WC and
%TBF by DXA and BF% by DXA (r= 0.26, 0.31 and 0.33; p value=0.05, 0.03 and
0.02, respectively). There was a significant correlation between LDL-C and fasting
insulin (r=0.72; p value=0.049).
3.5 Discussion
3.5.1 Main findings and implications
The present study shows that nearly half of the survivors of childhood ALL at one
centre in Saudi Arabia had unhealthy weight status (underweight, overweight or
obesity) by applying international approaches to defining weight status based on BMI
for age and 30.3 % had unhealthy weight by applying Saudi approaches based on
BMI for age (El-Mouzan et al., 2007) after an average of 6.2 years completion of
chemotherapy. While this was a small single centre study if these results were
replicated across other non-western countries they would give cause for concern
about unhealthy weight status in survivors of ALL. The causes of unhealthy body
weight in ALL Saudi survivors are beyond the scope of the present study, therefore,
future studies for the investigation is recommended, but factors which have been
shown to be related to the development of obesity in ALL were described in chapter 1
(section 1.5.6). The important clinical implication for the present study is that
promoting regular physical activity and behavioural and dietary interventions designed
to prevent unhealthy body weight amongst ALL survivors would seem to be important
given the fact that over-fatness was quite common. Moreover, preventing unhealthy
body weight is likely to be more effective than weight reduction programmes for those
patients/survivors already overweight or obese. The intervention programmes for
weight reduction in cancer survivors that involved the patients and their family in
behavioral, dietary and physical activity modification are more likely to be effective
than dietary modification alone (Slawta et al., 2006).  Further research is needed to
evaluate the effectiveness of prevention and intervention programmes for unhealthy
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body weight in survivors of ALL in Saudi Arabia and this point is discussed in the final
chapter of this thesis.
Secondary aims of the present study were to examine over-fatness from DXA and
BIA in the first remission amongst Saudi standard risk ALL survivors. Over-fatness
was present in over half of the sample by using DXA and over one third of the sample
by using BIA. It is possible that DXA might identify more cases of overnutrition or
undernutrition than simpler measures based on BMI for age and sex. BMI for age has
limited ability to identify body fatness rather than lean mass information (Wells and
Fewtrell, 2008). It is likely that BMI based approaches to defining overweight and
obesity will underestimate the scale of the problem in survivors of ALL as discussed
in the introduction chapter (section 1.4.5.1.5). Underestimation of overweight and
obesity might be even greater using the local (Saudi) reference data, and this is
probably because the Saudi BMI reference data had been collected in the period
2004 – 2005 probably after the childhood obesity epidemic had affected Saudi Arabia
(El Mouzan et al., 2010). To be more precise, Al-Hazzaa, (2007b) studied a nationally
representative sample from 1988 to 1996. They showed that for adolescents age 10 –
20 years BMI at 50th percentile and 90th percentile was rising during the 8 years prior
the data collected by El Mouzan et al., (2010) (clarified in figure 3.5.1).
Estimates of obesity prevalence using the IOTF approach (Cole et al., 2000) are
known to be highly conservative in their assessment of overweight and obesity (Reilly
et al., 2010b) (as discussed in section1.4.5.1.5) i.e. they have a high false negative
rate (a high proportion of those defined as obese by BMI using IOTF (Cole et al.,
2000) method will have over-fatness) and yet the estimate from use of Saudi
population reference data (El-Mouzan et al., 2007) was even more conservative. For
example, in the present study, the IOTF (Cole et al., 2000) definition identified 32% of
the survivors as either overweight or obese while the Saudi definition (El-Mouzan et
al., 2007) only found 21%.
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Figure 3.5.1: BMI at 50th percentile and 90th percentile trends over 8 years in
Saudi adolescents
Source: modified from Al-Hazzaa, (2007b)
The present study therefore suggests that caution should be used when applying BMI
for age to define paediatric overweight and obesity in ALL survivors, and even more
caution should be used when considering whether or not to use local (national)
reference data for BMI when these reference data have been ‘contaminated’ by the
obesity epidemic. Some believe that ideally such reference data should have been
collected in the period that pre obesity epidemic; such data might then be considered
as a ‘‘standard’’. Data that have been collected in recent years shows a relatively
higher prevalence of increase in unhealthy weight status described norms, El-Ghaziri
et al., (2011) examined the impact of the using national vs. international IOTF (Cole et
al., 2000), Cole et al., (2007), WHO (de Onis et al., 2007), CDC (Kuczmarski et al.,
2000)  amongst 499 (age: 10 – 14 years) Kuwaiti adolescents.  They found that
prevalence of combined of overweight and obesity was 36.7% and prevalence of
obesity was 14.6% by using Kuwaiti reference data and these prevalence were
significantly (p value < 0.01) lower when compared to the international approaches
Years Years
%
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they tested.  They concluded that more recent national reference data for BMI should
be considered with caution in terms of defining unhealthy weight status. The present
study may support the argument that using the international definitions for defining
weight status is superior to the Saudi definition in ALL survivors.
MS in children and adolescent has no universally accepted definition, and MS
prevalence depends on the definition of MS being used. By using both of the currently
common definitions, prevalence of MS amongst the survivors was uncommon;
however, it was more common in the overweight and obese survivors rather than
non-overweight. Similarly, Goodman et al., (2005) found same findings that obesity in
children is stronger predictor of cardiovascular risk factors (Martinez-Vizcaino et al.,
2011).
 However, the present study has shown that the prevalence of   metabolic syndrome
component(s) was common and they were probably increasing with survivor age.
Previous studies  such as The Quebec Family Study, (Katzmarzyk et al., 2001) found
significant persisting of MS components from childhood into adulthood as described
in section 1.3.5.3.2. Moreover, Berenson et al., (1998) have shown that pathological
processes associated with the progress of atherosclerosis or CVD, fatty streaks and
fibrous plaques in the coronary and aorta arteries began during childhood. With these
MSC manifesting in ALL survivors in medium term, early existence of cardiovascular
risk factors will emerge as major and challenging in clinical settings. Therefore, health
professionals should pay more attention to overweight and obesity among survivors.
Also, early screening for unhealthy weight status, various MSC, and early intervention
MS or MSC amongst ALL survivors should be considered. Further research focused
on effectiveness of promotion of modification of lifestyle in survivors of ALL is needed
as discussed in the final chapter of this thesis.
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3.5.2 Unhealthy weight status prevalence in the general population in Saudi
Arabia
There has been a marked increase in overweight and obesity in Saudi children and
adolescents in the last two decades (Al-Hazzaa, 2007a) as described elsewhere in
this thesis. In Jeddah, for example, (the second largest city in Saudi Arabia) school
children were surveyed in 1994 (n= 2708) and 2000 (n= 2542). The researchers
found BMI percentiles at the equivalent percentiles were elevated  between 1994 and
2000 (Abalkhail, 2002). It is shown clearly in figure 3.5.1 modified from Al-Hazzaa,
(2007b).
The present study findings regarding the apparently high prevalence of overweight
and obesity by applying the international approaches, prevalence of overweight and
obesity combined was (by CDC (Kuczmarski et al., 2000) and WHO (de Onis et al.,
2007) approaches) broadly resembled the more recent national Saudi survey (El
Mouzan et al., 2010) that applied a multi-stage probability random sampling design:
and which investigated 19,317 (50.8% boys) healthy children and adolescents aged
5- 18 yr old. El Mouzan et al., (2010) estimated the prevalence of overweight and
obesity  (defined by BMI Z score +1 and +2 according to 2007 WHO cut-offs) and
(CDC defined  BMI >85th for overweight percentile and >95th percentile for obesity)
relative to 2005 Saudi reference data for BMI from Al Herbish et al., (2009) . This
large cross-sectional study found that prevalence of overweight and obesity combined
in the overall sample according to WHO and CDC approaches was 33.2 and 26.1%;
respectively. However, the prevalence of overweight and obesity combined defined
according to Saudi reference data by El Mouzan et al., (2010) in Saudi children  was
34.4% whereas the present study found the prevalence was much lower (21.4%) by
using same reference data. This suggested that although the prevalence of
overweight and obesity for the ALL survivors in the present study (shown in table
3.4.2) seemed high with all four definitions used, the prevalence may actually be
lower in the sample than the prevalence in the general population in Saudi Arabia,
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due possibly to differences in sample size between the current study and El Mouzan
et al., (2010) study  the nature of the disease, its treatment, and their impact on
obesity risk.
El-Hazmi and Warsy (2002) reported that 18.8% of children and adolescents in Saudi
Arabia aged 6 –18 yrs, recruited from different Saudi regions between 1994 - 1998
(n= 11,080),  were overweight or obese combined (according to the IOTF (Cole et al.,
2000) definition). However, the present study found much higher prevalence (32.1%)
by using same definition if the data collection period is not taken in the account. The
difference in prevalence between the prevalence of overweight and obesity in the
present study and El-Hazmi and Warsy (2002) in probably due to the time period of
about 8 years between the two studies.
To best our knowledge, there is no literature that uses the new Saudi reference data
to investigate the prevalence of underweight in children and adolescents in Saudi
general population. Moreover, there is no study Saudi study of underweight
prevalence which was nationally representative. However, in a study  that aimed  to
investigate the prevalence of anaemia and nutritional status at high altitude, 14.2% of
513 children and adolescents aged 6–13 years were underweight defined by WHO
(BMI for age < 5th percentile) in 2005 (Abou-Zeid et al., 2006). That is quite similar to
the prevalence of underweight obtained from the present study sample of ALL
survivors (12.5%) using the same one definition and same age group.
The present study findings found the lowest prevalence of underweight (8.9%) was
produced by Saudi reference data (El-Mouzan et al., 2007) versus the other
international approaches. The prevalence was highest by the CDC approach (17.9%).
These findings were inconsistent with Al Herbish et al., (2009) when they found that
there is more underweight in Saudi children compared to the USA, it implies that a
high prevalence of underweight may be ‘normal’ for Saudi Arabia by using
international definitions such as CDC approach.
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3.5.3 Comparisons with studies of medium term survivors
A few studies have reported on weight status in medium-term (defined as the period
after end of treatment up to 5 years) survivors of childhood ALL (see table 1.5.1). For
instance, Chow et al., (2007) in the USA found that out of 165 ALL childhood
survivors (103/165 standard risk), the prevalence  of overweight (defined as BMI= 25-
29 or BMI= 85th – 94th percentile ) and obesity (defined as BMI≥ 30 or BMI≥ 95th
percentile ) after completion of therapy was 32%. Quite a similar finding using same
reference data CDC was reported by the present study (29%) that the similarity may
be because both studies used modern treatment protocols (with chemotherapy but no
CRT) and most /all survivors in both studies were diagnosed as having standard risk
ALL.
Breene et al., (2011) assessed 77 ALL survivors (7.8% treated by high risk protocol in
one English centre). They reported that prevalence of overweight and obesity
combined (defined as BMI z score > 1.2 – 2.3 and BMI z score > 2.3 relative to UK
reference data) was 47.2%. In contrast, by applying the international and national
definitions, the prevalence of overweight and obesity seemed to be lower in Saudi
survivors than the UK survivors. Breene et al., (2011)  recruited, from a single centre,
a mixed type of ALL survivors who had been treated with chemotherapy and CRT and
so was a less homogenous group than in the present study.  Love et al., (2011)
recruited 102  childhood survivors of ALL and reported the prevalence of overweight
and obesity (defined as BMI > 85th based on CDC reference data) was 45%, higher
than the present study findings by all four definitions used: some of them had been
treated with CRT (included both who received 18 Gy and >20 Gy radiation doses)
which may increase overweight or obesity risk. Moreover, Oeffinger et al., (2003)
reported that survivors treated with >20 Gy CRT have an increased risk of overweight
compared to their siblings, although lower radiation doses have also been associated
with increases BMI over time (Garmey et al., 2008).
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Therefore, it seemed that the prevalence of overweight and obesity in medium term
post end of the therapy is highly influenced by many factors such as type of ALL at
diagnosis, treatment protocols, including CRT either low or high doses, obesity
definition and sample size.
3.5.4 Comparisons with studies of long term (from after end of treatment up to
20 years) survivors of ALL
It is worth noting that the present study was carried out in medium term, adolescent,
survivors, and so, one of big challenges is tracking of unhealthy adolescent weight
into adulthood. In adulthood, the prevalence of overweight and obesity in 1,765 US
adults who had survived childhood ALL (median age was 23.0 years) were 29.8%
and 13.8%; respectively, and the prevalence was lower than the prevalence of
overweight and obesity combined in US general population (64.5%) during the same
period (1999- 2000) (Oeffinger et al., 2003, Ogden et al., 2006). However, the
prevalence of overweight and obesity in the present study (28%) was much lower
than Oeffinger et al., (2003) study of US adults.
As mentioned in the Method chapter, the present study was based on modern ALL
treatment protocol in which CRT was not used, Similarly a retrospective Swiss study
showed that the rates of obesity and of being overweight amongst 54 standard risk
ALL survivors who were all not treated with CRT and diagnosed between 1990 –
2000 were 18% and 30%, respectively (Asner et al., 2008).
In a study with a large sample size in adults, a report of the childhood cancer
survivors study (CCSS) in USA (data collected between 1995- 1996) found that the
prevalence of overweight and obesity amongst  1,665 ALL adult survivors (aged 20-
47 years) were 22.5% and 18.5%, respectively (Meacham et al., 2005). Therefore,
the prevalence of overweight and obesity was highly increased according to the
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present study, but in adults, by using the same reference data (Meacham et al.,
2005).
A  longitudinal study  in the USA that examined 248 ALL and lymphoma patients
diagnosed between 1979 – 1984 who were treated according to standard risk (CRT
used for (n=89/190) and high risk (n=50) protocols found that the prevalence of
overweight (85th – 94th percentile for BMI) and obesity (≥ 95th percentile) was 35.0%
for those aged <18 years and 39.3% for those aged ≥ 18 years at the last evaluation
(Razzouk et al., 2007). Relatively similar findings were found by the present study
when same reference data (CDC definition) was used in medium term even though
Razzouk et al., (2007) study recruited survivors who were treated before obesity
became epidemic in the USA. CRT may play intrinsic role in increasing body weight
than using modern protocols.
In contrast, a few studies have reported a relatively low prevalence of obesity in long
term survivors of childhood cancer. For instance,  in a Swedish study  of childhood
ALL survivors aged 20 – 32 years,  47 ALL survivors (19 had CRT) 34.3% of adult
survivors were reported as being overweight but no one was obese (BMI ≥30 kg/m2)
(Jarfelt et al., 2005). However, even though they recruited survivors who had been
treated with CRT they found no obesity amongst them possibly due to the relatively
small sample size.
It should be emphasised that there is no study, to our best knowledge, which in
standard risk ALL survivors examined the tracking of unhealthy weight status from
childhood into adulthood, therefore, future studies of this kind are recommended. The
above comparisons of ALL studies in long term survivors with the medium term
survivors (present study) could be influenced by differences in obesity definitions, ALL
classifications at diagnosis, using different treatment protocols, notably using CRT in
treatment. Also, comparison with general population is highly recommended to clarify
the question “Is the prevalence of unhealthy of weight status in ALL survivors more
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common than norms population?” as it is not clear from most previous studies of
survivors.
3.5.5 Comparison with studies from non-western countries
Prevalence of unhealthy weight status might be different in the general population in
non-western countries than in western countries, and rates of change in obesity
prevalence are likely to be different since the ‘nutrition transition’ has occurred at
different times across the world (Popkin and Penny, 2004). Few comparisons with
other non-western literature can be made though, because there are so few studies in
non-western countries, which used modern protocols for ALL with no CRT, and which
used the most modern/accepted definitions of weight status which were used in the
present study. Moreover, to our best knowledge, studies of weight status in ALL
patients and ALL survivors outside western countries are very scarce. A quarter of
children and adolescents (mean age 10.4 years) who were Iranian ALL survivors
(14/55) who were treated with chemotherapy only or chemotherapy and  CRT
between 2003 – 2007 (35 months since completion the therapy) were  obese (BMI>
95th percentile relative to Iranian reference ) (Reisi et al., 2009).  Moreover, the
prevalence of overweight (BMI> 75th and < 95th percentile) amongst those Iranian
survivors was 20%. However, this prevalence of both overweight and obesity was
much higher than the present study (21%) although they Iranian study recruited a
similar sample size in medium term  survivors and used national BMI reference data
rather than the international approaches. The Iranian study included survivors who
had been treated with CRT whereas the present study did not, which might contribute
to differences between the two studies..
In a study in Thailand  carried out between 2003 - 2005, ALL survivors (n =258;
46.9%   standard risk) with median (range) age 12.2 years (3.6 - 23.2) obesity/
overweight (not defined in this paper) prevalence amongst those who had not been
treated by CRT (n= 91) was 10% which was lower than all definitions used in the
173
173
present study, however, the prevalence was higher (32%) amongst those who had
been treated by CRT (Pakakasama et al., 2010). However, the survivors were treated
according to different treatment protocols which may be considered as
heterogeneous group of survivors and the definition of obesity may be influenced in
reporting weight status.
3.5.6 Factors associated with overweight/obesity in ALL
3.5.6.1 Impact of age of diagnosis on weight status in ALL
Razzouk et al., (2007) suggested that weight status at diagnosis of ALL is crucial in
predicting weight status in adulthood. In UK and USA studies there is a tendency for
patients diagnosed with ALL at younger ages to be at greater risk of later obesity and
excessive weight gain (Oeffinger et al., 2003, Reilly et al., 2000b). To be more
precise, Razzouk et al., (2007) found that being overweight and obese significantly
increased amongst those diagnosed with ALL or lymphoma between the ages of 0-6
from 6% at diagnosis up to 41% at adulthood.  This finding was consistent with the
present study findings.
The present study found that  use of definitions of weight status from the Cole et al.,
(2007) , IOTF (Cole et al., 2000), CDC (Kuczmarski et al., 2000) and WHO (de Onis
et al., 2007)  identified that  the proportion of both overweight and obese survivors
aged 6 years or less at the time of diagnosis was higher than those who were older
than 6 years old at diagnosis. Also, exploratory analyses in the present study
suggested that underweight (defined by WHO (de Onis et al., 2007) and CDC
(Kuczmarski et al., 2000)) was possibly more common for those were diagnosed at
age 6 years or younger. However, in the exploratory analyses in the present study
BMI z score was not related significantly to age at diagnosis. Further research with
larger samples will be needed to examine how age at diagnosis plays role in
excessive weight gain in countries such as Saudi Arabia.
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3.5.6.2 Impact of gender on weight status
High BMI for age in this present study was not apparently affected by gender. In
contrast, in large multi-centre retrospective cohort study  (n= 1,765) found amongst
ALL adult survivors that female patients who had been treated by CRT ≥20 Gy were
at risk of obesity (BMI ≥ 30 kg/m2) than males (Oeffinger et al., 2003). A large sample
size for a future study to investigate the impact of gender on weight status in
homogeneous group would be useful.
3.5.7 Over-fatness
The DXA used in the present study provided a direct estimate of body composition
with high precision and possibly reasonable accuracy compared with most ‘field ‘
methods of body composition (Fewtrell, 2003). Animal studies have shown a linear
correlation, and fairly good agreement too, between lean fat mass and FM assessed
by DXA and by chemical carcass analysis (Brunton et al., 1997; Fusch et al., 1999).
DXA also, is a simple, fast and safe measurement in clinical settings compare to
other approaches such as underwater weighing approach which is inappropriate in
some hospitalised cases. Warner et al., (2004) recommended using DXA in ALL
survivors suggesting that it was a more accurate measurement than other non-
invasive methods such as BIA, isotopic water dilution. However, DXA measurements
in at least some studies (Wong et al., 2002) have been shown to be less accurate
relative to 4 components models might and so DXA might produce an overestimate or
underestimate the true value of %TBF (Wong et al., 2002). Nevertheless, 4
component model approaches are too complicated in measuring body composition in
clinical practice.
In addition, BIA is also, a fast, simple and safe device and it shows less inter-observer
variation than some alternative methods (Schaefer et al., 1994). Pietrobelli et al.,
(2003) recommended BIA devices for measuring body composition in children.
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However, Warner et al., (2004) found that the accuracy of BIA depends on the
regression equations which are used for predicting total body water and/or FFM.
The question of whether ALL survivors might be over- fat even if they did not have a
high BMI for age, was asked in part because of general concerns over the ability of
BMI to identify excessively fat individuals,  and in part because of the possibility that
ALL survivors might have a condition resembling sarcopenic obesity  with very low
lean body mass (Prado et al., 2008). A previous showed that over-fat children with
ALL might not have a high BMI (Warner, 2008). In the present study over-fatness
from DXA was present in over half of the sample, but prevalence of overweight and
obesity from BMI based definitions was lower. Consequently, the present study found
that DXA for definition of over-fatness had “fair agreement” with the Saudi approach
(El-Mouzan et al., 2007) for obesity and the other international approaches.
However, by using BIA, over-fatness prevalence (35.9%) was closer to the
prevalence estimates which were produced by the international approaches for
overweight and obesity other than the national approach. Therefore, BIA was scored
from fair to moderate agreement with all approaches. Similarly,  Sampei et al., (2001)
examined the agreement between BMI and %TBF by using BIA device in 10- and 11
year old Japanese adolescents (n= 436), and reported the kappa analysis value of
0.49, which was higher than the present study results by using all BMI based
definitions.
This finding suggests that the weight and height based measures and definitions of
overweight and obesity from Cole et al., (2007), IOTF(Cole et al., 2000),  CDC
(Kuczmarski et al., 2000), WHO (de Onis et al., 2007) and Saudi reference data (El-
Mouzan et al., 2007) all using BMI for age tend to be quite conservative and may
underestimate the prevalence of over-fatness in childhood, adolescent and young
adult survivors of ALL. This is consistent with expectations based on BMI because it
does not take the actual body composition into account. The use of BMI based
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definitions of obesity tend to be conservative in the general population, but there is
less evidence from children and adolescents with chronic disease. Warner et al.,
(1997) investigated the validity of BMI for assessment of excess adiposity by using
DXA and skinfold thickness measurements to estimate fatness amongst 143 (43 were
long-term cancer survivors) UK patients with chronic disease. They concluded that
BMI underestimates the excess of adiposity in children with chronic disease. Also,
more generally it is known that BMI based definitions using as screening tool for
obesity have a high false negative rate in children and adults (Reilly et al., 2010b).
More excessively fat individuals exist in clinical and population samples than are
identified by a high BMI for age.
Jarfelt et al., (2005) found that in Swedish ALL young adult survivors (n= 47) aged 20-
32 years (19 was treated by CRT) had high %TBF assessed by DXA for both males
(29.2 %, range (24.0- 37.5)) and females (37.5% (25.4- 44.5)). %TBF in female
survivors was high (35.9%, range (23.4- 42.3)) for those were treated without CRT.
Furthermore, a high % TBF for those treated with CRT only existed in girls (33.5%). In
contrast, Marinovic et al., (2005) found that the elevation of %TBF assessed by DXA
for one year (35 out of 37 were standard risk) after completion of ALL therapy in
survivors (median age was 7.9 years) was slightly lower than the control healthy
group (n= 74). However, the short time after completion of the therapy in Marinovic et
al., (2005) study might influence to the ability to find a difference in %TBF between
ALL survivors and control group.
Most of the DXA-based studies to date have concluded that over-fatness is common
in ALL survivors (Murphy et al., 2006, Warner, 2008a, Janiszewski et al., 2007, Jarfelt
et al., 2005, Nysom et al., 1999). However, all of these studies are from patients from
the western world and many of these studies were of patients who had CRT, and not
all were studies of patients in 1st remission after completion of therapy. The present
study suggests that over-fatness is not confined to ALL patients during treatment, nor
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confined to the western world, nor confined to patients treated for ALL on older
protocols using CRT.
The present study found different estimates of over-fatness provided from using DXA
and BIA methods. Both of devices are based on different assumptions and prediction
equations.  It was reported that it is difficult and might be unreliable to make
comparisons between studies used different brands of BIA as they are based on
different prediction equations (Warner et al., 2004). Moreover, BIA and DXA devices
that used in the present study are depended on different reference data and
population based reference values. Therefore, Warner et al., (2004) stated that when
the general applicability of impedance equations can not be assumed in malignancy
survivors so,  recommended the use of more than one body composition analyser, as
in the present study. Furthermore, very lean and very obese subjects are more likely
to lead to greater errors in prediction of body composition because some of the body
composition methods are produced from subjects close to the average body
composition values (Fogelholm et al., 1996). Also, the present study supports
producing a large representative population based reference data values and trends
over different populations. Future studies needs to validate these devices used in the
present study in diseased patients such as those with malignancies and MS.
3.5.8 Metabolic syndrome
3.5.8.1 Metabolic syndrome in Saudi Arabia general population
There is scarce MS literature in Saudi childhood or adolescents. Al-Daghri (2010) in a
cross-sectional study examined a large sample of 1,231 healthy children aged 10 –
18 year olds for prevalence of MS (defined according to NCEP III definition). The
overall prevalence of MS by Al-Daghri (2010) was 9.4% which was quite similar to the
present study when compared using the same age group and same definition (8.1%).
Therefore, the existence of MS in children and adolescent amongst Saudi ALL
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survivors may be reflect what is happening in the general population. Gurney et al.,
(2006) studied the prevalence of MS (defined as NECP III definition) amongst 75 (50
survivors had CRT) adult survivors of childhood ALL compared to population norms
(n= 730) from 1999 - 2002 National Health and Nutrition Examination Study (NHNES)
data in the USA. The mean age and time since diagnosis was 30 years and 25 years;
respectively. They showed that prevalence of MS amongst survivors was (16.6%)
while population norms was 17.5%, which was not significantly different (p value=
0.87). However, 60% of the survivors treated by CRT had two or more MS
components compared to the 20% that did not receive CRT. Moreover, one important
issue in presence of MS during childhood is tracking into adulthood. By using similar
modified MS definitions for children in the present study (5.4%), the prevalence of MS
was increased comparing Gurney et al., (2006) study.
A hospital-based Saudi study  was carried out on 37 obese children (57.9% male)
from the Endocrinology clinic at KFSH&RC and the mean age (SD) was 9.8 years
(3.5) (Taha et al., 2009). They defined MS according to modified NCEP III and WHO
definitions and obesity as BMI > 95th percentile based on CDC definition.  The
prevalence of MS was 29.7% in Taha et al., (2009) study higher than the prevalence
of MS (18.8%) amongst overweight or obese survivors in the present study.
However, the sample size of Taha et al., (2009) study was too small to be
representative of the general population and they recruited only obese children.
3.5.8.2 Metabolic syndrome components and metabolic syndrome in survivors
with ALL
Relatively few studies have considered metabolic syndrome among medium term
survivors of ALL. For instance, Trimis et al., (2007) carried out a study in 80 (50 was
males) survivors of ALL and median interval since completion of therapy was 6.3
years. Out of 80, 62 survivors were treated only by chemotherapy (Group A) whereas
the others (n = 18) had been treated with CRT (18 Gy) (Group B). They defined MS
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according to NCEP III definition modified by Weiss et al., (2004). Trimis et al., (2007)
found MS prevalence in the overall sample was 11%. However, the MS prevalence
amongst group A was 8% which was not far away from the present study finding
(5.4%) based on the same definition but slightly different criteria. In group B, MS was
present in 22% (Trimis et al., 2007). Therefore, the present study and Trimis et al.,
(2007) revealed that MS was present in survivors post end of therapy.  Even though
survivors who had received CRT in treatment in Trimis et al., (2007) study had
doubled prevalence of MS, the present study and Trimis et al., (2007)  are highlighted
a possible role of chemotherapy in these disturbances. Similarly, in a longer term
study, Oeffinger et al., (2001) studied cardiovascular risk factors amongst 26 young
adult (median age: 20.9 years) survivors of childhood ALL. The median time off-
therapy was 13.3 years. Ten of the sample had been treated by CRT, whereas the
remaining patients were treated with chemotherapy only.  Cardiovascular risk factors
were defined as follows: BMI ≥ 30; SBP ≥ 130 mm Hg; DBP ≥ 85 mm Hg, total
cholesterol ≥ 200 mg/dL; LDL-C ≥ 130 mg/dL; cholesterol-to-high-density lipoprotein
ratio ≥ 5.0; TG ≥ 200 mg/dL; glucose ≥ 110 mg/dL; insulin ≥ 14 µU/ml. Survivors with
2 or more cardiovascular risk factors comprised 27% of the total sample. They also
reported that 19% (3 out of 16) of those treated only by chemotherapy had ≥ 2
cardiovascular risk factors, compared to 40% (4 out of 10) of those treated with CRT.
Therefore, the prevalence of MS in paediatrics by both used definitions in the present
study.
No study was found in the literature search that addressed MS in survivors with
childhood standard risk ALL treated on modern protocols outside western countries.
However, an Iranian study was found that did not use a modern protocol in treating
ALL (ALL-BFM chemotherapy protocols which includes CRT routinely) (Reisi et al.,
2009). They examined prevalence of MS (defined as NCEP III modified by de Ferranti
et al. (2004)) amongst 55 children aged 6- 19 years (mean age was 10.4 years). They
found that 20% of the sample had the MS: MS was present in 71% of obese survivors
(defined as BMI> 95th percentile). Moreover, they demonstrated that the prevalence of
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MS was high in survivors treated with CRT (26%) versus chemotherapy (12%);
however, this finding was not statistically significant (p value= 0.15), possibly due to
the small sample size. So, they reported high prevalence of MS in ALL survivors than
the present study even with similar sample size may be due to the Iranian study used
different MS definition and some of survivors were treated with CRT.
Obesity has a central role in the MS components as it is associated with a higher
body fatness. Indeed, in Saudi survivors central obesity (defined by WC
measurement) was positively associated with HOMA-IR, triglycerides, and BP and
inversely associated with HDL-C. Also, almost half of the survivors by using both
used of central obesity cut-offs had hyperglycaemia. Survivors of childhood ALL are
at increased risk for late obesity, 10 to 20 years after therapy (Oeffinger et al., 2003).
A high HOMA-IR (defined as 1.77 (Arshi et al., 2010) was found in almost a  third
(29.1%) of the sample. Sharma et al., (2011) used HOMA-IR instead of fasting
glucose to  define MS (defined according NECP III modified by de Ferranti et al.,
(2004)) amongst African American children. The sample was 105 (57% girls) aged 9
to 13 years. They found that the specificity and sensitivity of HOMA-IR as one of the
MS components to define MS were 83% and 88%; respectively.  Therefore, the
prevalence of MS was found to be doubled (38%) in the sample studied by Sharma et
al., (2011) when using HOMA-IR but only 17% when using blood glucose as one of
the MSC. Sharma et al., (2011) preferred using HOMA-IR instead of fasting glucose
as it was claimed to be related to insulin resistance to predict MS. Furthermore, as
indicated from the correlations between HOMA-IR index and serum parameters,
insulin resistance is correlated with an abnormal lipid profile. Different cut-offs for
HOMA-IR have been reported in the paediatric literature and these will alter the
prevalence of abnormal HOMA-IR, but a further discussion of this point is beyond the
scope of the present study.
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Interestingly, time-dependent variables did not influence the present study results
except in serum TG, even though some survivors had completed therapy just 1 month
to 1 year before the present study. Our findings showed that metabolic alterations,
suggestive of MS and MS components were detectable relatively early after the
completion of therapy.
The present study supports the view that chemotherapy without radiotherapy leads to
MS and associated cardiovascular risk factor development in ALL survivors.
Prevalence of the MS components was quite high in Saudi survivors. Therefore, early
prevention and intervention strategies should be investigated and developed by
further future studies. Efforts should be directed by health professionals and their
families at the identification of survivors at high risk. Early modification of life style
after the end of therapy such as healthy diet, increasing physical activity and stress
reduction may vital to prevent cardiovascular risk factors in ALL survivors in future
(Trimis et al., 2007).
3.5.9 Weaknesses and Strengths of the present study
Sample size
Some limitations in the present study affect the interpretation of the results. First,
small sample size of standard risk ALL survivors and the cross-sectional study design
are limitations. In the present study, 77 survivors were available at the study time and
72% of them were eligible. Sample sizes in other studies that were carried out
prospectively amongst short term ALL survivors are also usually small. For instance,
Pakakasama et al., (2010) recruited 258 ALL survivors (median age was12.2 years),
however, only 121 of them were standard risk ALL and no body composition
measurements were made. In addition, Reisi et al., (2009) studied 55 and of the
survivors 30 had been treated by chemotherapy with CRT. Moreover, the Warner et
al., (2004) study carried out amongst 35 children ALL survivors who had CRT to
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identify body composition and obesity. On the other hand, the present study sample
was fairly homogenous i.e. all survivors were standard risk ALL, all treated on same
protocol and all treated on same centre and none got CRT.
Study design and methods
No gold standard for body weight status was used in the present study, so differences
between the different approaches can be described, but it is difficult to assess the
accuracy of the methods. Specifically, it is not clear which definition of underweight is
correct (as described in 1.4). Since no gold standard for definition of underweight
exists. For underweight evidence of a link to health outcomes would help validate any
underweight definition.
For obesity, gold standards of measuring body fatness would be needed to define
excess body fatness highly accurately (multi-component models) (Wells et al., 1999)
and none were available. So, the present study used several approaches to
predicting body fatness such as BMI, DXA and BIA devices.  A recent systematic
review concluded that a high BMI for age is a good simple proxy for excessive fatness
(Reilly et al., 2010b). Also, BIA showed a good correlation with BMI and triceps
skinfold thickness (Vizcaino et al., 2007), with relatively a higher precision of the DXA
than other body compositions methodology (Jebb et al., 1993).
The Third caveat is that some details were out of the scope of the present study for
instance, physical activity and nutritional habits of the study participants could not be
measured given constraints on time and financial resources. Future studies of lifestyle
of ALL patients and ALL survivors outside the western world would be useful, and
these have been very useful in understanding the causes of obesity in ALL patients
and survivors in the western world (Reilly, 2009)
Fourth, using a control group or a comparison group was not practical in the present
study. A healthy control group or a ‘positive control’ group with chronic disease would
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have been useful to compare prevalence of unhealthy weight status in ALL patients
with that of the control or comparison group- this would have allowed us to test if what
seemed like a high or low prevalence was specific to ALL or was just the result of the
‘background’ prevalence in the general Saudi population. As an alternative to having
a comparison group the present study used the most recently available data from the
general Saudi population on prevalence of obesity and MS.
Another limitation was the short time was between end of the therapy and the present
study (mean= 6.2 years)-longer term follow up studies would be more useful, but
studies of long term survivors in ALL are very scarce and almost non existent outside
the western world. The present study showed the prevalence of MS and weight status
in medium-term which is an essential for early control and prevention of the diseases.
In addition, long-term follow up of ALL survivors who had been treated on modern
protocols will not be possible for some time and will need future studies.
Finally, the weighted Kappa statistic (k) may be not valuable in the case of rare
observations. The small sample size and low prevalence of some of the categories of
weight status meant that some of the prevalence estimates were based on very small
numbers and this limits the kappa statistic and resulted in quite large confidence
intervals for the k statistics test in the present study (Viera and Garrett, 2005). The
sample sizes were small for some of the analyses in this chapter and so these were
described as exploratory, and some analyses were not undertaken as these would
probably have been too exploratory to have been useful (e.g. reasons for
misclassifications between different methods, or patterns of misclassifications, where
numbers classified differently were often just 1-4 patients).
3.5.10 Conclusions
The prevalence of underweight, overweight and obesity, as well as over-fatness, was
quite high amongst standard risk ALL Saudi survivors in the present study, though it
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cannot be confirmed if the prevalence of unhealthy weight status was higher or lower
than in the general population. MS is present in overweight or obese survivors, but
apparently not in those of healthy weight.
In future, weight status should be evaluated by a health professional such as qualified
dietician in ALL late effect and follow up clinics, by frequent assessments for weight
status. Managing any abnormal weight status and prevention as a first line
management would be useful. There are also many documents on paediatric weight
management, e.g. Scottish Intercollegiate Guidelines Network (SIGN) (Scottish
Intercollegiate Guidelines Network, 2010) (see appendix F),  National Institute for
Health and Clinical Excellence (NICE) (National Institute for Health and Clinical
Excellence, 2010) and The American Academy of Pediatrics (AAP) recommendations
(Spear et al., 2007) which recommend monitoring overweight children, adolescents
and adults  because no Saudi weight management guidelines are available yet.
185
185
Chapter 4
Prevalence and secular trends in weight status at diagnosis
in patients with Childhood acute lymphoblastic leukaemia
in the UK
This chapter describes a study which is now published, publication details as follows:
J Hum Nutr Diet. 2013 Jun 20. doi: 10.1111/jhn.12112
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4.1 Introduction
An unhealthy weight at the point of diagnosis of childhood malignancies has been
found to have adverse effects in at least some studies. Lange et al., (2005)
retrospectively reviewed 768 children and young adults from the USA aged between
one and 20 who had been diagnosed with AML. The prevalence of obesity (BMI ≥95 th
percentile) and underweight (BMI ≤10th percentile) according to the CDC definition at
diagnosis was 14.8% and 10.9% respectively. Survival hazard ratio was 1.85 (95% CI
= 1.19- 2.87) (p value= 0.006) and 1.88 (95% CI = 1.25- 2.83) (p value= 0.002) in
underweight and obesity patients; respectively. It was concluded that being either
underweight or obesity at diagnosis could reduce the survival rate of AML patients.
Moreover, underweight and overweight/obesity may have specific adverse effects on
the success of treatment of childhood ALL as noted in chapter 1. A retrospective
study examined 4,260 patients aged between two and 19 to evaluate the effect of
obesity (defined as BMI ≥ 95th based on the CDC reference) on the prognosis of ALL
treatment (Butturini et al., 2007). The five-year EFS rate and risk relapse was
significantly reduced (p value =0.02) in non-obese (72%) versus obese patients
(77%). It was therefore concluded that obesity at diagnosis is an independent
predictor of the relapse risk in children with ALL. Another retrospective study from
Brazil  examined the prognostic impact of overweight in 181 children (median (range)
age: 4.8 years (range: 3.2-6.3)) with newly diagnosed ALL on five-year EFS (Gelelete
et al., 2011). It was found that 35.9% of them were either ‘overweight’ (BMI score >
+1.0) or ‘clinically obese’ (BMI z score > +2.0) relative to WHO reference data.
Obesity and overweight were shown to be predict the relapse risk- the five-year EFS
was significantly lower (p value= 0.02) in the overweight/obese (58.8%) compared to
the non-overweight (76.7%) patients.
Weight status is vital and plays an important role as described above. However, the
lack of investigation into the role of weight status in childhood cancer research is
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increasingly being acknowledged (Rogers and Ladas, 2011). Moreover, increasing
attention is now being paid to the importance of an unhealthy weight status as a
prognostic factor of treatment-related complications. Despite a paucity of evidence of
the impact of  weight status on childhood cancer, nutritional/weight status is
becoming a cause for concern to some clinicians responsible for the care of patients
with ALL and other childhood malignancies (Rogers and Ladas, 2011). The effect of
an unhealthy weight status has also received increasing attention as child and
adolescent obesity becomes more common. In a number of  the more common
childhood malignancies, overweight or obesity is a common consequence of the
disease, its treatment, or lifestyle responses to treatment among families (Reilly,
2009).
One under-researched issue concerns the prevalence of an unhealthy weight status
among children at the diagnosis of malignancy. Likewise, little is known about the
related issue of secular changes in weight status in patient populations over time. The
accuracy of data on prevalence may be hindered by the definition of weight status
used and limitations imposed by the sample size; many different definitions and
reference datasets have been used, and many previous studies have used very small
samples. Prevalence estimates have been limited by the absence of agreed
definitions of the terms underweight, overweight, and obesity. The emergence of
recent definitions of underweight, overweight, and obesity based on BMI for age
provides an opportunity to estimate the prevalence of unhealthy weight status (Cole
et al., 2007, Cole et al., 2000) as discussed in section 2.1.3.
Accurate prevalence estimates have also been hindered by the use of small and
possibly unrepresentative samples of children with cancer. For instance, Breene et
al., (2011) examined the changes in weight status in 134 UK children with ALL who
were treated by UKALL 97/97-99 protocols at a single UK centre. Therefore,
prevalence estimates for being underweight or overweight and obesity are not
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currently available for large nationally representative samples of patients. In addition,
older studies generally did not base their prevalence estimates on what are now well-
established definitions of weight status (Reilly, 2010) using BMI for age (Cole et al.,
2000, Cole et al., 1995, Reilly et a; 2010) some of which became available only
recently such as the definition of underweight from Cole et al., (2007).
4.2 Aims
The prevalence of unhealthy weight status at diagnosis of ALL is still unknown and
this may be why there is no formal requirement to screen ALL patients for weight
status at diagnosis at the moment. Therefore, the present study aimed to investigate
the prevalence of unhealthy weight status at diagnosis of ALL in different trials, and
also to examine secular trends in weight status in ALL amongst UK children. In order
to avoid the problem of small sample sizes at single treatment centres, the researcher
can benefit from the availability of  anonymous existing UK national trial data for
childhood ALL. These trials are particularly valuable because most patients in the UK
are included (80 – 95% of UK patients with ALL) (Mitchell et al., 2010). The present
study will therefore aim to utilise the UK national trial data to describe prevalence and
secular trends in unhealthy weight status in childhood ALL. The measures used to
define unhealthy weight status will be consistent with the most recent evidence-based
definitions of what constitutes an unhealthy weight, and the most recent definitions
which are accepted internationally e.g. Cole et al., (2007).
4.3 Methods
4.3.1 Participants
This is a retrospective study of anonymised national trial data obtained at or around
the time of diagnosis of ALL by clinical staff responsible for entering patients with ALL
onto trials in the UK. All patients enrolled were ALL patients diagnosed in the UK who
were entered into the trial protocols from successive UKALL national treatment trials
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covering the period 1985 to 2002, as the present thesis explained in details in section
2.2. Also, inclusion and exclusion criteria were given in the general method chapter in
section 2.2.
4.3.2 UKALL trials
Sample of UKALL X trial, UKALL XI trial and UKALL 97/ 97-99 was 1635 patients (1-
14 years), 2090 patients (1 – 14 years) and 1935 patients (1 – 18 years); respectively,
as described in the general method chapter, section 2.2.
4.3.3 Measures and definitions of unhealthy weight status
4.3.3.1 Weight, height and BMI
Weight and height were measured to 0.1 kg and 0.1 cm respectively. The present
study was based on anonymised clinical measures of weight and height which were
made around the time of diagnosis, to estimate body surface area in order to
calculate drug dosages. So, they were measured for clinical purpose by different
nurses, as described in section 2.2.6.1.
BMI was calculated using the following equation: weight (Kg)/ height (m) 2. Further
details are outlined in the Methods chapter. Weight status was classified based on
three definitions.
4.3.3.2 IOTF and Cole et al. (2007) definitions
The BMI-based definitions of children and adolescents overweight and obesity
described in the IOTF (Cole et al., 2000) have assumed increasing popularity over
recent years (Reilly et al., 2010b). These facilitate international comparisons of
obesity prevalence and use age and gender-specific cut-offs for absolute BMI.
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Overweight and obesity are defined in this study according to the IOTF approach
(Cole et al., 2000).
Furthermore, Cole et al., (2007) more recently proposed underweight/ thinness for
children and adolescents. Underweight cut offs are corresponding to 16, 17 and 18
kg/m2 adult BMI grades.  However, the present study classified the different grades of
underweight by Cole et al. (2007) as underweight instead of using the terms used by
Cole et al. (2007): grade 1, 2 and 3 underweight, these terms were all collapsed with
one underweight category which is conceptually equivalent to BMI of < 18 at age 18.
4.3.3.3 UK 1990 definition
Weight status using BMI for age relative to UK 1990 population reference data was
defined in the present study as the following: healthy weight (BMI z score <1.04 (less
than the 85th centile )), overweight (BMI z score 1.04≤ 1.64 (above the 85 th centile,
but below 95th centile)) and obese (BMI z score >1.64 (above the 95th centile)) (King
et al., 2010, Cole et al., 1995, Barlow and Dietz, 1998, Reilly et al., 2010b). BMI z
score was calculated by using software available in: www.healthforallchildren.com.
4.3.4 Statistical analysis
Results are expressed as median (Interquartile range: Q1, Q3) unless otherwise
stated. Data normality was tested using normality testing (parametric when p value
>0.05). Differences in the prevalence of an unhealthy weight status between boys and
girls were tested for significance using a Pearson’s Chi Square and Fisher’s exact
tests. Secular trends in unhealthy weight status at diagnosis (BMI z score) between
the three UKALL trials were tested for significance using the Kruskal-Wallis and
Mann-Whitney tests by using Minitab software version 16.1.1. Trends in the
prevalence of unhealthy weight status were tested for significance using a Chi Square
Test for Trends by using Medcalc software version 11.5.0.0.
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The weighted kappa (k) test (Landis and Koch, 1977) as described in figure 3.3.1 was
used to test agreement between the different definitions of weight status, i.e. Cole et
al., (2007)/IOTF (Cole et al., 2000) and UK 1990 (Cole et al., 1995) definitions with a
calculation of a 95% confidence interval (CI); k statistic scores were interpreted based
on (Landis and Koch, 1977).
4.4 Results
4.4.1 UKALL X trial
4.4.1.1 Characteristics of the sample
 As illustrated in figure 4.4.1, 1,040 patients were potentially eligible for inclusion in
the present study, based on the dataset provided by the CTSU at Oxford of whom
75.0% (n= 780) were boys and 25.0% (n= 260) girls (most of the girls were classified
as low risk as discussed in section 2.2.4.1).
All patients had the data (weight, height, age and gender) that are essential to
calculate BMI z score based on UK 1990 definition (Cole et al., 1995) except 7
patients who had missing data (number of missed height: 7 patients; weight: 3
patients and weight and height: 4 patients). Consequently, 1,033 patients potentially
eligible for the present study (74.9% males, 25.1% Females) with UK 1990 reference
data.
Furthermore,  some patients who were ineligible because their weight status could
not be calculated according to the Cole et al., (2007) and IOTF (Cole et al., 2000)
definitions because some patients were beyond the Cole et al., (2007) and IOTF
(Cole et al., 2000) definitions ranges of age. Therefore, patients who were ineligible
for the Cole et al., (2007) and IOTF (Cole et al., 2000) definitions only (age was < 2.0
years) were 116 and so 917 patients were included with definitions based on Cole et
al ., (2007) and IOTF (Cole et al., 2000) as illustrated in figure 4.4.1. The median age
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(range) at diagnosis of ineligible patients by the IOTF (Cole et al., 2000) definition
was 1.6 years (1.3, 1.8) with no significant difference between genders (Mann-
Whitney test; p value= 0.85). Also, the median (range) BMI z score for those patients
was - 0.46 (-1.32, 0.49), and there was no significant difference between boys and
girls (Mann-Whitney test; p value= 0.08) as shown in table 4.4.1.
Table 4.4.1: UKALL X trial summary anthropometric measures of ineligible
patients at diagnosis of ALL, median (Q1, Q3)
Boys
(n= 64, 55.2%)
Girls
(n= 52, 44.8%)
Total sample
(n= 116)
Age (yr) 1.6 (1.3, 1.8) 1.6 (1.1, 1.9) 1.6 (1.3, 1.8)
Height z score © 0.29 (-0.23, 1.12) -0.41 (-0.91, 0.13) - 0.01 (-0.60, 0.81)
Weight z score © * - 0.12 (1.12)* - 0.60 (1.16)* - 0.23 (1.20)*
BMI z score © - 0.39 (-1.01, 0.60) - 0.9 (-1.80, 0.29) - 0.46 (-1.32, 0.49)
©  z score calculated by comparing patients against UK reference population (Cole et al., 1995);
* Normal distribution; mean (SD) was used
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Figure 4.4.1: UKALL X trial flow diagram
♂: Male; ♀: Female; Ht: height; Wt: weight; UK 1990 definition (Reilly et al., 2010b), Cole et al., (2007) , IOTF: International Obesity Task Force(Cole et al.,
2000)
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The median (range) age of the eligible sample (shown in table 4.4.2) based on UK
1990 (Cole et al., 1995) definition was 4.5 years (2.9, 8.1) with no significant
difference between genders (Mann-Whitney test; p value= 0.68). The median BMI z
score of the whole sample was -0.28 (-1.06, 0.47) with no significant difference
between boys or girls (Mann-Whitney test; p value = 0.65).
Table 4.4.2: UKALL X trial summary anthropometric measures at diagnosis of
ALL, median (Q1, Q3)
Boys
(n= 774, 74.9%)
Girls
(n= 259, 25.1%)
Total sample
(n= 1033)
P value
Age (yr) 4.5 (2.9, 7.2) 4.4 (2.5, 10.6) 4.5 (2.9, 8.1) 0.68
Height z score © 0.13 (-0.59, 0.84) -0.11 (-0.80, 0.60) 0.10 (-0.67, 0.78) 0.01
Weight z score © * - 0.11 (1.03)* - 0.26 (1.16)* - 0.14 (1.06)* 0.06
BMI z score © - 0.27 (-1.05, 0.47) - 0.38 (-1.09, 0.48) - 0.28 (-1.06, 0.47) 0.65
©  z score calculated by comparing patients against UK reference population (Cole et al., 1995);
* Normal distribution; mean (SD) was used
4.4.1.2 Weight status of UKALL X sample
4.4.1.2.1 Weight status defined by different definitions
As shown in table 4.4.3, applying the Cole et al. (2007)/IOTF (Cole et al., 2000)
definitions showed that the prevalence of patients with healthy weight status (not
underweight, not overweight, not obese) was 70.3% (n= 645). The prevalence of
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underweight amongst the sample was 19.4% (n= 178). Overweight and obesity were
present in 8.7% (n= 80) and 1.5 % (n= 14) patients at diagnosis; respectively using
the Cole et al. (2007) and IOTF (Cole et al., 2000) approaches.
Table 4.4.3: Prevalence of weight status at diagnosis in UKALL X trial
Cole et al.1/IOTF2 UK 19903Weight status
N % N %
Thinness 178 19.4% ----- * ----- *
Healthy 645 70.3% 895 86.6
Overweight 80 8.7% 85 8.2
Obesity 14 1.5% 53 5.1
Overweight/ obesity 94 10.2 138 13.3
1Thinness calculated by comparing patients BMI against age and gender  based on Cole et al. cut offs
Cole et al., (2007); 2Healthy, overweight and obesity calculated by comparing patients BMI against age
and gender according to IOTF cut offs (Cole et al., 2000); 3UK 1990 defined weight status as  healthy
weight (BMI z score <1.04), overweight (BMI z score 1.04≤ 1.64) and obese (BMI z score  >1.64) (King
et al., 2010); * There is no definition for underweight by using UK 1990 reference data.
The prevalence of different categories of weight status was also assessed by
applying the definitions based on UK 1990 reference data (Cole et al., 1995). Patients
who were a healthy weight accounted for 86.6% (n= 895) of the total sample.
However, the prevalence of patients defined as being overweight or obese was 8.2%
(n= 85) and 5.1% (n= 53) respectively.
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Patients ineligible had median age (range) at diagnosis for thin and overweight/obese
patients was 4.3 years (3.3 , 9.3) and 3.9 years (2.9 , 5.9); respectively, with no
significant difference between them (Mann-Whitney test; p value= 0.05). Also, the
median (range) BMI z score for thin was -1.8 (-2.3, -1.5) and for overweight/obese
was 1.6 (1.4, 2.1).
4.4.1.2.2 Weight status according to gender
Using the Cole et al. (2007)/ IOTF (Cole et al., 2000) definitions according to gender,
the prevalence of healthy weight status was similar in both boys and girls: 70.4% (n=
500) and 70.1 % (n= 145) respectively. Underweight/thinness was present in 144
boys (20.3%) and 34 (16.4%) girls. Boys who were overweight or obese accounted
for 9.3 % (n= 66) of the sample and girls 13.5% (n= 28). The prevalence of weight
status did not differ significantly between genders (Pearson chi-square test; p
value=0.53).
By applying the UK 1990 definitions (Cole et al., 1995), 87.5% (n=678) of boys and
83.8% (n=217) of girls were of a healthy weight at the diagnosis of ALL. Patients who
were identified as overweight or obese accounted for 12.5% (n=96) of boys and
16.3% (n=42) of girls, as shown in table 4.4.4.
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Table 4.4.4: Prevalence of weight status categories at diagnosis defined by
Cole et al. / IOTF and UK1990 definition according to gender in UKALL X trial
Thinness Healthy Overweight Obesity
n % N % n %  n %
Boys 144 20.3 500 70.4 56 7.9 10 1.4
Cole et al. /
IOTF Girls 34 16.4 45 70.1 24 11.6 4 1.9
Boys ----∆ ----∆ 678 87.5 60 7.8 36 4.7
UK 1990
Girls ----∆ ----∆ 217 83.8 25 9.7 17 6.6
∆There is no definition for underweight by using UK 1990 reference data
4.4.2 UKALL XI trial
4.4.2.1 Characteristics of the sample
The present study potential sample size was 2,090 patients. However, a number of
patients at diagnosis who could be classified for their weight status had missing data
(height or weight) needed to calculate BMI z score (n=59). Hence, the present study
included 2,031 patients (56.8% boys, 43.2% girls) according to UK 1990 definition
(Cole et al., 1995).
However, some patients ineligible for the Cole et al., (2007)/IOTF (Cole et al., 2000)
definitions  (age  < 2.0 years) :154  in total (53.2% boys, 46.8% girls) while 1877 (57.1
% were males) patients were eligible as illustrated in figure 4.4.2.
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Figure 4.4.2: UKALL XI trial flow diagram
♂: Male; ♀: Female; Ht: height; Wt: weight; IQR: Q1, Q3; UK 1990 definition (Reilly et al., 2010b), Cole et al. Cole et al., (2007) , IOTF: International Obesity
Task Force(Cole et al., 2000)
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The median age (range) at diagnosis of ineligible patients by IOTF (Cole et al., 2000)
definition was 1.5 years (1.5, 1.5) with no significant difference between boys and
girls. Also, the median (range) BMI z score for those patients was 0.01(-0.77, 0.92)
with no significant difference between boys and girls (Mann-Whitney test; p value=
0.50) as shown in table 4.4.5.
Table 4.4.5: UKALL XI trial anthropometric measures of ineligible ALL patients
at diagnosis
Boys
(n= 82, 53.2%)
Girls
(n= 72, 46.8%)
Total sample
(n= 154)
Age (yr) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5)
Height z score © 0.79 (0.12, 1.89) 0.24 (-0.53, 1.92) 0.91 (-1.92, 1.89)
Weight z score © 0.49 (-0.43, 1.23) - 0.91 (-0.13, 1.20) 0.50 (-0.42, 1.24)
BMI z score © - 0.12 (-0.92, 0.73) - 0.10 (-0.87, 1.12) 0.01(-0.77, 0.92)
© z score calculated by comparing patients against UK reference population (Cole et al., 1995)
The median (range) age of the eligible sample (table 4.4.6) for which the UK 1990
reference data were used (Cole et al., 1995) was 4.5 years (2.5, 7.5); age differences
were not significant between genders (Mann-Whitney test, p value = 0.79). The
median (range) BMI z score of the sample was -0.10 (-0.82, 0.77), with no significant
difference in BMI z score between boys and girls (Mann-Whitney test; p value=0.31).
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Table 4.4.6: UKALL XI trial anthropometric measures at diagnosis
Boys
(n= 1153, 56.8%)
Girls
(n= 878, 43.2%)
Total sample
(n= 2031)
P value
Age (yr) 4.5 (3.5, 7.5) 4.5 (2.5, 7.5) 4.5 (2.5, 7.5) 0.79
Height z score © 0.16 (-0.69, 1.00) 0.20 (-0.55, 1.04) 0.17 (-0.66, 1.01) 0.38
Weight z score © 0.20 (-0.75, 0.86) - 0.10 (-0.69, 0.91) 0.12 (-0.72, 0.88) 0.96
BMI z score © - 0.02 (-0.81, 0.79) - 0.10 (-0.85, 0.72) - 0.10 (-0.82, 0.77) 0.31
© z score calculated by comparing patients against UK reference population (Cole et al., 1995)
4.4.2.2 Weight status of UKALL XI sample
4.4.2.2.1 Weight status defined by different definitions
Applying the Cole et al. (2007)  and IOTF(Cole et al., 2000, Cole et al., 2007)
definitions healthy weight accounted for 70.9% (n=1,330) of the sample. The
prevalence of underweight in the eligible patients based on Cole et al., (2007) was
16.0% (n=301). Moreover, overweight/obesity using IOTF (Cole et al., 2000) was
found in 13.1% (n=246) of the patients.
Using the UK 1990 definition (Cole et al., 1995), a healthy body weight was found in
81.6% (n=1,657) of patients, whilst patients who were either overweight or obese
accounted for 18.2% (n=374) of the sample (see table 4.4.7).
Patients ineligible had median age (range) at diagnosis for thin and overweight/obese
patients was 4.5 years (3.5 , 8.3) and 4.5 years (3.5 , 6.8); respectively, with no
significant difference between them (Mann-Whitney test; p value= 0.40). Also, the
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median (range) BMI z score for thin was -1.7 (-2.3, -1.5) and for overweight/obese
was 1.7 (1.5, 2.1).
Table 4.4.7:  Prevalence of weight status in UKALL XI trial
Cole et al. 1 /IOTF2 UK 1990Weight status
n % n %
Thinness 301 16.0 --- * --- *
Healthy 1330 70.9 1657 81.6
Overweight 202 10.8 228 11.2
Obesity 44 2.3 146 7.2
Overweight/ obesity 246 13.1 374 18.2
1Thinness calculated by comparing patients BMI against age and gender  based on Cole et al. cut offs
Cole et al., (2007); 2Healthy, overweight and obesity calculated by comparing patients BMI against age
and gender according to IOTF cut offs (Cole et al., 2000)]; 3UK 1990 defined weight status as  healthy
weight (BMI z score <1.04), overweight (BMI z score 1.04≤ 1.64) and obese (BMI z score  >1.64) (King
et al., 2010); * There is no definition for underweight by using UK 1990 reference data.
4.4.2.2.2 Weight status according to gender
When the sample was divided according to gender, the prevalence of underweight
amongst boys was 16.3% (n=175), whereas overweight/obese patients at diagnosis
accounted for 12.5% (n=134) based on the Cole et al., (2007)/IOTF (Cole et al., 2000)
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definitions. In girls, underweight was found in 15.6% (n=126) of patients whilst 13.8%
(n=112) were overweight/obese. No significant difference between the genders in
terms of weight status was found (Pearson chi-square test; p value= 0.61).
When the UK 1990 definition (Cole et al., 1995) was used, the prevalence of
overweight/obesity was 19.1% (n= 221) amongst boys and 17.5% (n=153) amongst
girls, whilst the remaining patients were classified as being of a healthy weight (80.8%
boys, 82.6% girls). (See table 4.4.8)
Table 4.4.8: Prevalence of weight status at diagnosis defined by Cole et al.
(2007)/ IOTF and UK1990 definition according to gender in UKALL XI trial
1Thinness calculated by comparing patients BMI against age and gender based on Cole et al. (2007)
definition; 2 Healthy, overweight and obesity calculated by comparing BMI against age and gender by
applying IOTF and UK 1990 definitions; ∆ There is no definition for underweight by using UK 1990
reference data
Thinness1 Healthy2 Overweigh2t Obesity2
n % n % n %  n %
Boys 175 16.3 762 71.5 114 10.6 20 1.9Cole et al. 1/
IOTF2
Girls 126 15.6 568 70.5 88 10.9 24 2.9
Boys --- ∆ --- ∆ 932 80.8 138 11.9 83 7.2
UK 19902
Girls --- ∆ --- ∆ 725 82.6 90 10.3 63 7.2
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4.4.3 UKALL 97/ 97- 99 trial
4.4.3.1.1 Characteristics of the sample
The sample comprised 1,935 patients (56.0% boys, 44.0% girls). A large number of
patients had missing data (number of missed height: 1037 patients; weight: 385
patients and weight and height: 652 patients). For 1037 (57.4% boys, 42.6% girls)
patients BMI could not be determined. Therefore, the number of patients eligible
based on UK 1990 definition (Cole et al., 1995) was 898 (54.3% boys, 45.7% girls).
The median (range) age was 4.5 years (3.5, 7.5) with no significant difference
between boys and girls (Mann-Whitney test; p value=0.36).
However, 50 patients were also too young to be classified according to the Cole et al.,
(2007)/IOTF (Cole et al., 2000) definitions of weight status  (age < 2.0), and so, 848
(54.4%were males) patients were included in the analyses with Cole et al., (2007)
and IOTF (Cole et al., 2000) definitions as illustrated in figure 4.4.3.
Median age (range) at diagnosis of ineligible patients by IOTF (Cole et al., 2000)
definition was 1.5 years (1.5, 1.5) with no significant difference between boys and
girls.  Also, the median (range) BMI z score for those patients was 0.41(-0.51, 1.42)
with no significant difference between boys and girls (Mann-Whitney test; p value=
0.70) as shown in table 4.4.9.
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Figure 4.4.3: UKALL 97/97-99 trial flow diagram
♂: Male; ♀: Female; Ht: height; Wt: weight; IQR: Q1, Q3; UK 1990 definition (Reilly et al., 2010b), Cole et al. (2007), IOTF: International Obesity Task
Force(Cole et al., 2000)
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Table 4.4.9: UKALL 97/ 97-99 trial anthropometric measures of ineligible ALL
patients at diagnosis
Boys
(n= 27, 54.0%)
Girls
(n= 23, 46.0%)
Total sample
(n= 50)
Age (yr) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5)
Height z score © 0.87 (0.42, 2.21) 1.21 (0.53, 1.94) 1.22 (-0.30, 2.23)
Weight z score © 0.49 (-0.50, 1.92) - 0.93 (1.60, 2.42) 0.54 (0.21, 1.92)
BMI z score © - 0.32 (-0.42, 0.79) - 0.50 (-0.81, 1.90) 0.41(-0.51, 1.42)
© z score calculated by comparing patients against UK reference population (Cole et al., 1995)
The median BMI z score of the sample based on UK 1990 definition (Cole et al.,
1995) was 0.78 (-0.18, 1.52) with no significant difference between the sexes (Mann-
Whitney test; p value = 0.48). More details are shown in table 4.4.10.
Table 4.4.10: UKALL 97/ 97-99 trial anthropometric measures at diagnosis
Boys
(n= 488, 54.3%)
Girls
(n= 410, 45.7%)
Total sample
(n= 898)
P value
Age (yr) 4.5 (3.5, 7.5) 4.5 (3.8, 8.5) 4.5 (3.5, 7.5) 0.36
Height z score© 0.25 (-0.54, 1.09) 0.23 (-0.86, 1.02) 0.24 (-0.66, 1.02) 0.11
Weight z score© 0.71 (-0.24, 1.46) 0.57 (-0.14, 1.45) 0.66 (-0.18, 1.46) 0.13
BMI z score© 0.78 (-0.13, 1.59) 0.72 (-0.29, 1.49) 0.78 (-0.18, 1.52) 0.48
© z score calculated by comparing patients against UK reference population (Cole et al., 1995)
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4.4.3.2 Weight status of UKALL 97/ 97-99 sample
4.4.3.2.1 Weight status in overall sample of UKALL 97/ 97-99 sample
Using the Cole et al., (2007) /IOTF (Cole et al., 2000) classifications  for unhealthy
weight status show, 5.8% (n=49) of the patients were underweight and that more than
one-third (34.5%) of the patients (n=293) were overweight or obese. By applying the
UK 1990 definition (Cole et al., 1995), the prevalence of overweight/obese patients
was 40.9% (n=367), with 531 (59.3%) patients classified as being of a healthy weight,
as illustrated in table 4.4.11.
Table 4.4.11: Prevalence of weight status in UKALL 97/97-99 trial
Cole et al.1 /IOTF2 UK 19903Weight status
n % n %
Thinness 49 5.8 --- ∆ --- ∆
Healthy 506 59.7 531 59.3
Overweight 218 25.7 169 18.8
Obesity 75 8.8 198 22.1
Overweight/ obesity 293 34.5 367 40.9
1Thinness calculated by comparing patients BMI against age and gender based on Cole et al. (2007)
cut offs; 2Healthy, overweight and obesity calculated by comparing patients BMI against age and
gender according to IOTF cut offs; 3UK 1990 defined weight status as  healthy weight (BMI z score
<1.04), overweight (BMI z score 1.04≤ 1.64) and obese (BMI z score >1.64); ∆ There is no definition for
underweight by using UK 1990 reference data
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Patients ineligible had median age (range) at diagnosis for thin and overweight/obese
patients was 4.5 years (3.5 , 10.0) and 4.5 years (3.5 , 7.5); respectively, with no
significant difference between them (Mann-Whitney test; p value= 0.69). Also, the
median (range) BMI z score for thin was -1.9 (-2.6, -1.5) and for overweight/obese
was 1.8 (1.5, 2.3).
4.4.3.2.2 Weight status according to gender
Using the Cole et al., (2007) /IOTF (Cole et al., 2000) definitions weight status did not
significantly differ between boys and girls (Pearson chi-square test; p value=0.07).
Underweight at diagnosis of ALL was observed in 6.1% (n=28) of boys and 5.4%
(n=21) of girls. Moreover, about one-third (31.0%) of boys (n=143) and 38.7%
(n=150) of girls were overweight or obese.
Overweight prevalence defined by UK 1990 definition (Cole et al., 1995) in boys and
girls was significantly different (Fisher’s exact test, p value= 0.008) and overweight
prevalence accounted for 15.6% (n=76) and 22.7% (n=93) of the sample respectively.
Moreover, obesity was present in 23.8% (n=116) and 20.0% (n=82) of boys and girls
respectively (not significant, Fisher’s exact test, p value= 0.20).  Further details are
shown in table 4.4.12.
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Table 4.4.12: Prevalence of weight status at diagnosis defined by Cole et al. /
IOTF and UK1990 definition according to gender
Thinness1 Healthy2 Overweight2 Obesity2
N % n % n %  n %
Boys 28 6.1 290 62.9 102 22.1 41 8.9Cole et
al/ IOTF
Girls 21 5.4 216 55.8 116 29.9 34 8.8
Boys --- ∆ --- ∆ 296 60.7 76 15.6 116 23.8UK 1990
Girls --- ∆ --- ∆ 235 57.3 93 22.7 82 20.0
1Thinness calculated by comparing patients BMI against age and gender based on Cole et al. definition;2 Healthy, overweight and obesity calculated by comparing BMI against age and gender by applying IOTF
and UK 1990 definitions; ∆ There is no definition for underweight by using UK 1990 reference data
4.4.3.3 Trends in prevalence of unhealthy weight status over time a cross all
three trials
Prevalence of unhealthy weight status at diagnosis in UK ALL in the three trials as
summarised in table 4.4.13.
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Table 4.4.13: Prevalence of unhealthy weight status at diagnosis in the three
trials
UKALL X trial UKALL XI trial UKALL 97/97-99 trial
Cole et al.1
/IOTF2
UK 19903 Cole et al.1
/IOTF2
UK 19903 Cole et al.1
/IOTF2
UK 19903
Weight status
% % % % % %
Thinness 19.4 ----- * 16.0 ----- * 5.8 ----- *
Overweight 8.7 8.2 10.8 11.2 25.7 18.8
Obesity 1.5 5.1 2.3 7.2 8.8 22.1
Overweight/
obesity
10.2 13.3 13.1 18.2 34.5 40.9
1Thinness calculated by comparing patients BMI against age and gender  based on Cole et al. cut offs
Cole et al., (2007); 2Healthy, overweight and obesity calculated by comparing patients BMI against age
and gender according to IOTF cut offs (Cole et al., 2000)]; 3UK 1990 defined weight status as  healthy
weight (BMI z score <1.04), overweight (BMI z score 1.04≤ 1.64) and obese (BMI z score  >1.64) (King
et al., 2010); * There is no definition for underweight by using UK 1990 reference data
4.4.3.3.1 Trends using Cole et al. (2007) / IOTF definitions of weight status
The prevalence of overweight and obesity (combined) using the IOTF (Cole et al.,
2000) definition  increased from 10.2% in UKALL X to 13.1% in UKALL XI and 34.5%
in UKALL 97/97-99 (see figure 4.4.4). The trend in the prevalence of overweight and
obesity between the three trials was statistically significant (Chi-square test for trend;
p value<0.0001). In contrast, the rate of underweight Cole et al., (2007) stood at
19.4% in UKALL X and decreased substantially to reach to 5.8% in UKALL 97/97-99
(Chi-square test for trend; p value <0.0001) . Consequently, the prevalence of a
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healthy body weight was almost 70% at the beginning (UKALL X) of the trials but fell
to 59.7% in the most recent trial for which data are available (UKALL 97/97-99).
Figure 4.4.4: Prevalence of weight status defined by IOTF/ Cole et al., (2007)
definitions trends over UKALL trials
Healthy weight, overweight and obesity calculated by comparing BMI against age and gender by
applying IOTF, Thinness child classified as cut-offs defined to pass through absolute BMI ≤18.5 at age
18
4.4.3.3.2 Weight status trends using the UK 1990 reference data (Cole et al.,
1995) a cross the three trials
The prevalence of overweight and obesity (combined) across the three trials using the
UK 1990 definitions (Cole et al., 1995) of weight status  increased from 13.3% in
UKALL X to 18.2% in UKALL XI and to 40.9% in UKALL 97/97-99. The trend in
prevalence of overweight and obesity between the three trials was statistically
significant (Chi-square test for trend; p value< 0.0001). The prevalence of a healthy
body weight consequently fell from 86.6% to 59.3% in the most recent trial for which
data are available (Figure 4.4.5).
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Figure 4.4.5: Prevalence of weight status defined by UK 1990 trends over
UKALL trials
UK 1990 defined weight status as healthy weight (BMI z score <1.04), overweight (BMI z score 1.04≤
1.64) and obese (BMI z score >1.64)
4.4.3.4 BMI z score trends over periods a cross all three trials
As shown in figure 4.4.6, the median BMI z score trend significantly increased
between the three different trials (Kruskal Wallis test; p value < 0.0001). There was
also a significant shift in BMI z score trend between the UKALL X and UKALL XI trials
(Mann-Whitney test; p value < 0.0001).
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Figure 4.4.6: BMI z score trend over UKALL X, UKALL XI, and UKALL 97/97-99
* Significant increase of BMI z score over time between UKALL X  and UKALL XI (Mann-Whitney test,
p value < 0.0001); * Significant increase of BMI z score over time between UKALL X , UKALL XI and
UKALL 97/ 97-99 (kruskall- Wallis test, p value < 0.0001)
4.4.3.5 Agreement between Cole et al. (2007)/ IOTF and UK 1990 definitions on
the prevalence of weight status
In terms of the agreement between the Cole et al., (2007) IOTF (Cole et al., 2000)
and UK 1990 (Cole et al., 1995) approaches based on BMI for age, applying weighted
kappa (k) statistic suggested “almost perfect”  agreement in defining overweight and
obesity (combined) (k= 0.85; 95% CI: 0.80 - 0.90) in UKALL X, (k= 0.81, 95% CI: 0.78
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– 0.85) in UKALL XI and (k= 0.85; 95% CI: 0.82- 0.90) in UKALL 97/97-99.  However,
the agreement between used definitions was ‘moderate’ in defining overweight alone
amongst the patients: (k= 0.59; 95% CI: 0.50 – 0.69) in UKALL X, (k= 0.49, 95% CI:
0.43 – 0.56) in UKALL XI, (k= 0.42, 95% CI: 0.35 – 0.49) in UKALL 97/97-99.
Similarly, ‘moderate’ agreement was suggested in defining obesity amongst those
patients: (k= 0.45, 95% CI: 0.45, 0.29 – 0.6) in UKALL X, (k= 0.47, 95% CI: 0.38 –
0.56) in UKALL XI, (k= 0.51, 95% CI: 0.44 – 0.58) in UKALL 97/97-99(see table
4.4.14).
Table 4.4.14: Agreements between IOTF and UK 1990 definitions to define
overweight, obesity and overweight and obesity (combined) by using weighted
kappa test
Kappa Confidence Interval Kappa Interpretation
Overweight 0.59 0.50 – 0.69 Moderate
Obesity 0.45 0.29 – 0.60 Moderate
UK
AL
L
 X
Overweight and obesity 0.85 0.80 – 0.90 Almost perfect
Overweight 0.49 0.43 – 0.56 Moderate
Obesity 0.47 0.38 – 0.56 Moderate
UK
AL
L
 XI
Overweight and obesity 0.81 0.78 – 0.85 Almost perfect
Overweight 0.42 0.35 – 0.49 Moderate
Obesity 0.51 0.44 – 0.58 Moderate
UK
AL
L
 97
/97
-99
Overweight and obesity 0.85 0.82 – 0.90 Almost perfect
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4.5 Discussion
4.5.1 Main findings and implications:
4.5.1.1 Prevalence of weight status categories in the trials:
This study has described a dramatic alteration in the pattern and prevalence of
underweight, overweight and obesity amongst newly diagnosed paediatric ALL
patients in the UK. The patient population had a high prevalence of underweight and
low prevalence of overweight and obesity in the mid to late 1980s, a picture that had
considerably changed by the early 2000s to a lower prevalence of underweight and
high prevalence of overweight and obesity. To be more precise, in the trial that ran in
the mid to late 1980s, the prevalence of underweight was around 19% according to
the Cole et al., (2007) definition. The prevalence had shifted to around 5% by the trial
which ended in 2002. In contrast, the rates of overweight and obesity (combined) at
the start of the trial (1985- 1990) were around 10% and 13% respectively according to
the IOTF (Cole et al., 2000) and UK 1990 (Cole et al., 1995) definitions. However,
prevalence of overweight and obesity (combined) substantially increased to around
34% and 40% when both definitions were applied.
Therefore, the present study demonstrates that, in the UK, more than 40% of all
patients with ALL were underweight, overweight or obese at diagnosis using the most
recent dataset available (from the UKALL 97/ 97-99 trial which ended in 2002 ). No
estimates of the prevalence and trends over time of underweight or overweight and
obesity have previously been available from nationally representative samples of
patients using the currently recommended definitions of weight status based on BMI
for age (Reilly et al., 2010b) so, the present study is the first study in this field.
It is important to note that our prevalence estimates were conservative the prevalence
of markedly high fatness would probably have been higher than the prevalence of
high BMI for age measured in the present study. The BMI for age has a high
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specificity but moderate sensitivity in the general population of children (Reilly et al.,
2010b) (in other words, some obese i.e. excessively fat patients may be missed when
BMI is used to define obesity, but the risk of wrongly being diagnosed as obese is
rare) for diagnosis of excessive weight in both children and adolescents (as
mentioned in 1.4.5.1.5). Also, in children with malignancy, Warner et al., (1997)
investigated the ability of BMI in predicting excess adiposity against body composition
techniques such as DXA and skinfold thickness. They found that BMI in children with
malignancy underestimates the prevalence of excessive fatness in patients with ALL.
Similarly, this underestimation of excessive body fatness was discovered and
discussed in chapter 3 (Aldhafiri et al., 2012).
Additionally, children with ALL in the UK typically experience substantial excessive
weight gain during and after therapy (Reilly, 2009). For example, Breene et al., (2011)
assessed changes in 134 patients who were treated by using UKALL 97/97-99 from
diagnosis up to three years after the end of the therapy. The patient’s median age
(range) at diagnosis was 4.6 years (1.1- 15.9). It was found that the mean (95% CI) of
the BMI z score significantly increased (<0.0001) from diagnosis 0.35 (0.20- 0.50)
until three years post-therapy 1.04 (0.85- 1.22). In addition, Reilly et al., (2000b)
examined excess weight gain amongst 98 patients in the 1980-1990s who were
treated by UKALL XI protocols in Scotland. They found that obesity (defined as BMI z
score> 2.0) was significantly (p value < 0.01) increased from < 2.0 % at diagnosis up
to 16.0% at 3rd year since diagnosis. Odame et al., (1994) stated that obesity was
seen very commonly amongst survivors of ALL (mean age at diagnosis was 3.4
years) who were treated on the UKALL VIII (n= 15 children) and UKALL X protocols
(n=25 children) (both trials included CRT at 1800 Gy) than control group.  They found
that Prevalence of obesity at diagnosis were 5.0 % and 10.0% amongst ALL patients
and control group; respectively. However, the prevalence of obesity in fourth year
since diagnosis was 39.0% in the ALL group and 22.5% in the control group. In the
USA, a recent study (Esbenshade et al., 2011) found that the prevalence of
overweight and obesity (defined as CDC: BMI >85th percentile) in 183 children whose
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(median age (range)) was 5.7 years (1.2, 20.9) was 55% at diagnosis, which steadily
increased to reach 70% by the end of the ALL standard risk therapy (based on
Children’s Oncology Group protocols) (for more details see the table 1.5.1).
Underweight and obesity at diagnosis might have a role in outcome of the treatment.
Institute of medicine recently reported that obesity has a role in incidence, recurrence,
progression and death amongst cancer patients (Patlak and Nass, 2012). This thesis
will deal with this issue in the following chapter (chapter 5).
4.5.1.2 Using national and international approaches for defining weight status
The present study used the international definitions amongst UK ALL children
because the national UK BMI cut-offs are not available for defining underweight. The
weighted kappa analysis pointed to some agreement between international and
national definitions, but this was not perfect. The reason for the difference between
the national (UK 1990) definitions and the Cole/IOTF approach to defining obesity
was investigated by Chinn and Rona (2002). They examined 6000 white English
healthy children aged 4 – 11 years between 1984 – 1994 by applying UK- specific
reference (BMI z score equivalent to BMI 25 and BMI 30 at ages 18, 19.5 and 23) and
IOTF (Cole et al., 2000) definitions. They found for example prevalence of overweight
by applying UK cut-off in boys was increased from 10.2% in 1984 up to 13.8% in
1994. However, the prevalence increased was 5.4% in 1984 up to 9.0% in 1994 by
applying IOTF (Cole et al., 2000) definition.  They showed also, that the greatest
difference between the national and international definitions is before the age of 5
years old than older children as same as to the present study when the median age in
all three used cohorts in the present study was 4.5 years. The varying difference is
due to converting each international BMI-cut offs point to overweight (BMI= 25) or
obese (BMI= 30) extrapolated back from age18. They concluded that the IOTF
definition of obesity is not compatible to UK reference curve for BMI cut-offs because
its data comes from different countries, and also because the BMI curves were
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modelled through BMI values at age 18 (while adolescents will still be growing) rather
than age 21 (when growth should have stopped).
Moreover, the present study showed no difference in weight status between boys and
girls using international and national definitions. In contrast, Chinn and Rona (2002)
found a substantial difference in the prevalence overweight and obesity in boys than
girls who were before age of 5 and so, the international definition would
underestimate the prevalence of obesity. Therefore, the present study with a large
and representative sample supports the view that there is no reason to believe that
girls with ALL are at greater risk of overweight and obesity than boys.
Similar to the present study, some other studies have examined differences between
definitions of weight status between national and international approaches. El-Ghaziri
et al., (2011) compared the impact of using international approaches (Cole et al.,
(2007), IOTF, WHO, CDC) for defining weight status in 499 Kuwaiti adolescents
(aged 10- 14 years) versus national approaches. They found that the international
approaches had almost perfect agreement to each other by using weighted kappa
statistic test. However, they showed that there were marked differences in defining
weight status categories between the national and international approaches.
Reilly et al., (2010b) in a systematic review of eight studies found that BMI for age
based on national reference data was superior (higher sensitivity and higher
diagnostic accuracy) for defining obesity than the IOTF approach.  The present study
similarly showed that obesity prevalence in all three trials was lower (4 – 14%) by
using the international definition than when using the national definition.
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4.5.2 Comparisons of the present study with ALL studies
4.5.2.1 UKALL X trial
The few studies (shown in table 4.5.1) that have examined weight status at diagnosis
of ALL in UK children had a relatively small sample sizes except Weir et al., (1998)
study. In the present study, almost the same UKALL X trial patients datasets that
used in the present study were  also, used and studied by Weir et al., (1998) and
Reilly et al., (1999b), but they applied different weight status approach. Weir et al.,
(1998) examined 1,025 children who median age at diagnosis was 4.4 years. They
found that prevalence of overweight and obese combined (defined as BMI z score >
0.5) was 24.3% whereas in the present study they were 13.3% and 10.2% by using
UK 1990 and IOTF approaches; respectively. Underweight at diagnosis prevalence
were 42.9% by Weir et al., (1998) study who defined underweight as BMI z score
< -0.5 but in the present study this was reduced by using Cole et al., (2007) definition
(19.4%). Therefore, it seems that the overnutrition and undernutrition definitions used
by Weir et al., (1998) overestimated prevalence compared to the current national and
international definitions.
Reilly et al., (1999b) studied 1,019 ALL patients at diagnosis who were treated by
UKALL X protocols. They found that prevalence of undernutrition (defined as BMI z
score < - 2.0) was 7.6 % and 6.7% in boys and girls; respectively. However, by
applying Cole et al., (2007) definition in the present study, the prevalence of
underweight was highly elevated to 20.3% and 16.4% in boys and girls; respectively.
Moreover , in Reilly et al., (1999b) study, the prevalence of overnutrition (BMI z score
> 2.0) was 2.6% and 3.2% in boys and girls; respectively. A similar prevalence of
obesity was observed in the present study amongst boys (1.4%) and girls (1.9%) by
using the IOTF definition of obesity (Cole et al., 2000). However, by applying UK 1990
definition (Cole et al., 1995), the prevalence of obesity was slightly higher in boys
(4.7%) and girls (6.6%). Reilly (1999b) used overnutrition definitions which appear to
have underestimated prevalence.  At the time of these studies, Weir et al., (1998) and
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Reilly et al., (1999b), no international definitions of overweight, obesity and
underweight based on BMI existed.
In addition, Odame et al., (1994) examined weight status in a small sample compared
to the present study. They recruited only 40 children in single centre whose mean age
(range) at diagnosis was 3.4 years (2.1- 5.2) with ALL in the first remission treated on
the UKALL VIII or X protocols. The prevalence of obesity reported (as BMI z score
>2.0) was 5%, similar to that obtained in the present study (5.1%; UKALL X data)
using the UK 1990 definition (Cole et al., 1995), with no significant difference between
the sexes. Although the prevalence of obesity was similar to the present study as they
used same reference data but, it might not support our findings because different cut-
offs were applied. However, in the present study, the prevalence of obesity was lower
(1.5%) when the IOTF definition was applied.
4.5.2.2 UKALL XI
A similar prevalence of obesity (defined by the IOTF (Cole et al., 2000)) to that
observed in the present study (UKALL XI) (2.3%) was reported by Reilly et al.,
(2000b), who stated that obesity (defined as a BMI z score > 2.0 relative to the UK
reference) was 2.0% amongst 98 children with ALL treated on the UKALL XI protocol
in Scotland. In contrast, the prevalence changed to 7.2% when the UK 1990 (Cole et
al., 1995) definition was used in the present study. However, the Reilly et al., (2000)
study had a relatively small sample size from one single centre and used different
reference data which likely influenced the prevalence estimates obtained. The
present study is likely to have provided a clearer and more informative picture as it
used a large representative sample and applied modern and widely accepted
definitions of weight status (Cole et al., 2000, Cole et al., 2007, Cole et al., 1995).
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Table 4.5.1:  Prevalence of overweight and obesity amongst UK children with
ALL at diagnosis
Author Methods Definition Prevalence of
overweight
Prevalence
of obesity
IOTF (n=917 ) 8.7 1.5 UKALL X trial
 1 – 14 years
UK 1990^ (n= 1033 ) 8.2 5.1
IOTF (n=1877 ) 10.8 2.3 UKALL XI trial
 1 – 14 years UK 1990^(n= 2031 ) 11.2 7.2
IOTF(n=848 ) 25.7 8.8
The present
study
 UKALL 97/ 97-99
 1 – 18 years
UK 1990^ (n= 898) 18.8 22.1
Weir et al.,
(1998)
 Retrospective study
 0.2 – 14.9 years
 UKALL X trial
 n= 1025
 BMI z score >0.5  24.3 ---
Odame et
al., (1994)
 Retrospective study
 2 – 8 years
 Treated by UKALL VIII
or X
 n= 40 (♂:21, ♀: 19 )
 BMI z score > 2.0 * ---  5.0%
♂: 5.0%
♀: 5.0%
Reilly et al.,
(2000b)
 Longitudinal study
 Mean (SD) age: 5.2
years (3.4)
 Treated by UKALL XI
 n= 98 (♂: 53, ♀: 45)

 BMI z score > 2.0* ---  2.0%
Breene et
al., (2011)
 Retrospective study
 Median age (range):
4.6 years (1.1- 15.9)
 Treated by UKALL 97
 n= 77 (♂:37, ♀:40)
 IOTF  27.3%  2.6%
♂: Male; ♀: Female; IOTF; International Obesity Force Task; * BMI z score relative to UK reference
data; ^UK 1990 defined weight status overweight (BMI z score 1.04≤ 1.64) and obese (BMI z score
>1.64) (King et al., 2010)
4.5.2.3 UKALL 97/97-99 trial
Breene et al., (2011) examined weight status changes in 77 paediatric ALL patients
who were treated on UKALL 97/97-99. The prevalence of overweight and obesity by
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applying IOTF definition (Cole et al., 2000) (combined) was around 30%, a result
similar to that obtained in the present study (34.5%) when the same definition was
applied IOTF definition (Cole et al., 2000). This would support the present study
findings even with large number of excluded patients (discussed later in this chapter).
Conclusions
The prevalence of unhealthy weight status depends on the cut-offs and reference
data that have been used and the sample size and the time. Therefore, the
prevalence was inconsistent in previous studies that used UKALL X dataset
compared to the present study. However, the present study used internationally
accepted definitions of being underweight (Cole et al., 2007) or overweight and
obesity (Cole et al., 2000) in childhood and adolescence. These international
definitions of weight status are widely used in research and are particularly suitable
for between-study and international comparisons. Also, UK 1990 cut-offs used in the
present study are recommended in the UK by clinicians and other health
professionals although no clear evidence-based definition of being underweight exists
with the UK 1990 BMI reference data (Reilly et al., 2000).
4.5.3 Comparison of the present study with general UK population of children
and adolescents studied of obesity prevalence at around the same time
Overweight and obesity amongst children and adolescents described in the present
study may reflect rapid secular trends in the general child population in the UK (Reilly,
2006b) (see table 4.5.2). Reilly and Dorosty (1999) studied 2630 English children
aged 6 – 15 years in cross sectional English health survey and a representative
sample. This survey was carried out between 1978- 1996. The prevalence of
overweight (BMI > 85th centile) and obesity (BMI> 95th centile) relative to UK
reference data at age six (n= 298) were 21.8% and 10.4% respectively. These
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prevalence estimates were higher than the present UKALL X trial (as it is around the
Reilly and Dorosty (1999) period) by using both definitions.
In a review of studies on the general population and using the same reference data
and definitions (it is possible to use the same reference data but different cut-points)
as the present study, Chinn and Rona (2002) examined 6000 white children aged 4 –
11 years from 1984-1994  in England. They used UK- specific reference (BMI z score
equivalent to BMI 25 and BMI 30 at ages 18, 19.5 and 23) and IOTF (Cole et al.,
2000) definitions.  They found in 1984 that the prevalence of overweight and obesity
defined by IOTF (Cole et al., 2000) was 8.4%. In 1994, the prevalence of overweight
and obesity increased to 13.5%. In UKALL X data for the present study showed quite
similar prevalence of overweight and obesity (10.2%) whereas UKALL XI had similar
prevalence of overweight and obesity (13.1%). However, Chinn and Rona (2002) did
not present the age group in their  study. In addition, Kinra et al., (2000) found a
roughly similar obesity prevalence (defined as BMI > 98th centile based on UK curves
for children ) (5%) in UK children the mid-1990s to the UKALL XI data used in this
study (~7%) by using same definition.
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Table 4.5.2: Prevalence of overweight and obesity in general population of children in the UK (1985- 1999)
Author Methods Definition Prevalence of
overweight
Prevalence
of obesity
IOTF (n=917) 8.7 1.5 UKALL X trial
 1 – 14 years
UK 1990^ (n= 1033 ) 8.2 5.1
IOTF (n=1877 ) 10.8 2.3 UKALL XI trial
 1 – 14 years
UK 1990^(n= 2031 ) 11.2 7.2
IOTF(n=848 ) 25.7 8.8
The present
study
 UKALL 97/ 97-99
 1 – 18 years
UK 1990^ (n= 898) 18.8 22.1
Reilly and
Dorosty
(1999)
 Cross-sectional; England (1978-
1990)
 2630; 6 – 15 yr
UK reference data
Overweight: BMI z score > 85th centile
Obesity: BMI z score > 95th centile
At age 6 yr:
21.8%
At age 6 yr:
10.4%
Lobstein et
al., (2003)
 1994 -1998 survey (England)
 2882, M: 51.5%; 17 yr
IOTF Total: 16% ♂: ~ 2%
♀: ~ 8%
Total: 4%
IOTF ♂: 9.0%
♀: 13.5%
♂: 1.7%
♀: 2.6%
Chinn and
Rona (2002)
 Cross-sectional; England (1994)
 ~6000; 4 – 11 yr
UK- Overweight: z score equivalent to BMI
25;Obesity:  z score equivalent to BMI 30
♂: 13.8%
♀: 13.5%
♂: 2.5%
♀: 2.2%
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M: Male; F: Female; yr: years; IOTF: International Obesity Force Task; n/a: not available; ^UK 1990 defined weight status overweight (BMI z score 1.04≤ 1.64) and obese (BMI
z score  >1.64) (King et al., 2010)
Kinra et al.,
(2000)
 Cross-sectional; England (Plymouth)
(1994-1996)
 20,973; F: 49%; 5 - 14 yr
UK 1990
Obesity: BMI z score >1.64
n/a ♂: 5.2%
♀: 4.8%
Total: 5.0%
Rudolf et al.,
(2001)
 Longitudinal; England (Leeds) (1998-
9999)
 1762; M: 44.6%; 7 - 11 yr
UK 1990
Overweight: BMI z score >1.04 (85th centile)
Obesity: BMI z score > 1.64 (95th centile)
♂:22.0%
♀:22.0%
♂: 11.0%
♀: 12.0%
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Lobstein et al., (2003) studied overweight and obesity among 2882 (51.5%
boys) English children and adolescents aged 5 – 17 years. Their study was
carried out in the mid to late 1990s (the period of time covered by the UKALL
XI and UKALL 97/97-99 data) and showed that the prevalence of overweight
and obesity (based on IOTF definition (Cole et al., 2000)) varied from 20%,
while the prevalence of overweight and obesity from the present UKALL X
and UKALL 97/97-99 data was higher (34.5%) and lower (13.1%) in UKALL XI
by using the same definition (IOTF) (Cole et al., 2000). Also, In a longitudinal
English study (in Leeds), 1,762 children in primary school aged 7 – 11 years
were examined from 1998 – 1999 (Rudolf et al., 2001). By applying UK 1990
definition of weight status, the prevalence of overweight and obesity were
22.0% and 11.5%; respectively. By using same period data and the same
definition, the present UKALL 97/97-99 data shows that the prevalence
overweight was similar (18.8%), but the prevalence of obesity (22.1%) was
extremely different.
In conclusion, the present study shows the prevalence of unhealthy weight
status in children at diagnosis of ALL in UK. Some differences in weight status
at diagnosis between the ALL patient population in the present study and the
general population are to be expected according to possible nutritional effects
of ALL before it is diagnosed and length of time before diagnosis and age at
typical diagnosis.
4.5.4 Secular trends in weight status in UK children and adolescents
The childhood overweight and obesity epidemic began in the UK in the mid to
late 1980s and developed rapidly at least until the mid to late 2000s as
mentioned in some studies above (Reilly and Dorosty, 1999, Reilly, 2006b,
Stamatakis et al., 2010). In British surveys of 11-16 year olds, boys (n=1,567)
in 1977 and girls (n= 2,217) in 1977 and both sexes (boys n= 389; girls n=
387) in 1997 examined overweight (defined as a BMI z score >1.33 relative to
UK 1990 reference) and obesity (defined as BMI z score >2.0 relative to the
UK 1990 reference) (McCarthy et al., 2003). The percentage increase
overtime between 1977 -1997 was 11- 13% in overweight and 7% in obesity.
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It was concluded that over the 10 to 20 years from the late 1980’s overweight
and obesity in young people has risen. However, it is worth noting that obesity
in UK children has tended to level off or decline beyond the mid to late 2000s
but not in all age groups especially the more deprived (Stamatakis et al.,
2010) . However, the likely prevalence for ALL patients at diagnosis today is
not studied yet so, it is not clear whether prevalence is similar to the general
population or not. On the other hand, the secular trends over time in
underweight children in the UK have not been well addressed and the author
could find no published studies on trends in prevalence of underweight in the
UK.
Dramatic increases in the prevalence of obesity in newly diagnosed children
with ALL in the UK seems to be a reflection of what happened in the general
UK childhood population. Obesity can only develop secondary to a chronic
state of positive energy balance, a higher energy intake consumed over total
energy expenditure or a decline in total energy expenditure (e.g. due to a low
level of physical activity). Children and adolescents need for their growth and
development a very small daily energy imbalance (the energy spent in
deposition of new tissue). Obesity as an energy balance disorder seems to
have very simple origins: increased energy (food) intake, reduction in energy
expenditure or both. In reality, the aetiology of obesity in general paediatric
population is more complex than the simple static model as mentioned
because many factors can influence energy intake and energy expenditure.
Also, the principal causes of the obesity epidemic in the paediatric population
remains inadequately understood for several reasons (Reilly et al., 2009).
First of all, measurement issue is one of the big challenges because
measurements of energy intake and expenditure have limited accuracy and
precision, especially energy intake. The energy imbalance that may cause
obesity can be very small and complicated to distinguish. Understanding
energy imbalance is also complex because a change in energy (food) intake
might produce compensatory modification in the other terms of the energy
balance equation (Reilly et al., 2007). Subtle societal effects on energy intake
and expenditure are more likely the underlying causes that lead to obesity
(Reilly et al., 2007). Children globally may consume a higher energy intake
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than they need especially because they and their parents may not be aware
of these effects (Cohen, 2008). Finally, causes of obesity may differ between
child groups within populations. For all these reasons, it is complex to
understand the aetiology of obesity in children.
Nevertheless, there are few well-established behaviours that have contributed
to the childhood obesity epidemic, but even these behaviours are contested
(Monasta et al., 2010). The well-established behaviours are: formula-feeding
in infancy; rapid growth in infancy and early childhood; high consumption of
sugar-sweetened drinks; high levels of sedentary behaviours such as TV
viewing and forms of screen-time or media use (Monasta et al., 2010).
Moreover, some evidence recently shows that both less sleep time and low
level of physical activity are considered as causes of childhood obesity (Reilly
et al., 2009).
For patients during and after of treatment of childhood cancer a good deal of
specific evidence on the aetiology and natural history of obesity is available,
particularly in ALL as discussed in details in 1.5.6. Consequently, this
evidence should inform strategies for prevention of obesity and reduction in
cardiovascular risk.
4.6 Nutritional screening for patients weight status from diagnosis
  In the UK there is currently no formal requirement to screen patients with
ALL for unhealthy weight status at diagnosis or any stage of treatment, and
routine measurement of patient weight and height was abandoned a decade
ago when the algorithm to estimate body surface area (to calculate drug
dosage) was changed. It seems that no policy responses in terms of changes
in clinical management around nutritional assessment and dietetic input for
example- to the dramatic secular trends in patient weight status described in
the present study. Clinical management appears to have proceeded largely
unchanged despite marked changes in weight status of patients. In the
absence of formal anthropometric screening for unhealthy weight status, few
patients who have unhealthy weight status would be identified, even by
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experienced paediatricians, paediatric dietitians, and paediatric nurses (Cross
et al., 1995, Smith et al., 2008) or parents (Parry et al., 2008) . Identification of
both underweight and overweight/obesity at diagnosis of ALL should be
relatively straightforward using the BMI in conjunction with widely available
centile charts (Reilly et al., 2010b), but there remains a widespread resistance
to using such charts routinely in paediatric practice (Flower et al., 2007).
Nonetheless, the present study supports the view that the assessment of
weight status should receive a higher priority in the management of childhood
ALL in future.
4.7 Weaknesses and strengths of the present study
A number of limitations may have affected the interpretation of the results of
this study.
Sample size
In the UKALL X dataset, the number of included girls (25.1%) was much lower
than boys (74.9%).The sample size of UKALL X trial was affected by low
percentage of girls aged 2 – 9 years old as at that time girls tended to be
defined as low risk ALL patients (Weir et al., 1998) unless certain additional
criteria were met (e.g. high WBC at diagnosis > 50 x 109/ L). Only standard
risk data patients were provided for UKALL X by the CTSU and so this
limitation could not be avoided. Also, the present study assessed only ~46%
of the whole UKALL 97/97-99 trial because of a lot of missing data (n= 1037).
However, despite these limitations the present study evaluated very large
number of (n= 3962) of ALL patients over different trials for the time period
1985 – 2002.
Design and methods limitations
The measurements used in the present used were collected retrospectively
and relied on routine collection of clinical measurements rather than an
(ideally) research-based approach. Height and weight were therefore
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measured around the time of the diagnosis and no data were excluded
because they were implausible data which looked like outliers (by using
scatter plot graph (n= 28; in all three trials)) were not excluded. Also, these
measurements were taken by many different health professionals, centres,
scales and stadiometers .  Nevertheless, it was possible to estimate the
prevalence of malnutrition using national datasets collected by routine clinical
measurements are not usually subject to a high degree of bias. A Scottish
study studied data from 15 health boards to examine whether the
anthropometric data that are collected routinely by the Scottish Child Health
Surveillance System are suitable for monitoring weight status (Armstrong and
Reilly, 2003). It was found that anthropometric data extracted from routine
collection could be useful in monitoring the prevalence of malnutrition-
individual measures might be subject to error but for large groups Armstrong
and Reilly (2003) concluded that errors for median or mean values and for
prevalence the effect of errors was likely to be quite small.
The present study assessed weight status solely according to BMI for age and
sex. The BMI is a conservative tool in predicting overweight and obesity
(Reilly et al., 2010b) as noted above, and its predictive validity for outcomes
and complications of the underweight definition used in the present study
have yet to be addressed and this is also true for the overweight definitions
used in the present study. Nonetheless, BMI remains the simplest approach
and provides a useful clinical and epidemiological definition of childhood
obesity (Reilly et al., 2010b) and this study used two approaches to examine
the prevalence of unhealthy weight in order to minimise the limitations of
each, and also focused on secular trends in the patient population rather than
make assessments of individual patients.
Thirdly, the large amount of missing data in the most recent dataset (UKALL
97/97-99) was a cause for concern. In the UKALL X and UKALL XI trials, the
algorithm of chemotherapy dosage relied on the surface area, which was
calculated by measuring and recording height and weight (Lilleyman and
Lennard, 1994, Chessells et al., 1997b).  However, when the algorithm only
depended on weight rather than the height measurement after UKALL 97/ 97-
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99, the recording of height declined substantially from 0.7%- 2.8% of heights
missing out of the total sample in UKALL X and UKALL XI data, up to 53.7%
out of the UKALL 97/97-99 total sample. It is not clear whether the missing
data (see follow diagram in figures 4.4.1, 4.4.2 and 4.4.3) may have biased
the estimation of weight status in the present study, particularly when the
prevalence of UK childhood overweight/obesity amongst patients treated on
the UKALL 97/79-99 protocols was higher (~40%) relative to the UKALL XI
trial as same as to that observed in the smaller study (~30%) (Breene et al.,
2011).
Generalising the findings of this study to other patient populations should be
approached with caution, though the availability of national trial data in the
present study should increase the opportunity to generalise them.
Furthermore, the childhood obesity epidemic is a global phenomenon and the
increases over time observed in the UKALL trial cohort reflect population
changes.
This study assessed weight status as measured by BMI for age and sex,
which conceptually refers to a chronic deficit or excess of energy. However,
this definition of malnutrition based on weight status used in this thesis could
be extended to micronutrient deficiency or excess. A deficiency or excess of
micronutrients has a clinical impact on outcomes, particularly important in
paediatric haematology and oncology (Rogers and Ladas, 2011) (described in
section1.4). However, this issue was beyond the scope of present study since
no routinely collected data are available for the nutritional status of other
nutrients in the UKALL trials.
4.8 Conclusions
Obesity has reached epidemic proportions in the general child population. The
prevalence of underweight, overweight and obesity at diagnosis in UK
children with ALL has undergone a remarkable shift over the lifespan of the
three trials examined in the present study according to both national and
international definitions. Whilst the prevalence of overweight and obesity has
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substantially increased over time, the prevalence of underweight has
decreased significantly, though it still existed in the most recent trial which had
data.
This prevalence over time of an unhealthy weight at diagnosis of childhood
ALL has to date probably gone largely unrecognised by clinicians and
researchers partly because no study in this field has been published,  so the
present study is the first study focused on this vital issue.
Generally speaking, it is well-known that underweight, overweight and obesity
have short and long- term adverse outcomes for the health of the paediatric
population (Reilly and Kelly, 2011, Pelletier and Frongillo, 2003, Reilly et al.,
2003) (as discussed in sections 1.2 and 1.3) and could therefore have
implications for the treatment outcome.
Finally, unhealthy weight status is sufficiently common at diagnosis in
childhood ALL to at least support the consideration of screening of weight
status at diagnosis. Therefore, early health interventions are important if long
and short term morbidity and mortality arising from underweight, overweight
and obesity are to be reduced. However, these interventions should ideally be
based on intervention strategies, and should use trained and qualified health
professionals, particularly nutrition care services.
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Chapter 5
Influence of weight status at diagnosis on survival in
UK patients treated for ALL
This chapter describes a study which is now accepted as a paper in Journal
of Pediatric Hematology and Oncology
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5.1 Introduction
There is some evidence from both developing and developed countries that
overweight/obesity and underweight/thinness at diagnosis are adverse
prognostic factors amongst ALL patients. Both underweight and
overweight/obesity might lead to increased risk of relapse or death as
discussed in the chapter (section 1.5.5). Briefly, Butturini et al., (2007)
examined 343 obese (BMI > 95th centile relative to US reference data) and
3,971 non-obese US ALL patients at diagnosis. They found that obese
patients  aged 10 years old and over at diagnosis had increased risk of
relapse with adjusted hazard ratio for relapse 1.65 (95% CI: 1.13 – 2.41)
relative to the non-obese.  A recent Brazilian study also, suggested that
obesity at diagnosis of ALL was an adverse prognostic factor (Gelelete et al.,
2011). They examined 181 patients with ALL aged < 10 years old. They
reported that 35.9% of the sample were overweight or obese (BMI above
+1SD relative to WHO reference data) (Gelelete et al., 2011). Furthermore, a
critical review of nine papers  concluded that undernutrition at diagnosis may
be an  adverse prognostic factor in ALL patients (Lobato-Mendizabal et al.,
2003). If it is confirmed that obesity and /or underweight increase the risk of
relapse in ALL that could lead to early intervention and treatment of unhealthy
weight status during ALL treatment. Particularly when the Chapter 4,  (UKALL
97/97-99) showed that the prevalence of obesity (defined conventionally and
using a conservative approach based on BMI for age) suggested that at least
20% of the patients at diagnosis of ALL were obese in the most recent UK trial
for which data are available . Also, if unhealthy weight status at diagnosis did
influence risk of relapse, therapy might even be tailored to take account of this
in future (e.g. more intensive therapy for obese patients for example).
On the other hand, there is some doubt about the question of whether weight
status at diagnosis influences relapse risk in ALL patients. Some evidence
showed that weight status at diagnosis might not influence weight status in
ALL patients; as described in chapter 1 (section 1.5.5). Briefly, Weir et al.,
(1998), Hijiya et al., (2006) and Baillargeon et al., (2006) all concluded that
overweight/obesity at diagnosis of ALL does not change relapse risk in both
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developing and developed countries.  Also, Pedrosa et al., (2000) in
developing countries (El Salvador and North Brazil) found that undernutrition
(defined as weight for height, weight for age and height for age z score < -
2.0) did not have an influence on relapse risk in ALL patients at diagnosis.
It is worth noting that Weir et al., (1998) previously studied the same UKALL X
data used in the present study and the present study was following Weir et al.,
(1998) study methods . When the Weir et al., (1998) study was going on in the
mid-1990’s  there was no consensus on the appropriate definitions of
underweight, overweight and obesity based on BMI, and so Weir et al. (1998)
could not have examined the influence of unhealthy weight status on relapse
risk using definitions of unhealthy weight status which are acceptable today.
In fact, Weir et al., (1998) focused on the effect of undernutrition at diagnosis
of ALL on risk of relapse and defined undernutrition as BMI z scores below -
0.5. Also, inconsistent findings between studies in this field mean that
additional evidence would be useful. Therefore, there was a need for a new
study which has a fairly homogenous sample, included a large sample size,
and used recent modern and accepted weight status definitions.
5.2 Aims
This chapter aimed to test the hypothesis that unhealthy weight status at
diagnosis is an independent prognostic factor for relapse in standard risk;
because standard risk patients are the largest single group of patients with
ALL, they provide a fairly homogenous group of patients, and only these data
were provided by the CTSU at Oxford as described (in section 2.2.2).  Also,
no clear underweight definition according to the UK 1990 reference data (Cole
et al., 1995) for BMI exists, and so the present study used the Cole et al.,
(2007) definition. The present study used more modern evidence based  and
recommended definitions of underweight, overweight, and obesity based on
BMI for age (Reilly et al., 2000a). The present study also aimed to estimate
the magnitude of any effect of overweight/obesity and underweight on risk of
relapse.
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5.3 Methods
5.3.1 Participants
The UKALL X trial from the UK was described in detail in the general methods
chapter (section 2.2.4.1). Briefly, UKALL X entered 1,635 patients aged 1 - 14
years old. A number of patients were excluded from the trial as they were
misdiagnosed (n= 23). Also, the present study excluded any patients
diagnosed with CNS disease at diagnosis (n= 12), those who were defined as
high risk (n= 213; high risk defined as presenting WBC > 100 x 109/L or
having Down’s Syndrome) and girls who were defined as low risk (n= 347; low
risk being defined as girls with presenting WBC < 20 x 109/L).  Therefore,
1,040  ALL patients (standard risk defined at the time of study as presenting
WBC < 100 x 109/L and age less than 15 years old) for which data were
provided by CTSU at Oxford were potentially eligible for inclusion in the
present study (Weir et al., 1998).
5.3.2 Measures of weight and height
As described in section 2.2.6.1, height and weight were measured to 0.1 cm
and 0.1 kg; respectively. These measurements were taken around the time of
diagnosis by different nurses at UK treatment centres for ALL for clinical
purposes (mainly for estimating drug dosage).
5.3.3 Weight status and other possible prognostic factors at diagnosis
The primary aim of the present study was to test whether the weight status at
diagnosis is a prognostic factor in childhood ALL. Weight status in the present
study was defined according to IOTF (Cole et al., 2000) and Cole et al.,
(2007) definitions as described in the methods chapter (section 2.1.3.1.4 and
2.1.3.1.5).  This chapter did not use the definition of thinness/underweight
using BMI with UK 1990 reference data (Cole et al., 1995) since thinness/
underweight is not defined using BMI with UK 1990 reference data (Cole et
al., 1995). However, the present study used BMI z scores expressed relative
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to UK 1990 reference data (Cole et al., 1995) only to test the influence of BMI
z scores at diagnosis as continuous variable on the time of relapse.
However, the present study also assessed other known or suspected
prognostic factors though they were not the primary aim. These other factors
were age at diagnosis, gender, white blood count (WBC) count at diagnosis,
intensification schedule of treatment, and ethnicity. Assessing these
prognostic factors could be essential since any association between weight
status and relapse rate might have been caused by artifactual association
with one or more of these tested prognostic factors. There is no reason to
suspect that the present study had a particularly selected sample as it
attempted to include all patients with standard risk ALL as defined at the time
of the UKALL trial. Some groups (e.g. girls) might appear to have been under-
represented, but that was because girls have been considered to be at lower
risk of relapse than boys and they received different treatment as a result.
5.3.4 Statistical analysis
Results are expressed as median (Interquartile: Q1, Q3) unless otherwise
stated. Patients who relapsed and did not relapse were used to define the
clinical outcome. First relapse was the key outcome variable for analysis.
Also, a censored survival time (time since diagnosis to the endpoint of
interest) was used in days for patients who had not relapsed. The influence of
each individual prognostic factor was assessed by applying log ranks testing
(Altman, 1991). It is worth mentioning that the log ranks test is used only for
categorical variables, and also that it is a univariable analysis which does not
allow for the potential testing of several prognostic factors simultaneously.
The Mann-Whitney test was used for non-parametric data to test the
significance of any differences in the mean between numerical variables.
Differences in the prevalence of an unhealthy weight status between boys and
girls were tested for significance using a Pearson’s Chi Square and Fisher’s
exact tests were used for two binary variables to determine whether two
population proportions are equal.
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The present study categorised the possible prognostic factors into subgroups.
Intensification of treatment was categorised into four groups to examine
significance of the influence of each group on the outcome of treatment: none,
early, late and early and late intensification interventions. Moreover, the
present study divided the patients’ age to different subgroups:  2.0 – 3.9, 4.0-
9.9 and 10.0- 14.9 years old to examine the impact of age group at diagnosis
on the risk of the relapse. These age cut offs were chosen to provide fairly
equal numbers of patients in subgroups. Ethnicity as a possible prognostic
factor was spilt into European and Non- European ethnicity because the
number of non-European origin patients was small.  Therefore, this chapter
used the log ranks test to examine the individual possible influences of
gender, intensification of treatment, age at diagnosis, ethnicity, and weight
status (Healthy, thin/underweight and overweight/obese as defined according
to IOTF (Cole et al., 2000) and Cole et al., (2007) definitions ) using SPSS
version 18.0 package.
For individual continuous variables (univariable analysis the Cox proportional
hazards model was used to test the influence of possible prognostic factors
on the outcome of relapse risk (Altman, 1991) using SPSS version 18.0
package. These variables were WBC count at diagnosis, age and BMI z
score. The overall survival probabilities were estimated by the Kaplan- Meier
method (Kaplan et al., 1968) using Originpro version 8.5.
To examine the possible influence of combined prognostic factors on the
outcome of relapse risk using a  multivariable analysis i.e. with several
potential prognostic factors considered together, stepwise proportional
hazards regression modelling was applied (Altman, 1991) using SPSS version
18.0 package . Intensification treatment in this model was split into two binary
variables as a factorial structure: coded to yes and no for early intensification
and yes and no for late intensification (Weir et al., 1998).
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5.4 Results
5.4.1 Excluded patients
From the potentially eligible patients who met study entry criteria (standard
risk patients with ALL) some patients had missing data for weight and height
(n= 7). Some ALL patients were ineligible to be included in the present study
because they were out of the IOTF (Cole et al., 2000) and Cole et al., (2007)
definitions age ranges. Hence, any patients aged less than 2 years old was
excluded (n= 116).  The characteristic of  continuous variables in patients,
who were excluded from the present study because they had missing data
and/ or they were less than 2 years old at diagnosis (n= 123), is described in
table 5.4.1.  The median (Q1, Q3) of age at diagnosis, BMI z score at
diagnosis and WBC count at diagnosis in excluded patients (n= 123) were 1.6
years (1.3, 1.9), -0.39 (-1.05, 0.59) and 7.2 (x 109 /L) (3.8, 20.1); respectively.
Also, the characteristics for categorical variables (gender, categories
intensification, categorised WBC count and ethnicity) in excluded patients (n=
123) at diagnosis and relapse rate is shown in table 5.4.2 and figure 5.4.1.
Table 5.4.1: Characteristics of continuous variables in excluded
patients, median (Q1, Q3)
Boys
(n=71 )
Girls
(n= 52 )
Overall sample
(n= 123 )
P
value*
Age at diagnosis (yr) 1.6 (1.3 , 1.8) 1.6 (1.1 , 1.9) 1.6 (1.3 , 1.9) 0.69
BMI z score - 0.31 (- 1.01 , 0.61) -0.55 (-1.35 , 0.57) -0.39 (-1.05, 0.59) 0.62
White blood cell count
at diagnosis (x 109 /L)
6.4 (3.4 , 15.9) 9.8 (4.6, 26.7) 7.2 (3.8 , 20.1) 0.11
* using Mann-Whitney test
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5.4.2: Characteristics for categorical variables in excluded patients at
diagnosis and relapse rate
Relapse
n (%)
No relapse
n (%)
Overall
n
P value 
Boys 32 (45.1) 39 (54.9) 71 0.31
Girls 12 (23.1) 40 (76.9) 52 < 0.001
Gender
Total 44 79 123 < 0.001
0 – 10 24 (35.3) 44 (67.7) 68 0.01
10 - 20 5 (25.0) 15 (75.0) 20 0.004
20 – 50 9 (45.0) 11 (55.0) 20 0.75
50 - 100 4 (44.4) 5 (55.6) 9 1.00
WBC
(x 109 /L)
Total * 42 75 117 < 0.001
None 13 (44.8) 16 (55.2) 29 0.60
Early 14 (43.8) 18 (56.2) 32 0.45
Late 10 (32.3) 21 (67.6) 31 0.01
Early and late 7 (22.6) 24 (77.4) 31 < 0.001
Intensification
Total 44 79 123 < 0.001
Ethnicity European 35 (32.7) 72 (67.3) 107 < 0.001
Non-European 7 (58.3) 5 (41.7) 12 0.68
Total* 42 77 119 < 0.001
* There are some missing data;  using fisher’s exact test
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5.4.2 Included patients
In the included sample, 917 patients were included in the analyses (as shown
in table 5.4.3 and figure 5.4.1), the median (Q1, Q3) age at diagnosis was 4.9
years (3.3, 8.8). Also, median (Q1, Q3) BMI z score at diagnosis was – 0.27 (-
1.03, 0.45). Finally, median (Q1, Q3) of WBC (x 109/ L) at diagnosis was 7.0 x
109/ L (3.0, 20.4).
Categorical variables (age at diagnosis, gender, WBC count at diagnosis,
intensification treatment and ethnicity) for the included patients and relapse
rate is illustrated in table 5.4.5.  The 22 patients who did not have a recording
of WBC at diagnosis were included because the weight status - the primary
aim of the present study- was definable.
Figure 5.4.1: Characteristics of continuous variables for excluded and
included patients
WBC: White blood cell counts
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5.4.3: Characteristics of continuous variables in included sample at
diagnosis, median (Q1, Q3)
Boys
(n= 710)
Girls
(n= 207)
Overall sample
(n= 917)
P
value *
Age (yr) 4.7 (3.3 , 7.8) 6.2 (3.5 , 11.4) 4.9 (3.3 , 8.8 ) < 0.001
BMI z score - 0.25 (-1.05, 0.43) - 0.33 (-0.9, 0.50) - 0.27 (- 1.03 , 0.45) 0.83
White blood cell
count (x 109 /L)
6.1 (2.9, 15.7) 16.9 (3.5 , 34.5) 7.0 (3.0 , 20.4) < 0.001
* using Mann-Whitney test
5.4.3 Prevalence of weight status at diagnosis in included patients
Table 5.4.4 gives weight status of those included in the analysis. Percentage
of healthy weight was 70.3% whereas 19.4% of the sample was thin
according to Cole et al. (2007) and 10.2% of them were either overweight or
obese as defined by IOTF (Cole et al., 2000). The prevalence of weight status
categories did not differ significantly between genders (Pearson chi-square
test; p value=0.53).
5.4.4 Prevalence of weight status at diagnosis in included patients
Cole et al., (2007)/ IOTF
Overall sample
Weight status
Boys
n (%)
Girls
n (%) n %
Thin/ Underweight 144 (20.3) 34 (16.4) 178 19.4
Healthy 500 (70.4) 45 (70.1) 645 70.3
Overweight/ obesity 66 (9.3) 28 (13.5) 94 10.2
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5.4.5: Characteristics of categorical variables of the included patients
and relapse rate
Relapse
n (%)
No relapse
n (%)
Overall
N P value
2.0 – 3.9 112 (31.9) 239 (68.1) 351 < 0.001
4.0 – 9.9 143 (37.8) 235 (62.2) 378 < 0.001
10.0 –14.9 82 (43.6) 106 (56.4) 188 0.02
Age (yr)
Total 337 (36.8) 580 (63.2) 917 < 0.001
Boys 277 (39.0) 433 (61.0) 710 < 0.001
Girls 60 (29.0) 147 (71.0) 207 < 0.001
Gender
Total 337 (36.8) 580 (63.2) 917 < 0.001
0 – 10 188 (35.3) 344 (64.7) 532 < 0.001
10 – 20 49 (36.3) 86 (63.7) 135 < 0.001
20 – 50 66 (39.8) 100 (60.2) 166 < 0.001
50 – 100 27 (43.5) 35 (56.5) 62 0.21
WBC
(x 109 /L)
Total * 330 (36.9) 565 (63.1) 895 < 0.001
Healthy weight 236 (36.6) 409 (63.4) 645 < 0.001
Underweight 67 (37.6) 111 (62.4) 178 < 0.001
Overweight/
obese
34 (36.2) 60 (63.8) 94 < 0.001
Weight status
Total 337 (36.8) 580 (63.2) 917 < 0.001
Non 97 (42.7) 130 (57.3) 227 0.003
Early 80 (35.2) 147 (64.8) 227 < 0.001
Late 81 (35.4) 148 (64.6) 229 < 0.001
Early and late 79 (33.8) 155 (66.2) 234 < 0.001
Intensification
Total 337 (36.8) 580 (63.2) 917 < 0.001
European 310 (37.3) 522 (62.7) 832 < 0.001Ethnicity
Non-European 26 (32.1) 55 (67.9) 81 < 0.001
Total* 336 (36.8) 577 (63.2) 913 < 0.001
*Note: there are some missing data as described above;  using fisher’s exact test
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5.4.4 Analysis of individual potential prognostic factors
By using the log rank test (for categorical variables), the factors that
influenced survival time significantly were as follows: gender (p value= 0.02);
age (p value= 0.01). (As shown in figure 5.4.2)
The following potential prognostic factors were not significantly associated
with risk of relapse using log ranks tests: Intensification (p value= 0.11); WBC
(x109/L) at diagnosis (p value= 0.19); weight status at diagnosis (p value =
0.90); ethnicity (European versus Non-European) (p value= 0.67) (shown in
figure 5.4.2).
Individual proportional hazard ratio analyses (for continuous variables at
diagnosis) showed that only one factor was significantly associated with risk
of relapse: age (p value = 0.001). Factors which did not have a statistically
significant influence on time to relapse were as follows: WBC count at
diagnosis (p value = 0.203) and BMI z score at diagnosis (p value = 0.423).
5.4.5 Stepwise proportional hazard modelling
By using stepwise (likelihood ratio) modelling, some explanatory variables had
a statistically significant influence on probability of relapse: age (p value <
0.0001), WBC count at diagnosis (p value = 0.005) and gender (p value <
0.0001). In other words, higher relapse risk was found in boys than in girls, in
older children at diagnosis, and in patients diagnosed with initial high WBC at
diagnosis. Using proportional hazards weight status had no significant impact
on risk of relapse (p value = 0.96).
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 Figure 5.4.2 Kaplan-Meier curves estimate individual potential prognostic factors
A: The curves were built with patients according only to the age categories at diagnosis; B: The curves were built with patients according only to gender; C: The curves were
built with patients according only to weight status at diagnosis using IOTF and Cole al. (2007) definitions; D: The curves were built with patients according only to ethnicity; E:
The curves were built with patients according only to intensification; D: The curves were built with patients according only to white blood cells count at diagnosis; p: p value
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5.5 Discussion
5.5.1 Main findings and implications
The present study found no evidence that weight status (underweight, overweight and
obesity) at diagnosis led to increased risk of relapse in children with standard risk ALL
in the UK.  The study provides no support for the view that treatment should be
stratified in underweight, overweight or obese patients not at high risk of relapse.
Despite the present study showing that weight status at diagnosis does not have an
impact on outcome of treatment amongst standard risk ALL patients in the UK. On
the other hand, the present study is contrary to other studies conclusions  when
obesity can impair outcome in a number of cancers (Patlak and Nass, 2012), and
there is other evidence that underweight, overweight, and  obesity at diagnosis can
adversely impact outcome of ALL as   discussed below (Gelelete et al., 2011,
Butturini et al., 2007, Lobato-Mendizabal et al., 2003, Antillon et al., 2008, Meji´a-
Aranguré et al., 1999, Viana et al., 1994, Reilly et al., 1994).
However, the present study confirmed that age at diagnosis, gender and WBC count
at presentation are prognostic factors   in the UK. It is well known now that age at
diagnosis, gender and WBC count presentation have a strong impact on the outcome.
Mitchell et al., (2010) studied 4 clinical trials which have conducted a total of 6516
patients. These trials which conducted in the UK from 1980 – 2001 were UKALL VIII,
UKALL X, UKALL XI and UKALL 97/97-99. They reported that female gender, age
between 1 and 9 years and WBC count under 50 x109/L features were consistently
associated with a more favourable prognosis.
Age at diagnosis has strong prognostic significance, reflecting the different underlying
biology of ALL in different age subgroups (Moricke et al., 2005). First of all, infants
(less than 1 year) with ALL particularly have shown high risk of relapse. Infants less
than 6 months, infants with high WBC counts at presentation and infants with poor
response to a prednisone therapy prophase are almost adverse prognostic features
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(Kosaka et al., 2004 , Hilden et al, 2006 ). Approximately 80% of infants with ALL
have an MLL gene rearrangement. Infants less than 6 months have higher MLL gene
translocation than older than 6 months (Pieters et al., 2007). Infants with ALL and
precence of MLL gene translocations have so high WBC counts and increased
chance to have CNS involvement. Therefore, the survival rate is poor in infants
especially who are younger than 6 months old (Pieters et al., 2007). Secondly, young
children (aged 1 to 9 years) have a better disease-free survival (DFS) than infants
(younger than 1 year), older children and adolescents ( aged ≥ 10 years)  (Mitchell et
al., 2010). The improved prognosis in young children with ALL is to some extent
explained by presence of favorable cytogenetic features (Moricke et al., 2005).
Thirdly, in patients with ALL who are aged ≥ 10 years (older children, adolescents and
young adults), the prognosis is inferior than children aged younger 10 years old even
though their outcomes have improved overtime (Nachman et al., 2009).
As noted from the present study WBC count at presentation is a strong prognostic
factor since it indicates a more aggressive form of the disease. WBC count under 50
x109/L at diagnosis is considered as a better cut-off even though the relationship
between WBC count and prognosis is not a step function but continues relationship.
ALL patients with B-precursor and WBC count at presentation have an increased risk
of relapse than patients presenting with low WBC count (Smith et al., 1995). The
median WBC count at diagnosis of ALL with B-precursor (<10 x109/L) is much lower
than patient with T-cell ALL (> 50 x109/L). However, WBC count at diagnosis of ALL
with T-cell does not have consistent effect like ALL patients with B-precursor
(Goldberg et al., 2003).
The present study showed that girls had significantly better prognosis than boys and
other studies showed similar findings (Mitchell et al., 2010 , Pui et al., 1999 ,
Chessels et al., 1995). The reason for boys having an adverse prognosis  is the
occurrence of testicular relapses. Also,  boys seem to have a higher risk of bone
marrow and CNS relapses than girls but, the reason for this  is unknown (Pui et al.,
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1999 , Chessels et al., 1995). Nevertheless, the recent clinical trials showed that the
boys prognosis overall is similar to girls because treatment protocols differ between
and girls (Pui et al., 2009, Silverman et al., 2001).
There are a number of biologically plausible mechanisms by which overweight and
obesity could increase risk of relapse in ALL and other cancers (Lange et al., 2005,
Zuccaro et al., 1991, Patlak and Nass, 2012). Briefly, for instance, consuming a high
amount of nutrients daily could lead to energy imbalance. This might cause oxidative
stress and fatty acid metabolism malfunction which encourage inflammation and
insulin resistance. Consequently, inflammation and insulin resistance could cause a
number of processes that might encourage either  cancer initiation and promotion
including DNA damage, delayed cell death, cell division and cell migration (Patlak
and Nass, 2012). On the other hand, adipose tissue can act as an endocrine organ
for example by producing some hormones (leptin and adiponectin), growth factors
(Insulin growth factor-1) and cytokines (AMP kinase) that can influence  cell
development (Patlak and Nass, 2012). Behan et al., (2009) suggested that excessive
adiposity can encourage cancer cells to be resistant to chemotherapy in leukaemic
patients.
Underweight/thinness  amongst ALL patients at diagnosis is associated with
functional impairment such as immune deficiency that increases risk of  relapse (Weir
et al., 1998) . Undernutrition can be associated with malabsorption, low drug protein
binding and these effects may prevent or reduce oxidative and some other important
metabolic process. These effects might reduce glomerular filtration which might
increase the toxicity of some chemotherapy (Murry et al., 1998). Moreover, Barr and
Gibson (2000) stated that many cancer patients in developing countries also, suffer
from protein- energy undernutrition and vitamin and mineral deficiency. Sala et al.,
(2012) prospectively studied 2,954 children and adolescents with cancer aged 1- 18
years old in 7 countries of Central America. They defined nutritional status using BMI
for age expressed relative to CDC reference data, weight for height, mid upper arm
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circumference and triceps skin fold thickness. So, severely nutritionally depleted at
diagnosis was defined as: albumin < 3.2 g/dl or triceps skin fold thickness < 5th centile
or mid upper arm circumference < 5th centile and moderately nutrition depleted as:
albumin 3.2- 3.5 g/dl or triceps skinfold thickness 5th – 10th centile or mid upper arm
circumference 5th – 10th centile. Prevalence of severe nutritional depletion was 45%
and 18% of them had moderately nutrition depletion. They also found a significant
difference for (p value < 0.001) EFS between adequately nourished, moderately
depleted and severely depleted patients. Also, they reported that 65% of adequately
nourished patients were surviving at 2 years from diagnosis compared to 48% of
severely depleted patients.
Undernourished patients (defined as weight less than 80% of the weight expected for
height) may have poorer  tolerance or poor compliance to the planned therapy
(Meji´a-Aranguré et al., 1999). Though limited compliance with 6-mercaptopurine
(anticancer drug) in developed countries such as USA and UK has been reported
(Barr and Gibson, 2000), it is possible that severe undernutrition in developing
countries is associated with increased risk of relapse because of poverty and the
associated limited access to treatment.
5.5.2  Comparisons with ALL previous studies
As the present study discussed above, the childhood cancer patient who lives in
developing countries has sometimes different problems compared to those in the
developed world, such as access to treatment and severity of undernutrition
(summarised in evidence table 1.5.3 and 1.5.4).
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5.5.2.1 Studies from developed countries
In contrast to the present study findings, there is evidence that overweight/obesity at
diagnosis might impair prognosis in higher-risk and/or older patients with ALL. In large
study, Butturini et al., (2007) studied 4,260 ALL patients in USA and they found that
hazard ratio of events and relapses in patients who were older than 10 years and
obese at diagnosis were 1.5 (p value= 0.01) and 1.5 (p value= 0.01). Even though
they included mixed ALL subgroups (low, standard and high risk groups) and the
patients were treated with type of ALL and therapy protocols which are considered as
independent prognosis of the disease (not fairly homogenous group like the present
study), they did not find an association between weight status and relapse in low risk
and/or younger patients, as the present study found.
In contrast, Hijiya et al., (2006) similar to the present study findings examined the
association between BMI at diagnosis and pharmacokinetics and outcome of
treatment in 621 USA children with ALL aged 2.4 – 16.9 years old. They reported that
weight status (defined as underweight BMI ≤ 10 th centile, overweight BMI ≥ 85 th
centile and obesity ≥ 95th centile) according to CDC reference data did not have any
effect on both toxicity and outcome of treatment in low, standard and high risk ALL
subgroups. It worth noting that they did not find effect of overweight/ obesity (19%)
even the prevalence with higher than the present study (10%). One other study from
a developed country found evidence that undernutrition at diagnosis is an adverse
prognostic factor in ALL. Reilly et al., (1994) with a small number of (n= 78) standard
risk ALL patients from UKALL X in the one treatment centre defined the weight status
at diagnosis in different method that applied in the present study using weight for
height z score < -0.5 for underweight and >0.5 for overweight and obesity. They found
that lower weight for height z score significantly (p value= 0.01) influenced relapse
risk. On the other hand, Weir et al., (1998) failed similar to the present study to find an
association between underweight and relapse risk. Weir et al., (1998) used the same
patient data from UKALL X data as the present study explained in the present study
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introduction, but they defined weight status using a different approach (BMI z score >
0.5 for overweight and < -0.5 for underweight) because in the mid 1990s there was no
consensus of definition of weight status (underweight, overweight and obesity) in
childhood. The present study reached the same conclusion as Weir et al., (1998)
even though the present study used more modern weight status definitions.
5.5.2.2 Studies from developing countries
Some studies from developing countries as mentioned in table 1.5.3 found evidence
that that overweight/obesity at diagnosis might impair prognosis in higher risk patients
with ALL rather than low or standard risk ALL patients as it is shown in the present
study. The Gelelete et al., (2011) study was conducted on 181 children with ALL
(median age 4.8 years) in Brazil and they were treated with different type of ALL and
therapy protocols. They reported in this heterogeneous group that obesity in
intermediate and/or high risk ALL was a prognostic factor for relapse.  However, they
recruited a relatively and not representative sample.
 On the other hand, the Baillargeon et al., (2006) study supports the present study
findings that there was no evidence that overweight/ obesity at diagnosis of standard
risk ALL is associated with adverse prognosis. However, Baillargeon et al., (2006)
studied the impact of obesity ( BMI > 95th percentile based on CDC reference data) in
322 standard risk ALL children aged 2 – 9 years old at diagnosis. They reported that
obesity at diagnosis was not a prognostic factor in their sample.
Undernutrition (including underweight) at diagnosis of ALL was reported to be an
adverse prognostic factor in some studies as noted above. Meji´a-Aranguré et al.,
(1999) in Mexico (17 cases and 76 controls) which was contrary to the present study,
however, the study sample size was small. Also, a Brazilian systematic review
(Viana et al., 1994), found that relapse risk amongst 128 ALL children and
adolescents was 8.2 times higher in undernourished patients (defined as height for
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age z score < -2.0) relative to patients who had height for age z score > - 2.0.
however, (Viana et al., 1994) study used old weight status definitions and they did not
differentiate between ALL subgroups i.e. whether the patient had low, standard and
high risk group.
Conversely, Pedrosa et al., (2000) studied two types of cancer (ALL and solid tumour)
patients in El Salvador and North Brazil: 283 children were either low risk (defined as
WBC count <25.000/ L, no CNS disease, no mediastinal mass and age at diagnosis >
1 years < 10 years old) or high risk ALL patients whereas 160 children had solid
tumours. They reported even though they mixed between different ALL subgroups
that survival rate was not significantly different for the malnourished patients at
diagnosis (defined as weight for age and height for age z score < -2.0 based on WHO
reference data) relative to the normally nourished patients.
The reasons for the obvious inconsistencies between the findings of the present study
and some other studies (Gelelete et al., 2011, Butturini et al., 2007, Meji´a-Aranguré
et al., 1999, Viana et al., 1994, Reilly et al., 1994) to address the question of the role
of weight status as a prognostic factor on outcome of treatment in childhood ALL are
not totally clear. Nevertheless, amongst patients who were overweight/ obese at
diagnosis the most likely explanation may lie in differences in patient characteristics
between different studies. The Butturini et al., (2007) and Gelelete et al., (2011)
studies found that that relapse rate was significantly increased in higher risk ALL
patients group who had overweight/ obesity at diagnosis of ALL. Gelelete et al.,
(2011) study reported that intermediate and high risk ALL patients (based on BFM-95
protocol (Schrappe et al., 2000)) had significantly (p value= 0.02) lower 5-year EFS
amongst only those were overweight/ obese.  All five studies to date have found no
risk of relapse in lower-risk patient groups or subgroups with ALL (present study plus
Baillargeon et al., (2006), Butturini et al., (2007), Gelelete et al., (2011) and Hijiya et
al., (2006)), i.e. in younger patients and those without a high WBC at diagnosis.
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Moreover, there is a wide difference in sample size between the different studies of
the influence of overweight and obesity at diagnosis on relapse risk in ALL in the
developed world that might be a cause of different associations of overweight/obesity
with outcome between different studies. For instance, Hijiya et al., (2006) recruited
468 standard risk and 153 high risk ALL patients while 797 low and standard  risk ALL
patients were included by Butturini et al., (2007) while the number of high risk ALL
patients was 263. In addition, some studies (Baillargeon et al., 2006, Pedrosa et al.,
2000) may have been too small, and in particular, obese and underweight
percentages have been relatively low in the sample to detect association between
weight status and relapse in ALL patients: for example, Baillargeon et al., (2006) may
have been small (n= 322 standard risk ALL patients) to detect on association between
overweight/ obesity (prevalence of overweight/ obesity combined was 26% ) and
relapse risk. Also, Pedrosa et al., (2000) recruited 443 (23% were undernourished) of
cancer patients only 252 were with ALL (the risk grade was not reported) and they
concluded that undernutrition does not have impact on the survival rate.
Most of the reviewed studies used different types of ALL and therapy protocols which
are considered as independent prognostic factors. Also, in some studies in the
developing world as motioned in table 1.5.4, undernutrition and relapse may be
confounded by factors related to socio-economic status for instance ability to access
treatment i.e. cost of drugs and availability of quality care. Generally, patient who are
undernourished may be poorer than those adequately nourished and consequently
they may not have the same access to the good quality care and treatment as noted
above.
Although the present study did not find an association between weight status at
diagnosis and influence risk of relapse, it is worth noting that systematic reviews have
found important short and long-term adverse consequences of childhood underweight
and obesity (Zuccaro et al., 1991, Reilly and Kelly, 2011, Black et al., 2008) as
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explained in detail in section 1.2 and 1.3, and the lack of associations with relapse in
typical patients with ALL does not mean that underweight, overweight, obesity are not
cause for concern. In addition, obesity increases markedly during and after ALL
therapy, and results largely from marked lifestyle changes such as high sedentary
behaviour and low physical activity which are presumably preventable to some
degree (Reilly, 2009).
5.5.3 Strengths and weaknesses of the present study
Sample size
As this thesis discussed in chapter 4.6.1, the number of included girls (n= 207;
22.6%) was much lower than number of boys (n=710; 77.4%), however, this limitation
was unavoidable according to study design. The definition of standard risk, low risk,
and high risk, as it was applied back at the time of UKALL X meant that many more
girls than boys were defined as low risk and so did not meet our entry criterion of
standard risk ALL at diagnosis. Therefore, in the present study presumably it would
have been useful to do the same survival analysis for low and high risk patients as
but we did not have the data to do so.
The present study had a relatively large sample size for studies of this kind, and the
inclusion of a relatively homogenous group of patients (only standard risk ALL
patients) from a national trial, all treated according to the same protocol in the UK. To
be more precise, Butturini et al., (2007)  was one of the largest sample size studies
amongst children with ALL. However, they enrolled a heterogeneous group of
patients when they included different risk groups of ALL and patients treated on
different treatment protocols (CCG 1881, CCG 1922 and CCG 1891).
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The present study design
 Limitations of collection method of the present study data and the limitations of using
BMI for age and sex were argued in details in section 2.2.4.1. Briefly, the present
study data were collected in routine clinical practice for the purposes of calculating
body surface area in order to prescribe drug dosage not in a research-based
approach, so, height and weight were collected by many health professionals and
measures were made using a variety of stadiometers and scales which could lead to
some errors. However, anthropometric data collection errors in epidemiological
studies with large samples are more likely to have quite small biases (i.e. small mean
or median value errors), though errors can be quite large for individual children
(Armstrong and Reilly, 2003). Moreover, a high BMI for age provides a good indicator
of children with excessive fat mass (Reilly et al., 2010b), but it is imperfect both in
healthy children and those with malignancy (Warner et al., 1997b, Aldhafiri et al.,
2012). However, BMI for age and sex is considered both reasonably valid as an
indicator of high fat mass and the simplest epidemiological tool nowadays (Reilly et
al., 2010b). Also, BMI for age and sex has high specificity, but moderate sensitivity in
detecting obesity in children and adolescents (Reilly et al., 2010b) . However, whether
or not the Cole et al. (2007) definition of thinness successfully predicts health
outcome and complications was not addressed yet by any studies that the author is
aware of.
In addition, the present study in common with previous studies to test for an impact of
underweight and overweight/obesity and outcome of ALL, we excluded patients
where obvious confounders were present (e.g. Downs Syndrome, which affects both
risk of obesity and risk of relapse from ALL), and the present study considered the
main established prognostic factors in our analyses. However, data on other potential
confounders, such as socio-economic status, (Lightfoot et al., 2012) were not
available, as in other studies (Baillargeon et al., 2006, Butturini et al., 2007, Gelelete
et al., 2011, Hijiya et al., 2006): for example, it is possible that consideration of socio-
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economic status might attenuate any associations between obesity and outcome of
childhood ALL for those studies which find associations (Lightfoot et al., 2012).
The dataset used in the present study was from a treatment trial which ended more
than 20 years ago, though for more than 10 years weight and height have not been
measured and recorded routinely in patients with ALL in the UK and so such studies
have not been possible for some time as discussed in 4.6.2. It is true that ALL
treatment protocols have changed since that time (Jeha and Pui, 2009), though not
radically (Jeha and Pui, 2009), and prevalence of overweight and obesity have
increased markedly (Reilly, 2006b). However, some studies (Whitaker et al., 2011)
showed that the prevalence of underweight in the UK children and adolescents was
lower than the present study findings by using UKALL 97/ 97-99 trial data.  examined
underweight/thinness (defined by Cole et al., (2007)) in 7078 English children and
adolescents (aged 2 – 15 years old) from 2001 – 2006. They reported that the
prevalence of underweight/thinness in the total sample was 5.7%, much lower than
the present study findings (19.4%) using same definitions.
Nonetheless, the strengths of the present study, noted above, combined with the
consistency with the other studies-also noted above- enhances confidence in our
conclusions.
5.6 Conclusion
The present study concludes that it is unlikely that weight status based on BMI for sex
and age at diagnosis has an adverse impact on outcome of childhood ALL for
patients not deemed to be at high risk of relapse. However, the present study
confirmed that age at diagnosis, gender, WBC at presentation can be regarded as
prognostic factors for standard risk ALL childhood patients in the UK, and these
findings are consistent with current treatment of ALL in the UK where all of these
factors are considered to influence risk of relapse.
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Chapter 6
Importance of adjusting dual energy X-ray output for body
size when assessing bone health: an example from
survivors of childhood acute lymphoblastic Leukaemia
This chapter describes a study which is now published, publication details as follows:
J Pediatr Hematol Oncol. 2013 Jan;35(1):e27-9. doi: 10.1097/MPH.0b013e3182678ed8
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6.1 Introduction
An adverse effect of childhood malignancy or its treatment on bone is a widespread
concern (Elmantaser et al., 2011, Elmantaser et al., 2010, van der Sluis and van den
Heuvel-Eibrink, 2008, Warner et al., 1998b, White et al., 2005), and there is
increasing evidence that skeletal morbidity is common in patients with ALL during and
after therapy as noted in section 1.5.7.5. DXA is used widely as a clinical indicator of
bone health.
The present study was originally not in the thesis plan until the author found results
from DXA measures of bone health of the ALL survivors described in chapter 2.
These data combined with literature searching by the author and a discussion with
experts in bone health at Yorkhill hospital (Professor Faisal Ahmed and Dr. Sheila
Khana) led to the present study. The literature found by the author suggested that
many authors did not use the adjustment to DXA output for body size described in
chapter 2 (section 2.1.8.2.1). In some specialties it has been well known for some
time that there is a need to correct DXA derived BMD data for body size, particularly
in children and adolescents with chronic disease, including malignancy (Warner et al.,
1998b, Ahmed et al., 2004). Such corrections are not universal in the literature in
other specialties though, and a number of recent reports on bone health in patients
with childhood cancer have been based on BMD data with no formal correction for
body size, but just an adjustment for age and sex (Al-Tonbary et al., 2011,
Muszynska-Roslan et al., 2009). For instance, Muszynska-Roslan et al., (2012)
assessed BMD recently for 69 children and adolescent survivors of ALL by using
DXA. However, even though they acknowledged the guidelines of the ISCD 2007
(Baim et al., 2008) to calculate z scores for sex and age, they used the unadjusted
BMD approach (using DXA manufacturer reference data, apparently adjusted for age
and sex only ) to assess BMD. They concluded that ALL survivors were not at risk of
low BMD. In addition, a recent study of BMD in patients with Neuroblastoma used
BMD data, without formal correction for body size, to conclude that impaired bone
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health was very common (Al-Tonbary et al., 2011). Also, Rayar et al., (2012) more
recently examined 124 patients with ALL aged less than 18 years old using  DXA.
However, they reported that prevalence of osteoporosis (defined as BMD z score -2.0
and below) was 11% among those patients, but without using adjustment for body
size which it is recommended by the ISCD 2007 (Baim et al., 2008) as mentioned in
chapter 2 (section 2.1.8.2). In summary, in some paediatric specialties it has become
fairly common in both clinical practice and research to present DXA bone health data
after an adjustment for body size. In other specialities, including Paediatric
Haematology and Oncology, this is not the norm and the need to make adjustments
of this sort is not well known. In addition, it is not clear which adjustment is best to
make, or how big a difference the choice of body size adjustment will make. The
present study was prompted by a series of recent publications in the Paediatric
Haematology and Oncology literature which did not report any adjustments to DXA
data for body size.
6.2 Aims
Adjusting DXA output for body size is regarded by specialists in bone health essential
to avoid misinterpretation in children and adolescents bone health status (Baim et al.,
2008). It is considered especially important in more vulnerable groups likely to have
suffered from growth or body composition abnormalities such as survivors of ALL.
Therefore, the aim of the present study was to examine the effect of using different
approaches to identify low bone mass and to examine the agreement between them:
manufacturers software (DXA Lunar Prodigy, software version 9.15), Warner et al.,
(1998b) and BMADLS (Kroger et al., 1995) approaches.
6.3 Methods
Briefly, 51 standard risk ALL Saudi survivors treated according to CCG 1891 (those
described in chapter 2, section 2.1.1) were scanned by using DXA (Lunar Prodigy,
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software version 9.15). No study was found which examined how relevant the DXA
device was to the Saudi population as described above in section 2.1.5.2. There is
currently no consensus as to how best to make the adjustment of DXA derived BMD
data for body size. For the present study we used the approach described by Warner
et al., (1998b), based on calculation of BMC z scores, BMADLS (Kroger et al., 1995)
and manufacturer’s reference data approach as described in details in the section
2.1.6.
The ISCD 2007 (Baim et al., 2008) recommended that the terms of osteopenia and
osteoporosis should not be used in children and adolescent except in some certain
conditions as mentioned in section 2.1.8.2. The present study therefore considered
low bone mass in survivors below z score -1.0 (Rayar et al., 2012). Finally, unhealthy
weight status defined according to Cole et al., (2007) and IOTF (Cole et al., 2000) as
described in chapter 2 (section 2.1.3.1.4 and 2.1.3.1.5).
6.3.1 Statistical analysis, power and sample size
Power of the present study was fixed by the size of the cohort of patients available to
us and so no formal power calculation was carried out, but paired comparisons of
preliminary corrected and uncorrected DXA data showed that the study was powered
adequately to compare between corrected and uncorrected data.
Means and standard deviations (SD) are presented in the results unless otherwise
stated.  Normality of data was tested by using formal Normality tests in Minitab
(Version 15.1.30.1). A two-sample t-test (when data followed a normal distribution)
was used to test the significance of the difference in the means between the
numerical variables in two different groups and to for three and more different groups
a one-way ANOVA was used. Also, the Mann-Whitney test was used for non-
parametric data to test the significance of the difference in the median between
numerical variables. A k analysis was carried out using MedCalc software version
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11.5. We used the weighted Kappa statistic (k) and 95% CI for this statistic to assess
the degree of agreement between BMD and BMC z score categories, with the
descriptors which summarise agreement proposed by (Landis and Koch, 1977) (as
described in figure 3.3.1).
6.4 Results
6.4.1 Characteristics of study participants
The number of consented survivors was 51 (33 males, 18 females) as it is clarified in
table 6.4.1.
Table 6.4.1: Characteristics of study participants mean (SD)
Males
(n= 33)
Females
(n= 18 )
Total
sample
(n= 51)
P value
Age (yr) 13.2 (4.6) 14.0 (3.1) 13.5 (4.1) 0.40
Height (m) 1.49 (0.19) 1.51 (0.11) 1.50 (0.17) 0.90
Weight (kg) 45.7 (16.8) 48.9 (17.6) 46.8 (16.9) 0.50
Time from diagnosis (yr) 9.2 (4.7) 9.0 (3.6) 9.1 (4.3) 0.90
 Time since completion of
therapy (yr)
6.6 (4.4) 5.6 (3.5) 6.3 (4.1) 0.40
% Total body fat by DXA* 24.7 (10.6) 37.6 (8.8) 29.2 (11.7) >0.001
CDC† BMI z score - 0.16 (1.6) 0.12 (1.3) - 0.06 (1.5) 0.50
† CDC US Centres for Disease Control and Prevention; *Dual X-ray Absorptiometry
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The mean (SD) of age for total sample was 13.5 years (4.1) without any significant
difference between the gender (p value= 0.4; (2 sample t test)). Mean (SD) of BMI z
score (based on CDC approach (Kuczmarski et al., 2000)) of the sample was - 0.06
(1.5) no significant difference between the gender (p value = 0.5 (2 sample t-test)).
However, there was a significant difference between male and females (p value >
0.001) in % total body fat by DXA and the mean (SD) for the sample was 29.2%
(11.7). Mean (SD) time from diagnosis was 9.1 year (4.3) and it was 6.3 year (4.1) for
time since completion of the therapy course; for more details see table 6.4.1.
6.4.2 Comparison of DXA data: corrected BMC versus BMADLS versus
uncorrected BMD data
6.4.2.1 Bone health assessment by applying DXA manufactures’ software
approach versus corrections for body size
The Mean (SD) of the sample for total body and lumbar spine aBMD z score that
produced by DXA manufacture’s software was – 0.8 (1.1) and – 1.2 (0.9); respectively
(table 6.4.2). No significant difference was found between the genders in both total
body (p value= 0.2) and lumbar spine aBMD z score (p value= 0.9) (table 6.4.3).
Table 6.4.2: Bone health z scores derived from DXA (mean and SD or median
and Q1, Q3 as appropriate) using three different approaches
Approaches Lumbar spine Total body
Manufacturer’s software - 1.2 (0.9) - 0.8 (1.1)
Adjusted BMC for BA* (Warner et al., 1998b) - 0.4 (0.6) - 0.3 (-0.5, 0.2)
BMADLS Θ (Kroger et al., 1995) - 0.9 (0.9) ----
P value <0.001^ 0.003
* Bone mineral content for bone area; ΘBone mineral apparent density of lumber spine
 BMADLS is only based on lumbar spine rather than total body; using one-way ANOVA test;  using two-sample t-
test
262
262
Table 6.4.3: Bone health z scores derived from DXA (mean and SD or median
(Q1, Q3) as appropriate) using three different approaches based on gender
Approach Males
(n 33)
Females
(n 18 )
Total sample
(n 51)
P
value
TB aBMD z score - 0.7 (11) - 1.0 (1.2) - 0.8 (1.1) 0.20
Ma
nu
fac
tur
er’
s s
oft
wa
re
LS aBMD z score - 1.2 (0.9) - 1.2 (1.0) - 1.2 (0.9) 0.90
TB BMC for BA z
score (median)
- 0.1 (- 0.4, 0.3) - 0.5 (- 0.7, 0.1) - 0.3 (- 0.5, 0.2) 0.06ª
Wa
rn
er 
et 
al.
, (1
99
8b
)
LS BMC for BAΔ z
score
- 0.4 (0.6) - 0.4 (0.6) -0.4 (0.6) 0.80
BM
AD
LS
(K
rog
er 
et 
al.
, 1
99
5)
BMADLS z score - 0.8 (0.8) - 1.1 (0.9) - 0.9 (0.9) 0.20
a Using Mann-Whitney test; TB aBMD: Total body areal bone mineral density; LS aBMD: Lumbar spine
areal bone mineral density; ө TB BMC for BA : Total body bone mineral density for bone area;  LS
BMC for BA: Lumbar spine bone mineral density for bone area;  BMADLS: Bone mineral apparentdensity of lumber spine
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The number of survivors who had lumbar spine aBMD and total body aBMD z score
between -1.0 to -2.0 was 18 (35.3 %) and 13 (25.5%); respectively. In addition, 21.6
% (11 survivors) and 15.7 (8 survivors) had lumbar spine and total body aBMD z
score below – 2.0; respectively. Therefore, If a z score below –1.0 was considered to
be of potential concern (Rayar et al., 2012), this would apply to 29 (56.9%) of the
survivors at the lumbar spine, and 21 (41.2%) for the total body using BMD derived
directly from DXA output, with no correction for body size (table 6.4.4).
Table 6.4.4:  Summary data for bone health cases and prevalence of potential
concern (defined as z score > -1.0 to -2.0 or < -2.0) of low bone mass by using
three different approaches
aBMD
n= 51
BMC for BA
n= 51
BMADLS
n= 51Z score
LS TB LS TB LS
-1.0 > to -2.0 n, (%) 18 (35.3) 13 (25.5) 6 (11.8)* 3 (5.9)* 18 (35.3)
<-2.0 n, (%) 11 (21.6) 8 (15.7) 0 (0.0)* 1 (2.0)* 6 (11.8)
Total (%) 56.9% 41.2% 11.8% 7.9% 47.1%
aBMD: Body areal bone mineral density; BMC for BA: Body mass content for bone area; BMADLS:Bone mineral apparent density for lumber spine; LS: Lumbar spine; TB: Total body; * p value > 0.05
using 2 proportions test compared the used methods with manufacture’s software reference data
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6.4.2.2 Bone health assessment by applying adjusted BMC for BA (Warner et al.
1998 approach)
As shown in table 6.4.2, the median (Q1, Q3) of the sample of total body BMC for BA
was - 0.3 (-0.5, 0.2) and the mean (SD) of lumbar spine BMC for BA for the sample
was – 0.4 (0.6). Table 6.4.3 illustrated that, the difference between total body BMC for
BA and lumbar spine BMC for BA in both boys and girls was not significant (p value=
0.06 and 0.8; respectively).
Only 6 (11.8%) survivors had lumbar spine BMC z scores between –1.0 and –2.0,
and none had a z score below –2.0. For the total body BMC, only 3 survivors (5.9%)
had BMC z scores between –1.0 and –2.0, with 1 (2%) below –2.0. If a z score – 1.0
and below was considered to be potential concern (Rayar et al., 2012), this would
apply to 6 (11.8%) of the survivors at lumbar spine, and 4 (7.9%) for the total body
BMC (table 6.4.4).
Mean (SD) % predicted BA for age for lumbar spine and total body was 90% (11) and
87% (12); respectively. Mean (SD) % predicted BMC for BA was 93% (11) for lumbar
spine and 97% (11) for the total body.
6.4.2.3 Bone health assessment by applying BMADLS (Kroger et al., 1995)
approach
The mean (SD) of the sample was -0.9 (0.9) with no significant difference between
genders (p value= 0.2 (2 sample t-test)) as stated in table 6.4.2 and 6.4.3.  Table
6.4.4 shown that number of survivors who had z scores between – 1.0 and – 2.0 was
18 (35.3%), while 6 (11.8%) of them had lumbar spine z scores below – 2.0. If a z
scores – 1.0 and below was considered to be potential concern (Rayar et al., 2012),
this would apply to 24 (47.1%) of the survivors at the lumbar spine.
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6.4.3 Comparison of bone health status and weight status
The Cole et al., (2007) and IOTF (Cole et al., 2000)  definitions of underweight,
overweight and obesity were used in the three used approaches (described in table
6.4.5 and figure 6.4.1). Using uncorrected BMD z scores (DXA manufactures’
software) for total body and lumbar spine found an excess of low BMD (defined as z
score > - 1.0) values in the underweight survivors: prevalence of low bone status
amongst the 9 underweight patients was 78% (7/9) and 89% (8/9); respectively. In
overweight/obese survivors: prevalence of low bone mass was 13% (2/16) and 31%
(5/16).
Once adjusted using the BMC for BA approach (using method of Warner et al.,
(1998b)), only 1/9 (11%) of the underweight survivors and 0/9 had low total body and
lumbar spine BMC; respectively. Similarly, amongst those who were overweight/
obese: 13% (2/16) had low total body BMC. Overweight/obese survivors who had low
lumbar spine BMC were 19% (3/16) of the overweight/ obese sample.
Using the BMADLS approach (Kroger et al., 1995), almost half of the underweight
survivors (56%, n= 5/9) had low bone density. One third (31%; n= 5/16) of the
overweight/ obese survivors had low bone density.
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Table 6.4.5: Prevalence of low bone status (defined by z score below -1.0)
based on weight status defined by Cole et al., (2007) and IOTF definitions
Approach
Healthy weight*
(26/51 patients)
(n, %)
Underweight *
(9/51 patients)
(n, %)
Overweight/ Obese*
(16/51 patients)
(n, %)
TB aBMD 12 (46.2) 7 (77.8) 2 (12.5)
Ma
nu
fac
tur
er’
s
so
ftw
are
LS aBMD 16 (61.5) 8 (88.9) 5 (31.3)
TB BMC for
BA
1 (3.8) 1 (11.1)  2 (12.5)
Wa
rn
er 
et 
al.
,
(19
98
b)
LS BMC for
BA
3 (11.5)  0 (0.0)  3 (18.8)
BM
AD
LS
(K
rog
er 
et 
al.
,
19
95
)
BMADLS 14 (53.8) 5 (55.6) 5 (31.3)
TB aBMD: Total body areal bone mineral density; LS aBMD: Lumbar spine areal bone  mineral density;
TB BMC for BA: Total body bone mineral content for bone area;  LS BMC for BA: Lumbar spine  bone
mineral content for bone area; BMADLS: Bone mineral apparent density for Lumbar Spine;* Underweight, overweight and obesity were defined based on Cole et al., (2007) and IOTF (Cole et al.,
2000);  p value > 0.05 using 2 proportions test compared the used methods with manufacture’s
software reference data
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Figure 6.4.1: Prevalence of low bone status defined by z score less than – 1.0
based on weight status by IOTF
IOTF: International Obesity Task Force; TB aBMD: total areal bone mineral density; LS aBMD: lumbar
spine areal bone mineral density; TB BMC: total body bone mineral content; LS BMC: lumbar spine
bone mineral content; BMADLS: Bone mineral apparent density for lumbar spine
6.4.4 Extent of agreement between three approaches for assessing bone health
using DXA
Agreement between BMD (uncorrected) and BMC (corrected) categories of possible
low bone mass (Z scores below –1) was ‘poor’ as defined by (Landis and Koch, 1977)
at the lumbar spine (k =0.18; 95% CI: 0.04 – 0.33) and for the total body (k= 0.13;
95% CI:  0.06 – 0.31).  Also, the agreement between BMC (corrected) and BMADLS
(Kroger et al., 1995) was ‘fair’ (k= 0.26; 95% CI: 0.08 – 0.45). A ‘Substantial’ level of
agreement was found between uncorrected lumbar spine BMD and BMADLS (Kroger
et al., 1995) approaches (k= 0.65; 95% CI: 0.45 – 0.85).  (See table 6.4.6)
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Table 6.4.6: Extent of agreement (weighted Kappa statistic) between three
different approaches to assess bone health using DXA
Approach Weighted
Kappa
95% CI Level of
agreement
(Landis and
Koch, 1977)
TB aBMD vs. TB BMC 0.13 -0.06 – 0.31 PoorManufacture’s
software vs. Warner
et al., (1998b) LS aBMD vs. LS BMC 0.18 0.04 – 0.33 Poor
Manufacture’s
software vs. BMADLS
LS aBMD vs. BMADLS 0.65 0.45 – 0.85 Substantial
Warner et al., (1998b)
vs. BMADLS
LS BMC vs. BMADLS 0.26 0.08 – 0.45 Fair
TB aBMD: total body areal bone mineral density; TB BMC: total body bone mineral content; LS aBMD:
lumbar spine areal bone mineral density; LS BMC: lumbar spine bone mineral content; BMADLS:lumbar spine bone mineral apparent density
6.5 Discussion
6.5.1 Main findings and implications
In the present study, a very high prevalence of low BMD z scores in both lumbar
spine and total body was observed when the standard approach recommended by
the DXA manufacturer’s software was used. Likewise, almost half of the sample had
a concerning bone mass (defined as z score > -1.0) when the BMADLS approach
(Kroger et al., 1995) was applied. Therefore, the extent of agreement level between
these approaches was “substantial” according to (Landis and Koch, 1977) definitions.
The conclusion that poor bone health was common among the patients might have
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been reached on the basis of these findings, particularly in view of the background
supplied by recent evidence that skeletal morbidity is common among patients with
ALL, and that there are more general concerns over poor bone health in patients with
ALL (Elmantaser et al., 2010, Elmantaser et al., 2011, van der Sluis and van den
Heuvel-Eibrink, 2008, White et al., 2005).
In contrast, this conclusion would not be appreciable when BMD is corrected for body
size particularly using the approach described by Warner et al., (1998b); due to the
relatively low prevalence of low BMC z scores of lumbar spine and total body being
found. The corrected data suggested an alternative conclusion in relation to the bone
health of these survivors i.e. that poor bone health was uncommon as shown in figure
6.5.1.
However, even though the present study provides evidence that using an adjusted
approach for body size does make a difference to the apparent bone health data from
DXA, it was not able to distinguish which is the best one as both of the approaches
led to different conclusions and the present study had no access to a gold standard
measure of none health. Other measures might have been available (e.g. blood
based markers of bone health) and would have been useful had the present study
been funded to include them. In addition, the relatively small sample made it difficult
to justify a more detailed analysis of the characteristics of the children and adolescent
survivors who were classified differently by the three different approaches. Further
studies which use larger sample sizes and have bone health as a primary aim would
be needed to provide a greater understanding of the reasons for differences in bone
health classifications between the different approaches.
One universal adjusted approach for body size would be more useful rather than
general recommendation of adjustment for bone size. Moreover, the present study
highlights to non specialists in bone health the need to pay more attention in
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interpreting the outcome data from DXA manufacturer’s software. Also, researchers
and health professionals should be more cautious in dealing with studies that report
low bone density in children or adolescents without making any adjustments for body
size.
Figure 6.5.1: Prevalence of low bone status (defined as z score -1.0)
LS: lumbar spine; aBMD: areal bone mineral density (DXA manufacture’s software method); BMC for
BA: bone mineral content for bone area for bone area (Warner et al., 1998 method); BMADLS: Bonemineral apparent density for lumbar spine method
Nevertheless, using all the three different approaches to define low bone mass
clarified the persistence of some apparent bone mass deficits, even after adjustment
for body size. This provides confidence that an apparently increased risk of impaired
bone health was real, rather than completely an artifact of the poor growth, delayed
puberty, or abnormal body composition, which characterizes many populations of
children and adolescents with chronic diseases (Ahmed et al., 2004, Buison et al.,
2005).
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The issue of whether or not to correct DXA BMD data in relation to body size might
have implications beyond the simple assessment of the prevalence of low bone mass.
Failure to adjust DXA BMD values for body size might also bias studies determining
correlations and the aetiology of low bone mass. As illustrated in Chapter 3 , the high
prevalence of high underweight subjects, where underweight is defined based on the
Cole et al., (2007) definition was observed. The present study intended to test an a
priori hypothesis that bone health would be poorer in underweight survivors compared
to other survivors. However, after correction, low total BMC for body size was
apparent in only 1 out of 9 (11%) of the underweight survivors and none had a low
lumbar spine BMC respectively. when BMADLS approach (Kroger et al., 1995) for
correction was used, the prevalence of low bone mass amongst underweight
survivors was sharply increased (56%).  Consequently, this example illustrates that
the consequences of misinterpreting BMD data obtained from DXA go beyond simple
conclusions about the prevalence of impaired bone health in a particular patient
group.
6.5.2 Comparison of the findings with other studies
BMD correction for body size is recommended widely (Lewiecki et al., 2008, Fewtrell,
2003); as similar conflicts reportedly arise with findings when investigating other
chronic diseases and also in general paediatric studies. For instance, Ahmed et al.,
(2004) made a similar conclusion to the present study when they used two different
methods amongst children with chronic disease. Moreover, they examined BMD in 26
children aged 5.5 -18.2 years with inflammatory bowel disease, using DXA. They
interpreted the data on the basis of two different approaches: the manufactures’
software based reference approach; by adjusting BMC for BA (Warner et al. 1988) as
in the present study. The prevalence of osteopenia defined by Ahmed et al., (2004)
(BMD z scores below -1.0) in the sample based on the first approach was about 65%,
however, after adjustment the prevalence was greatly decreased to 22%.
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It is now common to use unadjusted BMD to make conclusions about bone health in
some specialties; this is not universal in general paediatric practice, in the paediatric
research literature, or in other childhood cancer literature. For example, van der Sluis
et al., (2002b) evaluated 61 children with ALL aged 1.6 – 16.8 years old. Out of the 61
(median age was 5.5 years) patients, 43 were classified as standard risk ALL. They
assessed the patients over 5 different periods from the point of diagnosis until the
third year of the therapy. They used the BMADLS approach (Kroger et al., 1995) to
correct BMD for bone size and the manufacture’s reference data approach. They
found that the BMD of lumbar spine was decreased significantly (p value= 0.01) from
diagnosis, but that the BMD of total body was normal. However, different findings
were produced using the BMADLS approach (Kroger et al., 1995) similar to the
present study findings. There was a lowering in BMADLS (Kroger et al., 1995), but no
significant difference shown between the point of diagnosis and the three years after
off-therapy. van der Sluis et al., (2002b) therefore demonstrated that children with
ALL were categorised as at risk of osteopenia, but there were conflicting conclusions
according to the different findings obtained using the different approaches. However,
they stated that ALL survivors are at risk of low bone mass even though there is no
consensus as to how best to adjust, as stated in the present study.
Moreover, in general paediatric practice, some of researchers in recent literature do
not use any adjusted method for bone size as recommended by ISCD 2007 (Baim et
al., 2008) and they consistently report a concern over low bone mass.  For instance,
Ibrahim et al., (2011) in a recent study assessed the BMD in a national survey
amongst adolescents (n=4002) in Egypt with short stature aged 10 – 18 years. They
used DXA as a diagnostic tool but they did not correct BMD for bone size. Thus, they
used BMD z scores for children and defined osteopenia as BMD z score -1.0 – 2.5,
and osteoporosis as BMD z ≥ -2.5. They also defined osteoporotic subjects as those
who had experienced 1 or more low- trauma fractures regardless of BMD
measurement. They reported that amongst stunted boys, 31.1% and 44.7% had
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osteopenia and osteoporosis; respectively.  Amongst stunted girls, 26.5% had
osteopenia and 5.4% had osteoporosis. They reported a high of prevalence of low
BMD in adolescents.
Also, in a recent study in childhood cancer, Al-Tonbary et al., (2011) reported BMD
using DXA at diagnosis in 27 children and adolescents (aged 1- 16 years) with
neuroblastoma. They defined low bone mass as a BMD z score < -1.0. They found
25.9% of the total sample had a low bone mass. However, they raised this issue
without correction of BMD for body size.
6.5.3 Bone density in children with ALL at diagnosis and during therapy
There are several studies that have examined BMD in children with ALL during
therapy and found deficits in bone turnover or other indicators of bone health. For
example, Halton et al., (1996) assessed BMD by DXA in 40 children consecutively
admitted (aged 0.3 – 14 years), all with ALL (standard risk: n= 18) at diagnosis, then
again after periods of 12 months and 24 months. They used the manufacturers DXA
reference data approach which is not recommended by ISCD 2007 (Baim et al.,
2008) to assess  low BMD (osteopenia defined here as BMD and BMC z score below
-1.0). They reported that the prevalence of osteopenia was 10% at diagnosis and that
it reached up to 76% of the sample at 24 months. However, they recruited a mixed
group of ALL patients treated with different therapy protocols in contrast to the
present study which had a fairly homogenous sample. Also, they used the term of
osteopenia with disregard to the history of bone fractures (Baim et al., 2008).
In addition, in a Canadian study by Rayar et al., (2012) 124 children with ALL were
assessed at diagnosis and during therapy, they defined osteopenia and osteoporosis
by using unadjusted BMD of lumbar spine z scores as -1.0 – 1.99 and -2.0 and below;
respectively. Even though it is unacceptable from an ISCD 2007 (Baim et al., 2008)
perspective to define osteopenia and osteoporosis without considering the history of
274
274
bone fractures and without corrections of BMC for body size, the prevalence of
osteopenia and osteoporosis was recorded as 30% and 11% at diagnosis.
Prevalence of patients with ALL who had osteopenia (defined as lumbar spine BMD z
score below -1.0) and osteoporosis (defined as lumbar spine BMD z score below -
2.0) were 39.5% and 8%; respectively, during maintenance therapy for ALL (Rayar et
al., 2012).
6.5.4 Comparison with previous studies amongst survivors of ALL
There are arguments as to whether or not survivors with childhood ALL are at risk of
low bone mass. Some studies (as summarised in table 6.5.1) have concluded that
ALL survivors are at risk of low bone mass in the medium-term (up to 5 yrs after end
treatment) using either adjusted or unadjusted BMD approaches. For instance, in a
relatively recent Turkish study, Gunes et al. (2010) examined 70 (aged 3.4 – 17.5
years) survivors of ALL; however, the ALL treatment protocol used included CRT and
the sample had only 23% (n= 16) classified as standard risk. Therefore, some of the
sample was exposed to very different therapy protocols (i.e. this study did not have a
homogeneous group). After using the DXA manufacturers reference data as an
approach, they reported that 44% and 41% of the sample were either osteopenic
(defined as BMD z score below -1.0) or osteoporotic (defined as BMD z score below -
2.0); respectively which is higher than found in the present study using the same
approach. Gunes et al., (2010) did not use an adjusted method as recommended
(Baim et al., 2008) and they reported about the prevalence of osteoporosis and
osteopenia amongst survivors without considering ISCD 2007 (Baim et al., 2008)
recommendations about both adjustments and terminology.
Moreover, Kelly et al., (2009) in a cross-sectional study examined patients (fewer
than in the present study) who were under- therapy (n= 21) and patient who were off-
therapy (n= 21). DXA was performed and the data interpreted using algorithm
adjusted BMD and BMC. They found adjusted BMC, BA and BMD z scores were less
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than 0.0 across the whole sample, and so were similar to the present study findings
when using all approaches. A similar conclusion was reported by Brennan et al.,
(1999a) when they examined 31 ALL patients (aged 6.8 – 28.6 years) who had been
treated with CRT, compared to 35 healthy adults (aged 21 – 25 years). However, they
used DXA manufacture’s reference data for assessing BMD which is not
recommended by ISCD 2007 (Baim et al., 2008). They found a low lumbar spine
BMD and low femoral neck BMD with a median score of – 0.74 and -0.43;
respectively.
Nonetheless, other researchers have conducted investigations on medium-term ALL
survivors and reported that bone mass does not seem to be affected amongst those
patients when using either adjusted or unadjusted BMD. Using a larger sample size
(n= 69) for a recent cross sectional study (Muszynska-Roslan et al., 2012) had a
similar number of standard risk ALL  (n=53) to the present study. They recruited
survivors of ALL mean (SD) ages 12.2 years (0.5), at least 5 years off-therapy. They
used an unadjusted BMD approach (using manufacture’s reference data approach) to
calculate z scores to define a low bone mass for total body and lumbar spine BMD z
scores below -2.0. They reported no significant difference in BMD z scores in both
total body BMD and lumbar spine BMD in survivors who were off-therapy for less than
or more than 2 years. Thus, it was suggested ALL survivors are not at risk of low
BMD by the authors of the study (Muszynska-Roslan et al., 2012).
Some other studies did not support other evidence suggesting that ALL survivors are
at risk of low bone mass. Kadan-Lottick et al., (2001) examined 75 (standard risk
survivors numbered 69) ALL survivors who had been off-therapy for 0.8 – 6.8 years.
By using an unadjusted BMD approach with z scores calculated relative to the
reference population based on age and sex, osteopenia (defined as total body BMD z
score below – 1.0) prevalence was found to be 11% which was less than the present
study findings (41.2%) with BMD z score below -1.0.  They reported that none had
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osteoporosis (defined in this study as BMD z score below – 2.0) whereas 16% of
Saudi survivors had BMD less than -2.0. Other than according to the ISCD 2007
(Baim et al., 2008) recommendation an adjusted method and, ideally a history of bone
fractures should be used to define either osteoporosis or osteopenia.
Marinovic et al., (2005) examined 37 survivors of ALL, a relatively small sample size,
in a longitudinal study for one year. They compared the survivors with healthy
children (n= 74) and used the BMADLS approach to adjust the BMD for body size.
They found a slight reduction in total body BMD after 2.2 years off-therapy. Brennan
et al., (2005) similarly examined 53 survivors of ALL aged 6 – 17 years who had been
treated by a more  modern protocol (without CRT) compared to healthy children (n=
187) aged 5 – 19 years old. They adjusted BMD using a BMADLS approach (Kroger et
al., 1995). Brennan et al., (2005) found that after adjustment total body BMD and total
body BMD were no different between survivors and controls and so adverse effects of
ALL on bone mass were not reported.
In longer -term (more than 5 yrs after end treatment) studies (as they are summarised
in table 6.5.2), it was uniformly found that bone mass seems to be adversely affected
as result of ALL or its treatment. Warner et al., (1999), using a relatively small sample
size (n= 35), examined survivors with childhood ALL. After adjusting BMC for BA,
they reported lumbar spine percentage predicted BMC at 92%, which was similar to
the present study at 93%. Percentage predicted BMC was decreased significantly
compared to the healthy children control group and lumbar spine percentage
predicted BMC in ALL group was low compared to other malignancies.
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Table 6.5.1: Some studies on bone mass of ALL survivors a medium-term period after therapy
Author
Place
Sample size
Gender
Age
Main methods Main results
Medium-term studies that supported ALL survivors at risk of low bone mass
Gunes et al. (2010)
Turkey
70
M: 41; F: 29
3.4 – 17.5 yr
  Used unadjusted BMD for BA approach
  Osteopenia: BMD z scores -1.0 to -2.0
Osteoporosis: BMD z scores  < -2.0
Treatment protocol had CRT, while SR patients were 23%
  Osteopenic: 44%; Osteoporotic: 41%
  During 2 years since off-therapy, BMD z score was
significantly decreased
  Fracture history: 12%
  No significant difference showed between patients who
treated with CRT and non-CRT (P> 0.05)
Kelly et al (2009)
USA
41
M: 25; F: 16
3 – 18 years
  Subjects: 21 patients (during therapy) and 20 patients (off-therapy)
  CRT: 9 patients
  Included 4 had history of fractures
  Using algorithm adjusted BMD and BMC to age, ethnicity, body size and BA
  BMC, BMD and BA z scores significantly below  0.0
Brenan et al (1999)
UK
31
M: 16; F: 15
6.8 – 28.6 yr
  All patients received CRT
  Patients were at least 2 years of therapy
  BMD unadjusted to BA
  Controls: 35 healthy children (21 – 25 years)
  LS BMD was highly significantly reduced in ALL patients:
median z score was – 0.74 (p=0.01)
Femoral BMD was also significantly reduced: median z
score was -0.43 (p= 0.03)
Medium-term studies that did not supported  ALL survivors at risk of low bone mass
Muzynska-Roslan
et al. (2012)
Poland
69
M: 46; F: 23
12.2 (0.5) yr
  SR ALL were 53
  25 of survivors had CRT
  Off-therapy within 5 years
  Used unadjusted BMD; Low bone mass: defined as BMD below -2.0
BMC z scores, TB BMD and LS BMD were not significant
between survivors who were off-therapy more or less than
2 years
Marinovic et al
(2005)
France
37
M: 20; F: 17
4.7 – 20.6 yr
  Longitudinal study for 1 year
  measured controls healthy children twice (n= 74)
  Adjusted BMD using BMADLS approach
  Median times was 2.2 years off-therapy
  Slight reducing (p= 0.6) in TB BMD after median times
2.2 years off-therapy.
  A significant elevate in median TB BMD in baseline (p=
0.03) and after one year (p= 0.01) when compare > 1.5
year with < 1.5 year since off-therapy
Brenan et al (2005)
UK
53
6- 17 yr
M: 22; F: 31
  CRT did not use; at least 2 years since off-therapy
  187 Healthy children as a control (aged 5- 19 years)
 Adjusted BMD using BMADLS approach
  The median of TB BMC, TB BMD was not differ from
survivors and controls
M: Male; F: Female; LS: lumbar spine; TB:  total body; BMD: Bone mineral density; BMC: bone mineral content; BMADLS: Bone mineral apparent density for lumbar spine;
SR: standard risk; CRT: Cranial radiation therapy; BA: Bone area
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In addition, Arikoski et al., (1998), by using BMADLS (Kroger et al., 1995) in a small
sample of survivors (n= 29; 55% treated with CRT), found that lumbar spine BMD was
significantly decreased compared to healthy children in the control group (n= 273).
Jarfelt et al., (2006) they examined small size (n= 35) survivors aged 20 – 30 years
with childhood ALL where half of them had been treated with CRT (quite a
heterogeneous ALL sample). They used two BMD adjusted approaches: DXA
manufacture’s reference data and BMADLS (Kroger et al., 1995) approaches.
Osteopenia was defined as BMD z scores below –2.5, and osteoporosis was defined
as BMD z score below – 2.5. They reported that based on following the manufacture’s
reference data approach, 1, 4 and 8 survivors had osteopenia in total body BMD,
lumbar spine and the femoral neck; respectively, with no significant differences
between survivors who had been treated or not by CRT. However, they used a non
recommended approach by not adjusting for bone size (Baim et al., 2008) and
reported the concern over low bone mass in ALL long-term survivors based on
unadjusted data. BMADLS (Kroger et al., 1995) was only used to assess survivors
who had been treated (or not) by CRT, and they found no significant difference
between who treated or not treated by CRT patients in total body, lumbar spine and
femoral neck BMD.
To sum up, inconsistent findings were found on bone mass, and inconsistency
probably occurred because of applying different approaches to adjust the BMD.
However, the findings relating to ALL survivors in long-term, suggest that low bone
mass may be an issue of concern and there are also studies of fracture risk which
suggest a cause for concern (Warner et al., 1999, Arikoski et al., 1999).
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Table 6.5.2: Some studies on bone mass ALL survivors a long-term period after
therapy
Author
Place
Sample size
Gender
Age
Main method Main results
Long-term studies that supported ALL survivors at risk of low bone mass
Jarfelt et al
(2006)
Sweden
35
M: 17
F: 18
20 – 30 years
19 survivors had CRT
Using DXA manufacture’s
reference data and BMADLS
Osteopenia: BMD z scre
above – 2.5
Osteoporosis: BMD z score
below -2.5
Median LS BMD z score – 0.4
One, 4 and 8 survivors had
Osteopenia in TB BMD, LS
and femoral neck;
respectively.
BMADLS showed no significant
difference between who had
or had not have CRT
Warner et al
(1999)
UK
35
M: 14
F: 21
7 – 19 years
Compare with other
malignancies group (n= 20)
and healthy children as a
control  group (n= 31)
Adjusted BMD using Warner
et al (1998) approach
PP BMC was reduced
significantly (P< 0.05) ALL
group (92.4%) compare to
control group (100.4%)
LS PP BMC had slower
improving in ALL compare to
other malignancies group
Arikoski et al
(1998)
Finland
29
M: 16
F: 13
12 – 30 years
CRT group: (n= 20)
Non-CRT group: (n= 9)
BMD adjusted by BMADLS
approach
Healthy children as control
group (n= 273) aged 12 –
30 years
LS BMD was significantly
decreased in ALL patients
(95.6%; p= 0.03) compare to
controls
Male who treated with CRT
had significant low LS and
femoral BMD
High dose of MTX was
significantly associated with
low LS BMD
M: Male; F: Female; LS: lumbar spine; TB:  total body; BMD: Bone mineral density; BMC: bone mineral content;
BMADLS: Bone mineral apparent density for lumbar spine; CRT: Cranial radiation therapy; PP: Percentage
predicted; MTX: methotrexate
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6.6 Strengths and limitations of the present study
The main strengths in the present study were the homogenous sample of survivors
(n= 51) treated for standard risk ALL, the most common childhood malignancy.
Another strength of the study was the sample size was either larger than many
previous studies (Kelly et al., 2009, Warner et al., 1999, Arikoski et al., 1998, Brennan
et al., 1999a, Jarfelt et al., 2006, Marinovic et al., 2005) or quite similar to others
(Muszynska-Roslan et al., 2012, Brennan et al., 2005). In addition, the present study
aimed to test the influence of adjusting or not adjusting DXA data for body size.
On the other hand, the present study had a number of limitations. It was not intended
to provide definitive conclusions in relation to the bone health of survivors of ALL-
issues of the prevalence, nature, and aetiology of bone health impairments in ALL
were beyond the scope of the present small study. The present study was
methodological, aimed solely at examining the impact of correction of BMD for size,
and it was adequate for this purpose. It should also be noted that, whilst serial
measurement using DXA is a helpful tool for assessing longitudinal changes in bone
health, it is insufficient on its own as a measure of bone health: the role of DXA in
diagnosing impaired bone health in children with chronic disease is complex and
remains unclear (Wong et al., 2008). Data not included in the present study (e.g.
fracture history) would provide clinically important information on bone health but
collecting such data was beyond the scope of the present study. Alternative means of
correcting DXA data are available (Fewtrell, 2003) but these were also beyond the
scope of the present study which aimed to provide a simple empirical demonstration
of the impact of using corrected versus uncorrected DXA BMD data.
6.7 Conclusions
Bone health remains a concern during and after treatment for childhood malignancy.
This study provides empirical evidence which strongly supports the recommendation
that BMD data from DXA should be interpreted cautiously, particularly in children and
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adolescents with malignancy. The use of DXA as a measure of bone health requires
an adjustment for body size. This is well known from studies of some specialities in
paediatrics (especially endocrinology), but is not widely used in studies of childhood
malignancy cited earlier (Kadan-Lottick et al., 2001, Rayar et al., 2012, Al-Tonbary et
al., 2011, Muszynska-Roslan et al., 2012, Halton et al., 1996, Brennan et al., 1999a)
in which DXA data produced bone health z scores based on age and sex reference
data, but not corrected for body size. Bone status of ALL survivors should be
screened regularly for clinical signs and fracture history. They should be referred to
be evaluated by a bone density specialist if there is a cause concern, and bone health
is one of a number of issues which could be dealt with by “Late Effects Clinics” in
ALL.
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Chapter 7
General discussion
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This final chapter synthesises the main findings of the thesis studies and considers
the implications of the studies in human nutrition for ALL patients in future. Also,
future research which improves on the limitations of this thesis will be considered and
discussed. Finally, general recommendations arising from this thesis studies will be
outlined.
7.1 Brief Summary of Main findings
This thesis studied weight status (underweight, overweight and obesity) during and
post- therapy for ALL child patients in the UK, Saudi survivors and its status at
diagnosis on the prognosis of treatment. The thesis also considered bone health in
survivors of ALL and highlighted methodological issues related to concerns regarding
low bone mineralisation as it is one of the main “late effects of ALL” hot topics.
The thesis dealt with the prevalence of unhealthy weight status over time and at
diagnosis of ALL in UK children who had been treated according to UKALL protocols
between 1985 and 2002 (Mitchell et al., 2010). The thesis included a large
representative sample size and used modern and widely accepted definitions of
weight status (Cole et al., 1995, Cole et al., 2000, Cole et al., 2007) which had not
previously been available when estimates of the prevalence of unhealthy weight
status had been made in UK patients with ALL. Prevalence of overweight and obesity
increased remarkably over the three trials, whilst prevalence of underweight reduced
over time. As the first study in this field this provides an obvious message to clinicians
and other health professionals as to just how common unhealthy weight status is at
diagnosis in ALL. This is valuable, because, although this is sometimes expressed as
a concern in the management of ALL no published evidence has previously been
provided estimating the prevalence of unhealthy weight status at diagnosis of ALL.
Also, while there were strong secular trends towards overweight and obesity in UK
children and adolescents (McCarthy et al., 2003), it seems that unhealthy weight
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status at diagnosis in ALL patients reflects exposure in the general population to an
obesity contaminated environment.
This thesis did not support the hypothesis that unhealthy weight status is an
independent prognostic factor for relapse risk amongst standard risk ALL patients.
Unhealthy weight status increases risk of several adverse consequences as
discussed in the introduction to this study (sections: 1.3 and 1.2) even if it is not
predictive of relapse risk in UK patients with ALL. The thesis supports using
anthropometric methods to identify unhealthy weight status, as these are simple and
practical even if they are imperfect. It is worth noting that there is no evidence
available that focuses on what is an appropriate time to intervene and identify
unhealthy weight status in ALL patients or when to intervene nutritionally in patients
with ALL, e.g. whether this should be during or post-therapy. However, there are
evidence based child obesity prevention and treatment guidelines which could be
used, such as SIGN (Scottish Intercollegiate Guidelines Network, 2010) (as
summarised in appendix F).
There is increasing evidence that paediatric nutritional screening tools are valid,
reliable and practical (Gerasimidis et al., 2010, Secker and Jeejeebhoy 2007, Hulst et
al., 2010). Currently, there is no consensus as to the ideal approach with which to
assess children on admission as at risk of developing malnutrition during their
hospital stay. Such a screening tool differs from measuring actual nutritional status in
conjunction with weight and height. For instance, Gerasimidis et al., (2010) developed
the Paediatric Yorkhill Malnutrition Score, which is a four-stage evaluation based on
four questions considering the BMI for age, recent weight loss, decreased nutrient
intake the previous week, and expected altered nutrition over the course of the next
week. The validity of using this tool was evaluated in comparison with a full dietetic
assessment (dietary history, anthropometric measurements, nutrition associated
physical examination, the ability to maintain age appropriate energy levels, and a
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review of medical notes). The patients (n= 247) were aged 1 -16 years old and there
were three classification risks: low, medium and high malnutrition risk. The nurse-
rated Paediatric Yorkhill Malnutrition Score found 59% of those to be admitted were
classified as high risk when using the four dietetic assessment tools. Also, according
to the nursing Paediatric Yorkhill Malnutrition Score; of those classified as at high risk
of malnutrition, 47% were confirmed as being high risk when given full dietetic
assessment.  There is as yet no evidence as to whether and how nutritional screening
tools such as these should be used in the management of ALL, but they would seem
to be potentially very useful and could be tested in future studies in this patient
population.
The thesis also assessed weight status, over-fatness and MS amongst Saudi
adolescent survivors of ALL drawn from a fairly homogenous group. It showed that
the prevalence of excess weight and obesity in survivors of ALL was quite high, even
though obesity prevalence is extremely high in the general population of Saudi
children and adolescents. We found that MS amongst ALL standard risk patients was
confined to those who were either overweight or obese. These findings might support
early intervention to provide weight management to patients with ALL. Other evidence
has shown that UK ALL patients experience excessive weight gain both during and
after therapy (Reilly, 2009).
BMI for age and sex in children and adolescents provides an effective and simple
indicator of body fatness (Reilly et al., 2010b); however, it is important to note that the
BMI-based estimates of the prevalence of overweight and obesity throughout the
whole thesis were conservative. BMI-based definitions of obesity, at best, have
moderate sensitivity for the detection of excessively fat individuals, with a low false
positive rate and a moderate high negative rate, both in the general child population
(Reilly, 2010) and in those with malignancy (Warner et al., 1997, Aldhafiri et al.,
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2012). Amongst Saudi ALL survivors, by using DXA and BIA high adiposity was more
prevalent than when defined using BMI-based definitions.
However, giving estimates of the prevalence of overweight and obesity in ALL
children and adolescents, using national or international definitions is debatable.
Studies carried out for the thesis found that the Saudi national definition more
conservatively estimated the prevalence of overweight and obesity compared with the
other widely used international definitions.  This might be because the Saudi
reference data has been “contaminated” by an obesity epidemic, and so, caution is
recommended when the Saudi definition is used in public health surveillance or in
clinical practice. Wright et al., (2002) recommended ‘fixing’ UK national reference
data for BMI in 1990, and not updating them, so that future national reference data
would not become contaminated by the obesity epidemic.
Survivors of childhood ALL suffer increased risk of several ‘late effects’ including
deterioration of bone health. The author noted, while carrying out the study described
in chapter 3, that DXA measures of bone health showed what seemed to be a high
prevalence of unhealthy bone results amongst Saudi survivors of childhood standard
risk ALL. Since there was already some concern over the bone health of patients with
ALL both during treatment and in long term survivors (Rayar et al., 2012, Warner et
al., 1999) it seemed worth considering this issue more extensively within this work. In
addition, following literature searches and discussions with child bone health experts
in Yorkhill hospital, determining the bone health of survivors of ALL as measured by
DXA became one of the aims of this thesis. The chapter concluded that bone health
remains a potential concern for survivors of ALL, even though the extent to which this
is a concern based on DXA measures depends very much on how DXA data are
treated. The chapter supports the ISCD 2007 recommendations (Baim et al., 2008)
which emphasise that bone health data produced using DXA devices should be
carefully interpreted with adjustments to correct for body size.
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7.2 Future research suggestions arising from this thesis
It is well-recognised that obesity is epidemic now in Saudi Arabia (El Mouzan et al.,
2010) and it has several complications (discussed further in chapter 1), but
unfortunately there is no evidence-based treatment protocol for obesity in the general
Saudi  population of children, or for the management of unhealthy weight in Saudi
children with malignancies. Evidence based guidelines from other countries might be
a useful starting point in the prevention and treatment of obesity in ALL patients and
survivors. So, the author discussed with Professor John Reilly a possible future
randomised controlled trial of the treatment of obesity and metabolic syndrome in
childhood. Then suggestion was discussed with the head of dietetic department in the
KFSH&RC and the initial approval was provided.
In this thesis, unhealthy weight status at diagnosis was not an independent prognostic
factor for relapse risk. It is possible that unhealthy weight status might have an
adverse impact on risk of relapse in other populations and settings as shown by other
studies (Gelelete et al., 2011, Butturini et al., 2007, Lobato-Mendizabal et al., 2003,
Antillon et al., 2008, Meji´a-Aranguré et al., 1999, Viana et al., 1994, Reilly et al.,
1994).The author and Prof. John Reilly, in  collaboration with KFSH&RC staff have
proposed to test this hypothesis again using  a large and fairly homogenous sample
which is already available in KFSH&RC.
7.2.1 Chapter 3: further research suggestions
The present study was carried out in only one centre in Saudi Arabia in a fixed and
limited number of survivors. The study used a cross sectional design and this has
some limitations, e.g. it can not measure change in variables over time, or confirm
causal relationships and researchers may be unable to rule out alternative
explanations. Therefore, more prospective studies on the weight status of Long term
standard risk ALL Saudi survivors would helpful, with a larger sample sizes.
Recruiting the survivors from multicentre rather than one centre would produce a
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larger and more representative sample.  Also, sophisticated methods for examining
over-fatness in ALL survivors should be used in future research.
The inclusion of nutritional status assessment (e.g. using BMI, DXA and/or BIA)
should be considered in follow up clinics for survivors of ALL.  The prevalence of
unhealthy weight status in ALL survivors might not be as high as in the general
population of children and adolescents in Saudi Arabia, but that is still a high
prevalence of unhealthy weight status and so monitoring of weight status is indicated
along with considering options for treatment of unhealthy weight status.
7.2.2 Chapter 4: further research
Although the chapter 4 study had a very large sample size of ALL patients at
diagnosis, weight status was assessed retrospectively. A prospective cohort study
that uses research-based measurement of height and weight (and possibly even body
composition) is recommended to minimise the error in measuring weight status, and
test the link between unhealthy weight status and outcomes. It is therefore
recommended that malnutrition and any adverse outcomes be studied at diagnosis,
during and after therapy in groups of patients with an acceptable sample size- the
chapter 4 study stopped at the end of UKALL 97/ 97-99 because that was when
weight and height data were no longer being measured at diagnosis of ALL in the UK,
and were no longer being recorded in the UKALL datasets. No national UKALL height
and weight data were therefore available for the past 10 years. The big question is
‘What would the prevalence of different weight status categories at diagnosis of ALL
be now?’ Prevalence of overweight and obesity appear to have levelled off in the
general population of UK children and adolescents in the 2000’s (Stamatakis et al.,
2010).
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7.2.3 Chapter 5: further research
As noted from study of chapter 5, height and weight which are essential for
calculating BMI for age and sex were collected for routine clinical purposes rather
than research purposes. Also, the UKALL dataset that used ended more than 20
years ago. Therefore, to avoid some of these limitations for future studies, research-
based measurements of weight and height collected prospectively would be advised.
Also, as noted above, the BMI for age provides limited information. Further studies to
investigate total body fat or body fat distribution using DXA or BIA may afford a better
insight into relationships between body fatness at diagnosis and outcome of treatment
for ALL (Rogers et al., 2005, Goodpaster, 2002).
Furthermore, there are some other potential variables that possibly attenuate any
associations between weight status and outcome of the treatment of ALL such as
socio-economic status (Lightfoot et al., 2012). Therefore, socio-economic status
should be included in future studies of the relationship between unhealthy weight and
outcome in ALL as it might be a confounder. However, socio-economic status has not
been included in previous ALL survival analyses and was not available from UKALL
trial databases for the work described in the present thesis.
7.2.4 Chapter 6: further research
There is currently no consensus as to the best approach to correct DXA bone health
data for body size. Chapter 6 showed that it not easy to reach a conclusion about  low
bone mass in the survivors of ALL because different corrections for body size gave
fairly different conclusions. However, irrespective of the issue of how to correct DXA
data for body size, serial measurement using DXA is a helpful tool for assessing
longitudinal changes in bone health within individual children and groups of children
(Fewtrell, 2003). For further research in bone health, it would be advisable to use
DXA in assessing bone health of children and adolescents with ALL in a large and
longitudinal prospective study. The data that are produced from DXA should be
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interpreted based on some correction for body size approach as described by chapter
6.
A number of recently published studies in childhood malignancies have not taken any
body size correction approach to interpreting DXA bone health data (e.g. Muszynska-
Roslan et al., 2012, Al-Tonbary et al., 2011, Rayar et al., 2012). In addition, measures
other than just DXA are helpful to understanding bone health- for example a fracture
history would provide clinically significant information on bone health (Baim et al.,
2008).
7.3 Clinical recommendations arising from this thesis
 Height measurement seems not to have been recorded in the most recent
UKALL trials as it is no longer needed to calculate the surface area in
algorithms required for chemotherapy. This study highlights the importance of
height in calculating a BMI z score and the ease with which this can be used to
diagnose the patient’s weight status; without recording of height and weight it
has become impossible to carry out surveillance on weight status of ALL
patients at diagnosis in the UK- this became impossible after around the end of
the UKALL 97/97-99 trial in 2002. Routine measurement and recording of
height and weight should possibly be restored in future UKALL trials, both to
help identify and manage unhealthy weight status and also for population
surveillance of unhealthy weight status.
 It would be useful if health professionals were to consider including more
sophisticated approaches to assessing fatness alongside the use of BMI;
techniques such as such as BIA or DXA might be most useful as they are the
most practical in clinical settings.
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 Establishing childhood underweight, overweight and obesity intervention
strategies from diagnosis could be considered in ALL. There are evidence
based clinical guidelines which could be used e.g. SIGN (Scottish
Intercollegiate Guidelines Network, 2010) (shown in Appendix F),  AAP (Spear
et al., 2007) and NICE (National Institute for Health and Clinical Excellence,
2010) to help ALL patients and survivors achieve improved lifestyles and
weight status. However, no specific guideline is available nowadays for weight
status of children with ALL.
 Trained and qualified health professionals are vital for the diagnosis,
monitoring and treatment of unhealthy weight in childhood cancer. Health
professionals such as dietitians have to be more aware of the need to evaluate
nutritional status and how to evaluate nutritional status in childhood cancer
management, and how to implement interventions.
 Finally, (Van Eys, 1998) stated that “Nutrition should be viewed for what it is:
supplying the most basic needs of children. No child has died from being fed
appropriately, but many die of starvation. The practice of paediatric oncology
should not contribute to that statistic”.
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ABSTRACT
 This study tested the hypothesis that being overweight/obese at diagnosis of childhood ALL was
related to risk of relapse. In a national cohort of 1033 patients from the UK there was no evidence that
weight status at diagnosis was related significantly to risk of relapse: log ranks test (p 0.90) with
overweight and obesity as the exposure (n 917); individual (p 0.42) and stepwise (p 0.96) proportional
hazards models,  with BMI Z score as the exposure. The study does not support the hypothesis that
being overweight/obese at diagnosis impairs prognosis in childhood ALL in the UK.
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INTRODUCTION
For at least some cancers, obesity impairs prognosis [1]. Treatment of ALL has improved [2] but the
influence of obesity on treatment outcomes is unclear: some evidence that overweight and obesity at
diagnosis both does [3,4] and does not [5,6] increase risk of relapse. Butturini et al [3] found that
impairment of prognosis was restricted to older obese patients (over the age of 10), yet most patients
with ALL are much younger than this at diagnosis. Gelelete et al [4] recently suggested that
overweight/obesity impaired prognosis of ALL for intermediate and high-risk subgroups (n 127), but
not for standard risk patients (n 44). Around 15% of children in the UK are obese (BMI>95th centile
relative to UK 1990 reference data) at the typical age at diagnosis of ALL [7]. Moreover, prevalence of
obesity in UK patients with ALL increases dramatically during treatment [8] and, if obesity does
impair prognosis in childhood ALL, these changes in weight status might also be important to risk of
relapse.
Since the issue of whether overweight and obesity impair prognosis in childhood ALL is inconclusive
[3-6],  the present study aimed to test the hypothesis that being overweight/obese is related to the risk
of relapse of childhood ALL.
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METHODS AND PROCEDURES
Dataset
The present study was based on secondary analysis of anonymised patient data from the UKALL X
treatment trial in the UK (1985-1990). In the UK the vast majority of patients diagnosed with ALL
have entered national trials for many years. The sample for the present study is described in detail
elsewhere [9], but in brief, 1635 patients were entered onto the trial. We excluded patients who were
incorrectly diagnosed or randomised (n 23). We also excluded those considered as high risk at the time
the trial took place (central nervous system disease at diagnosis and/or presenting white blood cell
count > 100 x 109/L; n 225), those considered low risk at that time (girls age 2-9 years with presenting
white blood cell count < 20 x 109/L; n 347). Exclusion of both high and low risk patients was done in
part to retain a relatively large and homogenous sample for analyses, but was also a pragmatic decision
based on the fact that electronic patient data were more available for standard risk patients. In addition,
those patients with no height or weight recorded (n 7) had to be excluded because their weight status
could not be assessed, leaving 1033 potentially eligible patients.
.
Exposure and Outcome Measures
In the present study BMI Z score at diagnosis, and being overweight and obese at diagnosis, the latter
defined using 6-monthly age and sex-specific cut-offs which are conceptually equivalent to adult BMI
based definitions of overweight (BMI of 25 kg/m2) and obesity (BMI of 30kg/m2) [10], were the main
exposures. The exposure variables were derived from routine clinic measures of weight and height at
diagnosis, for the purposes of calculating body surface area for drug dosage. The established and
potential prognostic factors were also included in the analyses: age, sex, white blood cell count at
diagnosis, randomisation allocation to intensive therapy (no intensification; early intensification; late
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intensification; both early and late intensification; the treatment protocol in the UK at the time),
ethnicity (defined as European origin or other). The outcome measure was time to first relapse; in
children who did not relapse during the follow-up period, this time was censored at the last date seen in
clinic, based on information held on trial records [9].
Statistical Analyses
The influence of individual known and potential prognostic factors was first tested in a univariate
manner using log ranks tests with patients categorised based on BMI for age and sex as underweight
[10]; healthy weight; overweight and obese combined [10]. In order to categorise subjects in this way,
we had to exclude those patients who were too young to have their weight status defined by the Cole-
IOTF method (all those under the age of two years, n 116).
To examine the possible independent influence of  weight status on risk of relapse we used stepwise
proportional hazards models with  known and potential prognostic factors considered together [9],
including BMI Z score as a continuous variable (n 1033).
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RESULTS
Characteristics of Study Participants at Diagnosis of ALL
At diagnosis median (IQR) age of patients was 4.9y (3.3, 8.8) and median (IQR) BMI Z score –0.27 (-
1.03, 0.45).
Being Overweight and Obese as Possible Prognostic Factors
Table 1 shows risk of relapse in relation to the various prognostic factors, known and potential.
From the univariate analysis of individual factors, using log ranks tests, those which influenced risk of
relapse were gender (p 0.02) and age (p 0.01). Being overweight/obese at diagnosis was not
significantly associated with risk of relapse (p 0.90). Kaplan Meier survival plots are shown in Figure
1.
Univariate proportional hazards ratio analysis with BMI Z score at diagnosis as a continuous variable
showed that this was not significantly associated with risk of relapse (p 0.42). From the stepwise
(likelihood ratio) modelling age (p<0.0001); white blood cell count at diagnosis (p 0.005); gender
(p<0.0001) were all significantly associated with risk of relapse in the expected directions, but weight
status was not significant after those variables had entered into the proportional hazards model (p
0.96).
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DISCUSSION
The present study found no evidence that being overweight/obese at diagnosis led to increased risk of
relapse in typical patients treated for childhood ALL in the UK. There are a number of  plausible
mechanisms by which overweight and obesity could increase risk of relapse [1,11,12], and evidence
that being overweight/obese at diagnosis might impair prognosis in higher-risk and/or older patients
with ALL [3,4]. However, there are important short and long-term adverse consequences of childhood
obesity [13,14], and an absence of associations with relapse in typical patients with ALL does not
mean that obesity is not a cause for clinical concern.
The reasons for the different conclusions between the studies to address the question of the impact of
overweight and/or obesity on risk of relapse in childhood ALL are not entirely clear. It is possible, but
unconfirmed, that the age and risk status of patients might be important to any association of obesity at
diagnosis with adverse outcome in ALL.
Two studies which reported increased risk of relapse associated with being overweight/obese at
diagnosis did so in older and/or higher risk patients [3,4], but one small recent study found increased
risk of relapse among all patients [15]; five studies to date have found no risk of relapse in lower-risk
patient groups or subgroups (present study plus [3-6]). A recent study in adults [16] found that obesity
was associated with significantly increased risk of mortality.
The present study had a number of strengths, in particular the relatively large sample size, and the
inclusion of a relatively homogenous group of patients from a national trial. The present study had a
number of limitations. Since the present study was restricted to patients considered to be standard risk
at the time (1985-1990) we cannot draw conclusions about the possible impact of obesity on relapse
among patients at higher or lower risk of relapse. It is possible that subtle associations between weight
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status and outcome (e.g. in ability to tolerate chemotherapy , or in drug pharmacokinetics) are masked
in standard risk patients but manifest in higher risk patients. The algorithm used for determining
chemotherapy doses in patients in the present study was based, in the main, on their actual body
surface area. There was no trial record of adjustment of doses in obese patients and we believe that this
was very rare. Differences in the algorithms used to calculate body surface area, and in the adjustment,
or lack of adjustment, for obesity may explain some of the inconsistencies between studies discussed
above.
 The Data on some potential confounders, such as socio-economic status [17] were not available. A
high BMI for age and sex provides an acceptable diagnostic method for identifying children with
excessive fat mass [18], but it is imperfect both in healthy children and those with malignancy [19,20].
Patient categorisations used in the present study (e.g. exclusion of high and low risk patient groups)
were those which applied at the time of the trial and are not identical to those which apply today.
Clinical trial data used in the present study are from older protocols, but since 2002 height and weight
have not been measured and recorded routinely in patients with ALL in the UK, and so the hypothesis
tested in the present study is not testable with recent national UK trial data. The strengths of the present
study, combined with a degree of consistency of findings with the other studies of non-high risk
patients, enhances confidence in our conclusions that for typical patients with ALL overweight/obesity
at diagnosis is unlikely to impair prognosis markedly.
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FIGURE 1. Kaplan-Meier Survival Plot: Relapse Risk in Relation to Weight Status.
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Table 1 Eligible patient characteristics at diagnosis and risk of relapse n (%)
Relapsed
n (%)
No relapse
n (%)
Overall
n
2.0 – 3.9 112 (31.9) 239 (68.1) 351
4.0 – 9.9 143 (37.8) 235 (62.2) 378
10.0 –14.9 82 (43.6) 106 (56.4) 188
Age (years )
Total 337 (36.8) 580 (63.2) 917
Boys 277 (39.0) 433 (61.0) 710
Girls 60 (29.0) 147 (71.0) 207
Gender
Total 337 (36.8) 580 (63.2) 917
0 - 10 188 (35.3) 344 (64.7) 532
10 - 20 49 (36.3) 86 (63.7) 135
20 – 50 66 (39.8) 100 (60.2) 166
50 - 100 27 (43.5) 35 (56.5) 62
White Blood Cell
Count
(x 109)
Total 330 (36.9) 565 (63.1) 895
Healthy weight 236 (36.6) 409 (63.4) 645Weight status
Underweight 67 (37.6) 111 (62.4) 178
317
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Overweight/ obese 34 (36.2) 60 (63.8) 94
Total 337 (36.8) 580 (63.2) 917
Non 97 (42.7) 130 (57.3) 227
Early 80 (35.2) 147 (64.8) 227
Late 81 (35.4) 148 (64.6) 229
Early and late 79 (33.8) 155 (66.2) 234
Intensification
Total 337 (36.8) 580 (63.2) 917
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Ethical approval
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Appendix C
CCG 1891 protocol modified by KFSH&RC
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Appendix D
IDF and the NCEP III modified by  Cook et al., (2008)
IDF definition
(having central obesity plus two or more
additional criteria)
NCEP III definition
(having at least three MS criteria)
10 – 15 years ≥ 16 years 5 – 19 years ≥ 19 years
WC≥ 90 th  centile WC ≥94 cm for men
and WC ≥ 80 cm for
women
WC ≥ 90th  centile WC ≥102 cm for men
and WC ≥ 88cm for
women
TG ≥ 1.7 mmol/L TG ≥ 1.7 mmol/L TG ≥ 1.24 mmol/L TG ≥ 1.69 mmol/L
HDL-C < 1.03
mmol/L
HDL-C < 1.03 mmol/L
in males and < 1.29 for
females
HDL-C ≤ 1.03
mmol/L
HDL-C ≤ 1.03 mmol/L
for men and HDL-C ≤
1.29 mmol/L for women
SBP ≥ 130 or
DBP ≥ 85 mm Hg
SBP ≥ 130 or DBP ≥
85 mm Hg
BP ≥ 90 th  centile SBP ≥ 130 or
DBP ≥ 85 mm Hg
FG ≥ 5.6 mmol/L FG ≥ 5.6 mmol/L FG ≥ 6.1 mmol/L FG ≥ 6.1 mmol/L
WC: Waist circumference; TG: Triglycerides; HDL-C: high density lipoprotein cholesterol; SBP: systolic
blood pressure; DBP: diastolic blood pressure; FG: Fasting glucose
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Appendix E
BMADlLS calculation
An example:
Girl with age 14.1 years old performed by DXA. The results were as following
BMDLS (L2-L4) = 0.815 g/cm2
Width of L2= 3.2 cm
Width of L3= 3.6 cm
Width of L4= 4.0 cm
Solution:
By applying the following equation:
BMADLS= aBMDLSX [4/ (Ω X width)];  (Ω= 3.14)
Width (L2-L4) = (3.2 + 3.6 + 4.0)/ 3
BMADLS= 0.815 X 0.353= 0.288
Then, adjust BMADLS according to mean (SD) age and gender reference data.
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Mean (SD) of bone mineral apparent density lumbar spine (BMADLS) in boys and girls suggested by
van der Sluis et al. (2002)
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